---
document_datetime: 2023-09-21 20:34:01
document_pages: 126
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0097-epar-assessment-report-variation_en.pdf
document_name: keytruda-h-c-3820-ii-0097-epar-assessment-report-variation_en.pdf
version: success
processing_time: 370.3880975
conversion_datetime: 2025-12-20 09:54:07.311087
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

20 May 2021 EMA/331504/2021 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Keytruda

International non-proprietary name: pembrolizumab

Procedure No. EMEA/H/C/003820/II/0097

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                | 6                                                                                                         |
|-------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation                                                                                                  | ..................................................................................................6       |
| 1.2. Steps taken for the assessment of the product                                                                      | ........................................................7                                                 |
| 2. Timetable................................................................................................            | 7                                                                                                         |
| 3. Scientific discussion................................................................................                | 7                                                                                                         |
| 3.1. Introduction                                                                                                       | ........................................................................................................7 |
| 3.1.1. Problem statement                                                                                                | ............................................................................................8             |
| 3.1.2. About the product                                                                                                | ........................................................................................... 10            |
| 3.1.3. The development programme/compliance with CHMP guidance/scientific advice......                                  | 11                                                                                                        |
| 3.1.4. General comments on compliance with GCP........................................................                  | 11                                                                                                        |
| 3.2. Non-clinical aspects............................................................................................   | 11                                                                                                        |
| 3.2.1. Ecotoxicity/environmental risk assessment.........................................................               | 12                                                                                                        |
| 3.2.2. Discussion and conclusion on non-clinical aspects................................................                | 12                                                                                                        |
| 3.3. Clinical aspects                                                                                                   | .................................................................................................. 12     |
| 3.3.1. Introduction.................................................................................................... | 12                                                                                                        |
| 3.3.2. Pharmacokinetics                                                                                                 | ............................................................................................ 13           |
| 3.3.3. Pharmacodynamics..........................................................................................       | 18                                                                                                        |
| 3.3.4. Discussion on clinical pharmacology...................................................................           | 18                                                                                                        |
| 3.3.5. Conclusions on clinical pharmacology.................................................................            | 19                                                                                                        |
| 3.4. Clinical efficacy                                                                                                  | .................................................................................................. 19     |
| 3.4.1. Dose response study(ies) .................................................................................       | 19                                                                                                        |
| 3.4.2. Main study(ies)                                                                                                  | ............................................................................................... 19        |
| 3.4.3. Discussion on clinical efficacy............................................................................      | 81                                                                                                        |
| 3.4.4. Conclusions on the clinical efficacy ....................................................................        | 87                                                                                                        |
| 3.5. Clinical safety                                                                                                    | .................................................................................................... 87   |
| 3.5.1. Discussion on clinical safety............................................................................        | 113                                                                                                       |
| 3.5.2. Conclusions on clinical safety..........................................................................         | 116                                                                                                       |
| 3.5.3. PSUR cycle                                                                                                       | ................................................................................................... 116   |
| 3.6. Risk management plan                                                                                               | ..................................................................................... 116                 |
| 3.7. Update of the Product information......................................................................            | 118                                                                                                       |
| 3.7.1. User consultation                                                                                                | .......................................................................................... 118            |
| 4. Benefit-Risk Balance...........................................................................                      | 119                                                                                                       |
| 4.1.1. Disease or condition ......................................................................................      | 119                                                                                                       |
| 4.1.2. Available therapies and unmet medical need.....................................................                  | 119                                                                                                       |
| 4.1.3. Main clinical studies.......................................................................................     | 119                                                                                                       |
| 4.2. Favourable effects............................................................................................     | 119                                                                                                       |
| 4.3. Uncertainties and limitations about favourable effects...........................................                  | 120                                                                                                       |
| 4.4. Unfavourable effects.........................................................................................      | 120                                                                                                       |
| 4.5. Uncertainties and limitations about unfavourable effects                                                           | ....................................... 121                                                               |
| 4.6. Effects Table....................................................................................................  | 121                                                                                                       |
| 4.7. Benefit-risk assessment and discussion...............................................................              | 122                                                                                                       |
| 4.7.1. Importance of favourable and unfavourable effects............................................                    | 122                                                                                                       |

<div style=\"page-break-after: always\"></div>

| 4.7.2. Balance of benefits and risks ..........................................................................        |   122 |
|------------------------------------------------------------------------------------------------------------------------|-------|
| 4.7.3. Additional considerations on the benefit-risk balance .........................................                 |   122 |
| 4.8. Conclusions ..................................................................................................... |   123 |
| 5. Recommendations...............................................................................                      |   123 |

6. APPENDIX ........................................................................................... 124

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation    | Definition                                                                                                        |
|-----------------|-------------------------------------------------------------------------------------------------------------------|
| 1L              | First-line                                                                                                        |
| 2L              | Second-line                                                                                                       |
| 3L+             | Third-line or later                                                                                               |
| 5-FU            | 5-fluorouracil                                                                                                    |
| AC              | Adenocarcinoma                                                                                                    |
| AE              | Adverse event                                                                                                     |
| AEOSI           | Adverse event of special interest                                                                                 |
| ALT             | Alanine aminotransferase                                                                                          |
| ASaT            | All Subjects as Treated                                                                                           |
| BICR            | Blinded independent central review                                                                                |
| CDE             | Center for Drug Evaluation                                                                                        |
| CHMP            | Committee for Medicinal Products for Human Use                                                                    |
| CI              | Confidence interval                                                                                               |
| COVID-19        | Coronavirus disease caused by severe acute respiratory syndrome coronavirus 2019                                  |
| CPS             | Combined positive score                                                                                           |
| CR              | Complete response                                                                                                 |
| CSR             | Clinical study report                                                                                             |
| CTCAE           | Common Terminology Criteria for Adverse Events                                                                    |
| dMMR            | Deficient mismatch repair                                                                                         |
| DOR             | Duration of response                                                                                              |
| EAC             | Esophageal adenocarcinoma                                                                                         |
| EC 50           | Half-maximal effective concentration                                                                              |
| ECOG            | Eastern Cooperative Oncology Group                                                                                |
| EGJ             | Esophagogastric junction                                                                                          |
| EMA             | European Medicines Agency                                                                                         |
| EORTC QLQ-C30   | European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items            |
| EORTC QLQ-OES18 | European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire in Oesophageal Cancer 18 |
| EQ-5D           | EuroQol 5-dimension                                                                                               |
| ESCC            | Esophageal squamous cell carcinoma                                                                                |
| ESMO            | European Society for Medical Oncology                                                                             |
| EU              | European Union                                                                                                    |
| FAS             | Full analysis set                                                                                                 |
| FDA             | Food and Drug Administration                                                                                      |
| HER-2           | Human epidermal growth factor receptor 2                                                                          |
| HR              | Hazard ratio                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                               |
|----------------|----------------------------------------------------------|
| IA             | Interim analysis                                         |
| IFNγ           | Interferon gamma                                         |
| IgG4           | Immunoglobulin G4                                        |
| IL-2           | Interleukin 2                                            |
| ISS            | Integrated summary of safety                             |
| ITT            | Intention to treat                                       |
| KM             | Kaplan-Meier                                             |
| LS             | Least squares                                            |
| MSI-H          | Microsatellite instability-high                          |
| ORR            | Objective response rate                                  |
| OS             | Overall survival                                         |
| mAb            | Monoclonal antibody                                      |
| MedDRA         | Medical Dictionary of Regulatory Activities              |
| NCCN           | National Comprehensive Cancer Network                    |
| NSCLC          | Non-small cell lung carcinoma                            |
| PD-1           | Programmed cell death-1                                  |
| PD-L1          | Programmed cell death-1 ligand-1                         |
| PD-L2          | Programmed cell death-1 ligand-2                         |
| PFS            | Progression-free survival                                |
| PK             | Pharmacokinetic                                          |
| PR             | Partial response                                         |
| PRO            | Patient-reported outcome                                 |
| Q3W            | Every 3 weeks                                            |
| Q6W            | Every 6 weeks                                            |
| QoL            | Quality of life                                          |
| RECIST 1.1     | Response Evaluation Criteria in Solid Tumors version 1.1 |
| RSD            | Reference Safety Dataset                                 |
| SAE            | Serious adverse event                                    |
| SAP            | Statistical analysis plan                                |
| SOC            | Standard of care                                         |
| SCC            | Squamous cell carcinoma                                  |
| SOP            | Standard Operating procedures                            |
| TNFα           | Tumor necrosis factor alpha                              |
| US             | United States                                            |
| VAS            | Visual analogue scale                                    |
| WBC            | White blood cell                                         |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Merck Sharp &amp; Dohme B.V. submitted to the European Medicines Agency on 11 November 2020 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include in combination with chemotherapy, first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults for Keytruda, based on the results from the pivotal KEYNOTE-590 (KN590) trial, a Phase 3, randomized, double-blind, placebo-controlled, multisite study to evaluate the efficacy and safety of pembrolizumab in combination with chemotherapy (cisplatin and 5-FU) versus chemotherapy (cisplatin with 5-FU) as first line treatment in participants with locally advanced unresectable or metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction; as a consequence sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version of the RMP (Version 30.1) has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0043/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP (P/0043/2018) covering the condition 'Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue) was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## Scientific advice

The MAH did seek Scientific Advice at the CHMP on the design of KEYNOTE-590, the pivotal trial for this application (EMEA/H/SA/2437/19/2017/II). Questions referred to the study population, choice of comparator, proposed endpoints and statistical plan.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Armando Genazzani

Co-Rapporteur:

Jan Mueller-Berghaus

| 2. Timetable                                         | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 11 November 2020 |
| Start of procedure:                                  | 28 November 2020 |
| CHMP Rapporteur Assessment Report                    | 22 January 2021  |
| CHMP Co-Rapporteur Assessment Report                 | 22 January 2021  |
| PRAC Rapporteur Assessment Report                    | 26 January 2021  |
| PRAC Outcome                                         | 11 February 2021 |
| CHMP members comments                                | 15 February 2021 |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 19 February 2021 |
| Request for supplementary information (RSI)          | 25 February 2021 |
| CHMP Rapporteur Assessment Report                    | 8 April 2021     |
| CHMP members comments                                | 12 April 2021    |
| Updated CHMP Rapporteur Assessment Report            | 19 April 2021    |
| Request for supplementary information (RSI)          | 23 April 2021    |
| CHMP Rapporteur Assessment Report                    | 6 May 2021       |
| CHMP members comments                                | 12 May 2021      |
| Updated CHMP Rapporteur Assessment Report            | N/A              |
| The Oral explanation was held on:                    | 18 May 2021      |
| Opinion                                              | 20 May 2021      |

## 3. Scientific discussion

## 3.1. Introduction

Within the current type II variation, the MAH is seeking an extension of indication for pembrolizumab, in combination with chemotherapy, to the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults, based on the results from an  analysis of the pivotal KEYNOTE-590 (KN590) trial.

<div style=\"page-break-after: always\"></div>

## 3.1.1. Problem statement

## Disease or condition

Locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults.

## State the claimed the therapeutic indication

'KEYTRUDA, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line  treatment  of  patients  with  locally  advanced  unresectable  or  metastatic  carcinoma  of  the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults (see section 5.1)'

## Epidemiology

In 2018, oesophageal cancer was the seventh most common cancer in terms of incidence (572,034 new cases) and the sixth leading cause of cancer-related death worldwide with 508,585 deaths. Over 77% of the new oesophageal cancer cases diagnosed worldwide occur in Asia, and incidence varies significantly between regions 1 . In most regions, including the US and Europe, males have a 2- to 3-fold higher incidence compared to females. In Western Europe, an estimated 13,938 new cases and 11,403 deaths are expected to occur in 2020 2 .

## Biologic features, aetiology and pathogenesis

Oesophageal cancers can be categorized into 2 main histological subtypes: squamous cell carcinoma (SCC) and adenocarcinoma (AC). While SCC is the most common subtype of oesophageal cancer globally (84% of all cases) with the highest incidence rates in Eastern Asia and Eastern Africa, AC is the most common subtype in high-income countries, with the highest incidence rates in Northern Europe, North America, and Oceania 3 . SCC typically occurs in the proximal two-thirds of the oesophagus, whereas AC is found in the distal third of the oesophagus and at the EGJ. AC tumours of the EGJ are classified based on Siewert types 4 . Siewert type I tumours are adenocarcinomas whose epicenter is located 1 to 5 centimeters proximally from the anatomical line of the cardia 5 . As regards risk factors, smoking and alcohol consumption have been associated with SCC in western countries, while AC generally occurs in patients with gastro-oesophageal reflux and a higher risk has been recognised for obese patients.

## Clinical presentation, diagnosis and stage/prognosis

Most patients are diagnosed at an advanced stage, and the prognosis for metastatic oesophageal cancer is generally poor, with an overall 5-year survival rate of 5%6. Treatment of advanced oesophageal cancer is largely palliative in intent.

1  Global Cancer Observatory (GCO). Oesophagus: Globacon 2018. Lyon (France): International Agency for Research on Cancer (IARC); 2019 Mar. 2 p.

2  Oesophagus - Global Cancer Observatory - IARC - https://gco.iarc.fr/today/data/factsheets/cancers/6-Oesophagus-factsheet.pdf

3  Arnold M, Ferlay J, van Berge Henegouwen MI, Soerjomataram I. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut. 2020;69:1564-71.

4  Ilson DH, van Hillegersberg R. Management of patients with adenocarcinoma or squamous cancer of the esophagus. Gastroenterology. 2018 Jan;154(2):437-51.

5  Escrig Sos J, Gomez Quiles L, Maiocchi K. The 8th edition of the AJCCTNM classification: new contributions to the staging of esophagogastric junction cancer. Cir Esp. 2019;97(8):432-7.

6  Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan-Feb;70(1):7-30.

<div style=\"page-break-after: always\"></div>

## Management

For  previously  untreated  patients  with  locally  advanced  unresectable  or  metastatic  carcinoma  of  the oesophagus,  NCCN  and  ESMO  guidelines  recommend  first-line  treatment  with  the  combination  of  a fluoropyrimidine (5-FU or capecitabine) with platinum agents (cisplatin, oxaliplatin, or carboplatin). Some of the first-line treatments recommended and/or used for oesophageal cancer are based on evidence that is extrapolated from data from either gastric or gastroesophageal junction trials 7   8   9 .

Triplet regimens with the addition of anthracycline or taxanes can also be considered in fit patients, although controversy remains as regards their clinical advantage. Taxane and platinum combinations can be also considered. In SCC, cisplatin-based combinations showed increased response rate but no survival gain compared with monotherapy; overall, results with palliative chemotherapy are worse than for AC tumours  7 8 9 .

An overview on clinical efficacy of currently available treatments has been provided by the MAH in the table below:

Table 1: First-line Treatment Outcomes from Phase 1 and 2 Studies in Oesophageal Cancer

| Treatment                                   | Histology   | No. of Patients   |   ORR (%) | PFS/TTP (months)   | OS (months)   | Reference   |
|---------------------------------------------|-------------|-------------------|-----------|--------------------|---------------|-------------|
| 5-FU + alpha 2a-interferon                  | SCC + AC    | 21                |        25 | n/a                | n/a           | {04LDGG}    |
| Cisplatin + 5-FU                            | SCC         | 44                |        35 | 6.2                | 7.6           | {04RYQR}    |
| Cisplatin + 5-FU                            | SCC         | 36a               |        33 | n/a                | 6.6           | {046BQQ}    |
| Cisplatin + 5-FU                            | SCC         | 30                |        30 | 3.6                | 5.5           | {04KC0F}    |
| Cisplatin + 5-FU                            | SCC         | 20                |        55 | n/a                | 20.5          | {04LDG2}    |
| Cisplatin + 5-FU + leucovorin               | SCC + AC    | 10                |        40 | n/a                | 10.6          | {04L90K}    |
| Cisplatin + 5-FU + adriamycin               | SCC         | 21                |        33 | n/a                | 8.0           | {04L90Y}    |
| Cisplatin + 5-FU + cetuximab                | SCC         | 32                |        34 | 5.9                | 9.5           | {04KC0F}    |
| Cisplatin + 5-FU + doxorubicin              | SCC         | 41                |        44 | 5.0                | 10.1          | {04L9F9}    |
| Cisplatin + 5-FU + folinic acid + etoposide | SCC         | 68                |        34 | n/a                | 9.5           | {04LDG0}    |

7  F. Lordick, C. Mariette, K. Haustermans, R. Obermannová and D. Arnold. Oesophageal Cancer: ESMO Clinical Practice Guidelines. Ann Oncol (2016) 27 (suppl 5): v50-v57

8  K. Muro, F. Lordick, T. Tsushima et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol (2019); 30: 34-43.

9  NCCN Guidelines Esophageal and Esophagogastric Junction Cancers version 2.2021

<div style=\"page-break-after: always\"></div>

| Cisplatin + capecitabine                 | SCC      |   45 |   58 | 4.7   | 11.2   | {04L9FC}   |
|------------------------------------------|----------|------|------|-------|--------|------------|
| Cisplatin + capecitabine                 | SCC      |   46 |   57 | 5.1   | 10.5   | {04L9FF}   |
| Cisplatin + paclitaxel                   | SCC + AC |   20 |   40 | 8.0b  | 11.0b  | {04LDFZ}   |
| Cisplatin + paclitaxel                   | SCC + AC |   59 |   52 | n/a   | n/a    | {04LDG8}   |
| Cisplatin + paclitaxel + nimotuzumab     | SCC      |   56 |   52 | 10.8  | 20.2   | {04LDFY}   |
| Cisplatin + vinorelbine                  | SCC      |   71 |   34 | 3.6   | 6.8    | {04L90P}   |
| Oxaliplatin + 5-FU + leucovorin (FOLFOX) | SCC      |   56 |   23 | 4.4   | 7.7    | {04LDH4}   |
| Paclitaxel + capecitabine                | SCC      |   48 |   58 | 6.7   | 13.2   | {04L9FF}   |
| Paclitaxel + carboplatin                 | SCC + AC |   35 |   43 | n/a   | 9      | {04L90V}   |
| Paclitaxel + nedaplatin                  | SCC + AC |   36 |   44 | 6.1   | 10.3   | {04L924}   |
| Paclitaxel + nedaplatin                  | SCC      |   36 |   46 | 7.1   | 12.4   | {04L9F8}   |

- Abbreviations: 5-FU = 5-fluorouracil; AC = adenocarcinoma; n/a = not available; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; SCC = squamous cell carcinoma; TTP = time to progression.
- a Number of eligible patients.

b Median PFS and OS were based on responding patients.

## 3.1.2. About the product

Keytruda (pembrolizumab) is a humanized mAb IgG4/kappa isotype directed against PD-1. By blocking the interaction between PD-1 and its ligands PD-L1/2, pembrolizumab enhances T cell lymphocyte activity with consequent stimulation of the immune-mediated anti-tumour activity. Pembrolizumab also modulates the level of IL2, TNFα, IFNγ, and other cytokines. The antibody potentiates existing immune responses in the presence of antigen only; it does not non-specifically activate T cells.

Pembrolizumab is currently approved in the EU for the treatment of melanoma, NSCLC, RCC, HNSCC, urothelial cancer, and cHL. Pembrolizumab has been approved both as monotherapy and in combination with other agents.

The scope of this variation is to include a new indication for Keytruda: in combination with chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults. The proposed indication is supported by the results from a single pivotal study, the KEYNOTE-590 (KN590) trial. A Phase 3, randomized, doubleblind,  placebo-controlled,  multicentre  study  to  evaluate  the  efficacy  and  safety  of  pembrolizumab  in combination with chemotherapy (cisplatin and 5-FU) versus chemotherapy (cisplatin and 5-FU) as first line treatment in participants with locally advanced unresectable or metastatic adenocarcinoma or squamous cell  carcinoma  of  the  oesophagus  or  advanced/metastatic  Siewert  type  1  adenocarcinoma  of  the gastroesophageal junction. A total of 700 patients were randomized to one of the two treatment arms. A dosing regimen of 200 mg Q3W is recommended.

The CHMP accepted the following indication:

KEYTRUDA, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line  treatment  of  patients  with  locally  advanced  unresectable  or  metastatic  carcinoma  of  the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express

<div style=\"page-break-after: always\"></div>

PD-L1 with a CPS ≥ 10.

## 3.1.3. The development programme/compliance with CHMP guidance/scientific advice

Scientific Advice was obtained from the CHMP on 23 March 2017, with questions relating to the design elements of Study KN590, such as the study population, comparator, endpoints and statistical analysis plan.

- As regards inclusion/exclusion criteria, the CHMP noted the exclusion of locally advanced carcinoma that is resectable or potentially curable by radiation therapy, as determined by local investigators; in this regard, it was advised to carefully select study centres with adequate expertise in the management of oesophageal cancer (i.e. high-volume centres with experienced surgeons and multidisciplinary teams as recommended by guidelines) since this is known to impact on patient's clinical outcome. The Applicant did not comment on this aspect within the submitted application; however, information has been requested in view of the OS results as stratified by geographic region.

- Although the chosen comparator was deemed adequate, it was suggested to consider the addition of a third treatment arm to test pembrolizumab monotherapy based on study KN180 results. The MAH did not follow the advice; however, the completed KN181 trial testing pembrolizumab in monotherapy for the same indication after prior systemic therapy has provided evidence for lack of benefit on clinical outcomes of the immunotherapeutic agent alone.

- Among the proposed stratification factors, it was recommended to include PD-L1 status. The MAH did not follow the advice, however, clinical characteristics of patients as stratified by CPS cut-off le vels (≥10 and &lt;10) showed balanced treatment arms and good representation of the two subgroups (CPS ≥10 and &lt;10) within the overall population was achieved providing unbiased result analysis and data interpretation.

- PFS as primary endpoint was considered acceptable if supported by a positive trend in OS. However, the CHMP highlighted that the magnitude of the effect in the overall population and in both biomarker positive and negative subgroups will be taken into account. In addition, to assess the overall clinical relevance of the results, the effect will also be considered in relation to the tolerability of the combination.

- On the statistical aspects of the study design, the need for compelling statistical significance based on a single pivotal trial was highlighted in support of the pursued extension of indication, and if superiority in PFS could not be provided, the exclusion of detrimental effect of treatment on mortality either in the interim or final analysis was requested to be shown.

## 3.1.4. General comments on compliance with GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH. The assessment of KN590 data did not raise concern over GCP compliance leading to request for GCP inspection.

## 3.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

<div style=\"page-break-after: always\"></div>

## 3.2.1. Ecotoxicity/environmental risk assessment

Pembrolizumab is a protein, which is expected to be metabolised in the body and biodegrade in the environment. Thus, according to the 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00), pembrolizumab is exempt from conducting Environmental Risk Assessment studies as the product and excipients are not expected to pose a significant risk to the environment.

## 3.2.2. Discussion and conclusion on non-clinical aspects

The applicant did not submit studies for the ERA. According to the guideline, in the case of products containing proteins as active pharmaceutical ingredient, an ERA justifying the lack of ERA studies is considered acceptable.

## 3.3. Clinical aspects

## 3.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Table 2: Tabular overview of the main clinical study

Table of All Clinical Trials

| Study ID                               | Phase   | Country/ Region                                                                                                                                                                                                                    | Study Title                                                                                                                                                                                                                                                                                 | Study design                                             | Dosing regimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Study population                                                                  | Participant exposure                                   |
|----------------------------------------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|--------------------------------------------------------|
| 3475-590 [Ref. 5.3.5.1: P590V01MK3475] |         | Argentina, Australia. Brazil, Canada, Chile, China, Colombia, Costa Rica, Denmark, France, Gemany, Guatemala, Hongkong, Japan, Malaysia, Peru, Romania, Russia, South Affica, South Korea, Spain, Taiwan, Thailand, Turkey, UK USA | A RandomizedDouble-Blind Placebo-Controlled Phase II Clinical Tnial of Pembrolizumab (MK-3475) in Combination with Cisplatin and5-Fluorouacilversus PlaceboinCombinationwith Cisplatin and 5-Fluorouracil as First-LineTreatment in Subjects with Advanced/ Metastatic Esophageal Carcinoma | Randomizeddouble-blind parallel-group, active-controlled | Anm 1: pembrolizumab 200 mgIVQ3Wplus cisplatin 80 mg/m² IV Q3W plus 5FU 800 mg/m²/day continuous IV infusion on eachDay1toDay5Q3W (total of 4000 mg/m² per 3-week cycle) Arm 2:Placebo IVQ3W plus cisplatin80mg/m²IVQ3W plus 5FU 800mg/m²/day continuous IV infusion on eachDay1toDay5Q3W (total of 4000 mg/m² per 3- week cycle) Duration: Pembrolizumab/placebo: 35 administration or approximately 2years Cisplatin capped at 6 doses 5FU per local standard.But nottoexceedamaximum of 35 cycles. | Males/females Age: ≥18 participants with advanced/metastatic esophageal carcinoma | Pembrolizumab plus chemotherapy: 373 Chemotherapy: 376 |

The clinical development program of pembrolizumab in support of the pursued indication in oesophageal cancer is schematized below:

<div style=\"page-break-after: always\"></div>

Table 3: clinical development program:

| Study Number/ Status                                           | Design                                                              | Population                                                                                                                       | Dosage, Regimen                                                                                         | Primary Efficacy Endpoint(s)   |
|----------------------------------------------------------------|---------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|--------------------------------|
| KEYNOTE-028 Ongoing Enrollment complete for oesophageal cohort | Phase 1 Multicenter, non-randomized, single-arm, multicohort        | PD-L1 positive participants Cohort A4 of advanced/metastatic oesophageal cancer participants N=23                                | Pembrolizumab monotherapy (10 mg/kg Q2W)                                                                | ORR                            |
| KEYNOTE-180 Ongoing                                            | Phase 2 Multicenter, non-randomized, single-arm, multicohort        | Advanced/metastatic oesophageal cancer participants, 3L+ N=121                                                                   | Pembrolizumab monotherapy (200 mg Q3W)                                                                  | ORR                            |
| KEYNOTE-181 Ongoing                                            | Phase 3 Multicenter, randomized, open label                         | Advanced/metastatic oesophageal cancer, 2L N=628                                                                                 | Pembrolizumab monotherapy (200 mg Q3W) or investigator's choice of paclitaxel, docetaxel, or irinotecan | OS                             |
| KEYNOTE-590 Ongoing                                            | Phase 3 Multicenter, randomized, double- blind, placebo- controlled | Locally advanced unresectable or metastatic oesophageal cancer, 1L Target N=700                                                  | Pembrolizumab (200 mg Q3W) or placebo in combination with chemotherapy                                  | OS, PFS                        |
| KEYNOTE-975 Ongoing                                            | Phase 3 Multicenter, randomized, double- blind, placebo- controlled | cTX N + M0 or cT2-T4aNXM0 ESCC (as defined by AJCC 8th edition), Siewert Type I adenocarcinoma of the EGJ, or EAC Target N = 600 | Pembrolizumab (200 mg Q3W, 8 cycles) and then 400 mg Q6W (5 cycles) with dCRT or placebo with dCRT      | OS, EFS                        |

## 3.3.2. Pharmacokinetics

Pembrolizumab  PK  disposition  has  been  characterized  via  pooled  population  PK  analyses  using  serum concentration-time data contributed from subjects across various clinical studies using a time-dependent PK (TDPK) model. The PK reference dataset for monotherapy includes all available PK data from subjects enrolled in studies KEYNOTE-001, KEYNOTE-002, KEYNOTE-006, KEYNOTE-010, and KEYNOTE-024, with an  overall  sample  size  of  2993.  This  serves  as  the  PK  reference  analysis  to  support  descriptions  of pembrolizumab pharmacokinetics in the USPI and EU SmPC.

Within the current application, the MAH provided PK data from KEYNOTE-181 (a Phase III randomized openlabel study of single agent pembrolizumab vs. physicians' choice of single agent docetaxel, paclitaxel, or irinotecan  in  subjects  with  advanced/metastatic  adenocarcinoma  and  squamous  cell  carcinoma  of  the oesophagus  that  have  progressed  after  first-line  standard  therapy),  which  has  a  comparable  patient population as KEYNOTE-590.

The results of systemic exposures are shown by tumour histology types, squamous cell carcinoma and adenocarcinoma.

<div style=\"page-break-after: always\"></div>

## Absorption

Pembrolizumab is dosed via the intravenous route and therefore is immediately and completely bioavailable.

## Distribution

Consistent with a limited extravascular distribution, the volume of distribution of pembrolizumab at steady state is small (6.0 L; coefficient of variation [CV]: 20%). As expected for an antibody, pembrolizumab does not bind to plasma proteins in a specific manner.

## Elimination

Pembrolizumab CL is approximately 23% lower (geometric mean, 195 mL/day [CV%: 40%]) after achieving maximal change at steady state compared with the first dose (252 mL/day [CV%: 37%]); this decrease in CL with time is not considered clinically meaningful. The geometric mean value (CV%) for the terminal half-life is 22 days (32%) at steady-state.

## Pharmacokinetic in target population

A substantial characterization of the key clinical pharmacology and immunogenicity findings of pembrolizumab as monotherapy has been provided in previous submissions.

The updated clinical pharmacology results specific to this submission include:

- PK data from subjects with advanced/metastatic squamous cancer and adenocarcinomas of the oesophagus (ESO) (KEYNOTE-181)
- A comparison of KN181 observed PK data with reference model (TDPK) predicted PK.

## Pembrolizumab PK data from KEYNOTE-181 study

PK samples with a 15 October 2018 visit cut-off date were measured for 318 subjects in KN181 ESO.

Table 4: Overview of pembrolizumab included in KN181 PK analysis

| Study   | Cohort/Part   | Treatment   | Cancer Type   |   Number of subjects providing PK | Datacutoff   |
|---------|---------------|-------------|---------------|-----------------------------------|--------------|
| KN181   | ESO           | 200 mg Q3W  | ESO           |                               318 | 15-Oct-2018  |

unique subjects providing PK samples, not all subjects have Cycle 1 day 1 samples.

ESo:esophaguscancer

Data Source: 04VNRS: analysis-p181pkdm02

PK schedule in KN181 200 mg Q3W: Pre-dose pembrolizumab serum concentrations (Ctrough) were obtained within 24 hours prior to dosing at Cycles 1, 2, 4, 6 and 8 and every 4 cycles (12 weeks) thereafter.

Phoenix™ WinNonlin® (Version 6.3.0.395) software was used for pharmacokinetic analysis.

Summary statistics of the observed pembrolizumab trough (pre-dose) and post-dose concentrations in ESO subjects from KN0181 are presented in the tables below:

Table 5: Overall PK results:

<div style=\"page-break-after: always\"></div>

## Overall PK Results

Summary Statistics of PembrolizumabPredose (Ctrough) Serum Concentration Values Following Administration of Multiple 2o0 mg I.V. Doses with a 3 Week Dosing Interval in KN181 Subjects

Data Source: 04VNRS: analysis-p181pkdm02

|               |                    | Adenocarcinoma   | Adenocarcinoma   | Squamouscell carcinoma   | Squamouscell carcinoma   |
|---------------|--------------------|------------------|------------------|--------------------------|--------------------------|
| NOMTAFD (day) | Cycle (week)       | N                | GM(%CV) (μg/mL)  | N                        | GM(%CV) (μg/mL)          |
| 21            | Cycle 2 (Week 3)   | 95               | 12.9 (35.1)      | 179                      | 15.5 (42.3)              |
| 63            | Cycle 4 (Week 9)   | 44               | 25.9 (43.6)      | 114                      | 29.1 (51.6)              |
| 105           | Cycle 6 (Week 15)  | 25               | 26.8 (57.9)      | 81                       | 38.5 (39.2)              |
| 147           | Cycle 8 (Week 21)  | 16               | 32.4 (52.3)      | 60                       | 42.7 (45.3)              |
| 231           | Cycle 12 (Week 33) | 9                | 42.0 (27.2)      | 32                       | 49.0 (41.9)              |
| 315           | Cycle 16 (Week 45) | 6                | 40.5 (30.3)      | 20                       | 48.1 (50.8)              |
| 399           | Cycle 20 (Week 57) |                  |                  | 13                       | 46.4 (38.6)              |
| 483           | Cycle 24 (Week 69) | 3                | 38.6 (32.7)      | 10                       | 46.9 (42.6)              |
| 567           | Cycle 28 (Week 81) |                  |                  | 8                        | 48.4 (49.3)              |
| 651           | Cycle 32 (Week 93) |                  |                  | 3                        | 59.4 (39.7)              |

<!-- image -->

Data Source: 04VNRS: analysis-p181pkdm02

The following figures show the individual and mean pre-dose concentration-time profiles:

<div style=\"page-break-after: always\"></div>

Figure 1:

Individual and Arithmetic MeanPredoseSerum Concentrations of Pembrolizumab Following Administration of Multiple 2o0 mg I.V. Doses with a 3 Week Dosing Interval in KN181 Subjects (a) Linear scale, (b) Log scale

<!-- image -->

Note: Grey lines represent individual concentration observations. Black dashed lines represent arithmetic mean concentrations and error bars are associated +/- SE. Actual times from CDR data were used for this analysis.

Data Source: 053SLR: analysis-p181pkdm02

The observed and predicted pembrolizumab concentration-time profiles following 200 mg Q3W administration at predose cycle 2 and at steady state with a time since last dose of maximum 22 days are illustrated in the following figure, stratified by histology type:

Figure 2:

Observed Concentration Data in KN181 Subjects Receiving 200 mg Q3W PembrolizumabwithReference Model-Predicted Pharmacokinetic Profile for 200 mg Q3W Dose Regimen Stratified by Histology type

<!-- image -->

a)After 1st dose onlog scale; b) At and after cycle 8(21 weeks)on 1og scale.Blue symbols are individual observed data (Actual time)from subjects with adenocarcinoma (Adeno)inKN181;red symbols are individual observed data (Actual time)fromsubjectswithsquamouscellcarcinoma（Squamous);blacklineismedianpredictedconcentrationsfrom the model for a regimen of 200 mg Q3W and the grey shaded area represents the 90% prediction interval. RLTVTM = relative time; TALD = Time after last dose.

Data Source: 04VNRS: analysis-p181pkdm02

<div style=\"page-break-after: always\"></div>

A comparison with other globally approved studies in different cancer indications (KEYNOTE-024 in NSCLC, KEYNOTE-045 and KEYNOTE-052 in UC, KEYNOTE-055 in HNSCC, KEYNOTE-087 in cHL, KEYNOTE-158 and KEYNOTE-164 in MSI-H) has been also provided, as shown in the following table and graph.

Table 6: Summary statistics of Observed pembrolizumab trough concentrations:

Summary Statistics of Observed Pembrolizumab Trough

Concentrations at Cycle 2 and Cycle 8 (Steady-state) in Various

Monotherapy Trials (KE YNOTE-024, -045, -052,

-055, -087, -158, -164, and -181)

| Time point      | Study/Indication   |   N | GM(%CV) (ug/mL)   | AM(SD) (μg/mL)   |   Min (μg/mL) |   Median (ug/mL) |   (μg/mL) |
|-----------------|--------------------|-----|-------------------|------------------|---------------|------------------|-----------|
| Cycle 2 Predose | KN024 NSCLC        | 132 | 11.1 (54)         | 12.3 (5)         |         0.535 |             12.2 |      28.5 |
| Cycle 2 Predose | KN045 UC           | 233 | 13.1 (47)         | 14.2 (5)         |         0.475 |             13.9 |      29.3 |
| Cycle 2 Predose | KN052 UC           | 286 | 11.1 (42)         | 11.9 (4)         |         2.07  |             11.5 |      26.2 |
| Cycle 2 Predose | KN055HNSCC         |  40 | 10.7 (47)         | 11.8 (5)         |         3.45  |             11.6 |      33.1 |
| Cycle 2 Predose | KN087 HL           | 200 | 14.4 (40)         | 15.4 (5)         |         3.06  |             15.3 |      30   |
| Cycle 2 Predose | KN164 MSIH         |  56 | 12.5 (35)         | 13.2 (5)         |         5.44  |             12.4 |      25.6 |
| Cycle 2 Predose | KN181 ESO          | 274 | 14.5 (41)         | 15.6 (6)         |         2.98  |             15   |      39.1 |
| Cycle 8 Predose | KN024NSCLC         |  82 | 30.6 (50)         | 33.6 (13)        |         5.26  |             32.7 |      64.1 |
| Cycle 8 Predose | KN045 UC           | 104 | 33.4 (64)         | 37.8 (17)        |         1.13  |             37.5 |      95.6 |
| Cycle 8 Predose | KN052 UC           |  59 | 28.0 (38)         | 29.9 (10)        |         8.15  |             27.9 |      59.8 |
| Cycle 8 Predose | KN055HNSCC         |   7 | 27.8 (41)         | 29.6 (11)        |        16.8   |             24.5 |      43.3 |
| Cycle 8 Predose | KN087 HL           |  68 | 43.9 (43)         | 47.4 (17)        |        13.9   |             47.5 |      92.4 |
| Cycle 8 Predose | KN164MSIH          |  34 | 33.6 (43)         | 36.2 (14)        |         8.4   |             33.7 |      78.8 |
| Cycle 8 Predose | KN181 ESO          |  76 | 40.3 (48)         | 44.2 (18)        |        10.5   |             40.8 |      99.5 |

GM = Geometric Mean; %CV = Geometric Coefficient of Variation; AM = Arithmetic Mean; SD = Standard Deviation; NSCLC = non-small cell lung cancer; UC = urothelial cancer; HNSCC = head and neck squamous cell carcinoma; HL = Hodgkin lymphoma; MSIH = micro satellite instability high cancer, colorectal cancer; ESO = esophageal cancer.

Figure 3:

TroughPembrolizumabConcentrationsatCycle2andCycle8

(Steady-state) Pre-dose in Various Monotherapy Trials (KEYNOTE-

024,-045,-052,-055,-087,-158,-164 and -181)

<!-- image -->

Cycle2Predose

<!-- image -->

Cycle8Predose

<div style=\"page-break-after: always\"></div>

## 3.3.3. Pharmacodynamics

## Mechanism of action

Pembrolizumab is an antibody that binds to the programmed death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. KEYTRUDA potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment.

## Dose regimen selection

Pembrolizumab is approved at a 2 mg/kg or 200 mg Q3W dosing regimen for multiple indications as monotherapy and in combination with small molecule or chemotherapy worldwide (e.g., melanoma, NSCLC, HNSCC, HL, UC, gastric cancer, MSI-H cancer, HCC and RCC).

Pembrolizumab is also approved at 400 mg Q6W in the EU for monotherapy and combination therapies indications.

A dosing regimen of 200 mg Q3W or 400 mg Q6W is recommended for pembrolizumab in the treatment of adult subjects with oesophageal cancer in combination with chemotherapy.

## PK/PD modelling

No new information regarding PK/PD modelling for pembrolizumab is available within this extension of indication.

## Immunogenicity

No new ADA data are provided in this submission.

## 3.3.4. Discussion on clinical pharmacology

Clinical pharmacology results to support the extension of indication for Keytruda to include a new indication in oesophageal cancer are available from study KEYNOTE-181.

Based on the existing robust characterization of pembrolizumab PK, a comparison was conducted between the observed PK of pembrolizumab for the current indication in Oesophageal Cancer (ESO) and the predictions from the reference PK model developed with pembrolizumab monotherapy data (KEYNOTE-001, -002, -006, -010, and -024).

Based on the previous and current population PK analysis, the pembrolizumab PK profile is typical for a therapeutic mAb, with a low systemic clearance (0.25 L/day) and a low volume of distribution (6 L) at steady state, that is predicted to be achieved after approximately 16 weeks (for the intended dosing regimen of 200 mg Q3W). Elimination half-life (t1/2) is 22 days.

Predose pembrolizumab serum concentrations (Ctrough) were obtained within 24 hours prior to dosing at Cycles 1, 2, 4, 6 and 8 and every 4 cycles (12 weeks) thereafter.

The observed concentrations in patients with advanced/metastatic squamous cell cancer and adenocarcinoma of the oesophagus treated with Pembrolizumab 200 mg Q3W generally fall within the range of predicted concentrations, both after first dose and at steady state.

The observed pembrolizumab serum concentration values at cycle 2 and cycle 8 are consistent with other globally approved studies in different cancer indications.

<div style=\"page-break-after: always\"></div>

The MAH did not provide any further PK data for the 1L oesophageal study KN590 (in combo with chemotherapy) but only PK data of the 2L supportive study KN181 (in mono). The existing immunogenicity assessment for pembrolizumab for the monotherapy setting is based on a sufficiently large dataset of patients across several indications, with very low observed rates of total treatment ADA across different pembrolizumab regimens (1.4 - 3.8%) as well as of neutralizing antibodies (0.4 - 1.6%). This analysis has not demonstrated impact on efficacy or safety, as currently summarized in the USPI and in the EU SmPC. This low rate of immunogenicity has been shown to be consistent across tumour type and no clinically meaningful consequences have been observed in the subjects with a positive immunogenicity reading. Based on the existing robust characterization of immunogenicity potential, alignment has been obtained with the US FDA and EMA that the current assessment of immunogenicity for pembrolizumab is adequate for non-adjuvant monotherapy settings.

Following the above outlined agreements, the MAH provided PK data from KEYNOTE-181 to demonstrate that pembrolizumab PK/exposures in oesophageal carcinoma are consistent with the PK from other indications that are approved in the EU.

## 3.3.5. Conclusions on clinical pharmacology

The observed concentration from study KN-181 falls within the 90% CI of the model predicted median concentration, independently of tumour histology (adenocarcinoma or squamous cell carcinoma).

## 3.4. Clinical efficacy

The efficacy data in this submission are based on a single study (KEYNOTE-590).

KEYNOTE-590 is an ongoing, Phase 3, randomized, double-blind, placebo-controlled, multisite study to evaluate the efficacy and safety of pembrolizumab in combination with chemotherapy (cisplatin and 5-FU) versus chemotherapy (cisplatin with 5-FU) as 1L treatment in participants with locally advanced unresectable metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction.

This submission is based on results from the IA for KEYNOTE-590 with a data cut-off date of 2 July 2020, which was after a minimum of 13 months of follow-up.

## 3.4.1. Dose response study(ies)

No dose-response studies were submitted as part of this application.

## 3.4.2. Main study(ies)

## Title of Study

A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Advanced/Metastatic Oesophageal Carcinoma (KEYNOTE-590)

<div style=\"page-break-after: always\"></div>

## Study Design for KEYNOTE-590

<!-- image -->

- *Stratification by:1) GeographicRegion;2)Histology;3)ECOG Performance Score
- **Durationof cisplatin treatmentwillbecapped at6doses,howevertreatmentwith5-FU maycontinueperlocal standard

## Methods

## Study participants

## Key inclusion criteria

1. Was ≥ 18 years of age on the day of signing informed consent.
2. Had histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the EGJ.
3. Had measurable disease per RECIST 1.1 as determined by the local site investigator/radiology assessment.
4. Had an ECOG PS of 0 to 1.
5. Provided either a newly obtained or archival tissue sample for PD-L1 by IHC analysis.

## Key exclusion criteria

1. Had locally advanced oesophageal carcinoma that was resectable or potentially curable with radiation therapy (as determined by local investigator). Subjects with Siewert type 1 adenocarcinoma of the EGJ with known HER-2/neu-positive tumours are not eligible.

<div style=\"page-break-after: always\"></div>

2. Had previous therapy for advanced/metastatic adenocarcinoma or squamous cell cancer of the oesophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the EGJ.
3. Had a known additional malignancy that was progressing or required active treatment.
4. Had known active central nervous system metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may have participated provided they met specific criteria.
5. Had an active autoimmune disease that had required systemic treatment in past 2 years.
6. Had a diagnosis of immunodeficiency or was receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment, or had a history of organ transplant, including allogeneic stem cell transplant.
7. Had a history of (non-infectious) pneumonitis that required steroids or had current pneumonitis.
8. Had an active infection requiring systemic therapy.
9. Had received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor or had previously participated in a pembrolizumab (MK3475) clinical trial.

## Treatments

Patients were randomised (1:1) to one of the following treatment arms:

- Pembrolizumab 200 mg on Day 1 of each three-week cycle in combination with cisplatin 80 mg/m 2  IV on Day 1 of each three-week cycle for up to six cycles and 5-FU 800 mg/m 2 IV per day on Day 1 to Day 5 of each three-week cycle, or per local standard for 5-FU administration.
- Placebo on Day 1 of each three-week cycle in combination with cisplatin 80 mg/m 2  IV on Day 1 of each three-week cycle for up to six cycles and 5-FU 800 mg/m 2  IV per day on Day 1 to Day 5 of each three-week cycle, or per local standard for 5-FU administration.

Treatment with pembrolizumab or chemotherapy continued until unacceptable toxicity or disease progression or a maximum of 24 months. Patients randomised to pembrolizumab were permitted to continue beyond the first RECIST v1.1-defined disease progression if clinically stable until the first radiographic evidence of disease progression was confirmed at least 4 weeks later with repeat imaging. Assessment of tumour status was performed every 9 weeks.

## Objectives/Endpoints

## Primary Objectives/Endpoints

- To compare OS between treatment arms in participants with ESCC whose tumours are PD-L1 biomarker-positive (CPS &gt;=10).
- To compare OS between treatment arms in participants with ESCC.
- To compare OS between treatment arms in participants whose tumours are PD-L1 biomarker-positive (CPS &gt;=10).
- To compare OS between treatment arms in all participants.
- To compare PFS per RECIST 1.1, as determined by investigator, in participants with ESCC.

<div style=\"page-break-after: always\"></div>

- To compare PFS per RECIST 1.1, as determined by investigator, between treatment arms in participants whose tumours are PD-L1 biomarker-positive (CPS &gt;=10).

-To compare PFS per RECIST 1.1, as determined by investigator, between treatment arms in all participants.

The study was considered to have met its primary objective if at least one hypothesis about superiority of pembrolizumab in combination with chemotherapy compared with placebo plus chemotherapy is significant.

## Secondary Objectives/Endpoints

## Key secondary objectives/Endpoints

- To evaluate ORR per RECIST 1.1, as determined by investigator, between treatment arms in all participants.

## Other secondary objectives/Endpoints

- To evaluate ORR per RECIST 1.1 as determined by investigator, between treatment arms in participants with ESCC whose tumours are PD-L1 biomarker-positive (CPS &gt;=10), in participants with ESCC, and in participants whose tumours are PD-L1 biomarker-positive (CPS &gt;=10).
- To evaluate DOR per RECIST 1.1 as determined by investigator between treatment arms in participants with ESCC whose tumours are PD-L1 biomarker-positive (CPS &gt;=10), in participants whose tumours are PD-L1 biomarker-positive (CPS &gt;=10), in participants with ESCC, and in all participants.

- To evaluate the safety and tolerability profile.

- To evaluate changes from baseline in HRQoL using the EORTC QLQ-C30 and EORTC QLQ-OES18 in all participants, in participants with ESCC whose tumours are PD-L1 biomarker-positive (CPS &gt;=10), in participants with ESCC, and in participants whose tumours are PD-L1 biomarker-positive (CPS &gt;=10), treated with pembrolizumab plus chemotherapy compared with placebo plus chemotherapy.

## Exploratory Objectives/Endpoints

- To characterize PRO utilities using EQ-5D-5L questionnaire in all participants, in participants with ESCC whose tumours are PD-L1 biomarker-positive (CPS &gt;=10), in ESCC participants, and in participants whose tumours are PD-L1 biomarker-positive (CPS &gt;=10) treated with pembrolizumab plus chemotherapy compared with placebo plus chemotherapy.
- To evaluate PFS per irRECIST as determined by investigator between treatment arms in all participants and in participants whose tumours are PD-L1 biomarker-positive (CPS &gt;=10), ESCC participants, and in ESCC participants whose tumours are PD-L1 biomarker-positive (CPS &gt;=10).
- To identify molecular (genomic, metabolic, and/or proteomic) biomarkers that may be indicative of clinical response/resistance, safety, pharmacodynamic activity, and/or the mechanism of action of pembrolizumab and other treatments. This could include the evaluation of MSI, WES, and/or GEP in available tumour tissue. Note: this is not applicable to China.

## Sample size

The sample size and power calculations for PFS and OS assumed the following:

- PFS follows an exponential distribution with a median of 6 months for the control group.

<div style=\"page-break-after: always\"></div>

- OS follows an exponential distribution with a median of 12 months for the control group.
- Enrollment period of 22 months
- An annual dropout rate of 5% for both PFS and OS

The sample size and power calculations were performed using R ('gsDesign' package).

The study was event-driven and originally planned to randomize approximately 700 subjects with 1:1 ratio into the two treatment groups: Pembrolizumab + Chemo and Placebo + Chemo.

One interim efficacy analysis was planned in this study, which is the main analysis for PFS, and an interim analysis for OS. A Lan-DeMets O'Brien-Fleming alpha-spending function was constructed to implement group sequential efficacy boundaries to control the Type I error for each OS hypothesis.

In the following the sample size calculation for the two primary hypotheses are listed:

1. With  460  PFS  events,  there  was  62.2%  power  to  detect  a  hazard  ratio  of  0.77 (pembrolizumab vs. Placebo) at alpha = 0.002% (one-sided) in subjects with PD-L1 CPS &gt;= 10, assuming PFS follows an exponential distribution with a median of 6 months in the control arm. In the scenario that the PFS hypothesis is rejected in ESCC, the PFS test has 62.2% power to detect an HR of 0.7 at an α level of 0.002 in subjects with PDL1 CPS ≥ 10. In the scenario that both of PFS hypotheses in ESCC and in PDL1 CPS ≥10 are rejected, the PFS test has 76.8% power to detect an HR of 0.75 at an α level of 0.002 in all subjects. In the scenario that the PFS null hypotheses in all populations and all OS null hypotheses are rejected, the PFS test has 95.1% power to detect an HR of 0.75 at an α level of 0.025 in all subjects.
2. With 233 OS events and one interim analysis at approx. 86% of the target number of events,  there  was  84.5%  power  to  detect  a  hazard  ratio  of  0.65  (pembrolizumab  vs. Placebo) at alpha = 0.012% (one-sided) in ESCC subjects with PD-L1 CPS &gt;= 10, assuming OS follows an exponential distribution with a median of 12 months in the control arm. Based on a target number of 455 events, the study has approximately 88.3% power at FA to detect an HR of 0.72 at an overall α level of 0.011 (1-sided) in ESCC subjects.

In the scenario that the OS hypothesis is rejected in ESCC with PD-L1 CPS ≥ 10 but is not rejected in ESCC, the OS test has approximatel y 89.9% power at FA to detect an HR of 0.65 at an overall α level of 0.006 (1-sided) in PD-L1 CPS ≥ 10. In the scenario that the OS hypothesis is rejected in ESCC but is not rejected in ESCC with PD-L1 CPS ≥ 10, the OS test has approximately 93.2% power at FA to detect an HR of 0.65 at an overall α level of 0.011 (1 -sided) in PD-L1 CPS ≥ 10. In the scenario that the OS hypotheses in ESCC with PD-L1 CPS ≥ 10 and in ESCC are both rejected, the OS test has approximately 96.2% power at FA to detect an HR of 0.65 at an overall α level of 0.023 (1 -sided) in PD-L1 CPS ≥ 10. In the scenario that OS hypotheses in ESCC with PD-L1 CPS ≥ 10, in ESCC, and in PD-L1 CPS ≥ 10 are all rejected, the OS test has approximately 94.2% power at FA to detect an HR of 0.75 at an overall α level of 0.023 (1-sided) in all subjects. In the scenario that OS hypotheses in all populations and all PFS null hypotheses are rejected, the OS test has approximately 94.6% power at FA to detect an HR of 0.75 at an overall α level of 0.025 (1-sided) in all subjects.

For both primary endpoints the enrolment period was assumed to be 22 months, the annual dropout rate was 5%, and the prevalence of ESCC with PDL1 CPS ≥10 is 38%, PD -L1 CPS ≥10 is 51% (all subjects), and ESCC is 73%.

Based on 749 subjects with at least 10 months of follow-up, the power of the ORR testing at the allocated α =0.025 is approximately 98.7% to detect a 15-percentage point difference between an underlying 35% response rate in the control arm and a 50% response rate in the experimental arm.

<div style=\"page-break-after: always\"></div>

## Randomisation

Treatment randomization occurred centrally using an interactive voice response system / integrated web response system (IVRS/IWRS). There are 2 treatment arms. Subjects were assigned randomly in a 1:1 ratio to pembrolizumab + cisplatin + 5-FU (Arm 1) or placebo + cisplatin + 5-FU (Arm 2).

Treatment randomization was stratified according to the following factors:

1. Geographic region (Asia versus Rest of World)
2. Histology (adenocarcinoma versus squamous cell carcinoma)
3. ECOG performance status (0 versus 1)

After  global  cohort  was  recruited,  further  subjects  from  China  were  planned  to  be  enrolled  up  to  106 subjects. This China Extension study was randomized in a 1:1 allocation with the same stratification factors as the global cohort. The randomization was implemented in IVRS.

## Blinding (masking)

A double-blinding technique was used. Pembrolizumab or placebo treatment was blinded to the subject, study site personnel, and Sponsor personnel.

## Statistical methods

## Interim analysis

One interim analysis was planned in addition to the final analysis for this study. For the interim and final analyses, all randomized subjects were included. Results of the interim analysis were reviewed by the DMC.

Table 7: Summary of Interim and Final analyses strategy:

<div style=\"page-break-after: always\"></div>

Table 15Summary of Interim and Final Analyses Strategy

| Analyses                                                                                                           | Key Endpoints                                                                                                                           | Timing                                                                                                                                                                                                                                                                                                                             | Estimated Time after First Subject Randomized                                                                      | Primary Purpose of Analysis                                                                                        |
|--------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| IA                                                                                                                 | PFS in ESCC; PFS in PD-L1 CPS≥10; PFS in All subjects; OS in ESCC with PD-L1 CPS≥10; OS in ESCC; OS in PD-L1 CPS≥10; OS in All subjects | (1) Enrollment is complete with a minimum follow-up of 13 months and (2)～ 460 investigator- assessed PFS events have been observed in ESCC and (3)~391 deaths have occurred in ESCC At this time ~200 deaths are expected to have occurred in ESCC withPD-L1 CPS≥10 and ~ 267 deaths are expected to have occurred in PD-L1 CPS≥10 | ~35 months                                                                                                         | ·Final PFS analysis ·Interim OS analysis                                                                           |
| FA                                                                                                                 | OSin ESCC with PD-L1 CPS≥10; OS in PD-L1 CPS≥10; OS in ESCC; OS in All subjects                                                         | (1) A minimum follow- up of 9 months after IA and (2)~233 deaths have occurred in ESCC with PD-L1 CPS≥10 and (3)~ 455 deaths have occurred in ESCC. At this time ~311 deaths are expected to have occurred in PD- L1 CPS≥10                                                                                                        | ~44 months                                                                                                         | · Final OS analysis                                                                                                |
| Abbreviations: FA = final analysis; IA = interim analysis; OS = overall survival; PFS = progression-free survival. | Abbreviations: FA = final analysis; IA = interim analysis; OS = overall survival; PFS = progression-free survival.                      | Abbreviations: FA = final analysis; IA = interim analysis; OS = overall survival; PFS = progression-free survival.                                                                                                                                                                                                                 | Abbreviations: FA = final analysis; IA = interim analysis; OS = overall survival; PFS = progression-free survival. | Abbreviations: FA = final analysis; IA = interim analysis; OS = overall survival; PFS = progression-free survival. |

Table 8: Censoring rules for primary and sensitivity analyses of PFS:

<div style=\"page-break-after: always\"></div>

Table 11 Censoring Rules for Primary and Sensitivity Analyses of Progression-free Survival

| Situation                                                                                                                                                | Primary Analysis                                                                                                                             | Sensitivity Analysis 1                       | Sensitivity Analysis 2                                                                                                                                                                       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PD or death documented after ≤l missed disease assessment, and before new anti-cancer therapy, if any                                                    | Progressed at date of documented PD or death                                                                                                 | Progressed at date of documented PD or death | Progressed at date of documented PD or death                                                                                                                                                 |
| Death or progression after ≥2 consecutive missed disease assessments without further valid non- PD disease assessments, or after new anti-cancer therapy | Censored at last disease assessment prior to the earlier date of≥2 consecutive missed disease assessment and new anti-cancer therapy, if any | Progressed at date of documented PDor death  | Progressed at date of documentedPDor death                                                                                                                                                   |
| No PD and no death; and new anticancer treatment is not initiated                                                                                        | Censored at last disease assessment                                                                                                          | Censored atlast disease assessment           | Progressed at treatment discontinuation due to reasons other than complete response; otherwise censored at last disease assessment if still on study treatment or completed study treatment. |
| NoPD and no death;new anticancer treatment iS initiated                                                                                                  | Censored at last disease assessment before new anticancer treatment                                                                          | Censored at last disease assessment          | Progressed at date of new anticancer treatment                                                                                                                                               |
| Abbreviations: PD = progressive disease                                                                                                                  | Abbreviations: PD = progressive disease                                                                                                      | Abbreviations: PD = progressive disease      | Abbreviations: PD = progressive disease                                                                                                                                                      |

## Multiplicity

The study uses the graphical method of Maurer and Bretz to provide strong multiplicity control for multiple hypotheses as well as interim analyses. According to this approach, study hypotheses may be tested more than once, and when a particular null hypothesis is rejected, the alpha allocated to that hypothesis can be reallocated to other hypothesis tests. Figure below shows the initial 1-sided α allocation for each hypothesis in the ellipse representing the hypothesis.

The weights for re-allocation from each hypothesis to the others are shown in the boxes on the lines connecting hypotheses. The boundaries provided in this section are calculated based on the estimated number of events at each analysis, and the actual boundaries will be determined from the actual number of events observed at the time of the analyses, using the spending functions specified.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviations: ORR = objective response rate; OS = overall survival; PFS = progression-free survival.

## Figure 4: Multiplicity Diagram for type I Error control

The study will test PFS twice, at IA1 and at IA2. The initial alpha assigned to PFS in ESCC will be 0.002. If PFS hypothesis in ESCC subjects is rejected, the alpha will be reallocated to PFS in subjects with PD-L1 CPS ≥ 10. If PFS hypothesis in subjects with PD-L1 CPS ≥ 10 is also rejected, the alpha will be reallocated to PFS in all subjects. If all the OS null hypotheses are rejected, 0.99 of the initially allocated alpha i.e. 0.023 to OS hypotheses will be reallocated to test the PFS hypothesis in all subjects. Thus, if the PFS null hypotheses in the ESCC and the PDL1 CPS ≥ 10 populations are rejected and the OS hypothesis in all subjects is not rejected the PFS null hypothesis in all subjects may be tested at α =0.002. If the PFS null hypotheses in the ESCC and the PDL1 CPS ≥ 10 populations are rejected and all the OS hypotheses are rejected, the PFS null hypothesis in all subjects may be tested at α =0.025.

The following table shows the boundary properties for PFS in IA1 and IA2 for each of these α levels, as assuming the estimated numbers of events are analyzed. IA2 will be the final analysis for PFS. The PFS efficacy boundaries will be set using the Lan-DeMets spending function that approximates an O'BrienFleming boundary.

Note that the final row indicates the total power to reject the null hypothesis for PFS at each a level. Also, note that if the OS null hypothesis in all subjects is rejected at the final analysis, PFS in all subjects may be tested again with its updated bounds, considering the alpha reallocation from the OS hypothesis.

Table 8: Efficacy Boundaries and Properties for Progression Free Survival Analyses

<div style=\"page-break-after: always\"></div>

| Analysis for ESCC                              | Value                | α=0.002   |         |
|------------------------------------------------|----------------------|-----------|---------|
| IA (Final):100%* N=547 Events: 460 Month: 35   | Z                    | 2.878     |         |
| IA (Final):100%* N=547 Events: 460 Month: 35   | p (l-sided) a        | 0.002     |         |
| IA (Final):100%* N=547 Events: 460 Month: 35   | HR at boundb         | 0.765     |         |
| IA (Final):100%* N=547 Events: 460 Month: 35   | P(Cross) if HR=1c    | 0.002     |         |
| IA (Final):100%* N=547 Events: 460 Month: 35   | P(Cross) if HR=0.7d  | 0.828     |         |
| Analysis for PD-L1 CPS ≥10                     | Value                | α=0.002   |         |
| IA (Final):100%* N=381 Events: 320 Month: 35   | Z                    | 2.878     |         |
| IA (Final):100%* N=381 Events: 320 Month: 35   | p (1-sided) a        | 0.002     |         |
| IA (Final):100%* N=381 Events: 320 Month: 35   | HR at boundb         | 0.725     |         |
| IA (Final):100%* N=381 Events: 320 Month: 35   | P(Cross) if HR=1c    | 0.002     |         |
| IA (Final):100%* N=381 Events: 320 Month: 35   | P(Cross) if HR=0.7d  | 0.622     |         |
| Analysis for All Subjects                      | Value                | α=0.002   | α=0.025 |
| IA (Final):100%* N = 749 Events: 630 Month: 35 | Z                    | 2.878     | 1.960   |
| IA (Final):100%* N = 749 Events: 630 Month: 35 | p (l-sided) a        | 0.002     | 0.025   |
| IA (Final):100%* N = 749 Events: 630 Month: 35 | HR at boundb         | 0.795     | 0.855   |
| IA (Final):100%* N = 749 Events: 630 Month: 35 | P(Cross) if HR=1c    | 0.002     | 0.025   |
| IA (Final):100%* N = 749 Events: 630 Month: 35 | P(Cross) if HR=0.75d | 0.768     | 0.951   |

Abbreviations: HR = hazard ratio; IA = interim OS analysis; PD-L1 = programmed cell death-ligand 1.

The number of events and timings are estimated approximately.

*Percentage of the target number of events at final analysis anticipated at interim analysis

p (1-sided) is the nominal α for testing.

bHR at bound is the approximate HR required to reach an efficacy bound.

cP (Cross if HR=1) is the probability of crossing a bound under the null hypothesis.

dP(Cross if HR=O.xx)is the probability of crossing a bound under the alternative hypothesis

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Abbreviations:5-FU: 5-fluorouracil

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 9: Disposition of Subjects (ITT Population)

|                                                      | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC   | SOC    | Total   | Total   |
|------------------------------------------------------|-----------------------|-----------------------|-------|--------|---------|---------|
|                                                      | n                     | (%)                   | n     | (%)    | n       | (%)     |
| Subjects in population                               | 373                   |                       | 376   |        | 749     |         |
| StatusforTrial                                       |                       |                       |       |        |         |         |
| Discontinued                                         | 265                   | (71.0)                | 311   | (82.7) | 576     | (76.9)  |
| Death                                                | 260                   | (69.7)                | 308   | (81.9) | 568     | (75.8)  |
| Associated With Covid-19                             | 1                     | (0.3)                 | 0     | (0.0)  | 1       | (0.1)   |
| Withdrawal By Subject                                | 5                     | (1.3)                 | 3     | (0.8)  | 8       | (1.1)   |
| Not Associated With Covid-19, No Further Information | 3                     | (0.8)                 | 2     | (0.5)  | 5       | (0.7)   |
| Not Associated With Covid-19, Subsequently Died      | 2                     | (0.5)                 |       | (0.3)  | 3       | (0.4)   |
| On-Going                                             | 108                   | (29.0)                | 65    | (17.3) | 173     | (23.1)  |
| StatusforStudy Medication                            |                       |                       |       |        |         |         |
| Started                                              | 370                   |                       | 370   |        | 740     |         |
| Completed                                            | 15                    | (4.1)                 | 1     | (0.3)  | 16      | (2.2)   |
| Discontinued                                         | 328                   | (88.6)                | 359   | (97.0) | 687     | (92.8)  |
| Adverse Event                                        | 49                    | (13.2)                | 44    | (11.9) | 93      | (12.6)  |
| Clinical Progression                                 | 36                    | (9.7)                 | 41    | (11.1) | 77      | (10.4)  |
| Complete Response                                    | 0                     | (0.0)                 | 1     | (0.3)  | 1       | (0.1)   |
| Physician Decision                                   | 9                     | (2.4)                 | 10    | (2.7)  | 19      | (2.6)   |
| Progressive Disease                                  | 204                   | (55.1)                | 239   | (64.6) | 443     | (59.9)  |
| Protocol Violation                                   | 0                     | (0.0)                 | 1     | (0.3)  | 1       | (0.1)   |
| Withdrawal By Subject                                | 30                    | (8.1)                 | 23    | (6.2)  | 53      | (7.2)   |
| On-Going                                             | 27                    | (7.3)                 | 10    | (2.7)  | 37      | (5.0)   |

If the overall count of subjects is calculated and displayed within a section in the first row, then it is used as the denominator for the percentage calculation. Otherwise, subjects in population is used as the denominator for the percentage calculation.

DatabaseCutoffDate:02JUL2020

Source:[P590V01MK3475:adam-adsl]

271 of the 1020 screened patients (27%) were not randomized because eligibility criteria were not met. Most common reason was that diagnosis was not confirmed (n=51); however, also a relevant number of participants were screen failures because they did not have an ECOG PS of 0 or 1 (n=47) or adequate organ functions (n=42) or had a condition that might confound study evaluations (n=34). Ten (10) patients were not enrolled due to a known history or being positive hepatitis B or C.

A total of 9 of 749 randomized patients did not receive any study medication (n=3 in the pembrolizumab plus chemotherapy arm and n=6 in the chemotherapy arm).

## Subsequent therapy

A similar proportion of patients, 43.5% and 47.8% of participants in the pembrolizumab plus chemotherapy and chemotherapy groups, respectively received new oncological medication, mostly chemotherapeutics. A low proportion of 32 patients received subsequent therapy with a checkpoint inhibitor in the chemotherapy arm (8.5%); however, also 21 patients received immunotherapy after pembrolizumab plus chemotherapy treatment (5.6%).

## Recruitment

A total of 1020 participants were screened and 749 were randomized (pembrolizumab plus chemotherapy: 373; chemotherapy: 376) across 168 global study centres in 26 countries.

## Conduct of the study

Changes to the original study protocols and their respective rationale are detailed below:

<div style=\"page-break-after: always\"></div>

Table 10-Protocol amendments:

| Document                        | Date of Issue   | Overall Rationale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 09/ Global            | 17-JUN-2020     | Due to higher than expected discordance rate in assessment of progressive disease between BICR (blinded independent central review）and investigator and following input from the US regulatory agency on the statistical analyses plan, the protocol is amended as follows: (i) change in primary endpoint from PFS by BICR to investigator-assessed and (i) elimination of one of the two planned efficacy interim analyses.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Amendment 08/ Global            | 03-JAN-2020     | 1. Based on results from the KN181 study, 3 primary objectives and corresponding hypotheses were added: OS in esophageal squamous cell carcinoma (ESCC) population; OS in ESCC whose tumors are PD-L1 biomarker-positive (CPS ≥10) population; and PFS in ESCC population. Secondary objectives updated accordingly with respect to ORR and DOR endpoints in the ESCC and ESCC PD-L1 CPS ≥10 populations. Exploratory objectives were updated for PFS per irRECIST in the ESCC and ESCC PD-L1 CPS ≥10 populations.  Due to the short interval (~5 months) between the last subject enrolled in the Global Cohort (n=711) and in the China Extension Study(n=38),these 2 subject groups are merged into 1 “Global Study\" for the primary analyses (N=749). 4. To include assessment of DOR, QoL (C30) and QoL (OES18) in all pre- specified populations. The statistical analyses plan is updated accordingly |
| Amendment07/Global              | Not activated   | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Amendment 06 / France- specific | 28-JAN-2019     | Apply changes from Global Amendment 05 to France-specific Amendment 03.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Amendment05/Global              | 12-DEC-2018     | To extend the enrollment period beyond the Global Cohort to achieve the required sample size of the China Cohort to investigate efficacy and safety in Chinese subjects.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Amendment 04 / China- specific  | 21-SEP-2018     | Remove all sampling, analysis and objectives for exploratory biomarkers for subjects from China as these were not approved by HGRAC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Amendment 03 / France- specific | 02-FEB-2018     | Apply changes from Global Amendment 02 to France-specific Amendment 01.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Amendment 02 / Global           | 19-DEC-2017     | Change primary biomarker from GEP to PD-L1; clarify 5-FU dosing: update statistical analysis plan; reduce PK/ADA sampling                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Amendment 01/France- specific   | 20-OCT-2017     | To address French HA requests for monthly pregnancy tests and mandatory audiograms for cisplatin use                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Original Protocol               | 14-MAR-2017     | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

## COVID-19-related Changes to the Conduct of the Study

There were no changes in the planned conduct of the study due to the COVID-19 pandemic. The Sponsor continued to follow its standard operating procedures (SOPs) for study conduct, monitoring, and oversight during the COVID-19 pandemic. A risk-based approach, consistent with recent Health Authority guidance on conducting clinical studies during the pandemic, was used to assess and mitigate the impact of the pandemic on study conduct in order to (1) assure the safety of study participants, study staff and health care providers, (2) maintain compliance with GCP principles, and (3) minimize risks to study data integrity. Contingency  measures  were  implemented  as  per  the  Sponsor's  SOP  for  exception  and  deviation management and as appropriate for the country, region and individual study site. Exceptions and deviations from SOPs were documented.

Clinical investigator study sites were advised to follow local and national guidance regarding the pandemic and to share any mitigation plans for study participant management with the IRB/EC and the Sponsor. Study sites were also advised to remain in contact with study participants to monitor for safety concerns, help ensure participants adhered to their study intervention schedule, and to keep participants informed of changes to the study and other study activities.

<div style=\"page-break-after: always\"></div>

Measures implemented by the Sponsor to manage key aspects of study conduct during the pandemic are summarized below (implementation date shown in parentheses). Not all measures were implemented at all study sites due to differences in local conditions and impact of the pandemic.

Table 11: study conduct measures during COVID-19 pandemic

| Process                                          | Measure (DateImplemented)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study site monitoring                            | ● Modifications to the frequency of onsite and remote monitoring were allowed due to national and local travel restrictions and/or study site restrictions to onsite monitoring (21-MAR-2020). ·Redacted/alternate methods for source data review and verification for critical data points in absence of remote access to electronic medical records were allowed under documented circumstances (06-MAR-2020). · Source data review and/or verification prior to database lock was /were waived for various countries and sites for this study (13-MAR-2020). |
| Protocol Deviations                              | · Study sites were queried as to the relationship of reported deviations to the COVID-19 pandemic; responses were documented (20-MAR-2020).                                                                                                                                                                                                                                                                                                                                                                                                                     |
| AE reporting                                     | · COVID-19 infection was to be reported following the protocol's AE and SAE reporting instructions [Sec. 12].                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Clinical supplies (including study intervention) | · An alternate location (eg, primary care center, pharmacy) for injectable and/or infusion administration of study intervention / other clinical supplies was allowed when participant travel was impacted, and administration could not be postponed (21-APR-2020).                                                                                                                                                                                                                                                                                            |
| Data management                                  | ·Alternative procedures were allowed for study sites using shared electronic devices to complete clinical outcome assessments (08-APR-2020). · Study sites were queried, and responses documented about the relationship of the following to the COVID-19 pandemic (08-APR-2020): OMissing participant study visits and data. 0  Participants who discontinued study intervention and/or the study.                                                                                                                                                             |
| Clinical laboratory and other facilities         | ●Alternate clinical laboratory facilities were allowed for collection of samples for study participants unable to visit the study site (16-APR-2020). · Alternate imaging facilities and delayed schedules for study-site and alternate facility imaging were allowed for protocol-required imaging (each to be reported as a protocol deviation) (24-MAR-2020).                                                                                                                                                                                                |
| Informed consent                                 | · Oral confirmation of participant consent (eg, via telephone) was allowed when in-person discussion and signature was not possible (30-MAR-2020).                                                                                                                                                                                                                                                                                                                                                                                                              |

Missing participant study visits and/or data were queried as per the Sponsor's standard processes. As per the  Sponsor's  standard  process,  missing  procedures  and  study  visits  were  to  be  reported  as  protocol deviations for that participant. Procedures and study visits conducted outside protocol-defined windows were also to be reported as protocol deviations. Participants with protocol deviations due to the pandemic are described below.

## Protocol deviations

Important protocol deviations ('those that may significantly impact the quality or integrity of key trial data or  that  may  significantly  affect  a  participant's  rights,  safety,  or  well-being')  were  reported  for  60 participants in this study (6%). None of the important protocol deviations were considered to be clinically important ('deviations that may compromise critical data analyses pertaining to primary efficacy and/or safety endpoints or the participant's safety').

<div style=\"page-break-after: always\"></div>

Table 12: Summary of Important Protocol Deviations

|                                                                                                                                                       | Pembrolizumab + SOC                                                                                       | Pembrolizumab + SOC                                                                                       | SOC                                                                                                       | SOC                                                                                                       | Total                                                                                                     | Total                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
|                                                                                                                                                       |                                                                                                           | (%)                                                                                                       | n                                                                                                         | (%)                                                                                                       | 1                                                                                                         | (%)                                                                                                       |
| Subjects in population                                                                                                                                | 373                                                                                                       |                                                                                                           | 376                                                                                                       |                                                                                                           | 749                                                                                                       |                                                                                                           |
| With one or more important protocol deviations                                                                                                        | 29                                                                                                        | (7.8)                                                                                                     | 31                                                                                                        | (8.2)                                                                                                     | 60                                                                                                        | (8.0)                                                                                                     |
| With no important protocol deviations                                                                                                                 | 344                                                                                                       | (92.2)                                                                                                    | 345                                                                                                       | (91.8)                                                                                                    | 689                                                                                                       | (92.0)                                                                                                    |
| Prohibited Medications                                                                                                                                | 1                                                                                                         | (0.3)                                                                                                     | 0                                                                                                         | (0.0)                                                                                                     | 1                                                                                                         | (0.1)                                                                                                     |
| Participant received radiation therapy for tumor control (with curative intent) while on treatment.                                                   | 1                                                                                                         | (0.3)                                                                                                     | 0                                                                                                         | (0.0)                                                                                                     | 1                                                                                                         | (0.1)                                                                                                     |
| Safety Reporting                                                                                                                                      | 25                                                                                                        | (6.7)                                                                                                     | 28                                                                                                        | (7.4)                                                                                                     | 53                                                                                                        | (7.1)                                                                                                     |
| Participant had a reportable Safety Event and/or follow up Safety Event information that was not reported per the timelines outlined in the protocol. | 25                                                                                                        | (6.7)                                                                                                     | 28                                                                                                        | (7.4)                                                                                                     | 53                                                                                                        | (7.1)                                                                                                     |
| Study Intervention                                                                                                                                    | 3                                                                                                         | (0.8)                                                                                                     | 3                                                                                                         | (0.8)                                                                                                     | 9                                                                                                         | (0.8)                                                                                                     |
| Participant was administered improperly stored study intervention that was deemed unacceptable for use.                                               | 3                                                                                                         | (0.8)                                                                                                     | 3                                                                                                         | (0.8)                                                                                                     | 9                                                                                                         | (0.8)                                                                                                     |
| Every subject is counted a single time for each applicable row and columm. DatabaseCutoff Date: 02JUL2020                                             | Every subject is counted a single time for each applicable row and columm. DatabaseCutoff Date: 02JUL2020 | Every subject is counted a single time for each applicable row and columm. DatabaseCutoff Date: 02JUL2020 | Every subject is counted a single time for each applicable row and columm. DatabaseCutoff Date: 02JUL2020 | Every subject is counted a single time for each applicable row and columm. DatabaseCutoff Date: 02JUL2020 | Every subject is counted a single time for each applicable row and columm. DatabaseCutoff Date: 02JUL2020 | Every subject is counted a single time for each applicable row and columm. DatabaseCutoff Date: 02JUL2020 |

## Prematurely Unblinding

As of the data cut-off, there were 11 confirmed inadvertent unblinding events that were determined to not significantly impact the study blind, validity of site's data, or reliability of study results. However, there were 21 premature 'emergency' unblinding events.  Emergency unblinding is done at the discretion of the investigator in situations where unblinded information is needed to provide proper medical management for  a  study  participant.  These  premature  unblinding  events  had  no  impact  on  the  data  analyses  per evaluation by the SQI process. Therefore, these participants were not excluded from the efficacy and safety analyses.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 13: Subjec t Characteristics (ITT)

|                                         | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC      | SOC    | Total    | Total   |
|-----------------------------------------|-----------------------|-----------------------|----------|--------|----------|---------|
|                                         | n                     | (%)                   | n        | (%)    | n        | (%)     |
| Subjects in population                  | 373                   |                       | 376      |        | 749      |         |
| Gender                                  |                       |                       |          |        |          |         |
| Male                                    | 306                   | (82.0)                | 319      | (84.8) | 625      | (83.4)  |
| Female                                  | 67                    | (18.0)                | 57       | (15.2) | 124      | (16.6)  |
| Age (Years)                             |                       |                       |          |        |          |         |
| <65                                     | 201                   | (53.9)                | 226      | (60.1) | 427      | (57.0)  |
| >= 65                                   | 172                   | (46.1)                | 150      | (39.9) | 322      | (43.0)  |
| Mean                                    | 62.8                  |                       | 62.0     |        | 62.4     |         |
| SD                                      | 9.8                   |                       | 9.2      |        | 9.5      |         |
| Median                                  | 64.0                  |                       | 62.0     |        | 63.0     |         |
| Range                                   | 28 to 94              |                       | 27 to 89 |        | 27 to 94 |         |
| Race                                    |                       |                       |          |        |          |         |
| AmericanIndian OrAlaskaNative           | 9                     | (2.4)                 | 12       | (3.2)  | 21       | (2.8)   |
| Asian                                   | 201                   | (53.9)                | 199      | (52.9) | 400      | (53.4)  |
| BlackOrAfricanAmerican                  | 5                     | (1.3)                 | 2        | (0.5)  | 7        | (0.9)   |
| Multiple                                | 5                     | (1.3)                 | 9        | (2.4)  | 14       | (1.9)   |
| American Indian Or Alaska Native, White | 3                     | (0.8)                 | 6        | (1.6)  | 9        | (1.2)   |
| Black Or African American, White        | 2                     | (0.5)                 | 3        | (0.8)  | 5        | (0.7)   |
| White                                   | 139                   | (37.3)                | 139      | (37.0) | 278      | (37.1)  |
| Missing                                 | 14                    | (3.8)                 | 15       | (4.0)  | 29       | (3.9)   |
| Ethnicity                               |                       |                       |          |        |          |         |
| Hispanic Or Latino                      | 42                    | (11.3)                | 57       | (15.2) | 99       | (13.2)  |
| Not Hispanic Or Latino                  | 315                   | (84.5)                | 296      | (78.7) | 611      | (81.6)  |
| Not Reported                            | 2                     | (0.5)                 | 1        | (0.3)  | 3        | (0.4)   |
| Unknown                                 | 12                    | (3.2)                 | 20       | (5.3)  | 32       | (4.3)   |
| Missing                                 | 2                     | (0.5)                 | 2        | (0.5)  | 4        | (0.5)   |
| Region                                  |                       |                       |          |        |          |         |
| Asia                                    | 196                   | (52.5)                | 197      | (52.4) | 393      | (52.5)  |
| Rest of World                           | 177                   | (47.5)                | 179      | (47.6) | 356      | (47.5)  |
| Primary Diagnosis                       |                       |                       |          |        |          |         |

<div style=\"page-break-after: always\"></div>

|                                                                 | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC   | SOC    | Total   | Total   |
|-----------------------------------------------------------------|-----------------------|-----------------------|-------|--------|---------|---------|
|                                                                 | n                     | (%)                   | n     | (%)    | n       | (%)     |
| Squamous Cell Carcinoma of the Esophagus                        | 274                   | (73.5)                | 274   | (72.9) | 548     | (73.2)  |
| Adenocarcinoma of the Esophagus                                 | 58                    | (15.5)                | 52    | (13.8) | 110     | (14.7)  |
| Adenocarcinoma of the Gastroesophageal Junction, Siewert Type I | 41                    | (11.0)                | 50    | (13.3) | 91      | (12.1)  |
| Metastatic Staging                                              |                       |                       |       |        |         |         |
| MO                                                              | 29                    | (7.8)                 | 37    | (9.8)  | 66      | (8.8)   |
| M1                                                              | 344                   | (92.2)                | 339   | (90.2) | 683     | (91.2)  |
| Brain Metastasis                                                |                       |                       |       |        |         |         |
| Yes                                                             | 1                     | (0.3)                 | 2     | (0.5)  | 3       | (0.4)   |
| No                                                              | 372                   | (99.7)                | 374   | (99.5) | 746     | (99.6)  |
| Current Disease Stage                                           |                       |                       |       |        |         |         |
| IB                                                              | 0                     | (0.0)                 | 1     | (0.3)  | 1       | (0.1)   |
| IIB                                                             | 1                     | (0.3)                 | 0     | (0.0)  | 1       | (0.1)   |
| III                                                             | 4                     | (1.1)                 | 6     | (1.6)  | 10      | (1.3)   |
| IIIA                                                            | 4                     | (1.1)                 | 5     | (1.3)  | 9       | (1.2)   |
| IIIB                                                            | 8                     | (2.1)                 | 12    | (3.2)  | 20      | (2.7)   |
| IIIC                                                            | 12                    | (3.2)                 | 13    | (3.5)  | 25      | (3.3)   |
| IV                                                              | 268                   | (71.8)                | 289   | (76.9) | 557     | (74.4)  |
| IVA                                                             | 9                     | (2.4)                 | 7     | (1.9)  | 16      | (2.1)   |
| IVB                                                             | 65                    | (17.4)                | 41    | (10.9) | 106     | (14.2)  |
| IVC                                                             | 1                     | (0.3)                 | 1     | (0.3)  | 2       | (0.3)   |
| IVE                                                             | 1                     | (0.3)                 | 1     | (0.3)  | 2       | (0.3)   |
| ECOGPerformance Scale                                           |                       |                       |       |        |         |         |
| 0                                                               | 149                   | (39.9)                | 150   | (39.9) | 299     | (39.9)  |
| 1                                                               | 223                   | (59.8)                | 225   | (59.8) | 448     | (59.8)  |
| 2                                                               | 1                     | (0.3)                 | 1     | (0.3)  | 2       | (0.3)   |
| Histology                                                       |                       |                       |       |        |         |         |
| Adenocarcinoma                                                  | 99                    | (26.5)                | 102   | (27.1) | 201     | (26.8)  |
| Squamous Cell Carcinoma                                         | 274                   | (73.5)                | 274   | (72.9) | 548     | (73.2)  |
| Disease Status                                                  |                       |                       |       |        |         |         |
| Metastatic                                                      | 344                   | (92.2)                | 339   | (90.2) | 683     | (91.2)  |
| Unresectable-LocallyAdvanced                                    | 29                    | (7.8)                 | 37    | (9.8)  | 66      | (8.8)   |
| PD-L1Status                                                     |                       |                       |       |        |         |         |
| CPS >= 10                                                       | 186                   | (49.9)                | 197   | (52.4) | 383     | (51.1)  |
| CPS <10                                                         | 175                   | (46.9)                | 172   | (45.7) | 347     | (46.3)  |
| Not evaluable                                                   | 6                     | (1.6)                 | 6     | (1.6)  | 12      | (1.6)   |
| Missing                                                         | 6                     | (1.6)                 | 1     | (0.3)  | 7       | (0.9)   |
| Database Cutoff Date: 02JUL2020                                 |                       |                       |       |        |         |         |

Sonrre' [P5001701N/K3475:adam-ade1]

## Numbers analysed

The primary efficacy analysis was based on the ITT population defined as all randomized participants. A total of 749 participants were included in the primary efficacy population, which is the Global Study population defined as all participants randomized in the study. The Global Study population included participants enrolled in the Global Cohort (n=711) and the China Extension Study (n=38). China Cohort has a separate analysis not in scope for this CSR.

Efficacy analyses were conducted in the populations identified as follows:

<div style=\"page-break-after: always\"></div>

## Study population

## Table 14: study population:

|                                         | Pembrolizumab+SoC             | SOC                           | Total                         |
|-----------------------------------------|-------------------------------|-------------------------------|-------------------------------|
| SubjectsRandomized                      | 373                           | 376                           | 749                           |
| Intention-to-Treat(ITT)Global Cohort    | 355                           | 356                           | 711                           |
| Intention-to-Treat (ITT) China Cohort   | 51                            | 55                            | 106                           |
| Intention-to-Treat(ITT)ESCC             | 274                           | 274                           | 548                           |
| Intention-to-Treat(ITT)PD-L1 CPS≥10     | 186                           | 197                           | 383                           |
| Intention-to-Treat(ITT)ESCCPD-L1 CPS≥10 | 143                           | 143                           | 286                           |
| All-Subjects-as-Treated (ASaT)          | 370                           | 370                           | 740                           |
| DatabaseCutoffDate:02JUL2020.           | DatabaseCutoffDate:02JUL2020. | DatabaseCutoffDate:02JUL2020. | DatabaseCutoffDate:02JUL2020. |

Source:[P590V01MK3475:adam-adsl]

## Outcomes and estimation

At this interim analysis (i.e. final for PFS and interim for OS), efficacy analyses were performed on PFS, OS, ORR, DOR, and PRO. As of the data cut-off (02 July 2020), the median follow-up time for participants was 12.6 months (range: 0.1-33.6 months) in the pembrolizumab plus chemotherapy group and 9.8 months (range: 0.1-33.6 months) in the chemotherapy group.

## Primary endpoint

Overall Survival

Figure 5: Patients with ESCC whose tumours express PD-L1 CPS ≥ 10

rigue1i-1

Kaplan-Meier Estimates of Overall Survival

(Subjects with Squamous Cell Carcinoma and PD-L1 CPS &gt;= 10, ITT Population)

Overall Survival

<!-- image -->

## NumberofSubjectsatRisk

| Pembrolizumab+Soc   |   143 |   134 |   119 |   96 |   78 |   61 |   51 |   29 |   16 |   7 | 3 0   |
|---------------------|-------|-------|-------|------|------|------|------|------|------|-----|-------|
| SOC                 |   143 |   124 |    99 |   70 |   48 |   34 |   24 |   15 |   10 |   4 | 1 0   |

<div style=\"page-break-after: always\"></div>

Analysis of Overall Survival

## (Subjects with Squamous Cell Carcinoma and PD-L1 CPS &gt;= 10, ITT Population)

| Treatment                                                                                                                                                                                                 | N                                                                                                                                                                                                         | Number of Events (%)                                                                                                                                                                                      | Person- Months                                                                                                                                                                                            | Event Rate/ 100 Person- Months                                                                                                                                                                            | Median Os t (Months) (95% CI)                                                                                                                                                                             | OS Rate at Month 12 in % t (95% CI)                                                                                                                                                                       |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizumab+SOC                                                                                                                                                                                         | 143                                                                                                                                                                                                       | 94 (65.7)                                                                                                                                                                                                 | 1997.6                                                                                                                                                                                                    | 4.7                                                                                                                                                                                                       | 13.9 (11.1, 17.7)                                                                                                                                                                                         | 54.5 (46.0, 62.3)                                                                                                                                                                                         |
| SOC                                                                                                                                                                                                       | 143                                                                                                                                                                                                       | 121 (84.6)                                                                                                                                                                                                | 1505.6                                                                                                                                                                                                    | 8.0                                                                                                                                                                                                       | 8.8 (7.8, 10.5)                                                                                                                                                                                           | 33.6 (26.0, 41.3)                                                                                                                                                                                         |
| Pairwise Comparisons                                                                                                                                                                                      | Pairwise Comparisons                                                                                                                                                                                      | Pairwise Comparisons                                                                                                                                                                                      | Pairwise Comparisons                                                                                                                                                                                      | Pairwise Comparisons                                                                                                                                                                                      | Hazard Ratio+ (95% CI)+                                                                                                                                                                                   | p-Value                                                                                                                                                                                                   |
| Pembrolizumab + SOC vs. SOC                                                                                                                                                                               | Pembrolizumab + SOC vs. SOC                                                                                                                                                                               | Pembrolizumab + SOC vs. SOC                                                                                                                                                                               | Pembrolizumab + SOC vs. SOC                                                                                                                                                                               | Pembrolizumab + SOC vs. SOC                                                                                                                                                                               | 0.57 (0.43, 0.75)                                                                                                                                                                                         | <0.00015                                                                                                                                                                                                  |
| fFrom product-limit (Kaplan-Meier)method forcensored data.                                                                                                                                                | fFrom product-limit (Kaplan-Meier)method forcensored data.                                                                                                                                                | fFrom product-limit (Kaplan-Meier)method forcensored data.                                                                                                                                                | fFrom product-limit (Kaplan-Meier)method forcensored data.                                                                                                                                                | fFrom product-limit (Kaplan-Meier)method forcensored data.                                                                                                                                                | fFrom product-limit (Kaplan-Meier)method forcensored data.                                                                                                                                                | fFrom product-limit (Kaplan-Meier)method forcensored data.                                                                                                                                                |
| Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (0 versus 1). | Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (0 versus 1). | Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (0 versus 1). | Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (0 versus 1). | Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (0 versus 1). | Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (0 versus 1). | Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (0 versus 1). |
| One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (O versus 1).                                                        | One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (O versus 1).                                                        | One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (O versus 1).                                                        | One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (O versus 1).                                                        | One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (O versus 1).                                                        | One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (O versus 1).                                                        | One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (O versus 1).                                                        |
| DatabaseCutoffDate:02JUL2020                                                                                                                                                                              | DatabaseCutoffDate:02JUL2020                                                                                                                                                                              | DatabaseCutoffDate:02JUL2020                                                                                                                                                                              | DatabaseCutoffDate:02JUL2020                                                                                                                                                                              | DatabaseCutoffDate:02JUL2020                                                                                                                                                                              | DatabaseCutoffDate:02JUL2020                                                                                                                                                                              | DatabaseCutoffDate:02JUL2020                                                                                                                                                                              |

Source:[P590V01MK3475:adam-adsl;adtte]

## Forest Plot of OS Hazard Ratio by Subgroup Factor (Subjects with Squamous Cell Carcinoma and PD-L1 CPS &gt;= 10, ITT Population)

<!-- image -->

|                   | N#Event   | HR   | 95%CI        |                           |
|-------------------|-----------|------|--------------|---------------------------|
| Overall           | 286/215   | 0.57 | (0.43, 0.75) |                           |
| Age Category      |           |      |              |                           |
| <65 years         | 166/131   | 0.57 | (0.40, 0.81) |                           |
| >= 65 years       | 120/84    | 0.59 | (0.39, 0.91) |                           |
| Disease Status    |           |      |              |                           |
| Metastatic        | 262/196   | 0.55 | (0.41, 0.73) |                           |
| ECOG              |           |      |              |                           |
| 0                 | 115/82    | 0.55 | (0.36, 0.85) |                           |
|                   | 171/133   | 0.59 | (0.42,0.83)  |                           |
| Geographic Region |           |      |              |                           |
| Asia              | 194/147   | 0.48 | (0.35, 0.67) |                           |
| Rest of World     | 92/68     | 0.79 | (0.49, 1.28) |                           |
| Sex               |           |      |              |                           |
| Male              | 230/177   | 0.57 | (0.42, 0.77) |                           |
| Female            | 56/38     | 0.58 | (0.31, 1.10) |                           |
|                   |           |      |              | 0.1                       |
|                   |           |      |              | Estimated HazardRatio(HR) |

<div style=\"page-break-after: always\"></div>

Figure 6: Patients with ESCC

rigue 11Kaplan-Meier Estimates of Overall Survival (Subjects with Squamous Cell Carcinoma, ITT Population)

Overall Survival

<!-- image -->

## NumberofSubjects atRisk

| Pembrolizumab+SOC   |   274 |   258 |   221 |   175 |   139 |   111 |   89 |   50 |   27 |   14 |   6 | 2 0   |
|---------------------|-------|-------|-------|-------|-------|-------|------|------|------|------|-----|-------|
| SOC                 |   274 |   247 |   203 |   146 |   103 |    75 |   57 |   34 |   23 |   13 |   4 | 1 0   |

Analysis of Overall Survival (Subjects with Squamous Cell Carcinoma, ITT Population)

| Treatment                | N   | Number of Events (%)   | Person- Months   | Event Rate/ 100 Person- Months   | Median Os t (Months) (95% CI)   | OS Rate at Month 12 in % t (95% CI)   |
|--------------------------|-----|------------------------|------------------|----------------------------------|---------------------------------|---------------------------------------|
| Pembrolizumab+SOC        | 274 | 190 (69.3)             | 3667.2           | 5.2                              | 12.6 (10.2,14.3)                | 51.0 (44.9, 56.8)                     |
| SOC                      | 274 | 222 (81.0)             | 3129.7           | 7.1                              | 9.8 (8.6, 11.1)                 | 37.9 (32.2, 43.7)                     |
| Pairwise Comparisons     |     |                        |                  |                                  | Hazard Ratio+ (95% CI)t         | p-Value                               |
| Pembrolizumab+SOC vs.SOC |     |                        |                  |                                  | 0.72 (0.60, 0.88)               | 0.0006$                               |

From product-limit (Kaplan-Meier) method for censored data.

Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (0 versus 1).

One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (O versus 1). DatabaseCutoffDate:02JUL2020.

Source:[P590V01MK3475:adam-adsl;adtte]

<div style=\"page-break-after: always\"></div>

## Forest Plot of OS Hazard Ratio by Subgroup Factor (Subjects with Squamous Cell Carcinoma, ITT Population)

Figure 7: Patients whose tumours express PD-L1 CPS ≥

<!-- image -->

|                  | N#Event   | HR   | 95%CI        |                          |
|------------------|-----------|------|--------------|--------------------------|
| Overall          | 548/412   | 0.72 | (0.60, 0.88) |                          |
| Age Category     |           |      |              |                          |
| <65 years        | 308/239   | 0.74 | (0.58, 0.96) |                          |
| >= 65 years      | 240/173   | 0.68 | (0.50, 0.92) |                          |
| DiseaseStatus    |           |      |              |                          |
| Metastatic       | 497/370   | 0.71 | (0.58,0.87)  |                          |
| ECOG             |           |      |              |                          |
| 0                | 208/137   | 0.66 | (0.47, 0.92) |                          |
| 1                | 340/275   | 0.75 | (0.59, 0.95) |                          |
| GeographicRegion |           |      |              |                          |
| Asia             | 360/264   | 0.63 | (0.49, 0.80) |                          |
| Rest of World    | 188/148   | 0.93 | (0.67, 1.28) |                          |
| Sex              |           |      |              |                          |
| Male             | 454/346   | 0.68 | (0.55, 0.84) |                          |
| Female           | 94/66     | 0.95 | (0.58, 1.54) |                          |
|                  |           |      |              | 0.1                      |
|                  |           |      |              | EstimatedHazardRatio(HR) |

10

## PDL1 CPS ≥ 10  was determined using the PD -L1 IHC 22C3 pharmDxTM kit.

rigure 11-)

Kaplan-Meier Estimates of Overall Survival

(Subjects with PD-L1 CPS &gt;= 10, ITT Population)

Overall Survival

<!-- image -->

## NumberofSubjectsatRisk

| Pembrolizumab+SoC   |   186 |   175 |   151 |   125 |   100 |   79 |   66 |   40 |   23 |   10 | 4 0   |
|---------------------|-------|-------|-------|-------|-------|------|------|------|------|------|-------|
| SOC                 |   197 |   174 |   142 |   102 |    73 |   55 |   42 |   28 |   13 |    6 | 1 0   |

<div style=\"page-break-after: always\"></div>

## Analysis of Overall Survival (Subjects with PD-L1 CPS &gt;= 10, ITT Population)

| Treatment               | N                       | Number of Events (%)    | Person- Months          | Event Rate/ 100 Person- Months   | Median Os t (Months) (95% CI)   | OS Rate at Month 12 in % t (95% CI)   |
|-------------------------|-------------------------|-------------------------|-------------------------|----------------------------------|---------------------------------|---------------------------------------|
| Pembrolizumab+SOC       | 186                     | 124 (66.7)              | 2594.2                  | 4.8                              | 13.5 (11.1, 15.6)               | 53.8 (46.3, 60.6)                     |
| SOC                     | 197                     | 165 (83.8)              | 2201.1                  | 7.5                              | 9.4 (8.0, 10.7)                 | 37.1 (30.3, 43.8)                     |
| PairwiseComparisons     | PairwiseComparisons     | PairwiseComparisons     | PairwiseComparisons     | PairwiseComparisons              | Hazard Ratio+ (95% CI)+         | p-Value                               |
| Pembrolizumab+SOCvs.SOC | Pembrolizumab+SOCvs.SOC | Pembrolizumab+SOCvs.SOC | Pembrolizumab+SOCvs.SOC | Pembrolizumab+SOCvs.SOC          | 0.62 (0.49, 0.78)               | <0.0001$                              |

From product-limit (Kaplan-Meier) method for censored data.

Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma).

One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma).

Database Cutoff Date: 02JUL2020.

Source: [P590V01MK3475: adam-adsl; adtte]

## Forest Plot of OS Hazard Ratio by Subgroup Factor (Subjects with PD-L1 CPS &gt;= 10, ITT Population)

<!-- image -->

|                         | N#Event   | HR   | 95%CI        |                          |
|-------------------------|-----------|------|--------------|--------------------------|
| Overall                 | 383/289   | 0.62 | (0.49, 0.78) |                          |
| Age Category            |           |      |              |                          |
| <65 years               | 226/178   | 0.71 | (0.52, 0.95) |                          |
| >= 65 years             | 157/111   | 0.56 | (0.39, 0.82) |                          |
| DiseaseStatus           |           |      |              |                          |
| Metastatic              | 355/266   | 0.61 | (0.48, 0.78) |                          |
| ECOG                    |           |      |              |                          |
| 0                       | 164/118   | 0.60 | (0.42, 0.87) |                          |
| 1                       | 218/170   | 0.65 | (0.48, 0.89) |                          |
| Geographic Region       |           |      |              |                          |
| Asia                    | 210/157   | 0.49 | (0.35, 0.67) |                          |
| Rest of World           | 173/132   | 0.82 | (0.58, 1.16) |                          |
| Histology               |           |      |              |                          |
| Adenocarcinoma          | 97/74     | 0.83 | (0.52, 1.34) |                          |
| Squamous Cell Carcinoma | 286/215   | 0.57 | (0.43, 0.75) |                          |
| Sex                     |           |      |              |                          |
| Male                    | 313/238   | 0.61 | (0.47, 0.80) |                          |
| Female                  | 70/51     | 0.67 | (0.39, 1.17) |                          |
|                         |           |      |              | 0.1 1                    |
|                         |           |      |              | EstimatedHazardRatio(HR) |

<div style=\"page-break-after: always\"></div>

Figure 8: All comer patients

riguc11 Kaplan-Meier Estimates of Overall Survival (ITT Population)

Overall Survival

<!-- image -->

## NumberofSubjects atRisk

| Pembrolizumab+SOC   |   373 |   348 |   295 |   235 |   187 |   151 |   118 |   68 |   36 |   17 |   7 | 2   |
|---------------------|-------|-------|-------|-------|-------|-------|-------|------|------|------|-----|-----|
| SOC                 |   376 |   338 |   274 |   200 |   147 |   108 |    82 |   51 |   28 |   15 |   4 | 1 0 |

Analysis of Overall Survival (ITT Population)

| Treatment                | N                        | Number of Events (%)     | Person- Months           | Event Rate/ 100 Person- Months   | Median Os t (Months) (95% CI)   | OS Rate at Month 12 in % t (95% CI)   |
|--------------------------|--------------------------|--------------------------|--------------------------|----------------------------------|---------------------------------|---------------------------------------|
| Pembrolizumab+SOC        | 373                      | 262 (70.2)               | 4935.1                   | 5.3                              | 12.4 (10.5, 14.0)               | 50.6 (45.4, 55.6)                     |
| SOC                      | 376                      | 309 (82.2)               | 4301.2                   | 7.2                              | 9.8 (8.8, 10.8)                 | 39.4 (34.4, 44.3)                     |
| PairwiseComparisons      | PairwiseComparisons      | PairwiseComparisons      | PairwiseComparisons      | PairwiseComparisons              | Hazard Ratio+ (95% CI)+         | p-Value                               |
| Pembrolizumab+ SOCvs.SOC | Pembrolizumab+ SOCvs.SOC | Pembrolizumab+ SOCvs.SOC | Pembrolizumab+ SOCvs.SOC | Pembrolizumab+ SOCvs.SOC         | 0.73 (0.62, 0.86)               | <0.00015                              |

From product-limit (Kaplan-Meier) method for censored data.

+ Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma) and ECOG performance status (O versus 1).

SquamousCell Carcinoma)andECOGperformancestatus(Oversus1).

DatabaseCutoffDate:02JUL2020.

Source:[P590V01MK3475:adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

## Forest Plot of OS Hazard Ratio by Subgroup Factor (ITT Population)

<!-- image -->

|                         | N#Event   | HR   | 95% CI       |                              |
|-------------------------|-----------|------|--------------|------------------------------|
| Overall                 | 749/571   | 0.73 | (0.62, 0.86) |                              |
| Age Category            |           |      |              |                              |
| <65 years               | 427/332   | 0.76 | (0.61, 0.95) |                              |
| >= 65 years             | 322/239   | 0.69 | (0.53, 0.89) |                              |
| DiseaseStatus           |           |      |              |                              |
| Metastatic              | 683/519   | 0.71 | (0.60, 0.85) |                              |
| ECOG                    |           |      |              |                              |
| 0                       | 299/207   | 0.72 | (0.55, 0.94) |                              |
| 1                       | 448/362   | 0.73 | (0.59, 0.90) |                              |
| GeographicRegion        |           |      |              |                              |
| Asia                    | 393/288   | 0.64 | (0.51, 0.81) |                              |
| Rest of World           | 356/283   | 0.83 | (0.66, 1.05) |                              |
| Histology               |           |      |              |                              |
| Adenocarcinoma          | 201/159   | 0.74 | (0.54, 1.02) |                              |
| Squamous Cell Carcinoma | 548/412   | 0.72 | (0.60, 0.88) |                              |
| Sex                     |           |      |              |                              |
| Male                    | 625/482   | 0.70 | (0.58, 0.84) |                              |
| Female                  | 124/89    | 0.89 | (0.59, 1.35) |                              |
|                         |           |      |              | 0.1 EstimatedHazardRatio(HR) |

<div style=\"page-break-after: always\"></div>

Figure 9: Progression Free Survival by Investigator

## Patients with ESCC

Figure 11-9

Kaplan-Meier Estimates of Progression-Free Survival Based on Investigator Assessment per RECIST 1.1

(Primary Censoring Rule)

(Subjects with Squamous Cell Carcinoma, ITT Population)

<!-- image -->

Number ofSubjects atRisk

| Pembrolizumab+SOC   | 274   |   211 |   156 |   71 |   57 |   41 |   35 |   19 |   13 |   3 | 2 0   |
|---------------------|-------|-------|-------|------|------|------|------|------|------|-----|-------|
| SOC                 |       |   205 |   127 |   45 |   26 |   16 |   11 |    5 |    2 |   1 | 0 0   |

laviel1-y

Analysis of Progression-Free Survival Based on Investigator Assessment per RECIST 1.1

(Primary Censoring Rule)

(Subjects with Squamous Cell Carcinoma, ITT Population)

| Treatment                 | N                         | Number of Events (%)      | Person- Months            | Event Rate/ 100 Person- Months   | Median PFS t (Months) (95% CI)   | PFS Rate at Month 6 in % t (95% CI)   |
|---------------------------|---------------------------|---------------------------|---------------------------|----------------------------------|----------------------------------|---------------------------------------|
| Pembrolizumab+SOC         | 274                       | 219 (79.9)                | 2202.6                    | 9.9                              | 6.3 (6.2, 6.9)                   | 62.1 (55.8, 67.7)                     |
| SOC                       | 274                       | 244 (89.1)                | 1645.9                    | 14.8                             | 5.8 (5.0, 6.1)                   | 48.8 (42.6, 54.6)                     |
| Pairwise Comparisons      | Pairwise Comparisons      | Pairwise Comparisons      | Pairwise Comparisons      | Pairwise Comparisons             | Hazard Ratio+(95% CI)+           | p-Value                               |
| Pembrolizumab+ SOC vs.SOC | Pembrolizumab+ SOC vs.SOC | Pembrolizumab+ SOC vs.SOC | Pembrolizumab+ SOC vs.SOC | Pembrolizumab+ SOC vs.SOC        | 0.65 (0.54,0.78)                 | <0.00015                              |

Fromproduct-limit(Kaplan-Meier)method for censored data.

Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (O versus 1).

One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (O versus 1). Progression-free survival is defined as time from randomization to disease progression, or death, whichever occurs first.

DatabaseCutoff Date:02JUL2020.

Source:[P590V01MK3475: adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

Figure 11-10 Forest Plot of PFS Hazard Ratio by Subgroup Factor Based on Investigator Assessment per RECIST 1.1 (Primary Censoring Rule) (Subjects with Squamous Cell Carcinoma, ITT Population)

<!-- image -->

|                  | N#Event   | HR   | 95%CI        |                             |
|------------------|-----------|------|--------------|-----------------------------|
| Overall          | 548/463   | 0.65 | (0.54, 0.78) |                             |
| Age Category     |           |      |              |                             |
| <65 years        | 308/266   | 0.73 | (0.57, 0.92) |                             |
| >= 65 years      | 240/197   | 0.59 | (0.44, 0.78) |                             |
| DiseaseStatus    |           |      |              |                             |
| Metastatic       | 497/423   | 0.65 | (0.53, 0.78) |                             |
| ECOG             |           |      |              |                             |
| 0                | 208/171   | 0.52 | (0.38, 0.71) |                             |
| 1                | 340/292   | 0.77 | (0.61, 0.97) |                             |
| GeographicRegion |           |      |              |                             |
| Asia             | 360/306   | 0.61 | (0.48, 0.76) |                             |
| Rest of World    | 188/157   | 0.72 | (0.52, 0.98) |                             |
| Sex              |           |      |              |                             |
| Male             | 454/394   | 0.65 | (0.53, 0.80) |                             |
| Female           | 94/69     | 0.70 | (0.43, 1.12) |                             |
|                  |           |      |              | Estimated Hazard Ratio (HR) |

DatabaseCutoffDate:02JUL2020

Source: [P590V01MK3475: adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

Figure 10: Patients whose tumours express PD-L1 CPS ≥ 10

Figure 11-11 Kaplan-Meier Estimates of Progression-Free Survival Based on Investigator Assessment p RECIST 1.1 (Primary Censoring Rule)

(Subjects with PD-L1 CPS &gt;= 10, ITT Population)

Survival

<!-- image -->

Progression-FreeS

## Number ofSubjectsatRisk

| Pembrolizumab+SOC   |   186 |   143 |   109 |   56 |   48 |   36 |   29 |   17 |   12 |   2 | 1 0   |
|---------------------|-------|-------|-------|------|------|------|------|------|------|-----|-------|
| SOC                 |   197 |   145 |    85 |   26 |   14 |   12 |    7 |    5 |    2 |   1 | 0 0   |

Analysis of Progression-Free Survival Based on Investigator Assessment per RECIST 1.1 (Primary Censoring Rule) (Subjects with PD-L1 CPS &gt;= 10, ITT Population)

| Treatment                   | N   | Number of Events (%)   | Person- Months   | Event Rate/ 100 Person- Months   | Median PFS t (Months) (95% CI)   | PFS Rate at Month 6 in % t (95% CI)   |
|-----------------------------|-----|------------------------|------------------|----------------------------------|----------------------------------|---------------------------------------|
| Pembrolizumab+SOC           | 186 | 140 (75.3)             | 1618.4           | 8.7                              | 7.5 (6.2, 8.2)                   | 65.6 (58.0, 72.1)                     |
| SOC                         | 197 | 174 (88.3)             | 1125.6           | 15.5                             | 5.5 (4.3, 6.0)                   | 45.9 (38.6, 52.8)                     |
| Pairwise Comparisons        |     |                        |                  |                                  | Hazard Ratio+ (95% CI)+          | p-Value                               |
| Pembrolizumab + SOC vs. SOC |     |                        |                  |                                  | 0.51 (0.41, 0.65)                | <0.0001s                              |

f From product-limit (Kaplan-Meier) method for censored data.

Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma).

One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma).

Progression-free survival is defined as time from randomization to disease progression, or death, whichever occurs first. DatabaseCutoffDate:02JUL2020.

Source:[P590V01MK3475: adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

Figure 11-12 Forest Plot of PFS Hazard Ratio by Subgroup Factor Based on Investigator Assessment per RECIST 1.1 (Primary Censoring Rule) (Subjects with PD-L1 CPS &gt;= 10, ITT Population)

<!-- image -->

|                         | N#Event   | HR   | IO %S6       |                          |                          |
|-------------------------|-----------|------|--------------|--------------------------|--------------------------|
| Overall                 | 383/314   | 0.51 | (0.41, 0.65) |                          |                          |
| AgeCategory             |           |      |              |                          |                          |
| <65 years               | 226/192   | 0.66 | (0.49, 0.88) |                          |                          |
| >= 65 years             | 157/122   | 0.44 | (0.31, 0.64) |                          |                          |
| DiseaseStatus           |           |      |              |                          |                          |
| Metastatic              | 355/294   | 0.53 | (0.42, 0.68) |                          |                          |
| ECOG                    |           |      |              |                          |                          |
| 0                       | 164/133   | 0.48 | (0.34, 0.68) |                          |                          |
| 1                       | 218/180   | 0.61 | (0.45, 0.82) |                          |                          |
| GeographicRegion        |           |      |              |                          |                          |
| Asia                    | 210/177   | 0.44 | (0.32, 0.60) |                          |                          |
| Rest of World           | 173/137   | 0.63 | (0.44, 0.88) |                          |                          |
| Histology               |           |      |              |                          |                          |
| Adenocarcinoma          | 97/78     | 0.49 | (0.30, 0.81) |                          |                          |
| Squamous Cell Carcinoma | 286/236   | 0.53 | (0.40, 0.69) |                          |                          |
| Sex                     |           |      |              |                          |                          |
| Male                    | 313/260   | 0.55 | (0.43, 0.71) |                          |                          |
| Female                  | 70/54     | 0.47 | (0.27, 0.82) |                          |                          |
|                         |           |      |              | 0.1                      | 10                       |
|                         |           |      |              | EstimatedHazardRatio(HR) | EstimatedHazardRatio(HR) |

Database Cutoff Date: 02JUL2020

Source:[P590V01MK3475: adam-adsl; adtte]

## Figure 11: All comer patients

Figure 11-13

Kaplan-Meier Estimates of Progression-Free Survival Based on Investigator Assessment per RECIST 1.1

(Primary Censoring Rule) (ITT Population)

<!-- image -->

NumberofSubjectsatRisk

Pembrolizumab+SOC

373

SOC

376

289

278

210

172

96

62

79

36

55

22

45

14

25

6

17

2

1

0

0

<div style=\"page-break-after: always\"></div>

## laviii-i

## Analysis of Progression-Free Survival Based on Investigator Assessment per RECIST 1.1 (Primary Censoring Rule) (ITT Population)

| Treatment                 | N                         | Number of Events (%)      | Person- Months            | Event Rate/ 100 Person- Months   | Median PFS t (Months) (95% CI)   | PFS Rate at Month 6 in % t (95% CI)   |
|---------------------------|---------------------------|---------------------------|---------------------------|----------------------------------|----------------------------------|---------------------------------------|
| Pembrolizumab+ SOC        | 373                       | 297 (79.6)                | 2981.5                    | 10.0                             | 6.3 (6.2, 6.9)                   | 62.4 (57.1, 67.3)                     |
| SOC                       | 376                       | 333 (88.6)                | 2235.1                    | 14.9                             | 5.8 (5.0, 6.0)                   | 48.7 (43.4, 53.7)                     |
| Pairwise Comparisons      | Pairwise Comparisons      | Pairwise Comparisons      | Pairwise Comparisons      | Pairwise Comparisons             | Hazard Ratio+ (95% CI)+          | p-Value                               |
| Pembrolizumab +SOC vs.SOC | Pembrolizumab +SOC vs.SOC | Pembrolizumab +SOC vs.SOC | Pembrolizumab +SOC vs.SOC | Pembrolizumab +SOC vs.SOC        | 0.65 (0.55, 0.76)                | <0.0001s                              |

From product-limit (Kaplan-Meier) method for censored data.

+ Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma) and ECOG performance status (O versus 1).

One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma) and ECOG performance status (O versus 1).

Progression-free survival is defined as time from randomization to disease progression, or death, whichever occurs first.

Database Cutoff Date:02JUL2020.

Source: [P590V01MK3475: adam-adsl; adtte]

Figure 11-14 Forest Plot of PFS Hazard Ratio by Subgroup Factor Based on Investigator Assessment per RECIST 1.1 (Primary Censoring Rule) (ITT Population)

|                         | N#Event   | HR   | I%S6         |                             |
|-------------------------|-----------|------|--------------|-----------------------------|
| Overall                 | 749/630   | 0.65 | (0.55, 0.76) |                             |
| Age Category            |           |      |              |                             |
| <65 years               | 427/372   | 0.69 | (0.56, 0.85) |                             |
| >= 65 years             | 322/258   | 0.62 | (0.48, 0.80) |                             |
| Disease Status          |           |      |              |                             |
| Metastatic              | 683/580   | 0.62 | (0.53, 0.74) |                             |
| ECOG                    |           |      |              |                             |
| 0                       | 299/248   | 0.57 | (0.45, 0.74) |                             |
| 1                       | 448/380   | 0.71 | (0.58, 0.87) |                             |
| GeographicRegion        |           |      |              |                             |
| Asia                    | 393/333   | 0.59 | (0.47, 0.73) |                             |
| Rest of World           | 356/297   | 0.70 | (0.56, 0.89) |                             |
| Histology               |           |      |              |                             |
| Adenocarcinoma          | 201/167   | 0.63 | (0.46, 0.87) |                             |
| Squamous Cell Carcinoma | 548/463   | 0.65 | (0.54, 0.78) |                             |
| Sex                     |           |      |              |                             |
| Male                    | 625/537   | 0.63 | (0.53, 0.75) |                             |
| Female                  | 124/93    | 0.74 | (0.49, 1.12) |                             |
|                         |           |      |              | 0.1                         |
|                         |           |      |              | Estimated Hazard Ratio (HR) |

DatabaseCutoffDate:02JUL2020

Source: [P590V01MK3475: adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

## Figure 12: Progression-free Survival by BICR primary endpoint

## Patients with ESCC

Figure 14.2-23 Kaplan-Meier Estimates of Progression-Free Survival Based on Central Radiology Assessment per RECIST 1.1 (Primary Censoring Rule)

(Subjects with Squamous Cell Carcinoma, ITT Population)

<!-- image -->

## NumberofSubjectsatRisk

Pembrolizumab+SOC

274

SOC

274

204

203

145

133

74

46

24

39

12

36

9

16

4

9

1

2

1

2

0

0

0

1a1C14.2Analysis of Progression-Free Survival Based on Central Radiology Assessment per RECIST 1.1 (Primary Censoring Rule)

(Subjects with Squamous Cell Carcinoma, ITT Population)

| Treatment                   | N   | Number of Events (%)   | Person- Months   | Event Rate/ 100 Person- Months   | Median PFS t (Months) (95% CI)   | PFS Rate at Month 6 in % t (95% CI)   |
|-----------------------------|-----|------------------------|------------------|----------------------------------|----------------------------------|---------------------------------------|
| Pembrolizumab+ SOC          | 274 | 189 (69.0)             | 2123.2           | 8.9                              | 6.4 (6.2, 7.9)                   | 60.3 (54.0, 66.0)                     |
| SOC                         | 274 | 210 (76.6)             | 1647.9           | 12.7                             | 6.2 (6.0, 6.3)                   | 56.5 (50.2, 62.3)                     |
| Pairwise Comparisons        |     |                        |                  |                                  | Hazard Ratio+ (95% CI)+          | p-Value                               |
| Pembrolizumab + SOC vs. SOC |     |                        |                  |                                  | 0.71 (0.58, 0.87)                | 0.0004s                               |

fFrom product-limit (Kaplan-Meier) method for censored data.

+ Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (0 versus 1).

One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (O versus 1). Progression-free survival is defined as time from randomization to disease progression, or death, whichever occurs first.

DatabaseCutoff Date:02JUL2020.

57

Source:[P590V01MK3475: adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

## Forest Plot of PFS Hazard Ratio by Subgroup Factor

## Based on Central Radiology Assessment per RECIST 1.1 (Primary Censoring Rule) (Subjects with Squamous Cell Carcinoma, ITT Population)

<!-- image -->

|                  | N#Event   | HR   | I%S6         |                           |
|------------------|-----------|------|--------------|---------------------------|
| Overall          | 548/399   | 0.71 | (0.58, 0.87) |                           |
| Age Category     |           |      |              |                           |
| <65 years        | 308/232   | 0.75 | (0.58, 0.97) |                           |
| >= 65 years      | 240/167   | 0.65 | (0.48, 0.90) |                           |
| DiseaseStatus    |           |      |              |                           |
| Metastatic       | 497/365   | 0.69 | (0.56, 0.84) |                           |
| ECOG             |           |      |              |                           |
| 0                | 208/142   | 0.59 | (0.42, 0.83) |                           |
| 1                | 340/257   | 0.79 | (0.62, 1.02) |                           |
| GeographicRegion |           |      |              |                           |
| Asia             | 360/257   | 0.65 | (0.51, 0.84) |                           |
| Rest of World    | 188/142   | 0.80 | (0.57, 1.11) |                           |
| Sex              |           |      |              |                           |
| Male             | 454/334   | 0.73 | (0.58, 0.91) |                           |
| Female           | 94/65     | 0.62 | (0.38, 1.02) |                           |
|                  |           |      |              | 0.1                       |
|                  |           |      |              | EstimatedHazardRatio (HR) |

Database CutoffDate:02JUL2020 Source:[P590V01MK3475: adam-adsl; adtte]

Figure 13: Patients whose tumours express PD-L1 CPS ≥ 10

Kaplan-Meier Estimates of Progression-Free Survival Based on Central Radiology Assessment per RECIST 1.1 (Sensitivity Censoring Rule 1)

(Subjects with PD-L1 CPS &gt;= 10, ITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## aul Analysis of Progression-Free Survival Based on Central Radiology Assessment per RECIST 1.1 (Sensitivity Censoring Rule 1)

## (Subjects with PD-L1 CPS &gt;= 10, ITT Population)

| Treatment                 | N                         | Number of Events (%)      | Person- Months            | Event Rate/ 100 Person- Months   | Median PFS t (Months) (95% CI)   | PFS Rate at Month 6 in % t (95% CI)   |
|---------------------------|---------------------------|---------------------------|---------------------------|----------------------------------|----------------------------------|---------------------------------------|
| Pembrolizumab + SOC       | 186                       | 145 (78.0)                | 1772.7                    | 8.2                              | 7.8 (6.2, 9.5)                   | 64.5 (57.1, 71.0)                     |
| SOC                       | 197                       | 186 (94.4)                | 1386.7                    | 13.4                             | 6.0 (5.1, 6.2)                   | 53.0 (45.7, 59.7)                     |
| Pairwise Comparisons      | Pairwise Comparisons      | Pairwise Comparisons      | Pairwise Comparisons      | Pairwise Comparisons             | Hazard Ratio+ (95% CI)+          | p-Value                               |
| Pembrolizumab+ SOC vs.SOC | Pembrolizumab+ SOC vs.SOC | Pembrolizumab+ SOC vs.SOC | Pembrolizumab+ SOC vs.SOC | Pembrolizumab+ SOC vs.SOC        | 0.60 (0.48, 0.75)                | <0.0001s                              |

From product-limit (Kaplan-Meier) method for censored data.

+ Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma).

One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma).

Progression-free survival is defined as time from randomization to disease progression, or death, whichever occurs first. Database Cutoff Date: 02JUL2020.

Source: [P590V01MK3475: adam-adsl; adtte]

Figure 14.2-2/ Forest Plot of PFS Hazard Ratio by Subgroup Factor Based on Central Radiology Assessment per RECIST 1.1 (Primary Censoring Rule) (Subjects with PD-L1 CPS &gt;= 10, ITT Population)

|                         | N#Event   | HR   | I%S6         |                              |                              |                              |
|-------------------------|-----------|------|--------------|------------------------------|------------------------------|------------------------------|
| Overall                 | 383/277   | 0.53 | (0.41, 0.68) |                              |                              |                              |
| Age Category            |           |      |              |                              |                              |                              |
| <65 years               | 226/167   | 0.64 | (0.47, 0.88) |                              |                              |                              |
| >= 65 years             | 157/110   | 0.43 | (0.29, 0.63) |                              |                              |                              |
| Disease Status          |           |      |              |                              |                              |                              |
| Metastatic              | 355/257   | 0.53 | (0.41, 0.69) |                              |                              |                              |
| ECOG                    |           |      |              |                              |                              |                              |
| 0                       | 164/117   | 0.55 | (0.38, 0.80) |                              |                              |                              |
| 1                       | 218/159   | 0.53 | (0.39, 0.74) |                              |                              |                              |
| GeographicRegion        |           |      |              |                              |                              |                              |
| Asia                    | 210/149   | 0.44 | (0.31, 0.62) |                              |                              |                              |
| Rest of World           | 173/128   | 0.65 | (0.45, 0.92) |                              |                              |                              |
| Histology               |           |      |              |                              |                              |                              |
| Adenocarcinoma          | 97/69     | 0.66 | (0.40, 1.10) |                              |                              |                              |
| Squamous Cell Carcinoma | 286/208   | 0.50 | (0.38, 0.67) |                              |                              |                              |
| Sex                     |           |      |              |                              |                              |                              |
| Male                    | 313/226   | 0.55 | (0.42, 0.72) |                              |                              |                              |
| Female                  | 70/51     | 0.47 | (0.26, 0.84) |                              |                              |                              |
|                         |           |      |              |                              | 10                           |                              |
|                         |           |      |              | Estim ated Hazard Ratio (HR) | Estim ated Hazard Ratio (HR) | Estim ated Hazard Ratio (HR) |

Database Cutoff Date: 02JUL2020

Source:[P590V01MK3475: adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

## Figure 14: All comer patients

Kaplan-Meier Estimates of Progression-Free Survival Based on Central Radiology Assessment per RECIST 1.1 (Primary Censoring Rule) (ITT Population)

<!-- image -->

NumberofSubjects atRisk

Pembrolizumab+SOC

373

SOC

376

285

280

200

174

101

60

80

32

54

16

46

11

5

12

1

2

1

2

0

0

0

Table 14.2-16 Analysis of Progression-Free Survival Based on Central Radiology Assessment per RECIST 1.1 (Primary Censoring Rule) (ITT Population)

| Treatment                | N                        | Number of Events (%)     | Person- Months           | Event Rate/ 100 Person- Months   | Median PFS t (Months) (95% CI)   | PFS Rate at Month 6 in % t (95% CI)   |
|--------------------------|--------------------------|--------------------------|--------------------------|----------------------------------|----------------------------------|---------------------------------------|
| Pembrolizumab+ SOC       | 373                      | 256 (68.6)               | 2915.4                   | 8.8                              | 6.5 (6.2, 8.0)                   | 61.8 (56.4, 66.7)                     |
| SOC                      | 376                      | 291 (77.4)               | 2216.4                   | 13.1                             | 6.0 (5.7, 6.2)                   | 53.7 (48.3, 58.8)                     |
| PairwiseComparisons      | PairwiseComparisons      | PairwiseComparisons      | PairwiseComparisons      | PairwiseComparisons              | Hazard Ratio+ (95% CI)+          | p-Value                               |
| Pembrolizumab+SOC vs.SOC | Pembrolizumab+SOC vs.SOC | Pembrolizumab+SOC vs.SOC | Pembrolizumab+SOC vs.SOC | Pembrolizumab+SOC vs.SOC         | 0.67 (0.56, 0.79)                | <0.0001s                              |

From product-limit (Kaplan-Meier) method for censored data.

One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma) and ECOG performance status(O versus 1).

+ Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma) and ECOG performance status (O versus 1).

Progression-free survival is defined as time from randomization to disease progression, or death, whichever occurs first. DatabaseCutoffDate:02JUL2020.

Source:[P590V01MK3475: adam-adsl; adtte]

22

<div style=\"page-break-after: always\"></div>

Forest Plot of PFS Hazard Ratio by Subgroup Factor Based on Central Radiology Assessment per RECIST 1.1 (Primary Censoring Rule) (ITT Population)

|                       | N#Event   | HR   | 95%CI        |                          |                          |                          |
|-----------------------|-----------|------|--------------|--------------------------|--------------------------|--------------------------|
| Overall               | 749/547   | 0.67 | (0.56, 0.79) |                          |                          |                          |
| Age Category          |           |      |              |                          |                          |                          |
| <65 years             | 427/322   | 0.70 | (0.56, 0.88) |                          |                          |                          |
| >= 65 years           | 322/225   | 0.62 | (0.47, 0.81) |                          |                          |                          |
| Disease Status        |           |      |              |                          |                          |                          |
| Metastatic            | 683/501   | 0.64 | (0.54, 0.77) |                          |                          |                          |
| ECOG                  |           |      |              |                          |                          |                          |
| 0                     | 299/208   | 0.63 | (0.48, 0.83) |                          |                          |                          |
| 1                     | 448/337   | 0.68 | (0.55, 0.84) |                          |                          |                          |
| GeographicRegion      |           |      |              |                          |                          |                          |
| Asia                  | 393/277   | 0.63 | (0.49, 0.80) |                          |                          |                          |
| Rest of World         | 356/270   | 0.71 | (0.55, 0.90) |                          |                          |                          |
| Histology             |           |      |              |                          |                          |                          |
| Adenocarcinoma        | 201/148   | 0.55 | (0.39, 0.77) |                          |                          |                          |
| SquamousCellCarcinoma | 548/399   | 0.71 | (0.58, 0.87) |                          |                          |                          |
| Sex                   |           |      |              |                          |                          |                          |
| Male                  | 625/458   | 0.67 | (0.55, 0.80) |                          |                          |                          |
| Female                | 124/89    | 0.65 | (0.43, 1.00) |                          |                          |                          |
|                       |           |      |              |                          | 10                       |                          |
|                       |           |      |              | EstimatedHazardRatio(HR) | EstimatedHazardRatio(HR) | EstimatedHazardRatio(HR) |

DatabaseCutoffDate:02JUL2020

Source:[P590V01MK3475: adam-adsl;adtte]

## Secondary Objectives

Objective response rate

## Table 15: All comer patients (ITT population)

## By investigator

lapie11-10 Summary ofBestOverall ResponseBased onInvestigatorAssessment perRECIST1.1withConfirmation (ITT Population)

|                                  | Pembrolizumab+SOC   | Pembrolizumab+SOC   | SOC   | SOC   |
|----------------------------------|---------------------|---------------------|-------|-------|
|                                  | n                   | %                   | n     | %     |
| Number of Subjects in Population | 373                 |                     | 376   |       |
| Complete Response (CR)           | 24                  | 6.4                 | 9     | 2.4   |
| Partial Response (PR)            | 144                 | 38.6                | 101   | 26.9  |
| BestOverallResponse(CR+PR)       | 168                 | 45.0                | 110   | 29.3  |
| Stable Disease (SD)              | 128                 | 34.3                | 174   | 46.3  |
| DiseaseControl(CR+PR+SD)         | 296                 | 79.4                | 284   | 75.5  |
| ProgressiveDisease (PD)          | 42                  | 11.3                | 59    | 15.7  |
| Not Evaluable (NE)               | 4                   | 1.1                 | 2     | 0.5   |
| No Assessment                    | 31                  | 8.3                 | 31    | 8.2   |

Responses are based on InvestigatorAssessment best assessment across timepoints,with confirmation.

NE: post-baseline assessment(s) available however not being evaluable (i.e., all post-baseline assessment(s) being NOT EVALUABLE or CR/PR/SD &lt;6 weeks from randomization).

No Assessment: no post-baseline assessment available for response evaluation.

DatabaseCutoffDate:02JUL2020

<div style=\"page-break-after: always\"></div>

## Table 16: By BICR

lable 14.2-49 Summary of Best Overall Response Based on Central Radiology Assessment per RECIST 1.1 with Confirmation (ITT Population)

|                                | Pembrolizumab+SOC   | Pembrolizumab+SOC   | SOC   | SOC   |
|--------------------------------|---------------------|---------------------|-------|-------|
|                                | n                   | %                   |       | %     |
| Number ofSubjects inPopulation | 373                 |                     | 376   |       |
| Complete Response (CR)         | 49                  | 13.1                | 25    | 6.6   |
| Partial Response (PR)          | 113                 | 30.3                | 84    | 22.3  |
| BestOverallResponse(CR+PR)     | 162                 | 43.4                | 109   | 29.0  |
| Stable Disease (SD)            | 126                 | 33.8                | 183   | 48.7  |
| DiseaseControl(CR+PR+SD)       | 288                 | 77.2                | 292   | 77.7  |
| Progressive Disease (PD)       | 46                  | 12.3                | 45    | 12.0  |
| Not Evaluable (NE)             | 7                   | 1.9                 | 8     | 2.1   |
| No Evidence of Disease (NED)   | 3                   | 0.8                 | 3     | 0.8   |
| No Assessment                  | 29                  | 7.8                 | 28    | 7.4   |

Responses arebased on Central RadiologyAssessment best assessment across timepoints,with confirmation.

StablediseaseincludesbothSDand Non-CR/Non-PD

NE: post-baseline assessment(s) available however not being evaluable (i.e., all post-baseline assessment(s) being NOT EVALUABLE or CR/PR/SD &lt; 6 weeks from randomization).

No Assessment: no post-baseline assessment available for response evaluation.

DatabaseCutoffDate:02JUL2020

Table 17: Patients with ESCC whose tumours express PD-L1 CPS

## By investigators

Table 14.2-51 Summary of Best Overall Response Based on Investigator Assessment per RECIST 1.1 with Confirmation

(Subjects with Squamous Cell Carcinoma and PD-L1 CPS ≥ 10, ITT Population)

|                                  | Pembrolizumab+ SOC   | Pembrolizumab+ SOC   | SOC   | SOC   |
|----------------------------------|----------------------|----------------------|-------|-------|
|                                  | n                    | %                    | 1n    | %     |
| Number of Subjects in Population | 143                  |                      | 143   |       |
| Complete Response (CR)           | 10                   | 7.0                  | 3     | 2.1   |
| Partial Response (PR)            | 63                   | 44.1                 | 37    | 25.9  |
| Best Overall Response(CR+PR)     | 73                   | 51.0                 | 40    | 28.0  |
| Stable Disease (SD)              | 43                   | 30.1                 | 69    | 48.3  |
| DiseaseControl(CR+PR+SD)         | 116                  | 81.1                 | 109   | 76.2  |
| Progressive Disease (PD)         | 16                   | 11.2                 | 20    | 14.0  |
| Not Evaluable (NE)               | 2                    | 1.4                  | 0     | 0.0   |
| No Assessment                    | 9                    | 6.3                  | 14    | 9.8   |

Responses are based on Investigator Assessment best assessment across timepoints, with confirmation.

NE: post-baseline assessment(s) available however not being evaluable (i.e., all post-baseline assessment(s) being NOT EVALUABLE or CR/PR/SD &lt; 6 weeks from randomization).

No Assessment: no post-baseline assessment available for response evaluation.

DatabaseCutoffDate:02JUL2020

## By BICR

Table 14.2-53 Summary of Best Overall Response Based on Central Radiology Assessment per RECIST 1.1 with Confirmation (Subjects with Squamous Cell Carcinoma and PD-L1 CPS ≥ 10, ITT Population)

|                                  | Pembrolizumab+ SOC   | Pembrolizumab+ SOC   | SOC   | SOC   |
|----------------------------------|----------------------|----------------------|-------|-------|
|                                  | n                    | %                    | n     | %     |
| Number of Subjects in Population | 143                  |                      | 143   |       |
| Complete Response (CR)           | 24                   | 16.8                 | 9     | 6.3   |
| Partial Response (PR)            | 44                   | 30.8                 | 31    | 21.7  |
| Best Overall Response (CR+PR)    | 68                   | 47.6                 | 40    | 28.0  |
| Stable Disease (SD)              | 41                   | 28.7                 | 70    | 49.0  |
| Disease Control(CR+PR+ SD)       | 109                  | 76.2                 | 110   | 76.9  |
| Progressive Disease (PD)         | 19                   | 13.3                 | 19    | 13.3  |
| Not Evaluable (NE)               | 4                    | 2.8                  | 2     | 1.4   |
| No Evidence of Disease (NED)     | 2                    | 1.4                  | 0     | 0.0   |
| No Assessment                    | 9                    | 6.3                  | 12    | 8.4   |

Responses are based on Central Radiology Assessment best assessment across timepoints,with confirmation.

Stable diseaseincludesbothSDand Non-CR/Non-PD.

NE: post-baseline assessment(s) available however not being evaluable (i.e., all post-baseline assessment(s) being NOT EVALUABLE or CR/PR/SD &lt; 6 weeks from randomization).

No Assessment: no post-baseline assessment available for response evaluation.

Database Cutoff Date: 02JUL2020

≥

10

<div style=\"page-break-after: always\"></div>

## Table 18: Patients with ESCC

## By investigators

Table 14.2-55 Summary of Best Overall Response Based on Investigator Assessment per RECIST 1.1 with Confirmation

(Subjects with Squamous Cell Carcinoma, ITT Population)

|                                  | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC   | SOC   |
|----------------------------------|-----------------------|-----------------------|-------|-------|
|                                  | n                     | %                     | n     | %     |
| Number of Subjects in Population | 274                   |                       | 274   |       |
| Complete Response (CR)           | 21                    | 7.7                   | 4     | 1.5   |
| Partial Response (PR)            | 99                    | 36.1                  | 81    | 29.6  |
| Best Overall Response(CR+PR)     | 120                   | 43.8                  | 85    | 31.0  |
| Stable Disease (SD)              | 97                    | 35.4                  | 126   | 46.0  |
| DiseaseControl(CR+PR+SD)         | 217                   | 79.2                  | 211   | 77.0  |
| Progressive Disease (PD)         | 32                    | 11.7                  | 39    | 14.2  |
| Not Evaluable (NE)               | 3                     | 1.1                   | 0     | 0.0   |
| No Assessment                    | 22                    | 8.0                   | 24    | 8.8   |

Responses are based on Investigator Assessment best assessment across timepoints, with confirmation.

NE: post-baseline assessment(s) available however not being evaluable (i.e., all post-baseline assessment(s) being NOT EVALUABLE or CR/PR/SD &lt; 6 weeks from randomization).

NoAssessment: no post-baseline assessment available for response evaluation.

DatabaseCutoffDate:02JUL2020

## By BICR

Table 14.2-57 Summary of Best Overall Response Based on Central Radiology Assessment per RECIST 1.1 with Confirmation (Subjects with Squamous Cell Carcinoma, ITT Population)

|                                  | Pembrolizumab+SOC   | Pembrolizumab+SOC   | SOC   | SOC   |
|----------------------------------|---------------------|---------------------|-------|-------|
|                                  | n                   | %                   | n     | %     |
| Number of Subjects in Population | 274                 |                     | 274   |       |
| Complete Response (CR)           | 40                  | 14.6                | 21    | 7.7   |
| Partial Response (PR)            | 77                  | 28.1                | 62    | 22.6  |
| Best Overall Response(CR+PR)     | 117                 | 42.7                | 83    | 30.3  |
| Stable Disease (SD)              | 89                  | 32.5                | 130   | 47.4  |
| DiseaseControl(CR+PR+SD)         | 206                 | 75.2                | 213   | 77.7  |
| Progressive Disease (PD)         | 38                  | 13.9                | 35    | 12.8  |
| Not Evaluable (NE)               | 6                   | 2.2                 | 2     | 0.7   |
| No Evidence ofDisease (NED)      | 3                   | 1.1                 | 2     | 0.7   |
| No Assessment                    | 21                  | 7.7                 | 22    | 8.0   |

Responses are based on Central Radiology Assessment best assessment across timepoints, with confirmation.

Stable diseaseincludesboth SDand Non-CR/Non-PD.

NE: post-baseline assessment(s) available however not being evaluable (i.e., all post-baseline assessment(s) being NOT EVALUABLE or CR/PR/SD &lt; 6 weeks from randomization).

No Assessment: no post-baseline assessment available for response evaluation.

Database Cutoff Date: 02JUL2020

Source: [P590V01MK3475: adam-adsl; adrs]

<div style=\"page-break-after: always\"></div>

## Table 19: Patients whose tumours express PD-L1 CPS ≥ 10

## By investigators

Table 14.2-59

Summary of Best Overall Response Based on Investigator Assessment per RECIST 1.1 with Confirmation (Subjects with PD-L1 CPS ≥ 10, ITT Population)

|                                  | Pembrolizumab+SOC   | Pembrolizumab+SOC   | SOC   | SOC   |
|----------------------------------|---------------------|---------------------|-------|-------|
|                                  |                     | %                   | 1n    | %     |
| Number of Subjects in Population | 186                 |                     | 197   |       |
| Complete Response (CR)           | 11                  | 5.9                 | 5     | 2.5   |
| Partial Response (PR)            | 84                  | 45.2                | 48    | 24.4  |
| Best Overall Response (CR+PR)    | 95                  | 51.1                | 53    | 26.9  |
| Stable Disease (SD)              | 55                  | 29.6                | 98    | 49.7  |
| Disease Control(CR+PR+ SD)       | 150                 | 80.6                | 151   | 76.6  |
| Progressive Disease (PD)         | 21                  | 11.3                | 27    | 13.7  |
| Not Evaluable (NE)               | 3                   | 1.6                 | 1     | 0.5   |
| No Assessment                    | 12                  | 6.5                 | 18    | 9.1   |

Responses are based on Investigator Assessment best assessment across timepoints, with confirmation.

randomization).

No Assessment: no post-baseline assessment available for response evaluation.

DatabaseCutoffDate:02JUL2020

## By BICR

Summary of Best Overall Response Based on Central Radiology Assessment per RECIST 1.1 with Confirmation (Subjects with PD-L1 CPS ≥ 10, ITT Population)

|                                  | Pembrolizumab+SOC   | Pembrolizumab+SOC   | SOC   | SOC   |
|----------------------------------|---------------------|---------------------|-------|-------|
|                                  | n                   | %                   | 1n    | %     |
| Number of Subjects in Population | 186                 |                     | 197   |       |
| Complete Response (CR)           | 30                  | 16.1                | 11    | 5.6   |
| Partial Response (PR)            | 57                  | 30.6                | 46    | 23.4  |
| Best Overall Response(CR+PR)     | 87                  | 46.8                | 57    | 28.9  |
| Stable Disease (SD)              | 57                  | 30.6                | 98    | 49.7  |
| Disease Control(CR+ PR+ SD)      | 144                 | 77.4                | 155   | 78.7  |
| Progressive Disease (PD)         | 24                  | 12.9                | 23    | 11.7  |
| Not Evaluable (NE)               | 5                   | 2.7                 | 3     | 1.5   |
| No Evidence of Disease (NED)     | 2                   | 1.1                 | 0     | 0.0   |
| No Assessment                    | 11                  | 5.9                 | 16    | 8.1   |

Responses arebased on CentralRadiologyAssessment best assessment across timepoints,with confirmation.

Stable disease includes both SD and Non-CR/Non-PD.

NE: post-baseline assessment(s) available however not being evaluable (i.e., all post-baseline assessment(s) being NOT EVALUABLE or CR/PR/SD &lt; 6 weeks from randomization).

No Assessment: no post-baseline assessment available for response evaluation.

Database Cutoff Date:02JUL2020

An analysis of the concordance of progression events assessed by investigator and BICR has been provided:

Concordance of Progression Events (Investigator vs. BICR) (Pembrolizumab + SOC vs SOC) (ITT Population)

|                                     | Pembrolizumab+SoC   | SOC         | Total       |
|-------------------------------------|---------------------|-------------|-------------|
| NumberofSubjectsinPopulation        | 373                 | 376         | 749         |
| InvestigatorAssessment-PD           | 246                 | 276         | 522         |
| BICR Agreed                         | 180 (73.2%)         | 194 (70.3%) | 374 (71.6%) |
| BICR andInvestigator agreed on time | 111 (45.1%)         | 131 (47.5%) | 242 (46.4%) |
| BICR has earlier time               | 54 (22.0%)          | 40 (14.5%)  | 94 (18.0%)  |
| BICR has later time                 | 15 (6.1%)           | 23 ( 8.3%)  | 38 (7.3%)   |
| BICR Disagreed                      | 66 (26.8%)          | 82 (29.7%)  | 148 (28.4%) |
| No BICR Assessment                  | 0 (0.0%)            | 0 (0.0%)    | 0 (0.0%)    |
| InvestigatorAssessment-NonPD        | 96                  | 67          | 163         |
| BICR Agreed                         | 84 (87.5%)          | 50 (74.6%)  | 134 (82.2%) |
| BICR Disagreed                      | 12 (12.5%)          | 17 (25.4%)  | 29 (17.8%)  |
| NoBICR Assessment                   | 0 (0.0%)            | 0 (0.0%)    | 0 (0.0%)    |

PD: Progressive Disease.

BICR:BlindedIndependent CentralReview.

DatabaseCutoff Date:02JUL2020

Source:[P590V01MK3475:adam-adsl;adintdt]

<div style=\"page-break-after: always\"></div>

## Duration of Response

## Table 20: All comer patients

Table 11-20 Summary of Time to Response and Duration of Response Based on Investigator Assessment per RECIST 1.1 in Subjects with Confirmed Response (ITT Population)

|                                                   | Pembrolizumab + SOC (N=373)   | SOC (N=376)       |
|---------------------------------------------------|-------------------------------|-------------------|
| Number of subjects with responset                 | 168                           | 110               |
| Time to Response (months)                         |                               |                   |
| Mean (SD)                                         | 2.3 (0.9)                     | 2.4 (1.2)         |
| Median (Range)                                    | 2.1 (1.1-8.3)                 | 2.1 (1.3-12.6)    |
| Response Duration+ (months)                       |                               |                   |
| Median (Range)                                    | 8.3 (1.2+ - 31.0+)            | 6.0 (1.5+ -25.0+) |
| Number(%+)ofSubjectswithExtendedResponseDuration: |                               |                   |
| ≥3 months                                         | 162 (98.8)                    | 106 (100.0)       |
| ≥6 months                                         | 117 (73.5)                    | 50 (50.4)         |
| ≥9 months                                         | 75 (48.2)                     | 22 (24.5)         |
| ≥12 months                                        | 60 (38.6)                     | 16 (17.8)         |
| ≥18 months                                        | 35 (29.4)                     | 5 (7.7)           |
| ≥24 months                                        | 6 (18.1)                      | 1 (6.1)           |

From product-limit (Kaplan-Meier) method for censored data.

Includes subjects with confirmed complete response or partial response.

\"+\" indicates there is no progressive disease by the time of last disease assessment.

Source:[P590V01MK3475: adam-adsl; adtte]

Figure 1l-15 Kaplan-Meier Estimates of Duration of Response in Subjects with Confirmed Response Based on Investigator Assessment per RECIST 1.1 (ITT Population)

)Remaining in Response

<!-- image -->

## Number ofsubjectsatrisk

Pembrolizumab+SOC

168

162

117

75

60

43

35

16

6

2

1

0

SOC

110

106

50

22

16

11

5

2

1

0

0

0

Database CutoffDate:02JUL2020

Timein Months

<div style=\"page-break-after: always\"></div>

## Table 21: Patients with ESCC whose tumours express PD-L1 CPS &gt;=10

Table 11-21

Summary of Time to Response and Duration of Response Based on Investigator Assessment per RECIST 1.1 in Subjects with Confirmed Response (Subjects with Squamous Cell Carcinoma and PD-L1 CPS ≥ 10, ITT Population)

|                                                                                                                                      | Pembrolizumab + SOC (N=143)   | SOC (N=143)        |
|--------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|--------------------|
| Number of subjects with responset                                                                                                    | 73                            | 40                 |
| Time to Response (months)                                                                                                            |                               |                    |
| Mean (SD)                                                                                                                            | 2.3 (0.9)                     | 2.2 (0.6)          |
| Median (Range)                                                                                                                       | 2.1 (1.4-8.3)                 | 2.1 (1.3-4.3)      |
| Response Duration (months)                                                                                                           |                               |                    |
| Median (Range)                                                                                                                       | 10.4 (2.2+ - 28.9+)           | 4.4 (1.5+ - 25.0+) |
| Number(%+) of Subjects with Extended Response Duration:                                                                              |                               |                    |
| ≥3 months                                                                                                                            | 71 (100.0)                    | 39 (100.0)         |
| ≥6 months                                                                                                                            | 57 (84.2)                     | 16 (45.9)          |
| ≥9 months                                                                                                                            | 37 (55.9)                     | 7 (22.3)           |
| ≥12 months                                                                                                                           | 30 (45.3)                     | 7 (22.3)           |
| ≥18 months                                                                                                                           | 16 (33.3)                     | 3 (11.1)           |
| ≥24 months                                                                                                                           | 3 (23.9)                      | 1 (11.1)           |
| Includes subjects with confirmed complete response or partial response.  From product-limit (Kaplan-Meier) method for censored data. |                               |                    |

Kaplan-Meier Estimates of Duration of Response in Subjects with Confirmed Response Based on Investigator Assessment per RECIST 1.1 (Subjects with Squamous Cell Carcinoma and PD-L1 CPS &gt;= 10, ITT Population)

<!-- image -->

Number ofsubjects at risk

Pembrolizumab+SOC

73

SOC

40

71

39

57

16

37

7

30

7

23

4

16

3

7

2

3

0

0

0

0

<div style=\"page-break-after: always\"></div>

## Table 22: Patients with ESCC

## Iavi11-22

## Based on Investigator Assessment per RECIST 1.1 in Subjects with Confimed Response

## Summary of Time to Response and Duration of Response (Subjects with Squamous Cell Carcinoma, ITT Population)

|                                                          | Pembrolizumab + SOC (N=274)   | SOC (N=274)       |
|----------------------------------------------------------|-------------------------------|-------------------|
| Number of subjects with responset                        | 120                           | 85                |
| Tine to Response (months)                                |                               |                   |
| Mean (SD)                                                | 2.2 (0.8)                     | 2.3 (1.2)         |
| Median (Range)                                           | 2.1 (1.1-8.3)                 | 2.1 (1.3-12.6)    |
| ResponseDuration(months)                                 |                               |                   |
| Median (Range)                                           | 9.1 (1.2+ -31.0+)             | 6.1 (1.5+ -25.0+) |
| Nunber (%+) of Subjects with Extended Response Duration: |                               |                   |
| ≥3 months                                                | 117 (100.0)                   | 83 (100.0)        |
| ≥6 months                                                | 87 (77.5)                     | 40 (50.4)         |
| ≥9 months                                                | 56 (51.4)                     | 18 (25.6)         |
| ≥12 months                                               | 45 (41.3)                     | 12 (17.1)         |
| ≥18 months                                               | 26 (32.1)                     | 4 (8.7)           |
| ≥24 months                                               | 5 (19.6)                      | 1 (8.7)           |

Includes subjects with confirmed complete response or partial response.

From product-limit (Kaplan-Meier) method for censored data.

\"+\" indicates there is no progressive disease by the time of last disease assessment. Database CutoffDate:02JUL2020

Source:[P590V01MK3475: adam-adsl; adtte]

riguv1i-1

Kaplan-Meier Estimates of Duration of Response in Subjects with Confirmed Response Based on Investigator Assessment per RECIST 1.1 (Subjects with Squamous Cell Carcinoma, ITT Population)

## (%)

<!-- image -->

## Number ofsubjectsatrisk

| Pembrolizumab+SOC   |   120 |   117 |   87 |   56 |   45 |   34 |   26 |   12 |   5 |   2 | 0   |
|---------------------|-------|-------|------|------|------|------|------|------|-----|-----|-----|
| SOC                 |    85 |    83 |   40 |   18 |   12 |    9 |    4 |    2 |   1 |   0 | 0 0 |

<div style=\"page-break-after: always\"></div>

Table 23: Patients whose tumours express PD-L1 CPS ≥ 10

Summary of Time to Response and Duration of Response Based on Investigator Assessment per RECIST 1.1 in Subjects with Confirmed Response (Subjects with PD-L1 CPS ≥ 10, ITT Population)

|                                                         | Pembrolizumab + SOC (N=186)   | SOC (N=197)       |
|---------------------------------------------------------|-------------------------------|-------------------|
| Number of subjects with responset                       | 95                            | 53                |
| Time to Response (months)                               |                               |                   |
| Mean (SD)                                               | 2.3 (1.0)                     | 2.3 (0.6)         |
| Median (Range)                                          | 2.1 (1.4-8.3)                 | 2.1 (1.3-4.3)     |
| Response Duration+(months)                              |                               |                   |
| Median (Range)                                          | 10.4 (1.9 - 28.9+)            | 5.6 (1.5+ -25.0+) |
| Nunber (%+)of Subjects with Extended Response Duration: |                               |                   |
| ≥3 months                                               | 91 (98.9)                     | 50 (100.0)        |
| ≥6 months                                               | 71 (80.2)                     | 22 (47.7)         |
| ≥9 months                                               | 46 (52.9)                     | 10 (23.2)         |
| ≥12 months                                              | 38 (43.7)                     | 10 (23.2)         |
| ≥18 months                                              | 22 (33.4)                     | 4 (10.4)          |
| ≥24 months                                              | 4 (24.0)                      | 1 (7.8)           |

From product-limit (Kaplan-Meier) method for censored data.

Includes subjects with confirmed complete response or partial response.

\"+\" indicates there is no progressive disease by the time of last disease assessment. Database Cutoff Date:02JUL2020

Source:[P590V01MK3475: adam-adsl; adtte]

Figure 11-18 Kaplan-Meier Estimates of Duration of Response in Subjects with Confirmed Response Based on Investigator Assessment per RECIST 1.1 (Subjects with PD-L1 CPS &gt;= 10, ITT Population)

<!-- image -->

Number ofsubjects at risk

Pembrolizumab+SOC S6 91 71 46 38 29 22 11 0 0 SOC 53 50 22 10 10 5 4 2 0 0

<div style=\"page-break-after: always\"></div>

Figure 15: Patients with ESCC whose tumours express PD-L1 CPS ≥ 10

riguCI1-10

Kaplan-Meier Estimates of Duration of Response in Subjects with Confirmed Response Based on Investigator Assessment per RECIST 1.1 (Subjects with Squamous Cell Carcinoma and PD-L1 CPS &gt;= 10, ITT Population)

<!-- image -->

## Patient-reported Outcomes-table 24:

Table 11-24

Analysis of Change fromBaseline in EORTC QLQ-C30 Global Health Status/QoL toWeek 18

(FAS Population)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Week 18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Week 18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Change fromBaseline toWeek 18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Change fromBaseline toWeek 18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Change fromBaseline toWeek 18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | LS Mean (95% C1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Pembrolizumab+SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 356                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 64.37 (21.23)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 225                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 65.00 (20.80)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 366                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | -1.74 (-4.24, 0.75)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | -1.74 (-4.24, 0.75)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 355                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 65.66 (20.06)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 206                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 66.42 (18.59)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 363                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | -1.64 (-4.21, 0.92)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | -1.64 (-4.21, 0.92)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Pairwise Comparison                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Difference in LS Means! (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | p-Valuet                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Pembrolizumab+SOCvs.SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | -0.10(-3.40,3.20)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0.9530                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction, stratification factors geographic region (Asia Versus Rest ofthe World) and tumor histology(Adenocarcinoma versusSquamousCell Carcinoma)and ECOGperformance status (O versus 1). For baseline and Week 18, Nis the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, Nis the number of subjects in the analysis population in each treatment group. | Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction, stratification factors geographic region (Asia Versus Rest ofthe World) and tumor histology(Adenocarcinoma versusSquamousCell Carcinoma)and ECOGperformance status (O versus 1). For baseline and Week 18, Nis the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, Nis the number of subjects in the analysis population in each treatment group. | Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction, stratification factors geographic region (Asia Versus Rest ofthe World) and tumor histology(Adenocarcinoma versusSquamousCell Carcinoma)and ECOGperformance status (O versus 1). For baseline and Week 18, Nis the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, Nis the number of subjects in the analysis population in each treatment group. | Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction, stratification factors geographic region (Asia Versus Rest ofthe World) and tumor histology(Adenocarcinoma versusSquamousCell Carcinoma)and ECOGperformance status (O versus 1). For baseline and Week 18, Nis the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, Nis the number of subjects in the analysis population in each treatment group. | Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction, stratification factors geographic region (Asia Versus Rest ofthe World) and tumor histology(Adenocarcinoma versusSquamousCell Carcinoma)and ECOGperformance status (O versus 1). For baseline and Week 18, Nis the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, Nis the number of subjects in the analysis population in each treatment group. | Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction, stratification factors geographic region (Asia Versus Rest ofthe World) and tumor histology(Adenocarcinoma versusSquamousCell Carcinoma)and ECOGperformance status (O versus 1). For baseline and Week 18, Nis the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, Nis the number of subjects in the analysis population in each treatment group. | Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction, stratification factors geographic region (Asia Versus Rest ofthe World) and tumor histology(Adenocarcinoma versusSquamousCell Carcinoma)and ECOGperformance status (O versus 1). For baseline and Week 18, Nis the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, Nis the number of subjects in the analysis population in each treatment group. | Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction, stratification factors geographic region (Asia Versus Rest ofthe World) and tumor histology(Adenocarcinoma versusSquamousCell Carcinoma)and ECOGperformance status (O versus 1). For baseline and Week 18, Nis the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, Nis the number of subjects in the analysis population in each treatment group. |

Source:[P590V01MK3475:adam-adsl; adpro]

<div style=\"page-break-after: always\"></div>

## Empirical Mean Change from Baseline and 95% CI for the EORTC QLQ-C30 Global Health Status/QoL Over Time byTreatment Group (FAS Population)

<!-- image -->

Database CutoffDate:02JUL2020

Source: [P590V01MK3475: adam-adsl; adpro]

## Analysisof ChangefromBaselineinOES-18DysphagiatoWeek18 (FAS Population)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Week18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Week18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | ChangefromBaselinetoWeek18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ChangefromBaselinetoWeek18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ChangefromBaselinetoWeek18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | LS Mean (95%CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Pembrolizumab+SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 355                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 33.18 (30.93)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 224                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 29.27 (34.06)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 366                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | -3.18 (-7.19, 0.82)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | -3.18 (-7.19, 0.82)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 350                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 37.87 (32.82)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 204                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 36.76 (35.43)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 359                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 2.36 (-1.77, 6.49)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 2.36 (-1.77, 6.49)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Pairwise Comparison                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Difference inLS Meanst (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | p-Valuet                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Pembrolizumab+SOCvs.SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | -5.54 (-10.93, -0.16)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.0436                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| ↑Based on a cLDA model with thePROscores as theresponse variable with covariatesfor treatment by study visit interaction,stratification factors geographic region(Asia versusRest oftheWorld)and tumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus1). For baseline and Week 18,N is the number of subjects in each treatment group with non-missing assessments at the specific time point;for change from baseline,N is the numberof subjects inthe analysis populationineach treatment group. DatabaseCutoffDate:02JUL2020 | ↑Based on a cLDA model with thePROscores as theresponse variable with covariatesfor treatment by study visit interaction,stratification factors geographic region(Asia versusRest oftheWorld)and tumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus1). For baseline and Week 18,N is the number of subjects in each treatment group with non-missing assessments at the specific time point;for change from baseline,N is the numberof subjects inthe analysis populationineach treatment group. DatabaseCutoffDate:02JUL2020 | ↑Based on a cLDA model with thePROscores as theresponse variable with covariatesfor treatment by study visit interaction,stratification factors geographic region(Asia versusRest oftheWorld)and tumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus1). For baseline and Week 18,N is the number of subjects in each treatment group with non-missing assessments at the specific time point;for change from baseline,N is the numberof subjects inthe analysis populationineach treatment group. DatabaseCutoffDate:02JUL2020 | ↑Based on a cLDA model with thePROscores as theresponse variable with covariatesfor treatment by study visit interaction,stratification factors geographic region(Asia versusRest oftheWorld)and tumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus1). For baseline and Week 18,N is the number of subjects in each treatment group with non-missing assessments at the specific time point;for change from baseline,N is the numberof subjects inthe analysis populationineach treatment group. DatabaseCutoffDate:02JUL2020 | ↑Based on a cLDA model with thePROscores as theresponse variable with covariatesfor treatment by study visit interaction,stratification factors geographic region(Asia versusRest oftheWorld)and tumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus1). For baseline and Week 18,N is the number of subjects in each treatment group with non-missing assessments at the specific time point;for change from baseline,N is the numberof subjects inthe analysis populationineach treatment group. DatabaseCutoffDate:02JUL2020 | ↑Based on a cLDA model with thePROscores as theresponse variable with covariatesfor treatment by study visit interaction,stratification factors geographic region(Asia versusRest oftheWorld)and tumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus1). For baseline and Week 18,N is the number of subjects in each treatment group with non-missing assessments at the specific time point;for change from baseline,N is the numberof subjects inthe analysis populationineach treatment group. DatabaseCutoffDate:02JUL2020 | ↑Based on a cLDA model with thePROscores as theresponse variable with covariatesfor treatment by study visit interaction,stratification factors geographic region(Asia versusRest oftheWorld)and tumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus1). For baseline and Week 18,N is the number of subjects in each treatment group with non-missing assessments at the specific time point;for change from baseline,N is the numberof subjects inthe analysis populationineach treatment group. DatabaseCutoffDate:02JUL2020 | ↑Based on a cLDA model with thePROscores as theresponse variable with covariatesfor treatment by study visit interaction,stratification factors geographic region(Asia versusRest oftheWorld)and tumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus1). For baseline and Week 18,N is the number of subjects in each treatment group with non-missing assessments at the specific time point;for change from baseline,N is the numberof subjects inthe analysis populationineach treatment group. DatabaseCutoffDate:02JUL2020 |

Source:[P590V01MK3475:adam-adsl;adpro]

## Analysis of Change from Baseline in OES-18 Pain to Week 18 (FAS Population)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Week 18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Week 18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | ChangefromBaselinetoWeek18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ChangefromBaselinetoWeek18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ChangefromBaselinetoWeek18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | LS Mean (95%CI)i                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Pembrolizumab+SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 355                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 15.43 (18.51)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 224                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 10.02 (15.85)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 366                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | -4.78 (-7.01, -2.56)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | -4.78 (-7.01, -2.56)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 350                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 17.30 (20.03)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 204                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 13.13 (17.79)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 359                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | -1.85 (-4.14, 0.45)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | -1.85 (-4.14, 0.45)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PairwiseComparison                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Difference in LS Meanst (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | p-Valuet                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Pembrolizumab+SOCvs.SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | -2.94 (-5.86, -0.02)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.0487                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Based onacLDA modelwith the PROscores as theresponse variable withcovariates for treatment by studyvisit interaction,stratificationfactorsgeographic region(Asia versusRest oftheWorld) andtumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus 1). For baseline and Week 18, N is the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, N is the numberof subjects in the analysispopulationineach treatmentgroup. | Based onacLDA modelwith the PROscores as theresponse variable withcovariates for treatment by studyvisit interaction,stratificationfactorsgeographic region(Asia versusRest oftheWorld) andtumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus 1). For baseline and Week 18, N is the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, N is the numberof subjects in the analysispopulationineach treatmentgroup. | Based onacLDA modelwith the PROscores as theresponse variable withcovariates for treatment by studyvisit interaction,stratificationfactorsgeographic region(Asia versusRest oftheWorld) andtumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus 1). For baseline and Week 18, N is the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, N is the numberof subjects in the analysispopulationineach treatmentgroup. | Based onacLDA modelwith the PROscores as theresponse variable withcovariates for treatment by studyvisit interaction,stratificationfactorsgeographic region(Asia versusRest oftheWorld) andtumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus 1). For baseline and Week 18, N is the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, N is the numberof subjects in the analysispopulationineach treatmentgroup. | Based onacLDA modelwith the PROscores as theresponse variable withcovariates for treatment by studyvisit interaction,stratificationfactorsgeographic region(Asia versusRest oftheWorld) andtumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus 1). For baseline and Week 18, N is the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, N is the numberof subjects in the analysispopulationineach treatmentgroup. | Based onacLDA modelwith the PROscores as theresponse variable withcovariates for treatment by studyvisit interaction,stratificationfactorsgeographic region(Asia versusRest oftheWorld) andtumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus 1). For baseline and Week 18, N is the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, N is the numberof subjects in the analysispopulationineach treatmentgroup. | Based onacLDA modelwith the PROscores as theresponse variable withcovariates for treatment by studyvisit interaction,stratificationfactorsgeographic region(Asia versusRest oftheWorld) andtumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus 1). For baseline and Week 18, N is the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, N is the numberof subjects in the analysispopulationineach treatmentgroup. | Based onacLDA modelwith the PROscores as theresponse variable withcovariates for treatment by studyvisit interaction,stratificationfactorsgeographic region(Asia versusRest oftheWorld) andtumorhistology(AdenocarcinomaversusSquamousCellCarcinoma)andECOGperformancestatus(Oversus 1). For baseline and Week 18, N is the number of subjects in each treatment group with non-missing assessments at the specific time point; for change from baseline, N is the numberof subjects in the analysispopulationineach treatmentgroup. |

Source: [P590V01MK3475: adam-adsl; adpro]

<div style=\"page-break-after: always\"></div>

## Ancillary Analyses

## Participants whose tumours express PD-L1 CPS &lt;10

Table 25: Subject Characteristics

## (Subjects with PD-L1 CPS &lt; 10, ITT Population)

|                                         | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC           | SOC          | Total         | Total        |
|-----------------------------------------|-----------------------|-----------------------|---------------|--------------|---------------|--------------|
|                                         | n                     | (%)                   | n             | (%)          | n             | (%)          |
| Subjects in population                  | 175                   |                       | 172           |              | 347           |              |
| Gender                                  |                       |                       |               |              |               |              |
| Male                                    | 145                   | (82.9)                | 152           | (88.4)       | 297           | (85.6)       |
| Female                                  | 30                    | (17.1)                | 20            | (11.6)       | 50            | (14.4)       |
| Age (Years)                             |                       |                       |               |              |               |              |
| < 65                                    | 98                    | (56.0)                | 95            | (55.2)       | 193           | (55.6)       |
| >= 65                                   | 77                    | (44.0)                | 77            | (44.8)       | 154           | (44.4)       |
| Mean SD Median                          | 62.9 9.8 64.0         |                       | 62.5 9.3 63.0 |              | 62.7 9.5 63.0 |              |
| Race                                    |                       |                       |               |              |               |              |
| American Indian Or Alaska Native Asian  | 2 88                  | (1.1) (50.3)          | 5 90          | (2.9) (52.3) | 7 178         | (2.0) (51.3) |
| Black Or African American               | 3                     | (1.7)                 | 1             | (0.6)        | 4             | (1.2)        |
| Multiple                                | 3                     | (1.7)                 | 3             | (1.7)        | 6             | (1.7)        |
| American Indian Or Alaska Native, White | 2                     | (1.1)                 | 3             | (1.7)        | 5             | (1.4)        |
| Black Or African American,              | 1                     | (0.6)                 | 0             | (0.0)        | 1             | (0.3)        |
| White                                   |                       |                       |               |              |               |              |
| White Missing                           | 74 5                  | (42.3) (2.9)          | 65 8          | (37.8) (4.7) | 139 13        | (40.1) (3.7) |
| Ethnicity                               |                       |                       |               |              |               |              |
| Hispanic Or Latino                      | 22                    | (12.6)                | 27            | (15.7)       | 49            | (14.1)       |
| Not Hispanic Or Latino                  | 148                   | (84.6)                | 132           | (76.7)       | 280           | (80.7)       |
| Not Reported                            | 0                     |                       |               |              |               |              |
|                                         |                       | (0.0)                 | 1             | (0.6)        | 1             | (0.3)        |
| Unknown                                 | 5                     | (2.9)                 | 12            | (7.0)        | 17            | (4.9)        |
| Region                                  |                       |                       |               |              |               |              |
| Asia                                    | 85                    | (48.6)                | 89            | (51.7)       | 174           | (50.1)       |

## Analysisof ChangefromBaseline in OES-18Reflux toWeek18 (FAS Population)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Week18                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Week18                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ChangefromBaselinetoWeek18                                                                                                                                                                                                                                                                                                                                                                                                                                               | ChangefromBaselinetoWeek18                                                                                                                                                                                                                                                                                                                                                                                                                                               | ChangefromBaselinetoWeek18                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | LSMean(95%CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Pembrolizumab+SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 355                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 15.96 (21.78)                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 224                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 14.88 (19.95)                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 366                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | -0.22 (-2.81, 2.36)                                                                                                                                                                                                                                                                                                                                                                                                                                                      | -0.22 (-2.81, 2.36)                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 350                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 16.10 (21.63)                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 204                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 16.09 (21.40)                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 359                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.71 (-1.96,3.38)                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.71 (-1.96,3.38)                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Pairwise Comparison                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Difference in LS Meanst (95%CI)                                                                                                                                                                                                                                                                                                                                                                                                                                          | p-Valuet                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Pembrolizumab+SOCvs.SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | -0.93 (-4.36, 2.49)                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.5932                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| ↑Based on a cLDA model with thePROscores as the response variable with covariatesfor treatment by study visit interaction,stratificationfactors geographicregion(Asia versusRest of theWorld)and tumorhistology(Adenocarcinoma versus Squamous Cell Carcinoma)and ECOG performance status(0versus 1). For baseline and Week18,N is the number of sbjects in each treatment group with non-missing assessments at the specific time point;for changefrom baseline,Nis the | ↑Based on a cLDA model with thePROscores as the response variable with covariatesfor treatment by study visit interaction,stratificationfactors geographicregion(Asia versusRest of theWorld)and tumorhistology(Adenocarcinoma versus Squamous Cell Carcinoma)and ECOG performance status(0versus 1). For baseline and Week18,N is the number of sbjects in each treatment group with non-missing assessments at the specific time point;for changefrom baseline,Nis the | ↑Based on a cLDA model with thePROscores as the response variable with covariatesfor treatment by study visit interaction,stratificationfactors geographicregion(Asia versusRest of theWorld)and tumorhistology(Adenocarcinoma versus Squamous Cell Carcinoma)and ECOG performance status(0versus 1). For baseline and Week18,N is the number of sbjects in each treatment group with non-missing assessments at the specific time point;for changefrom baseline,Nis the | ↑Based on a cLDA model with thePROscores as the response variable with covariatesfor treatment by study visit interaction,stratificationfactors geographicregion(Asia versusRest of theWorld)and tumorhistology(Adenocarcinoma versus Squamous Cell Carcinoma)and ECOG performance status(0versus 1). For baseline and Week18,N is the number of sbjects in each treatment group with non-missing assessments at the specific time point;for changefrom baseline,Nis the | ↑Based on a cLDA model with thePROscores as the response variable with covariatesfor treatment by study visit interaction,stratificationfactors geographicregion(Asia versusRest of theWorld)and tumorhistology(Adenocarcinoma versus Squamous Cell Carcinoma)and ECOG performance status(0versus 1). For baseline and Week18,N is the number of sbjects in each treatment group with non-missing assessments at the specific time point;for changefrom baseline,Nis the | ↑Based on a cLDA model with thePROscores as the response variable with covariatesfor treatment by study visit interaction,stratificationfactors geographicregion(Asia versusRest of theWorld)and tumorhistology(Adenocarcinoma versus Squamous Cell Carcinoma)and ECOG performance status(0versus 1). For baseline and Week18,N is the number of sbjects in each treatment group with non-missing assessments at the specific time point;for changefrom baseline,Nis the | ↑Based on a cLDA model with thePROscores as the response variable with covariatesfor treatment by study visit interaction,stratificationfactors geographicregion(Asia versusRest of theWorld)and tumorhistology(Adenocarcinoma versus Squamous Cell Carcinoma)and ECOG performance status(0versus 1). For baseline and Week18,N is the number of sbjects in each treatment group with non-missing assessments at the specific time point;for changefrom baseline,Nis the | ↑Based on a cLDA model with thePROscores as the response variable with covariatesfor treatment by study visit interaction,stratificationfactors geographicregion(Asia versusRest of theWorld)and tumorhistology(Adenocarcinoma versus Squamous Cell Carcinoma)and ECOG performance status(0versus 1). For baseline and Week18,N is the number of sbjects in each treatment group with non-missing assessments at the specific time point;for changefrom baseline,Nis the |

Source:[P590V01MK3475:adam-adsl;adpro]

(85.6)

(14.4)

(55.6)

(44.4)

94

7

(2.0)

(51.3)

4

(1.2)

6

(1.7)

5

(1.4)

1

(0.3)

(40.1)

13

(3.7)

(14.1)

(80.7)

1

(0.3)

17

(4.9)

(50.1)

<div style=\"page-break-after: always\"></div>

(49.9)

(71.2)

(16.7)

(12.1)

(10.4)

(89.6)

2

(0.6)

(99.4)

1

(0.3)

1

(0.3)

4

(1.2)

5

(1.4)

12

(3.5)

13

(3.7)

(72.3)

8

(2.3)

50

2

(0.6)

(36.3)

(63.4)

1

(0.3)

(28.8)

(71.2)

(89.6)

(10.4)

| Rest of World                                                   | 90                  | (51.4)              | 83   | (48.3)   | 173   | (49.9)   |
|-----------------------------------------------------------------|---------------------|---------------------|------|----------|-------|----------|
| Primary Diagnosis                                               |                     |                     |      |          |       |          |
|                                                                 | Pembrolizumab + SOC | Pembrolizumab + SOC | SOC  | SOC      | Total | Total    |
|                                                                 | n                   | (%)                 | n    | (%)      | n     | (%)      |
| Squamous Cell Carcinoma of the Esophagus                        | 121                 | (69.1)              | 126  | (73.3)   | 247   | (71.2)   |
| Adenocarcinoma of the Esophagus                                 | 35                  | (20.0)              | 23   | (13.4)   | 58    | (16.7)   |
| Adenocarcinoma of the Gastroesophageal Junction, Siewert Type I | 19                  | (10.9)              | 23   | (13.4)   | 42    | (12.1)   |
| Metastatic Staging                                              |                     |                     |      |          |       |          |
| M0                                                              | 16                  | (9.1)               | 20   | (11.6)   | 36    | (10.4)   |
| M1                                                              | 159                 | (90.9)              | 152  | (88.4)   | 311   | (89.6)   |
| Brain Metastasis                                                |                     |                     |      |          |       |          |
| Yes                                                             | 1                   | (0.6)               | 1    | (0.6)    | 2     | (0.6)    |
| No                                                              | 174                 | (99.4)              | 171  | (99.4)   | 345   | (99.4)   |
| Current Disease Stage                                           |                     |                     |      |          |       |          |
| IB                                                              | 0                   | (0.0)               | 1    | (0.6)    | 1     | (0.3)    |
| IIB                                                             | 1                   | (0.6)               | 0    | (0.0)    | 1     | (0.3)    |
| III                                                             | 1                   | (0.6)               | 3    | (1.7)    | 4     | (1.2)    |
| IIIA                                                            | 3                   | (1.7)               | 2    | (1.2)    | 5     | (1.4)    |
| IIIB                                                            | 4                   | (2.3)               | 8    | (4.7)    | 12    | (3.5)    |
| IIIC                                                            | 7                   | (4.0)               | 6    | (3.5)    | 13    | (3.7)    |
| IV                                                              | 119                 | (68.0)              | 132  | (76.7)   | 251   | (72.3)   |
| IVA                                                             | 5                   | (2.9)               | 3    | (1.7)    | 8     | (2.3)    |
| IVB                                                             | 34                  | (19.4)              | 16   | (9.3)    | 50    | (14.4)   |
| IVE                                                             | 1                   | (0.6)               | 1    | (0.6)    | 2     | (0.6)    |
| ECOG Performance Scale                                          |                     |                     |      |          |       |          |
| 0                                                               | 59                  | (33.7)              | 67   | (39.0)   | 126   | (36.3)   |
| 1                                                               | 115                 | (65.7)              | 105  | (61.0)   | 220   | (63.4)   |
| 2                                                               | 1                   | (0.6)               | 0    | (0.0)    | 1     | (0.3)    |
| Histology                                                       |                     |                     |      |          |       |          |
| Adenocarcinoma                                                  | 54                  | (30.9)              | 46   | (26.7)   | 100   | (28.8)   |
| Squamous Cell Carcinoma                                         | 121                 | (69.1)              | 126  | (73.3)   | 247   | (71.2)   |
| Disease Status                                                  |                     |                     |      |          |       |          |
| Metastatic                                                      | 159                 | (90.9)              | 152  | (88.4)   | 311   | (89.6)   |
|                                                                 | Pembrolizumab + SOC | Pembrolizumab + SOC | SOC  | SOC      | Total | Total    |
|                                                                 | n                   | (%)                 | n    | (%)      | n     | (%)      |
| Unresectable - Locally Advanced                                 | 16                  | (9.1)               | 20   | (11.6)   | 36    | (10.4)   |
| Database Cutoff Date: 02JUL2020                                 |                     |                     |      |          |       |          |

## Overall survival

<div style=\"page-break-after: always\"></div>

Figure 16: Kaplan-Meier Estimates of Overall Survival (Subjects with PD-L1 CPS &lt; 10, ITT Population)

<!-- image -->

Table 2.7.3-esophageal3: 1

Analysis of Overall Survival

(Subjects with PD-L1 CPS &lt; 10, ITT Population)

| Treatment                   | N   | Number of Events (%)   | Person- Months   | Event Rate/ 100 Person- Months   | Median OS † (Months) (95% CI)   | OS Rate at Month 12 in% † (95% CI)   |
|-----------------------------|-----|------------------------|------------------|----------------------------------|---------------------------------|--------------------------------------|
| Pembrolizumab + SOC         | 175 | 132 (75.4)             | 2187.2           | 6.0                              | 10.5 (9.7, 13.5)                | 47.3 (39.7, 54.5)                    |
| SOC                         | 172 | 139 (80.8)             | 2024.8           | 6.9                              | 10.6 (8.8, 12.0)                | 42.5 (35.0, 49.7)                    |
| Pairwise Comparisons        |     |                        |                  |                                  | Hazard Ratio ‡ (95% CI) ‡       | p-Value                              |
| Pembrolizumab + SOC vs. SOC |     |                        |                  |                                  | 0.86 (0.68, 1.10)               | 0.1174 §                             |

†  From product-limit (Kaplan-Meier) method for censored data.

‡ Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma).

§ One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma).

Database Cutoff Date: 02JUL2020.

Source:  [P590V01MK3475: adam-adsl; adtte]

47.3 (39.7, 54.5)

42.5 (35.0, 49.7)

p-Value

<div style=\"page-break-after: always\"></div>

<!-- image -->

Database Cutoff Date: 02JUL2020

Figure 17: Forest Plot of OS Hazard Ratio by Subgroup Factor (Subjects with PD-L1 CPS &lt; 10, ITT Population)

## Progression Free Survival

<!-- image -->

Progression-free survival is defined as time from randomization to disease progression, or death, whichever occurs first.

<div style=\"page-break-after: always\"></div>

## Figure 18: Progression-Free Survival Based on Investigator Assessment Per RECIST 1.1 (Primary Censoring Rule) (Subjects with PDL1 &lt; 10, ITT Population)

## Analysis of Progression-Free Survival Based on Investigator Assessment Per RECIST 1.1

## (Primary Censoring Rule)

(Subjects with PD-L1 CPS &lt; 10, ITT Population)

| Treatment                   | N   | Number of Events (%)   | Person- Months   | Event Rate/ 100 Person- Months   | Median PFS † (Months) (95% CI)   | PFS Rate at Month 12 in% † (95% CI)   |
|-----------------------------|-----|------------------------|------------------|----------------------------------|----------------------------------|---------------------------------------|
| Pembrolizumab + SOC         | 175 | 148 (84.6)             | 1288.2           | 11.5                             | 6.2 (6.0, 6.4)                   | 19.0 (13.4, 25.5)                     |
| SOC                         | 172 | 154 (89.5)             | 1084.1           | 14.2                             | 6.0 (5.0, 6.2)                   | 15.0 (10.0, 21.1)                     |
| Pairwise Comparisons        |     |                        |                  |                                  | Hazard Ratio ‡ (95% CI) ‡        | p-Value                               |
| Pembrolizumab + SOC vs. SOC |     |                        |                  |                                  | 0.80 (0.64, 1.01)                | 0.0272 §                              |

†  From product-limit (Kaplan-Meier) method for censored data.

‡ Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma).

§ One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma).

Database Cutoff Date: 02JUL2020.

Analysis of ObjectiveResponsewithConfirmationBased onInvestigator Assessment per RECIST 1.1

## (Subjects with PD-L1 CPS &lt; 10, ITT Population)

|                   |     |                              |                                      | Differencein%Pembrolizumab+SOCvs.SOC   | Differencein%Pembrolizumab+SOCvs.SOC   |
|-------------------|-----|------------------------------|--------------------------------------|----------------------------------------|----------------------------------------|
| Treatment         | N   | Numberof Objective Responses | Objective Response Rate (%) (95% CI) | Estimate(95%CI))                       | p-Valuelt                              |
| Pembrolizumab+SOC | 175 | 68                           | 38.9 (31.6, 46.5)                    | 6.8 (-3.3, 16.8)                       | 0.0930                                 |
| SOC               | 172 | 55                           | 32.0 (25.1, 39.5)                    |                                        |                                        |

Based on Miettinen&amp;Nurminenmethod stratifiedbygeographicregion(Asia versus Rest of theWorld) andtumor histology (Adenocarcinoma versus SquamousCellCarcinoma).

If One-sided p-value for testing. HO: difference in % = 0 versus H1: difference in % &gt; 0. ResponsesarebasedonInvestigatorAssessmentperRECIST1.1withconfirmation. DatabaseCutoffDate:02JUL2020

## Patients with adenocarcinoma of the oesophagus

## Baseline Characteristics

## Table 26: Subject Characteristics (Subjects with Adenocarcinoma, ITT Population)

(85.1)

(14.9)

(59.2)

(40.8)

83

|                        | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC      | SOC    | Total    | Total   |
|------------------------|-----------------------|-----------------------|----------|--------|----------|---------|
|                        | n                     | (%)                   | n        | (%)    | n        | (%)     |
| Subjects in population | 99                    |                       | 102      |        | 201      |         |
| Gender                 |                       |                       |          |        |          |         |
| Male                   | 84                    | (84.8)                | 87       | (85.3) | 171      | (85.1)  |
| Female                 | 15                    | (15.2)                | 15       | (14.7) | 30       | (14.9)  |
| Age (Years)            |                       |                       |          |        |          |         |
| < 65                   | 49                    | (49.5)                | 70       | (68.6) | 119      | (59.2)  |
| >= 65                  | 50                    | (50.5)                | 32       | (31.4) | 82       | (40.8)  |
| Mean                   | 62.3                  |                       | 59.1     |        | 60.7     |         |
| SD                     | 11.9                  |                       | 10.2     |        | 11.2     |         |
| Median                 | 65.0                  |                       | 59.5     |        | 62.0     |         |
| Range                  | 28 to 83              |                       | 27 to 79 |        | 27 to 83 |         |
| Race                   | Race                  | Race                  | Race     | Race   | Race     | Race    |

19.0 (13.4, 25.5)

15.0 (10.0, 21.1)

p-Value

<div style=\"page-break-after: always\"></div>

6

(3.0)

(17.9)

2

(1.0)

6

(3.0)

3

(1.5)

3

(1.5)

(69.2)

12

(6.0)

(14.9)

(77.1)

1

(0.5)

12

(6.0)

3

(1.5)

(16.4)

(83.6)

| American Indian Or Alaska Native        | 3                 | (3.0)             | 3                 | (2.9)             | 6                 | (3.0)             |
|-----------------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| Asian                                   | 18                | (18.2)            | 18                | (17.6)            | 36                | (17.9)            |
| Black Or African American               | 0                 | (0.0)             | 2                 | (2.0)             | 2                 | (1.0)             |
| Multiple                                | 2                 | (2.0)             | 4                 | (3.9)             | 6                 | (3.0)             |
| American Indian Or Alaska Native, White | 1                 | (1.0)             | 2                 | (2.0)             | 3                 | (1.5)             |
| Black Or African American, White        | 1                 | (1.0)             | 2                 | (2.0)             | 3                 | (1.5)             |
| White                                   | 69                | (69.7)            | 70                | (68.6)            | 139               | (69.2)            |
| Missing                                 | 7                 | (7.1)             | 5                 | (4.9)             | 12                | (6.0)             |
| Ethnicity                               |                   |                   |                   |                   |                   |                   |
| Hispanic Or Latino                      | 10                | (10.1)            | 20                | (19.6)            | 30                | (14.9)            |
| Not Hispanic Or Latino                  | 82                | (82.8)            | 73                | (71.6)            | 155               | (77.1)            |
| Not Reported                            | 0                 | (0.0)             | 1                 | (1.0)             | 1                 | (0.5)             |
| Unknown                                 | 5                 | (5.1)             | 7                 | (6.9)             | 12                | (6.0)             |
| Missing                                 | 2                 | (2.0)             | 1                 | (1.0)             | 3                 | (1.5)             |
| Region                                  |                   |                   |                   |                   |                   |                   |
| Asia                                    | 16                | (16.2)            | 17                | (16.7)            | 33                | (16.4)            |
| Rest of World                           | 83                | (83.8)            | 85                | (83.3)            | 168               | (83.6)            |
| Primary Diagnosis                       | Primary Diagnosis | Primary Diagnosis | Primary Diagnosis | Primary Diagnosis | Primary Diagnosis | Primary Diagnosis |

<div style=\"page-break-after: always\"></div>

(54.7)

(45.3)

15

(7.5)

(92.5)

2

(1.0)

(99.0)

1

(0.5)

1

(0.5)

1

(0.5)

7

(3.5)

5

(2.5)

(76.1)

3

(1.5)

27

1

(0.5)

2

(1.0)

(45.3)

(53.7)

2

(1.0)

(92.5)

15

(7.5)

|                                                                 | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC   | SOC     | Total   | Total   |
|-----------------------------------------------------------------|-----------------------|-----------------------|-------|---------|---------|---------|
|                                                                 | n                     | (%)                   | n     | (%)     | n       | (%)     |
| Adenocarcinoma of the Esophagus                                 | 58                    | (58.6)                | 52    | (51.0)  | 110     | (54.7)  |
| Adenocarcinoma of the Gastroesophageal Junction, Siewert Type I | 41                    | (41.4)                | 50    | (49.0)  | 91      | (45.3)  |
| Metastatic Staging                                              |                       |                       |       |         |         |         |
| M0                                                              | 8                     | (8.1)                 | 7     | (6.9)   | 15      | (7.5)   |
| M1                                                              | 91                    | (91.9)                | 95    | (93.1)  | 186     | (92.5)  |
| Brain Metastasis                                                |                       |                       |       |         |         |         |
| Yes                                                             | 1                     | (1.0)                 | 1     | (1.0)   | 2       | (1.0)   |
| No                                                              | 98                    | (99.0)                | 101   | (99.0)  | 199     | (99.0)  |
| Current Disease Stage                                           |                       |                       |       |         |         |         |
| IB                                                              | 0                     | (0.0)                 | 1     | (1.0)   | 1       | (0.5)   |
| III                                                             | 1                     | (1.0)                 | 0     | (0.0)   | 1       | (0.5)   |
| IIIA                                                            | 1                     | (1.0)                 | 0     | (0.0)   | 1       | (0.5)   |
| IIIB                                                            | 4                     | (4.0)                 | 3     | (2.9)   | 7       | (3.5)   |
| IIIC                                                            | 2                     | (2.0)                 | 3     | (2.9)   | 5       | (2.5)   |
| IV                                                              | 69                    | (69.7)                | 84    | (82.4)  | 153     | (76.1)  |
| IVA                                                             | 2                     | (2.0)                 | 1     | (1.0)   | 3       | (1.5)   |
| IVB                                                             | 18                    | (18.2)                | 9     | (8.8)   | 27      | (13.4)  |
| IVC                                                             | 1                     | (1.0)                 | 0     | (0.0)   | 1       | (0.5)   |
| IVE                                                             | 1                     | (1.0)                 | 1     | (1.0)   | 2       | (1.0)   |
| ECOG Performance Scale                                          |                       |                       |       |         |         |         |
| 0                                                               | 46                    | (46.5)                | 45    | (44.1)  | 91      | (45.3)  |
| 1                                                               | 52                    | (52.5)                | 56    | (54.9)  | 108     | (53.7)  |
| 2                                                               | 1                     | (1.0)                 | 1     | (1.0)   | 2       | (1.0)   |
| Histology                                                       |                       |                       |       |         |         |         |
| Adenocarcinoma                                                  | 99                    | (100.0)               | 102   | (100.0) | 201     | (100.0) |
| Disease Status                                                  |                       |                       |       |         |         |         |
| Metastatic                                                      | 91                    | (91.9)                | 95    | (93.1)  | 186     | (92.5)  |
| Unresectable - Locally Advanced                                 | 8                     | (8.1)                 | 7     | (6.9)   | 15      | (7.5)   |
| Database Cutoff Date: 02JUL2020                                 |                       |                       |       |         |         |         |

<div style=\"page-break-after: always\"></div>

## Overall Survival

| Pembrolizumab+SOC   |   99 |   90 |   74 |   60 |   48 |   40 |   29 |   18 |   9 | 3   |   1 |   0 | 0   |
|---------------------|------|------|------|------|------|------|------|------|-----|-----|-----|-----|-----|
| SOC                 |  102 |   91 |   71 |   54 |   44 |   33 |   25 |   17 |   5 |     |   2 |   0 | 0 0 |

<!-- image -->

Database Cutoff Date: 02JUL2020

Figure 19: Kaplan-Meier Estimates of Overall Survival (Subjects with Adenocarcinoma, ITT Population)

Table 14.2-184 Analysis of Overall Survival (Subjects with Adenocarcinoma, ITT Population)

| Treatment               | N   | Number of Events (%)   | Person- Months   | Event Rate/ 100 Person- Months   | Median Os t (Months) (95% CI)   | OS Rate at Month 12 in % t (95% CI)   |
|-------------------------|-----|------------------------|------------------|----------------------------------|---------------------------------|---------------------------------------|
| Pembrolizumab+SOC       | 99  | 72 (72.7)              | 1268.0           | 5.7                              | 11.6 (9.7, 15.2)                | 49.5 (39.3, 59.0)                     |
| SOC                     | 102 | 87 (85.3)              | 1171.4           | 7.4                              | 9.9 (7.8, 12.3)                 | 43.1 (33.4, 52.5)                     |
| PairwiseComparisons     |     |                        |                  |                                  | Hazard Ratio+(95%CI)+           | p-Value                               |
| Pembrolizumab+SOCvs.SOC |     |                        |                  |                                  | 0.74 (0.54, 1.02)               | 0.0309$                               |

From product-limit (Kaplan-Meier) method for censored data.

Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (O versus 1).

One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (O versus 1). DatabaseCutoffDate:02JUL2020.

Source:[P590V01MK3475:adam-adsl;adtte]

<div style=\"page-break-after: always\"></div>

## Progression Free Survival

| Pembrolizumab+SOC   |   99 |   78 |   54 |   25 |   22 |   14 | 10 6 4 1 0 0 0   |
|---------------------|------|------|------|------|------|------|------------------|
| SOC                 |  102 |   73 |   45 |   17 |   10 |    6 | 3 1 0 0 0 0 0    |

<!-- image -->

Progression-free survival is defined as time from randomization to disease progression, or death, whichever occurs first. Database Cutoff Date: 02JUL2020

Figure 20: Progression-Free Survival Based on Investigator Assessment Per RECIST 1.1 (Primary Censoring Rule)  (Subjects with Adenocarcinoma, ITT Population)

Table 14.2-186 Analysis of Progression-Free Survival Based on Investigator Assessment per RECIST 1.1 (Primary Censoring Rule) (Subjects with Adenocarcinoma, ITT Population)

| Treatment               | N   | Number of Events (%)   | Person- Months   | Event Rate/ 100 Person- Months   | Median PFS t (Months) (95% CI)   | PFS Rate at Month 12 in % t (95% CI)   |
|-------------------------|-----|------------------------|------------------|----------------------------------|----------------------------------|----------------------------------------|
| Pembrolizumab+SOC       | 99  | 78 (78.8)              | 778.8            | 10.0                             | 6.3 (6.0, 8.1)                   | 27.0 (18.1, 36.6)                      |
| SOC                     | 102 | 89 (87.3)              | 589.2            | 15.1                             | 5.7 (4.1, 6.2)                   | 12.0 (6.3, 19.9)                       |
| Pairwise Comparisons    |     |                        |                  |                                  | Hazard Ratio+(95% CI)+           | p-Value                                |
| Pembrolizumab+SOCvs.SOC |     |                        |                  |                                  | 0.63 (0.46, 0.87)                | 0.0019s                                |

From product-limit (Kaplan-Meier) method for censored data.

Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (O versus 1).

One-sided p-value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and ECOG performance status (0 versus 1). DatabaseCutoffDate:02JUL2020.

Source:[P590V01MK3475: adam-adsl; adtte]

Efficacy by histology and PD-L1 status is summarised in the following table:

Table 27: Efficacy by histology and PD-L1 status

<div style=\"page-break-after: always\"></div>

|                         | ESCC              | ESCC              | AC                | AC                |
|-------------------------|-------------------|-------------------|-------------------|-------------------|
|                         | CPS ≥10 N=286     | CPS <10 N=247     | CPS ≥ 10 N=97     | CPS <10 N=100     |
| OS HR (95% CI)          | 0.57 (0.43, 0.75) | 0.99 (0.74, 1.32) | 0.83 (0.52, 1.34) | 0.66 (0.42, 1.04) |
| PFS HR (95% CI)         | 0.53 (0.40, 0.69) | 0.83 (0.64, 1.11) | 0.49 (0.30, 0.81) | 0.76 (0.49, 1.19) |
| ORR difference (95% CI) | 22.8 (11.6, 33.4) | 2.7 (-9.2, 14.5)  | 27.5 (7.7, 45.6)  | 19.8 (0.4, 37,4)  |

The Applicant was requested to provide the results (HR with 95% CIs by subgroup) of the following two models: (i) A model fitting the main factors treatment arm, geographic region, tumour histology, and PDL1 status together with two-way interaction terms of treatment with one of the three remaining factors, and (ii) a model of treatment, PD-L1, histology, treatment*PDL1, Treatment * Histology, stratified by ECOG and geographic region.

Table 4 Comparison of Multivariate Cox Regression Models Using Likelihood Ratio Test (ITT Population)

| Model Fit Statistics        |   Full Model |   Simple Model |   Likelihood Ratio Test Statisticst | p-valuet   |
|-----------------------------|--------------|----------------|-------------------------------------|------------|
| -2 LOG Ls (With Covariates) |      6610.11 |        6619.54 |                                9.43 | 0.0931     |
| Degree of Freedom           |        15    |          10    |                                5    |            |

↑ Likelihood ratio test statistics is the difference of -2 LOG L between full model and simple model, and it yields an approximate Chi-squared distribution.

1-sided p-value from Chi-squared test.

§ Log likelihood from Cox regression model.

Database Cutoff Date: 02JUL2020

Table 5 Multivariate Cox Regression Analysis for Overall Survival (ITT Population)

| Region/Histology/PD-L1 Status   | Treatment   | N     | Number of Events (%)   | Hazard Ratio (95% CI)t   |
|---------------------------------|-------------|-------|------------------------|--------------------------|
| Asia/EAC/CPS>=10                | P+SOC SOC   | 8 8   | 4 (50.0) 6 (75.0)      | 0.50 (0.31, 0.82)        |
| Asia/EAC/CPS<10                 | P+SOC SOC   | 8 9   | 6 (75.0) 8 (88.9)      | 0.69 (0.43, 1.12)        |
| Asia/SCC/CPS>=10                | P+SOC SOC   | 96 98 | 61 (63.5) 86 (87.8)    | 0.57 (0.43, 0.75)        |
| Asia/SCC/CPS<10                 | P+SOC SOC   | 77 80 | 55 (71.4) 59 (73.8)    | 0.78 (0.58, 1.05)        |
| ROW/EAC/CPS>=10                 | P+SOC SOC   | 35 45 | 26 (74.3) 37 (82.2)    | 0.64 (0.44, 0.94)        |
| ROW/EAC/CPS<10                  | P+SOC SOC   | 47 38 | 35 (74.5) 34 (89.5)    | 0.88 (0.61, 1.27)        |
| ROW/SCC/CPS>=10                 | P+SOC SOC   | 47 46 | 33 (70.2) 36 (78.3)    | 0.72 (0.51, 1.03)        |
| ROW/SCC/CPS<10                  | P+SOC SOC   | 43 45 | 36 (83.7) 38 (84.4)    | 0.99 (0.70, 1.41)        |

Based on Cox regression model with Efron's method of tie handling, with covariates of treatment, PD-L1 status, tumor histology, geographic region, and all two-factor interactions.

DatabaseCutoffDate:02JUL2020

Source:[P590V01MK3475:adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

Table 6 Interaction Tests from Multivariate Cox Regression Analysis (ITT Population)

| Effect                                                                                                                                      | Wald Chisquare TestStatistic                                                                                                                | p-valuet                                                                                                                                    |
|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment                                                                                                                                   | 12.9248                                                                                                                                     | 0.0003                                                                                                                                      |
| PD-L1                                                                                                                                       | 0.5462                                                                                                                                      | 0.4598                                                                                                                                      |
| Histology                                                                                                                                   | 0.0290                                                                                                                                      | 0.8645                                                                                                                                      |
| Treatment*PD-L1                                                                                                                             | 3.3444                                                                                                                                      | 0.0674                                                                                                                                      |
| Treatment*Histology                                                                                                                         | 0.0108                                                                                                                                      | 0.9169                                                                                                                                      |
| ↑ 2-sided p-value from Wald's test based on a Cox regression model stratified by ECOG and geographic region. Database Cutoff Date:02JUL2020 | ↑ 2-sided p-value from Wald's test based on a Cox regression model stratified by ECOG and geographic region. Database Cutoff Date:02JUL2020 | ↑ 2-sided p-value from Wald's test based on a Cox regression model stratified by ECOG and geographic region. Database Cutoff Date:02JUL2020 |

Source:[P590V01MK3475:adam-adsl; adtte]

Table 7 Multivariate Cox Regression Analysis for Overall Survival (ITT Population)

| Histology/PD-L1 Status   | Treatment   | N       | Number of Events (%)   | Hazard Ratio (95% CI)t   |
|--------------------------|-------------|---------|------------------------|--------------------------|
| EAC/CPS>=10              | P+SOC SOC   | 43 53   | 30 (69.8) 43 (81.1)    | 0.64 (0.45, 0.91)        |
| EAC/CPS<10               | P+SOC SOC   | 55 47   | 41 (74.5) 42 (89.4)    | 0.87 (0.61, 1.25)        |
| SCC/CPS>=10              | P+SOC SOC   | 143 144 | 94 (65.7) 122 (84.7)   | 0.63 (0.48, 0.81)        |
| SCC/CPS<10               | P+SOC SOC   | 120 125 | 91 (75.8) 97 (77.6)    | 0.86 (0.66, 1.11)        |

↑Based on Cox regression model with Efron's method of tie handling, stratified by ECOG and gcographic region with covariates of treatment,PD-L1 status,tumor histology,interaction of treatment and PD-L1 status, and interaction of treatment and tumor histology.

DatabaseCutoff Date:02JUL2020

Source:[P590V01MK3475: adam-adsl;adtte]

## EU patient population

## Baseline Characteristics

Table 28: Subject Characteristics in EU and Rest of World (ITT Population)

|                                  | EU       | EU     | Ex-EU    | Ex-EU   | Total    | Total   |
|----------------------------------|----------|--------|----------|---------|----------|---------|
|                                  | n        | (%)    | n        | (%)     | n        | (%)     |
| Subjects in population           | 114      |        | 635      |         | 749      |         |
| Gender                           |          |        |          |         |          |         |
| Male                             | 92       | (80.7) | 533      | (83.9)  | 625      | (83.4)  |
| Female                           | 22       | (19.3) | 102      | (16.1)  | 124      | (16.6)  |
| Age (Years)                      |          |        |          |         |          |         |
| < 65                             | 68       | (59.6) | 359      | (56.5)  | 427      | (57.0)  |
| >= 65                            | 46       | (40.4) | 276      | (43.5)  | 322      | (43.0)  |
| Mean                             | 61.4     |        | 62.6     |         | 62.4     |         |
| SD                               | 9.3      |        | 9.5      |         | 9.5      |         |
| Median                           | 61.0     |        | 63.0     |         | 63.0     |         |
| Range                            | 27 to 79 |        | 30 to 94 |         | 27 to 94 |         |
| Race                             |          |        |          |         |          |         |
| American Indian Or Alaska Native | 0        | (0.0)  | 21       | (3.3)   | 21       | (2.8)   |
| Asian                            | 3        | (2.6)  | 397      | (62.5)  | 400      | (53.4)  |
| Black Or African American        | 0        | (0.0)  | 7        | (1.1)   | 7        | (0.9)   |

(83.4)

(16.6)

(57.0)

(43.0)

94

21

(2.8)

(53.4)

7

(0.9)

<div style=\"page-break-after: always\"></div>

14

(1.9)

9

(1.2)

5

(0.7)

(37.1)

29

(3.9)

(13.2)

(81.6)

3

(0.4)

32

(4.3)

4

(0.5)

(52.5)

(47.5)

| Multiple                                | 0                 | (0.0)             | 14                | (2.2)             | 14                | (1.9)             |
|-----------------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| American Indian Or Alaska Native, White | 0                 | (0.0)             | 9                 | (1.4)             | 9                 | (1.2)             |
| Black Or African American, White        | 0                 | (0.0)             | 5                 | (0.8)             | 5                 | (0.7)             |
| White                                   | 82                | (71.9)            | 196               | (30.9)            | 278               | (37.1)            |
| Missing                                 | 29                | (25.4)            | 0                 | (0.0)             | 29                | (3.9)             |
| Ethnicity                               |                   |                   |                   |                   |                   |                   |
| Hispanic Or Latino                      | 3                 | (2.6)             | 96                | (15.1)            | 99                | (13.2)            |
| Not Hispanic Or Latino                  | 79                | (69.3)            | 532               | (83.8)            | 611               | (81.6)            |
| Not Reported                            | 2                 | (1.8)             | 1                 | (0.2)             | 3                 | (0.4)             |
| Unknown                                 | 26                | (22.8)            | 6                 | (0.9)             | 32                | (4.3)             |
| Missing                                 | 4                 | (3.5)             | 0                 | (0.0)             | 4                 | (0.5)             |
| Region                                  |                   |                   |                   |                   |                   |                   |
| Asia                                    | 0                 | (0.0)             | 393               | (61.9)            | 393               | (52.5)            |
| Rest of World                           | 114               | (100.0)           | 242               | (38.1)            | 356               | (47.5)            |
| Primary Diagnosis                       | Primary Diagnosis | Primary Diagnosis | Primary Diagnosis | Primary Diagnosis | Primary Diagnosis | Primary Diagnosis |

(73.2)

(14.7)

(12.1)

66

(8.8)

(91.2)

3

(0.4)

(99.6)

1

(0.1)

1

(0.1)

10

(1.3)

9

(1.2)

20

(2.7)

25

(3.3)

(74.4)

16

(2.1)

(14.2)

2

(0.3)

2

(0.3)

(39.9)

(59.8)

2

(0.3)

(26.8)

|                                                                 | EU   | EU      | Ex-EU   | Ex-EU   | Total   | Total   |
|-----------------------------------------------------------------|------|---------|---------|---------|---------|---------|
|                                                                 | n    | (%)     | n       | (%)     | n       | (%)     |
| Squamous Cell Carcinoma of the Esophagus                        | 66   | (57.9)  | 482     | (75.9)  | 548     | (73.2)  |
| Adenocarcinoma of the Esophagus                                 | 27   | (23.7)  | 83      | (13.1)  | 110     | (14.7)  |
| Adenocarcinoma of the Gastroesophageal Junction, Siewert Type I | 21   | (18.4)  | 70      | (11.0)  | 91      | (12.1)  |
| Metastatic Staging                                              |      |         |         |         |         |         |
| M0                                                              | 11   | (9.6)   | 55      | (8.7)   | 66      | (8.8)   |
| M1                                                              | 103  | (90.4)  | 580     | (91.3)  | 683     | (91.2)  |
| Brain Metastasis                                                |      |         |         |         |         |         |
| Yes                                                             | 0    | (0.0)   | 3       | (0.5)   | 3       | (0.4)   |
| No                                                              | 114  | (100.0) | 632     | (99.5)  | 746     | (99.6)  |
| Current Disease Stage                                           |      |         |         |         |         |         |
| IB                                                              | 0    | (0.0)   | 1       | (0.2)   | 1       | (0.1)   |
| IIB                                                             | 0    | (0.0)   | 1       | (0.2)   | 1       | (0.1)   |
| III                                                             | 2    | (1.8)   | 8       | (1.3)   | 10      | (1.3)   |
| IIIA                                                            | 0    | (0.0)   | 9       | (1.4)   | 9       | (1.2)   |
| IIIB                                                            | 5    | (4.4)   | 15      | (2.4)   | 20      | (2.7)   |
| IIIC                                                            | 4    | (3.5)   | 21      | (3.3)   | 25      | (3.3)   |
| IV                                                              | 84   | (73.7)  | 473     | (74.5)  | 557     | (74.4)  |
| IVA                                                             | 5    | (4.4)   | 11      | (1.7)   | 16      | (2.1)   |
| IVB                                                             | 11   | (9.6)   | 95      | (15.0)  | 106     | (14.2)  |
| IVC                                                             | 1    | (0.9)   | 1       | (0.2)   | 2       | (0.3)   |
| IVE                                                             | 2    | (1.8)   | 0       | (0.0)   | 2       | (0.3)   |
| ECOG Performance Scale                                          |      |         |         |         |         |         |
| 0                                                               | 52   | (45.6)  | 247     | (38.9)  | 299     | (39.9)  |
| 1                                                               | 62   | (54.4)  | 386     | (60.8)  | 448     | (59.8)  |
| 2                                                               | 0    | (0.0)   | 2       | (0.3)   | 2       | (0.3)   |
| Histology                                                       |      |         |         |         |         |         |
| Adenocarcinoma                                                  | 48   | (42.1)  | 153     | (24.1)  | 201     | (26.8)  |

<div style=\"page-break-after: always\"></div>

(73.2)

(91.2)

66

(8.8)

| Squamous Cell Carcinoma         | 66   | (57.9)   | 482   | (75.9)   | 548   | (73.2)   |
|---------------------------------|------|----------|-------|----------|-------|----------|
| Disease Status                  |      |          |       |          |       |          |
| Metastatic                      | 103  | (90.4)   | 580   | (91.3)   | 683   | (91.2)   |
| Unresectable - Locally Advanced | 11   | (9.6)    | 55    | (8.7)    | 66    | (8.8)    |

<div style=\"page-break-after: always\"></div>

## Overall Survival

Subject Characteristics in EU and Rest of World (ITT Population)

|                                 | EU                              | EU                              | Ex-EU                           | Ex-EU                           | Total                           | Total                           |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                 | n                               | (%)                             | n                               | (%)                             | n                               | (%)                             |
| PD-L1 Status                    |                                 |                                 |                                 |                                 |                                 |                                 |
| CPS >= 10                       | 57                              | (50.0)                          | 326                             | (51.3)                          | 383                             | (51.1)                          |
| CPS < 10                        | 56                              | (49.1)                          | 291                             | (45.8)                          | 347                             | (46.3)                          |
| Not evaluable                   | 0                               | (0.0)                           | 12                              | (1.9)                           | 12                              | (1.6)                           |
| Missing                         | 1                               | (0.9)                           | 6                               | (0.9)                           | 7                               | (0.9)                           |
| Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 |

Source:  [P590V01MK3475: adam-adsl]

Table 2.7.3-esophageal3: 1 Analysis of Overall Survival (ITT Population, EU)

| Treatment                   | N   | Number of Events (%)   | Person- Months   | Event Rate/ 100 Person- Months   | Median OS † (Months) (95% CI)   | OS Rate at Month 12 in% † (95% CI)   |
|-----------------------------|-----|------------------------|------------------|----------------------------------|---------------------------------|--------------------------------------|
| Pembrolizumab + SOC         | 61  | 44 (72.1)              | 830.5            | 5.3                              | 11.4 (8.0, 17.2)                | 49.2 (36.2, 60.9)                    |
| SOC                         | 53  | 45 (84.9)              | 610.0            | 7.4                              | 11.0 (8.0, 13.3)                | 47.2 (33.4, 59.8)                    |
| Pairwise Comparisons        |     |                        |                  |                                  | Hazard Ratio ‡ (95% CI) ‡       | p-Value                              |
| Pembrolizumab + SOC vs. SOC |     |                        |                  |                                  | 0.72 (0.47, 1.10)               | 0.0619 §                             |

†  From product-limit (Kaplan-Meier) method for censored data.

‡  Based on Cox regression model with Efron's method of tie handling with treatment as a covariate tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma) and ECOG performance status (0 versus 1).

§  One-sided p-value based on log-rank test tumor histology (Adenocarcinoma versus Squamous Cell Carcinoma) and ECOG performance status (0 versus 1). Database Cutoff Date: 02JUL2020.

Source:  [P590V01MK3475: adam-adsl; adtte]

In patients with PD-L1 CPS ≥ 10, the median OS was 11.4 months vs. 8.6 months with a HR of 0.6, and the 12  months  OS  rates  was  48%  vs.  35%  in  the  pembrolizumab  plus  chemotherapy  group  [n=31]  and chemotherapy group [n=26], respectively.

Median OS and 12 months OS rates are in favour of the pembrolizumab + chemotherapy group for European patients with CPS≥10 (OS HR 0.60) . No clinically meaningful benefit could be observed for the EU population with CPS&lt;10 (OS HR 0.85, median OS 9.7 vs. 12.6 months, 12 month OS rates 48.3% vs. 59.3% for pembrolizumab+chemotherapy vs chemotherapy, respectively).

The OS KM curves for European patients with PD-L1 CPS ≥ 10 and with PD-L1 CPS &lt;10, are shown below:

(51.1)

(46.3)

12

(1.6)

7

(0.9)

49.2 (36.2, 60.9)

47.2 (33.4, 59.8)

p-Value

0.72 (0.47, 1.10)

<div style=\"page-break-after: always\"></div>

<!-- image -->

In the EU subgroup the HR for OS 0.72 was in line with the results of the overall study population. However, despite limited numbers of EU participants, the benefit of pembrolizumab appears to be lower for patients with PDL1 CPS &lt;10 (OS HR 0.85, PFS HR 0.72) compared to CPS ≥10 (OS HR 0.6, PFS HR 0.48).

A PFS benefit was observed (HR 0.55) across all EU participants. This appeared also more pronounced for patients with PD-L1 CPS ≥ 10 (PFS HR 0.48) compared to patients with CPS &lt;10 (PFS HR 0.72). There were no  relevant  differences  between  histology  regarding  the  treatment  effect  of  pembrolizumab  in  the  EU population.

## Ex-Asia Versus Asia Participant Population

## Baseline Characteristics

## Table 22: Subject Characteristics in Asia and Rest of World (ITT Population)

|                        | Asia   | Asia   | Rest of World   | Rest of World   | Total   |
|------------------------|--------|--------|-----------------|-----------------|---------|
|                        | n      | (%)    | n               | (%) n           | (%)     |
| Subjects in population | 393    |        | 356             |                 | 749     |
| Gender                 |        |        |                 |                 |         |
| Male                   | 354    | (90.1) | 271             | (76.1) 625      | (83.4)  |

(83.4)

<div style=\"page-break-after: always\"></div>

(16.6)

(57.0)

(43.0)

94

21

(2.8)

400

7

(0.9)

14

(1.9)

9

(1.2)

5

(0.7)

(37.1)

29

(3.9)

(13.2)

(81.6)

3

(0.4)

32

(4.3)

4

(0.5)

393

(47.5)

| Female                                                                                                                                       | 39            | (9.9)                                 | 85            | (23.9)                              | 124             | (16.6)                         |
|----------------------------------------------------------------------------------------------------------------------------------------------|---------------|---------------------------------------|---------------|-------------------------------------|-----------------|--------------------------------|
| Age (Years)                                                                                                                                  |               |                                       |               |                                     |                 |                                |
| < 65 >= 65 Mean                                                                                                                              | 216 177 62.8  | (55.0) (45.0)                         | 211 145 62.0  | (59.3) (40.7)                       | 427 322 62.4    | (57.0) (43.0)                  |
| Race                                                                                                                                         |               |                                       |               |                                     |                 |                                |
| American Indian Or Alaska Native Asian Black Or African American Multiple American Indian Or Alaska Native, White Black Or African American, | 0 393 0 0 0 0 | (0.0) (100.0) (0.0) (0.0) (0.0) (0.0) | 21 7 7 14 9 5 | (5.9) (2.0) (2.0) (3.9) (2.5) (1.4) | 21 400 7 14 9 5 | (2.8) (53.4) (0.9) (1.9) (1.2) |
| Ethnicity                                                                                                                                    |               |                                       |               |                                     |                 | (0.7)                          |
| White Missing Hispanic Or Not                                                                                                                | 0 0           | (0.0) (0.0)                           | 278 29        | (78.1) (8.1)                        | 278 29 99 611   | (37.1) (3.9) (13.2) (81.6)     |
| Latino Hispanic Or Latino Not Reported Unknown Missing Asia                                                                                  | 1 388 0 4 0   | (0.3) (98.7) (0.0) (1.0) (0.0)        | 98 223 3 28 4 | (27.5) (62.6) (0.8) (7.9) (1.1)     | 3 32 4 393      | (0.4) (4.3) (0.5)              |
| Region                                                                                                                                       |               |                                       |               |                                     |                 |                                |
| Rest of World                                                                                                                                | 393 0         | (100.0) (0.0)                         | 0 356         | (0.0) (100.0)                       | 356             | (52.5) (47.5)                  |

<div style=\"page-break-after: always\"></div>

## Subject Characteristics in Asia and Rest of World (ITT Population)

|                                                                 | Asia   | Asia    | Rest of World   | Rest of World   | Total   | Total   |
|-----------------------------------------------------------------|--------|---------|-----------------|-----------------|---------|---------|
|                                                                 | n      | (%)     | n               | (%)             | n       | (%)     |
| Squamous Cell Carcinoma of the Esophagus                        | 360    | (91.6)  | 188             | (52.8)          | 548     | (73.2)  |
| Adenocarcinoma of the Esophagus                                 | 17     | (4.3)   | 93              | (26.1)          | 110     | (14.7)  |
| Adenocarcinoma of the Gastroesophageal Junction, Siewert Type I | 16     | (4.1)   | 75              | (21.1)          | 91      | (12.1)  |
| Metastatic Staging                                              |        |         |                 |                 |         |         |
| M0                                                              | 30     | (7.6)   | 36              | (10.1)          | 66      | (8.8)   |
| M1                                                              | 363    | (92.4)  | 320             | (89.9)          | 683     | (91.2)  |
| Brain Metastasis                                                |        |         |                 |                 |         |         |
| Yes                                                             | 0      | (0.0)   | 3               | (0.8)           | 3       | (0.4)   |
| No                                                              | 393    | (100.0) | 353             | (99.2)          | 746     | (99.6)  |
| Current Disease Stage                                           |        |         |                 |                 |         |         |
| IB                                                              | 0      | (0.0)   | 1               | (0.3)           | 1       | (0.1)   |
| IIB                                                             | 1      | (0.3)   | 0               | (0.0)           | 1       | (0.1)   |
| III                                                             | 4      | (1.0)   | 6               | (1.7)           | 10      | (1.3)   |
| IIIA                                                            | 5      | (1.3)   | 4               | (1.1)           | 9       | (1.2)   |
| IIIB                                                            | 6      | (1.5)   | 14              | (3.9)           | 20      | (2.7)   |
| IIIC                                                            | 14     | (3.6)   | 11              | (3.1)           | 25      | (3.3)   |
| IV                                                              | 291    | (74.0)  | 266             | (74.7)          | 557     | (74.4)  |
| IVA                                                             | 5      | (1.3)   | 11              | (3.1)           | 16      | (2.1)   |
| IVB                                                             | 66     | (16.8)  | 40              | (11.2)          | 106     | (14.2)  |
| IVC                                                             | 1      | (0.3)   | 1               | (0.3)           | 2       | (0.3)   |
| IVE                                                             | 0      | (0.0)   | 2               | (0.6)           | 2       | (0.3)   |
| ECOG Performance Scale                                          |        |         |                 |                 |         |         |
| 0                                                               | 157    | (39.9)  | 142             | (39.9)          | 299     | (39.9)  |
| 1                                                               | 236    | (60.1)  | 212             | (59.6)          | 448     | (59.8)  |
| 2                                                               | 0      | (0.0)   | 2               | (0.6)           | 2       | (0.3)   |
| Histology                                                       |        |         |                 |                 |         |         |
| Adenocarcinoma                                                  | 33     | (8.4)   | 168             | (47.2)          | 201     | (26.8)  |
| Squamous Cell Carcinoma                                         | 360    | (91.6)  | 188             | (52.8)          | 548     | (73.2)  |
| Disease Status                                                  |        |         |                 |                 |         |         |
| Metastatic                                                      | 363    | (92.4)  | 320             | (89.9)          | 683     | (91.2)  |
| Unresectable - Locally Advanced                                 | 30     | (7.6)   | 36              | (10.1)          | 66      | (8.8)   |

(73.2)

(14.7)

(12.1)

(8.8)

(91.2)

3

(0.4)

(99.6)

1

(0.1)

1

(0.1)

10

(1.3)

9

(1.2)

20

(2.7)

25

(3.3)

(74.4)

16

(2.1)

(14.2)

2

(0.3)

2

(0.3)

(39.9)

(59.8)

2

(0.3)

(26.8)

(73.2)

(91.2)

(8.8)

<div style=\"page-break-after: always\"></div>

Subject Characteristics in Asia and Rest of World (ITT Population)

|                                 | Asia                            | Asia                            | Rest of World                   | Rest of World                   | Total                           | Total                           |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                 | n                               | (%)                             | n                               | (%)                             | n                               | (%)                             |
| PD-L1 Status                    |                                 |                                 |                                 |                                 |                                 |                                 |
| CPS >= 10                       | 210                             | (53.4)                          | 173                             | (48.6)                          | 383                             | (51.1)                          |
| CPS < 10                        | 174                             | (44.3)                          | 173                             | (48.6)                          | 347                             | (46.3)                          |
| Not evaluable                   | 6                               | (1.5)                           | 6                               | (1.7)                           | 12                              | (1.6)                           |
| Missing                         | 3                               | (0.8)                           | 4                               | (1.1)                           | 7                               | (0.9)                           |
| Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 |

Source:  [P590V01MK3475: adam-adsl]

The MAH assessed whether the higher OS observed in participants from Asia were the result of differences in baseline characteristics, prior disease treatment or posttreatment antineoplastic therapy received between regions.

Table 23: Post-Trial Management  (ITT Population)

|                                 | Asia Pembro + SOC               | Asia Pembro + SOC               | Asia SOC                        | Asia SOC                        | Rest of World Pembro + SOC      | Rest of World Pembro + SOC      | Rest of World SOC               | Rest of World SOC               | Total                           | Total                           |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                 | n                               | (%)                             | n                               | (%)                             | n                               | (%)                             | n                               | (%)                             | n                               | (%)                             |
| Subjects in population          | 196                             |                                 | 197                             |                                 | 177                             |                                 | 179                             |                                 | 749                             |                                 |
| Oncologic Drugs/Biologic        | Oncologic Drugs/Biologic        | Oncologic Drugs/Biologic        | Oncologic Drugs/Biologic        | Oncologic Drugs/Biologic        | Oncologic Drugs/Biologic        | Oncologic Drugs/Biologic        | Oncologic Drugs/Biologic        | Oncologic Drugs/Biologic        | Oncologic Drugs/Biologic        | Oncologic Drugs/Biologic        |
| Yes                             | 105                             | (53. 6)                         | 107                             | (54. 3)                         | 58                              | (32. 8)                         | 70                              | (39. 1)                         | 340                             | (45. 4)                         |
| No                              | 91                              | (46. 4)                         | 90                              | (45. 7)                         | 119                             | (67. 2)                         | 109                             | (60. 9)                         | 409                             | (54. 6)                         |
| Radiation                       | Radiation                       | Radiation                       | Radiation                       | Radiation                       | Radiation                       | Radiation                       | Radiation                       | Radiation                       | Radiation                       | Radiation                       |
| Yes                             | 27                              | (13. 8)                         | 18                              | (9.1)                           | 1                               | (0.6)                           | 6                               | (3.4)                           | 52                              | (6.9)                           |
| No                              | 169                             | (86. 2)                         | 179                             | (90. 9)                         | 176                             | (99. 4)                         | 173                             | (96. 6)                         | 697                             | (93. 1)                         |
| Oncology Surgery                | Oncology Surgery                | Oncology Surgery                | Oncology Surgery                | Oncology Surgery                | Oncology Surgery                | Oncology Surgery                | Oncology Surgery                | Oncology Surgery                | Oncology Surgery                | Oncology Surgery                |
| Yes                             | 11                              | (5.6)                           | 10                              | (5.1)                           | 8                               | (4.5)                           | 1                               | (0.6)                           | 30 719                          | (4.0) (96.                      |
| No                              | 185                             | (94. 4)                         | 187                             | (94. 9)                         | 169                             | (95. 5)                         | 178                             | (99. 4)                         |                                 | 0)                              |
| Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 | Database Cutoff Date: 02JUL2020 |

## Age Category

Table 24 : ITT Population Sizes by Age Categories

| Age (Years)                  | ITTPopulation (N=749)        | ITTPopulation (N=749)        | SubjectswithSquamous Cell Carcinoma(N=548)   | SubjectswithSquamous Cell Carcinoma(N=548)   | Subjects with PD-L1 CPS>=10 (N= 383)   | Subjects with PD-L1 CPS>=10 (N= 383)   | SubjectswithSquamousCell CarcinomaandPD-L1CPS>=10 (N=286)   | SubjectswithSquamousCell CarcinomaandPD-L1CPS>=10 (N=286)   |
|------------------------------|------------------------------|------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------|----------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                              | Pembrolizumab+SOC            | SOC                          | Pembrolizumab+SOC                            | SOC                                          | Pembrolizumab+SOC                      | SOC                                    | Pembrolizumab+SOC                                           | SOC                                                         |
| <65                          | 201                          | 226                          | 152                                          | 156                                          | 99                                     | 127                                    | 78                                                          | 88                                                          |
| 65 -74                       | 135                          | 118                          | 98                                           | 91                                           | 69                                     | 56                                     | 52                                                          | 41                                                          |
| 75 -84                       | 36                           | 30                           | 23                                           | 25                                           | 18                                     | 12                                     | 13                                                          | 12                                                          |
| ≥85                          | 1                            | 2                            | 一                                            | 2                                            | 0                                      | 乙                                      | 0                                                           | 2                                                           |
| DatabaseCutoffDate:02JUL2020 | DatabaseCutoffDate:02JUL2020 | DatabaseCutoffDate:02JUL2020 | DatabaseCutoffDate:02JUL2020                 | DatabaseCutoffDate:02JUL2020                 | DatabaseCutoffDate:02JUL2020           | DatabaseCutoffDate:02JUL2020           | DatabaseCutoffDate:02JUL2020                                | DatabaseCutoffDate:02JUL2020                                |

(51.1)

(46.3)

12

(1.6)

7

(0.9)

340

1)

4)

409

9)

6)

697

6)

1)

719

4)

0)

<div style=\"page-break-after: always\"></div>

## Primary Efficacy Endpoint Results by Specific Age Category

Overall survival

Table 25 : Efficacy Results for Overall Survival by Age Categories

| Pembrolizumab+SOCvs.SOC                                                                                                                                                           | Age (Years)                                                                                                                                                                       | ITTPopulation,Subjects withSquamousCell CarcinomaandPD-L1 CPS>=10t                                                                                                                | ITTPopulation,Subjects withSquamousCell Carcinoma                                                                                                                                 | ITTPopulation,Subjects withPD-L1 CPS>=10f                                                                                                                                         | ITTPopulation                                                                                                                                                                     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HR (95% CI)                                                                                                                                                                       | <65                                                                                                                                                                               | 0.57 (0.40,0.81)                                                                                                                                                                  | 0.74 (0.58,0.96)                                                                                                                                                                  | 0.71 (0.52,0.95)                                                                                                                                                                  | 0.76 (0.61,0.95)                                                                                                                                                                  |
| HR (95% CI)                                                                                                                                                                       | 65 -74                                                                                                                                                                            | 0.55 (0.33,0.91)                                                                                                                                                                  | 0.64 (0.45,0.91)                                                                                                                                                                  | 0.52 (0.34,0.80)                                                                                                                                                                  | 0.64 (0.48,0.85)                                                                                                                                                                  |
| HR (95% CI)                                                                                                                                                                       | 75 -84                                                                                                                                                                            | 0.90 (0.36,2.29)                                                                                                                                                                  | 0.93 (0.49, 1.76)                                                                                                                                                                 | 0.85 (0.36,2.02)                                                                                                                                                                  | 0.98 (0.57,1.69)                                                                                                                                                                  |
| Based on Coxregressionmodel with treatment as a covariate. Note: there were 3participants with age>=85years and hence this category is not analyzed. DatabaseCutoffDate:02JUL2020 | Based on Coxregressionmodel with treatment as a covariate. Note: there were 3participants with age>=85years and hence this category is not analyzed. DatabaseCutoffDate:02JUL2020 | Based on Coxregressionmodel with treatment as a covariate. Note: there were 3participants with age>=85years and hence this category is not analyzed. DatabaseCutoffDate:02JUL2020 | Based on Coxregressionmodel with treatment as a covariate. Note: there were 3participants with age>=85years and hence this category is not analyzed. DatabaseCutoffDate:02JUL2020 | Based on Coxregressionmodel with treatment as a covariate. Note: there were 3participants with age>=85years and hence this category is not analyzed. DatabaseCutoffDate:02JUL2020 | Based on Coxregressionmodel with treatment as a covariate. Note: there were 3participants with age>=85years and hence this category is not analyzed. DatabaseCutoffDate:02JUL2020 |

## Progression free survival

Table 26: Efficacy Results for PFS by INV Per RECIST 1.1 by Age Categories (Primary Censoring Rule)

| Pembrolizumab+SOCvs.SOC                                                                                                                                                      | Age (Years)                                                                                                                                                                  | ITT Population, Subjects with SquamousCellCarcinoma                                                                                                                          | ITT Population,Subjects with PD-L1 CPS>=10t                                                                                                                                  | ITTPopulation                                                                                                                                                                |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| HR (95% CI)                                                                                                                                                                  | <65                                                                                                                                                                          | 0.73 (0.57,0.92)                                                                                                                                                             | 0.66 (0.49,0.88)                                                                                                                                                             | 0.69 (0.56,0.85)                                                                                                                                                             |
| HR (95% CI)                                                                                                                                                                  | 65 -74                                                                                                                                                                       | 0.57 (0.41, 0.79)                                                                                                                                                            | 0.45 (0.30, 0.67)                                                                                                                                                            | 0.56 (0.42,0.75)                                                                                                                                                             |
| HR (95% CI)                                                                                                                                                                  | 75 -84                                                                                                                                                                       | 0.73 (0.39, 1.37)                                                                                                                                                            | 0.50 (0.21,1.19)                                                                                                                                                             | 0.93 (0.54,1.62)                                                                                                                                                             |
| Based onCoxregressionmodelwithtreatment as a covariate. Note:there were3participants with age>=85years and hence this category is not analyzed. DatabaseCutoffDate:02JUL2020 | Based onCoxregressionmodelwithtreatment as a covariate. Note:there were3participants with age>=85years and hence this category is not analyzed. DatabaseCutoffDate:02JUL2020 | Based onCoxregressionmodelwithtreatment as a covariate. Note:there were3participants with age>=85years and hence this category is not analyzed. DatabaseCutoffDate:02JUL2020 | Based onCoxregressionmodelwithtreatment as a covariate. Note:there were3participants with age>=85years and hence this category is not analyzed. DatabaseCutoffDate:02JUL2020 | Based onCoxregressionmodelwithtreatment as a covariate. Note:there were3participants with age>=85years and hence this category is not analyzed. DatabaseCutoffDate:02JUL2020 |

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 27: Summary of Efficacy for trial KEYNOTE-590.

| Title: A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Advanced/Metastatic Oesophageal Carcinoma (KEYNOTE-590)   | Title: A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Advanced/Metastatic Oesophageal Carcinoma (KEYNOTE-590)   | Title: A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Advanced/Metastatic Oesophageal Carcinoma (KEYNOTE-590)   | Title: A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Advanced/Metastatic Oesophageal Carcinoma (KEYNOTE-590)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                              | IND: 123,482; EudraCT: 2017-000958-19                                                                                                                                                                                                                                                                                         | IND: 123,482; EudraCT: 2017-000958-19                                                                                                                                                                                                                                                                                         | IND: 123,482; EudraCT: 2017-000958-19                                                                                                                                                                                                                                                                                         |
| Design                                                                                                                                                                                                                                                                                                                        | Phase 3, randomized, double-blind, placebo-controlled,                                                                                                                                                                                                                                                                        | Phase 3, randomized, double-blind, placebo-controlled,                                                                                                                                                                                                                                                                        | Phase 3, randomized, double-blind, placebo-controlled,                                                                                                                                                                                                                                                                        |
| Hypothesis                                                                                                                                                                                                                                                                                                                    | Superiority                                                                                                                                                                                                                                                                                                                   | Superiority                                                                                                                                                                                                                                                                                                                   | Superiority                                                                                                                                                                                                                                                                                                                   |
| Treatments groups                                                                                                                                                                                                                                                                                                             | Pembrolizumab + SOC                                                                                                                                                                                                                                                                                                           | Pembrolizumab + SOC                                                                                                                                                                                                                                                                                                           | pembrolizumab 200 mg Q3W + Cisplatin and 5-Fluorouracil 800 mg/m2/day continuous IV infusion on each of Days 1 to 5 Q3W (total of 4000 mg/m2 per 3-week cycle) 373 randomized pts                                                                                                                                             |
| Treatments groups                                                                                                                                                                                                                                                                                                             | SOC                                                                                                                                                                                                                                                                                                                           | SOC                                                                                                                                                                                                                                                                                                                           | Placebo IV Q3W + Cisplatin and 5- Fluorouracil 800 mg/m2/day continuous IV infusion on each of Days 1 to 5 Q3W (total of 4000 mg/m2 per 3-week cycle) 376 randomized pts                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                     | Co-Primary endpoint                                                                                                                                                                                                                                                                                                           | OS PFS                                                                                                                                                                                                                                                                                                                        | Time from randomization to death due to any cause Time from randomization to PD, based upon RECIST 1.1 by Investigator, or death, whichever occurred earlier                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                                                 | Secondary endpoint      | ORR DoR                 | proportion of subjects who have a CR or a PR by Investigator time from first documented evidence of CR or PR until disease progression or death   | proportion of subjects who have a CR or a PR by Investigator time from first documented evidence of CR or PR until disease progression or death   |
|-------------------------------------------------|-------------------------|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| Database lock                                   | 30-JUL-2020             | 30-JUL-2020             | 30-JUL-2020                                                                                                                                       | 30-JUL-2020                                                                                                                                       |
| Results and Analysis                            | Results and Analysis    | Results and Analysis    | Results and Analysis                                                                                                                              | Results and Analysis                                                                                                                              |
| Analysis description                            | Primary Analysis        | Primary Analysis        | Primary Analysis                                                                                                                                  | Primary Analysis                                                                                                                                  |
| Analysis population and time point description  | Intent to treat         | Intent to treat         | Intent to treat                                                                                                                                   | Intent to treat                                                                                                                                   |
| Descriptive statistics and estimate variability | Treatment group         | Treatment group         | Pembrolizumab + SOC                                                                                                                               | SOC                                                                                                                                               |
| Descriptive statistics and estimate variability | Number of subject       | Number of subject       | 373                                                                                                                                               | 376                                                                                                                                               |
| Descriptive statistics and estimate variability | OS (median months)      | OS (median months)      | 12.4                                                                                                                                              | 9.8                                                                                                                                               |
| Descriptive statistics and estimate variability | 95% CI                  | 95% CI                  | 10.5, 14                                                                                                                                          | 8.8, 10.8                                                                                                                                         |
| Descriptive statistics and estimate variability | PFS (median months) 6.5 | PFS (median months) 6.5 |                                                                                                                                                   | 6                                                                                                                                                 |
| Descriptive statistics and estimate variability | 95% CI                  | 95% CI                  | 6.2, 8                                                                                                                                            | 5.7, 6.2                                                                                                                                          |
| Descriptive statistics and estimate variability | ORR (CR+PR) 45          | ORR (CR+PR) 45          |                                                                                                                                                   | 29.3                                                                                                                                              |
| Descriptive statistics and estimate variability | DOR (median months) 8.3 | DOR (median months) 8.3 | (1.2+ - 31)                                                                                                                                       | 6 (1.5 - 25)                                                                                                                                      |
| Effect estimate per comparison                  | Co-Primary endpoint SOC | Co-Primary endpoint SOC | Pembrolizumab + SOC vs                                                                                                                            | OS                                                                                                                                                |
|                                                 |                         |                         | HR                                                                                                                                                | 0.73                                                                                                                                              |
|                                                 |                         |                         | 95% CI                                                                                                                                            | 0.62, 0.86                                                                                                                                        |
|                                                 |                         |                         | P-value                                                                                                                                           | <0.0001                                                                                                                                           |
|                                                 | Co-Primary              | Co-Primary              | Pembrolizumab + SOC vs SOC                                                                                                                        | PFS                                                                                                                                               |
|                                                 | endpoint                | endpoint                | HR                                                                                                                                                | 0.67                                                                                                                                              |
|                                                 |                         |                         | 95% CI                                                                                                                                            | 0.56, 0.79                                                                                                                                        |
|                                                 |                         |                         | P-value                                                                                                                                           | <0.0001                                                                                                                                           |

## 3.4.3. Discussion on clinical efficacy

In support of this application, data are presented from the pivotal KEYNOTE-590 (KN590) trial, an ongoing Phase 3, randomized, double-blind, placebo-controlled, multisite study to evaluate the efficacy and safety of pembrolizumab in combination with chemotherapy (cisplatin and 5-FU) versus chemotherapy (cisplatin with 5-FU) alone as first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults.

## Design and conduct of clinical studies

The study design of KEYNOTE-590 study can be considered overall appropriate to support a MA in the sought indication, although several methodological aspects were raised.

The inclusion/exclusion criteria define a study population characterised by relatively fit patients (ECOG 01) with an advanced disease status (unresectable or metastatic tumours) and who were treatment-naïve. Overall, the study is representative of the population for which palliative chemotherapy is indicated as

<div style=\"page-break-after: always\"></div>

front-line approach. Recruitment occurred in centres with adequate expertise in the management of oesophageal cancer, i.e. high-volume centres with experienced surgeons and multidisciplinary teams, as recommended by CHMP at the time of the provided Scientific Advice.

EMA Scientific Advice on the design of KEYNOTE-590 was given on 23 March 2017. At that time, study KEYNOTE-180 in 3L+ oesophageal cancer was still ongoing and only preliminary results from the phase I trial KEYNOTE-028 in PD-L1 positive (CPS ≥ 1%) patients were available (n=23; ORR of 40% reported according to investigator assessment with responses observed only in GEP-positive patients). Based on these data, the CHMP recommended to wait for KEYNOTE-180 study results before starting recruitment of KEYNOTE-590, in order to make an informed decision on the definition of a biomarker as stratification factor and on the possible addition of a pembrolizumab monotherapy arm in the KN590 study design (possibly in a biomarker selected population).

The MAH did not follow the advice to include PD-L1 status as a stratification factor. KN590 enrolment started before biomarker analyses from KN180 were available. However, it was required that subjects had to provide a tissue sample for biomarker analysis at enrolment.

The MAH opted not to include a pembrolizumab monotherapy arm. KN028 ORR data as reported by an independent assessment from a database cut-off date as of 31 January 2018 were 18.2%. Available study outcomes from KN180 (ORR in CPS ≥10 population 13.8% and 21.5% in KN180 and KN181, respectively) further support that the omission of a monotherapy arm can be considered acceptable in the 1L setting.

Pembrolizumab was used at the 200 mg Q3W dose which was approved in both monotherapy and chemotherapy combined regimens across different indications; this is considered acceptable. The chosen comparator (cisplatin and 5-FU) is deemed adequate and in line with current clinical recommendations. Although being the most widely used chemotherapy combination, several other options are currently contemplated by clinical guidelines in the treatment of advanced oesophageal cancer. Oxaliplatin in combination with 5-FU or capecitabine are also recommended as preferred regimens in the current NCCN guideline and would be expected to be used in clinical practice. In addition, three drug regimens (including docetaxel or epirubicin) are recommended and used for medically fit patients. The broad indication (in combination with platinum and fluoropyrimidine based chemotherapy) and the proposed extrapolation from the combination (cisplatin with 5-FU) are accepted as a large difference in the benefit/risk between different platinum compound would not be reasonably expected. Oxaliplatin is used as an alternative treatment option in relation to safety. A reference to section 5.1 of the SmPC is included in the indication (section 4,1) in order to reflect the drug regimens used in the study.

The study recruited 749 patients with both histologies: squamous cell cancer (ESCC) and adenocarcinoma (AC) of the oesophagus. Enrolment of patients with adenocarcinoma of the gastroesophageal junction (EGJ) were restricted to Siewert I tumours (as reflected in section 5.1 of the SmPC). The exclusion of HER-2 positive EGJ AC patients is endorsed by the CHMP, as the standard treatment for these patients includes trastuzumab in addition to chemotherapy.

Stratification factors included geographic region (Asia versus Rest of World), tumour  histology (Adenocarcinoma versus Squamous Cell Carcinoma) and ECOG performance status (0 versus 1). PD-L1 expression status was expected to be assessed by IHC, which is in line with routine clinical practice, and was quantified by means of the CPS score. Recruitment was not stratified by CPS, contrary to the Scientific Advice provided by the CHMP that underlined a generally expected variability of response to treatment based  on  PD-L1  status.  Among  primary  endpoints,  PD-L1-based  subgroup  analyses  were  conducted although restricted to the CPS≥10 stratum while the CPS&lt;10 category was tested in a non pre -specified exploratory  analysis.  Comparison  between  treatment  arms  within  the  CPS ≥ 10  and  its  complementary (CPS&lt;10) subgroup showed balanced clinical and disease characteristics. The lack of stratification by PDL1 status is not cause of concern in the current application.

<div style=\"page-break-after: always\"></div>

The assumptions made for median PFS (6 months) and median OS (12 months) in the control arm are in line with the available historical data of chemotherapy in 1L setting and support the sample size calculation.

The original protocol was revised with 9 Amendments in total. Among the most relevant modifications, the change in biomarkers from GEP assayed in a central laboratory to PD-L1 tested in a local facility (Amendment n.02, 19-DEC-2017) based on recommendations from emerging data in KN180 trial showing a prevalence of PD-L1 in oesophageal cancer of approximately 45% using CPS ≥ 10, and the utility of this level of expression across a range of PD-L1 CPS cut points in identifying responders to pembrolizumab. The amendment was adopted relatively early (i.e. nine months after the original protocol); moreover, the study aimed at recruiting 'all comers' and stratification was regardless of biomarkers. Therefore, this is not considered problematic in terms of data collection and analysis.

In the original  protocol,  the  study  had  PFS  per  RECIST1.1  by  BICR  and  OS,  both  in  'all  comers'  (ITT population)  and  in  subjects  with  GEP-biomarker  positive  tumours  (later  changed  to  PD-L1  biomarker positive tumours; Amendment n.2), as dual primary endpoints. With Amendment n.8 (03-JAN-2020), the OS analysis within the ESCC tumour subtype, the ESCC tumour with CPS ≥ 10, and the PFS analysis in the ESCC population were implemented, driven by data analysed from study KN181. The study was considered to have met its primary objective if at least one of the above hypotheses was statistically significant. At the time of the amendment n. 8, recruitment was completed with a total of 749 subjects enrolled in a 1:1 ratio in the pembrolizumab and control arm. One of the two interim analysis (IA) originally planned was removed with Amendment 9 (17-JUN-2020). They were originally planned to be conducted at 448 PFS events in patients with ESCC after approximately32 months (IA1), and at 487 PFS events in patients with ESCC after approx. 40 months (IA2). With amendment No. 9 these two interim analyses were combined to one analysis after 460 investigator-assessed PFS events in patients with ESCC after approx. 35 months. This change was justified by input from the FDA.

The overall Type I error was controlled at 2.5% (1-sided), with 1.2% initially allocated to OS in ESCC with PD-L1 CPS ≥ 10, 1.1% to OS in ESCC, 0 to OS in PD-L1 CPS ≥ 10, 0 to OS in all subjects, 0.2% to PFS in ESCC, 0 to PFS in PD-L1 CPS ≥ 10, and 0 to PFS in all subjects.

Finally, with Amendment n. 9 (17-JUN-2020), the MAH has also replaced the original BICR-based PFS analysis with Investigator-based analysis in view of a higher than expected discordance rate between Investigator and BICR response evaluation (26%). A sensitivity analysis testing PFS results based on BICR-assessment was in agreement with the Investigator-based results. Censoring of PFS-events led to less than expected PFS-events assessed by BICR. Sensitivity analysis were conducted to assess PFS and ORR as determined by BICR, which demonstrated overall similar results with these of investigator assessment and support the assumption that the B/R assessment is not seriously impacted by this change. Sensitivity analyses were conducted by BICR within the ITT population and by subgroup analysis. Given the differences in treatment effect on OS by geographic location, which did not emerge in the PFS assessment, it was questioned whether a different approach in PFS result analysis was possibly undertaken in Asia and Rest of World relatively to the centralised assessment. The higher than expected discordance rate observed in the overall population was generally consistent across Asia and ROW regions; no differences between areas were noted.

Overall, statistical methods appeared not controversial. The rate of protocol deviations was similar in both arms and no concern is raised over possible impact of protocol deviations on efficacy results.

## Efficacy data and additional analyses

The MAH presented the results of the interim analysis (i.e. final for PFS) of study KN-590 (data cut-off date of 02-JUL-2020) based on the ITT population, as defined by all randomized patients (i.e. a total of 749 patients, 373 in pembrolizumab plus chemotherapy, 376 in the chemotherapy arm), with a median

<div style=\"page-break-after: always\"></div>

follow-up of 12.6 months (range: 0.1-33.6 months) in the pembrolizumab plus chemotherapy group and 9.8 months (range: 0.1-33.6 months) in the chemotherapy group.

Baseline characteristics as well as demographics appear well balanced between treatment arms in the ITT population, although a higher prevalence of subjects aged ≥ 65 years populated the experimental arm (46.1% vs 39.9%); distribution of histology, region, ECOG score and PD-L1 expression were all similar between groups. Diversity in both geographical localization (Asia and Rest of World, 52.5% vs 47.5% respectively) and PD-L1 score (CPS ≥ 10 vs &lt;10, 51.1% vs 46.3% respectively with 1.5% not evaluable and 0.9% missing) was well represented. The study population was mainly composed of male participants (83.4% vs 16.6%), metastatic status was prevailing over unresectable tumours (91.2% vs 8.8%), and the majority of patients harboured squamous cell carcinoma histology (73.2% SCC vs 26.8% adenocarcinoma). However, the age distribution of the study population (with only 43.3% ≥ 65 years) is not considered representative and rather reflects the eligibility criteria only allowing patients in good performance status (ECOG PS 0 or 1) and with adequate organ function. Only a small proportion of patients was included with locally advanced/non-metastatic disease (n=66; 8.8%). Even though PD-L1 status did not constitute a stratification factor, the distribution of clinical variables across the trial groups when analysed by CPS score (i.e. ESCC and PD-L1 CPS ≥ 10, PD-L1 positive tumours) as well as the assessment of baseline characteristics within the ESCC group showed a balanced diversity in treatment arms.

51.1%  of  all  participants  had  tumours  that  expressed  PD-L1  CPS ≥ 10.  This  proportion  was  balanced between treatment arms (49.9% vs. 52.4% for Pembro+Chemo vs. Chemo, respectively). In KEYNOTE590, the prevalence in PD-L1 CPS ≥ 10 was also generally similar between oesophageal squamous cell (52%) and adenocarcinoma (48%) .

In participants with ESCC and PD-L1 CPS ≥ 10, pembrolizumab as add-on to chemotherapy provided a statistically significant improvement in OS compared with chemotherapy alone (HR: 0.57; 95% CI: 0.43, 0.75; p&lt;0.0001, which is below the p-value crossing boundary of 0.0067 for statistical significance) with a 5 month gain in median OS in the experimental arm relatively to control (13.9 months vs 8.8 months, respectively). A total of 215 events have occurred within this group at this stage, which accounts for a 92.5% of the expected total events assumed at FA. Therefore, data can be considered mature. The subgroup analysis reveals consistency of results across patient pre-specified categories (age, sex, disease status, ECOG score), although a higher magnitude of effect was reached in Asia (OS HR:0.48; 95% CI: 0.35, 0.67) compared to Rest of World (OS HR:0.79; 95% CI: 0.49, 1.28).

Within the entire ESCC group regardless of PD-L1 score, the positive effect of pembrolizumab on OS was attenuated in magnitude but remains statistically significant compared to control (HR: 0.72; 95% CI: 0.60, 0.88; p&lt;0.0006). Variability of response by geographic region (Asia HR: 0.63; 95% CI: 0.49, 0.80; Rest of World HR:0.93; 95% CI: 0.67, 1.28) can be observed and a differential extent of benefit emerges also between sexes, the two geographic regions can be considered numerically adequate for statistical evaluation and well represented although two third of the total ESCC tumours were localised in Asia.

As  part  of  exploratory  analyses,  the  MAH  presented  efficacy  data  in  the  adenocarcinoma  subtype.  As expected, the majority of cases were localised in Rest of World (83.6% vs 16.4% in Asia); this is the only notable difference in baseline characteristics compared to the ESCC participants. A survival advantage with pembrolizumab  was  observed  also  in  the  adenocarcinoma  group,  although  with  a  highest  degree  of variability  of  response  as  reflected  by  a  wider  CI  (HR:  0.74;  95%  CI:  0.54,  1.02;  p&lt;0.0006  Overall, histology did not appear to be the most relevant  driver for a different treatment effect of pembrolizumab. Results for patients with ESCC and adenocarcinoma by PD-L1 status were provided. Interpretation of data is  hampered  by  the  limited  patient  numbers,  especially  in  the  smaller  subgroup  of  patients  with adenocarcinoma, the fact that these data represent a subgroup analysis of a subgroup and randomization was not stratified for both histology and PD-L1 expression status. OS results for patients with ESCC and

<div style=\"page-break-after: always\"></div>

CPS&lt;10 indicated no benefit for the addition of pembrolizumab (OS HR 0.99). In the subgroup of patients with adenocarcinoma, OS data appear not reliable; the OS benefit for adenocarcinoma patients was more pronounced in the PD-L1 CPS &lt;10 than their counterpart CPS ≥10 subpopulation (OS HR 0.66 vs. 0.83) which lacks biological plausibility and is not consistent with literature data for CPI in oesophageal-gastric adenocarcinoma; finally, by analysing the data with one Cox-proportional hazards model fitting two-way interactions of treatment with histology and PD-L1 status instead of performing subgroup analyses, the larger treatment effect for PD-L1 negative patients reverse to smaller treatment effects in comparison to PD-L1 positive patients. Although acknowledging that results of these models need to be interpreted with caution, as they were not pre-specified, the more powerful analysis is reasoned by the fact that all patients are included in this model fit and more covariates can be considered as confounders. The results of this model show homogeneous results in treatment effects for the PD-L1 negative population, meaning that for both histologies patients with CPS&lt;10 have larger OS hazard ratios than patients with CPS≥10. This was also  in  line  with  results  for  PFS  and  ORR  that  showed  a  more  pronounced  treatment  effect  for adenocarcinoma patients with CPS≥10 compared to patients with CPS &lt;10.

The analysis of efficacy within the totality of PD-L1 positive tumours including both the squamous and adenocarcinoma subtype showed advantage of pembrolizumab plus chemotherapy vs control in terms of OS (HR: 0.62; 95% CI: 0.49, 0.78; p&lt;0.0001) with a 5 month gain in median OS in the experimental arm relative to control (13.5 months vs 9.4 months, respectively). However, results stratification by histology demonstrated a higher efficacy of pembrolizumab in the squamous histology (HR: 0.57; 95% CI: 0.43, 0.75) compared to adenocarcinoma (HR: 0.83; 95% CI: 0.52, 1.34); the geographic location impacted point estimates favouring Asia (HR: 0.49; 95% CI: 0.35, 0.67) over Rest of World (HR: 0.82; 95% CI: 0.58, 1.16). Similarly to the observation reported for the ESCC group, Asia was the prevailing region within this group (63.3% vs 36.7% in Rest of World).

Efficacy data in complementary CPS&lt;10 tumours have been presented as exploratory analysis. CHMP had highlighted the necessity to account for biomarker status when planning stratification and analyses strategy and emphasised that 'at the time of assessment, the magnitude of the effect in the overall population and in both biomarker positive and negative subgroups will be taken into account' (procedure EMEA/H/SA/2437/19/2017/II). Within this category of patients, the CI of overall survival HR crossed 1 (HR: 0.86; 95% CI: 0.68, 1.10) and no gain in median OS was observed (10.5 vs 10.6 months). Overall, data confirm that response is PD-L1-dependent, as previously observed in other indications as well as in the oesophageal second line setting (KEYNOTE-181). Unlik e the CPS≥10 population, in the CPS&lt;10 group the effect of the combination pembrolizumab+chemotherapy was overall marginal compared to chemotherapy alone. The OS HR was 0.86 (95% CI: 0.68, 1.10). Median OS (10.5 vs 10.6 months) as well as OS rates at 12 and 18 months (differences 4.8% and 3.9%) were similar between the two treatment groups. Given the biological plausibility of a target-dependent response, the net advantage of pembrolizumab as add-on to chemotherapy does not appear convincing in this patient subgroup that represented a significant proportion (46%) of the ITT population.

In the ITT population encompassing all histologies and PD-L1 status, pembrolizumab demonstrated superiority on OS relative to control (HR: 0.73; 95% CI: 0.62, 0.86; p&lt;0.0001) with a 3 months gain in median OS (12.4 vs 9.8 months in control). With a total of 571 events reported at this IA, the trial reached 91% data maturity (627 events expected at FA). Among the pre-specified subgroup analysis, a different performance for pembrolizumab can be recognised by geographic location (Asia HR:0.64; 95% CI: 0.51, 0.81; Rest of World HR:0.83; 95% CI: 0.66, 1.05), while consistency has been shown across the remaining clinical categories.

In comparing the baseline characteristics between Asia and Rest of World, it emerges a higher prevalence of male participants (90.1% vs 76.1%), squamous cell carcinoma (91.6% vs 52.8%) and tumours with CPS ≥10 (53.4% vs 48.6%) in the former group. However, differences in magnitude of effect by geographic location persists in the individual analysis of the ESCC and CPS ≥10 subcategories. No differences emerged

<div style=\"page-break-after: always\"></div>

between geographic area in terms of patient characteristics or study conduct or patient management that could possibly justify the observed better response to treatment in Asians; furthermore, no inadequacy in study recruitment emerged across study centres. In the European population, a non-statistically significant survival advantage of pembrolizumab over control can be observed (HR 0.72; 95% CI 0.47, 1.10; p=ns); hence a favourable  trend  for  efficacy  can  be  concluded  upon,  although  the  limited  sample  size  is  not expected to provide statistical power. As for all participants, the benefit of pembrolizumab appears to be associated with PD-L1 expression. Median OS and 12 months OS rates are in favour of the chemotherapy group for European patients with CPS &lt;10.

The Investigator-Based PFS Analysis showed superiority of pembrolizumab plus chemotherapy versus chemotherapy alone within the ESCC population (HR:0.65; 95% CI:0.54, 0.78; p&lt;0.0001), PD-L1 positive group (HR:0.51; 95% CI:0.41, 0.65; p&lt;0.0001) and ITT population (HR:0.65; 95% CI:0.55, 0.76; p&lt;0.0001). Unlike OS, PFS results were consistent across all pre-specified patient categories, including geographic location. The BICR-based assessment was overall consistent with local analysis showing advantage of pembrolizumab over control in terms of PFS across the different patient groups, namely the ESCC population (HR:0.71; 95% CI:0.58, 0.87; p&lt;0.0004), PD-L1 positive group (HR:0.60; 95% CI:0.48, 0.75; p&lt;0.0001) and ITT population (HR:0.67; 95% CI:0.56, 0.79; p&lt;0.0001). Among the exploratory analyses, results in patients with CPS&lt;10 showed no clinically meaningful advantage of pembrolizumab + chemotherapy over chemotherapy alone (HR: 0.80; 95% CI: 0.64, 1.01; p=0.02 with a gain of only 0.2 months in PFS median vs control). A beneficial effect was observed in adenocarcinoma patients (HR=0.63, 95% CI: 0.46,0.87; p=0.0019 and gain in 1.4 months in median PFS).

Histology (AC vs ESCC) was one of the stratification factors. In participants with AC, baseline characteristics were  generally  similar  between  arms  and  consistent  with  the  all  comer  patient  population.  A  higher proportion of patients in the pembrolizumab plus chemotherapy group were ≥ 65 years of age (50.5% vs 31.4%) in the adenocarcinoma population. As expected, fewer patients with adenocarcinoma were from Asia (16.4%) compared with all participants (52.5%).

For all comer patients, the treatment benefit of pembrolizumab + chemotherapy was similar for patients with adenocarcinoma and patients with squamous carcinoma of the oesophagus.

Overall, patients appeared to benefit from the addition of pembrolizumab regardless of histology; however to enable a complete assessment of efficacy by PD-L1 expression status and histology, the MAH provided also PFS and ORR results for patients with ESCC and adenocarcinoma by PD-L1 status (CPS &lt;10 and CPS ≥10).

PFS and ORR data indicate a trend towards a lower treatment effect in the PD-L1 negative population.

Available study data with checkpoint inhibitors suggest a predictive value of PD-L1 expression status for gastro-esophageal adenocarcinoma (Study ONO-4538-12: Opdivo in metastatic gastric cancer, KEYNOTE059: Keytruda in ≥3L gastric or GE junction carcinoma, KEYNOTE -061: Keytruda in 2L gastric cancer, study KEYNOTE-181: Keytruda in 2L oesophageal cancer, study KEYNOTE-062: Keytruda in 1L gastric cancer).

The MAH provided analyses intended to disentangle the interaction effects of the Geographic Region, ESCC/AC patients, and PD-L1 positive/negative patients with the treatment effect.

The results of the Cox regression analysis show that there is an interaction effect of treatment with PD-L1.

The results (HR with 95% CIs by subgroup) of the following two models were provided: (i) A model fitting the main factors treatment arm, geographic region, tumour histology, and PD-L1 status together with twoway interaction terms of treatment with one of the three remaining factors, and (ii) a model of treatment, PD-L1, histology, treatment*PDL1, Treatment * Histology, stratified by ECOG and geographic region.

<div style=\"page-break-after: always\"></div>

Contrary to the subgroup analyses, patients with CPS ≥ 10 show more beneficial effects from treatment than patients with CPS&lt;10 for both histologies ESCC and adenocarcinoma (estimates for HR 0.86 and 0.87 for SCC and AC, respectively).The beneficial treatment effect for patients with CPS&lt;10 could not be confirmed.

Discordance between Investigator- and BICR-based assessment emerged in the evaluation of ORR. Within the ITT population, ORR (CR+PR) was judged similarly by Investigators (45% vs 29.3% in pembrolizumab and control arm, respectively) and centralised analysis (43.4% vs 29% in pembrolizumab and control arm, respectively). A sensitivity analysis testing PFS results based on BICR-assessment was in agreement with the Investigator-based results.

Available data for patients ≥ 75 years (n=69; 9% of study population) suggest that these elderly patients do not derive a benefit by the addition of pembrolizumab to chemotherapy (OS HR 0.98, PFS HR 0.93) in the overall study population. A total of 32 patients aged ≥ 75 years for PD-L1 CPS ≥ 10 were enrolled in KEYNOTE 590 (18 in the pembrolizumab combination and 14 in the control). Taking also the considerably worse toxicity profile for patients ≥ 75 years into account, information about limited efficacy and safety data is included in section 4.4 and 5.1 of the SmPC.

Overall, a trend towards a lower OS benefit was also observed for female subjects (OS HR 0.89 [0.59, 1.35] compared to male subjects (OS HR 0.7 [0.58, 0.84]. For female subjects whose tumour s express CPS ≥10, OS HR was 0.67 (n=70; 95% CI 0.39, 1.17). Although conclusions are limited by even smaller numbers in this biomarker selected female subgroups, results are reassuring for female patients with CPS ≥10.

The double blinded nature of the study vs placebo makes interpretation of PRO result unbiased. No differences were observed between treatment arms in the baseline global health status/QoL scores; also, changes from baseline in global health status/QoL scores evaluated at week 18 were similar between pembrolizumab plus chemotherapy (LS mean: -1.74 points [95% CI: -4.24, 0.75]) and chemotherapy alone (LS means of -0.10 points (95% CI: -3.40, 3.20); the variation on this parameter at week 18 can be considered not clinically significant (&lt;-10% cut-off). The OES-18 scores for Dysphagia, Pain and Reflux were all comparable between experimental and control arm.

## 3.4.4. Conclusions on the clinical efficacy

In KEYNOTE-590, statistically significant OS, PFS and ORR results were demonstrated in the overall study population with oesophageal or gastroesophageal junction carcinoma.  In patients whose tumours express PD-L1 CPS&lt;10, although the experimental arm carried a numerical advantage in the OS and PFS HRs compared to the control group (0.86 and 0.80, respectively), no gain in median survivals was achieved with the combined therapy vs chemotherapy alone (10.5 vs 10.6 months for OS and 6.0 vs 6.1 months for PFS, in the experimental and control arm, respectively). A clinically meaningful benefit for the addition of pembrolizumab to chemotherapy could not be shown for subjects whose tumours express PD-L1 CPS &lt;10.

## 3.5. Clinical safety

## Introduction

The safety profile of pembrolizumab in combination with chemotherapy (cisplatin and 5-fluorouracil) for the first-line  treatment  of  patients  with  locally  advanced  unresectable  or  metastatic  carcinoma  of  the oesophagus and gastroesophageal junction (Siewert type 1) is from the ongoing double-blind placebocontrolled  phase  3  study  KEYNOTE-590,  which  is  the  pivotal  for  this  application.  Safety  analyses  are

<div style=\"page-break-after: always\"></div>

presented  by  treatment  group  (pembrolizumab/placebo  +  cisplatin  and  5-fluorouracil),using  the  ASaT population (those who received at least 1 dose of study medication) as of the data cut-off of 02-JUL-2020.

Adverse events (AEs) were coded using MedDRA Version 23.0 and reported according to NCI CTCAE Version 4.03.

In addition, the safety profile of pembrolizumab in combination with chemotherapy observed in KEYNOTE590 has been compared to the established safety profile for pembrolizumab monotherapy in all approved indications  (Reference  Safety  Dataset,  RSD)  and  in  participants  with  advanced/metastatic oesophageal cancer in ≥2L (KEYNOTE -028 [Cohort A4], KEYNOTE-180, and KEYNOTE-181). The following 4 datasets are thus presented:

Table 28: Safety Datasets

| Dataset                                    | Population                                                                                                                                                                                                                                                                                                                                                                                                                                        | Nomenclature in Tables                | Nomenclature in Text                          |
|--------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|-----------------------------------------------|
| KEYNOTE- 590 pembrolizumab + chemotherapy  | (N=370): Safety data from participants with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction adenocarcinoma (Siewert type 1) who received pembrolizumab in combination with chemotherapy in KEYNOTE-590.                                                                                                                                                                                      | KN590 Data for MK-3475 + Chemotherapy | Pembrolizumab plus chemotherapy group 1       |
| KEYNOTE- 590 chemotherapy                  | (N=370): Safety data from participants with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction adenocarcinoma (Siewert type 1) who received placebo in combination with chemotherapy in KEYNOTE-590                                                                                                                                                                                             | KN590 Data for Placebo + Chemotherapy | Chemotherapy group 2                          |
| Pembrolizumab Oesophageal Monotherapy      | (N=458): Pooled safety data from participants with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction adenocarcinoma (Siewert type 1) treated with pembrolizumab monotherapy in KEYNOTE-028 (Cohort A4), KEYNOTE-180, and KEYNOTE-181.                                                                                                                                                          | Pembrolizumab Oesophageal Monotherapy | Pembrolizumab oesophageal monotherapy group 3 |
| Pembrolizumab monotherapy reference safety | (N=5884): Pooled safety data from participants treated with pembrolizumab monotherapy, including 2076 participants with advanced melanoma from KEYNOTE- 001, -002, -006, and -054; 2022 participants with NSCLC from KEYNOTE-001, -010, -024, and -042; 909 participants with HNSCC from KEYNOTE-012, -040, - 048, and -055; 241 participants from HL in KEYNOTE- 013 and -087, and 636 participants from bladder cancer in KEYNOTE-045 and -052. | Reference Safety Dataset for MK-3475  | Pembrolizumab monotherapy RSD 4               |

Abbreviations: HL=Hodgkin lymphoma; HNSCC=head and neck squamous cell carcinoma; N=number; NSCLC=non-small cell lung cancer; RSD=reference safety dataset.

1 Includes all subjects who received at least one dose of Pembrolizumab or chemotherapy in KN590.

2 Includes all subjects who received at least one dose of chemotherapy in KN590.

- 3  Includes all subjects who received at least one dose of Pembrolizumab in KN181, KN180 and KN028.

4

Includes all subjects who received at least one dose of Pembrolizumab in KN001 Part B1, B2, B3, D, C, F1,

F2, F3, KN002 (original phase), KN006, KN010.

## Patient exposure

Table 29: Summary of Drug Exposure (ASaT Population)

KN590 Data for

KN590 Data for

Pooled Oesophageal

Reference Safety

<div style=\"page-break-after: always\"></div>

0.03 to 32.46

1.00 to 59.00

|                             | Pembrolizumab + Chemotherapy †† (N=370)   | Placebo + Chemotherapy ¶¶ (N=370)   | Safety Dataset for Pembrolizumab Monotherapy ‡‡ (N=458)   | Dataset for Pembrolizumab Monotherapy §§ (N=5884)   |
|-----------------------------|-------------------------------------------|-------------------------------------|-----------------------------------------------------------|-----------------------------------------------------|
| Duration On Therapy (month) |                                           |                                     |                                                           |                                                     |
| Mean                        | 7.7                                       | 5.8                                 | 4.1                                                       | 7.3                                                 |
| Median                      | 5.68                                      | 5.11                                | 2.10                                                      | 4.86                                                |
| SD                          | 6.84                                      | 4.76                                | 5.27                                                      | 6.79                                                |
| Range                       | 0.03 to 26.02                             | 0.10 to 26.58                       | 0.03 to 24.38                                             | 0.03 to 32.46                                       |
| Number of cycle             |                                           |                                     |                                                           |                                                     |
| Mean                        | 11.0                                      | 8.5                                 | 6.9                                                       | 11.6                                                |
| Median                      | 8.00                                      | 7.00                                | 4.00                                                      | 8.00                                                |
| SD                          | 9.35                                      | 6.43                                | 7.97                                                      | 10.17                                               |
| Range                       | 1.00 to 35.00                             | 1.00 to 35.00                       | 1.00 to 51.00                                             | 1.00 to 59.00                                       |

Each subject is counted once on each applicable duration category row.

Duration of Exposure is calculated as (last dose date - first dose date +1)/30.4367 (months).

†† Includes all subjects who received at least one dose of Pembrolizumab or chemotherapy in KN590.

¶¶ Includes all subjects who received at least one dose of chemotherapy in KN590.

‡‡ Includes all subjects who received at least one dose of Pembrolizumab in KN181, KN180 and KN028.

§§ Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012-HNSCC, KN013-Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 21MAR2019)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052:26SEP2018)

Database Cutoff date for Oesophageal (KN028: 31JAN2018, KN180: 30JUL2018, KN181: 15OCT2018, KN590: 02JUL2020)

Table 30: Drug Exposure by Duration (ASaT Population)

|                      | KN590DataforPembrolizumab+ Chemotherapyit (N=370)   | KN590DataforPembrolizumab+ Chemotherapyit (N=370)   | KN590DataforPembrolizumab+ Chemotherapyit (N=370)   | KN590Data forPlacebo+ Chemotherapyl (N=370)   | KN590Data forPlacebo+ Chemotherapyl (N=370)   | KN590Data forPlacebo+ Chemotherapyl (N=370)   | Pooled Esophageal SafetyDataset for Pembrolizumab Monotherapyit (N=458)   | Pooled Esophageal SafetyDataset for Pembrolizumab Monotherapyit (N=458)   | Pooled Esophageal SafetyDataset for Pembrolizumab Monotherapyit (N=458)   | ReferenceSafetyDataset for Pembrolizumab Monotherapy (N=5884)   | ReferenceSafetyDataset for Pembrolizumab Monotherapy (N=5884)   | ReferenceSafetyDataset for Pembrolizumab Monotherapy (N=5884)   |
|----------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
|                      |                                                     | (%)                                                 | Person-years                                        | n                                             | (%)                                           | Person-years                                  | n                                                                         | (%)                                                                       | Person-years                                                              | n                                                               | (%)                                                             | Person-years                                                    |
| Duration of Exposure |                                                     |                                                     |                                                     |                                               |                                               |                                               |                                                                           |                                                                           |                                                                           |                                                                 |                                                                 |                                                                 |
| >0 m                 | 370                                                 | (100.0)                                             | (237.9)                                             | 370                                           | (100.0)                                       | (179.8)                                       | 458                                                                       | (100.0)                                                                   | (157.9)                                                                   | 5,884                                                           | (100.0)                                                         | (3,555.3)                                                       |
| >=1 m                | 326                                                 | (88.1)                                              | (236.4)                                             | 325                                           | (87.8)                                        | (178.5)                                       | 349                                                                       | (76.2)                                                                    | (154.0)                                                                   | 5,033                                                           | (85.5)                                                          | (3,527.1)                                                       |
| >=3m                 | 269                                                 | (72.7)                                              | (226.0)                                             | 260                                           | (70.3)                                        | (167.3)                                       | 182                                                                       | (39.7)                                                                    | (128.5)                                                                   | 3,620                                                           | (61.5)                                                          | (3,291.8)                                                       |
| >=6m                 | 167                                                 | (45.1)                                              | (186.9)                                             | 131                                           | (35.4)                                        | (117.3)                                       | 83                                                                        | (18.1)                                                                    | (92.6)                                                                    | 2,612                                                           | (44.4)                                                          | (2,926.0)                                                       |
| >=12m                | 79                                                  | (21.4)                                              | (126.6)                                             | 39                                            | (10.5)                                        | (53.3)                                        | 39                                                                        | (8.5)                                                                     | (62.0)                                                                    | 1,281                                                           | (21.8)                                                          | (1,915.3)                                                       |

Each subject is counted once on each applicableduration category row.

Duration of Exposure is calculated as (last dose date -first dose date +1)/30.4367(months).

If Includes all subjects who received at least one dose of Pembrolizumab or chemotherapy in KN590.

# Includes all subjects who received at least one dose of Pembrolizumab in KN181, KN180 and KN028.

Includes all subjects who received at least one dose of chemotherapy in KN590.

Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C,F1, F2, F3, KN002 (original phase), KN006, KN010, KN012-HNSCC, KN013-Cohort 3 (HodgkinLymphoma),KN024,KN040,KN042,KN045,KN048,KN052,KN054,KN055andKN087

Databasecutoff dateforMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054:02OCT2017)

Database cutoff date forLung (KN001-NSCLC:23JAN2015,KN010:30SEP2015,KN024:10JUL2017,KN042:04SEP2018)

DatabasecutoffdateforcHL(KN013-Cohort3:28SEP2018,KN087:21MAR2019)

Databasecutoff dateforBladder(KN045:26OCT2017,KN052:26SEP2018)

Database Cutoff date for Esophageal(KN028: 31JAN2018,KN180: 30JUL2018,KN181:15OCT2018,KN590: 02JUL2020)

Table 31: Table: Summary of Drug Administration by Regimen Component (ASaT Population)

<div style=\"page-break-after: always\"></div>

|                              | Pembrolizumab+SOC (N= 370)   | Pembrolizumab+SOC (N= 370)   | Pembrolizumab+SOC (N= 370)   | SOC (N= 370)                 | SOC (N= 370)                 | SOC (N= 370)                 |
|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
| Number of Cycles             | Pembrolizumab n (%)          | Cisplatin n (%)              | 5-Fluorouracil n (%)         | Placebo (Unspecified) n (%)  | Cisplatin n (%)              | 5-Fluorouracil n (%)         |
| >=1                          | 370 (100.0)                  | 369 (99.7)                   | 370 (100.0)                  | 370 (100.0)                  | 370 (100.0)                  | 370 (100.0)                  |
| >=2                          | 339 (91.6)                   | 335 (90.5)                   | 337 (91.1)                   | 337 (91.1)                   | 331 (89.5)                   | 333 (90.0)                   |
| >=3                          | 321 (86.8)                   | 314 (84.9)                   | 316 (85.4)                   | 317 (85.7)                   | 312 (84.3)                   | 314 (84.9)                   |
| >=4                          | 292 (78.9)                   | 282 (76.2)                   | 289 (78.1)                   | 285 (77.0)                   | 274 (74.1)                   | 282 (76.2)                   |
| >=5                          | 267 (72.2)                   | 245 (66.2)                   | 262 (70.8)                   | 265 (71.6)                   | 241 (65.1)                   | 260 (70.3)                   |
| >=6                          | 240 (64.9)                   | 206 (55.7)                   | 232 (62.7)                   | 235 (63.5)                   | 205 (55.4)                   | 227 (61.4)                   |
| >=7                          | 213 (57.6)                   | 0 (0.0)                      | 138 (37.3)                   | 204 (55.1)                   | 0 (0.0)                      | 135 (36.5)                   |
| >=8                          | 194 (52.4)                   | 0 (0.0)                      | 126 (34.1)                   | 176 (47.6)                   | 0 (0.0)                      | 116 (31.4)                   |
| >=9                          | 175 (47.3)                   | 0 (0.0)                      | 107 (28.9)                   | 139 (37.6)                   | 0 (0.0)                      | 94 (25.4)                    |
| >=10                         | 143 (38.6)                   | 0 (0.0)                      | 84 (22.7)                    | 111 (30.0)                   | 0 (0.0)                      | 75 (20.3)                    |
| >=11                         | 132 (35.7)                   | 0 (0.0)                      | 74 (20.0)                    | 97 (26.2)                    | 0 (0.0)                      | 68 (18.4)                    |
| >=12                         | 116 (31.4)                   | 0 (0.0)                      | 62 (16.8)                    | 86 (23.2)                    | 0 (0.0)                      | 60 (16.2)                    |
| >=13                         | 105 (28.4)                   | 0 (0.0)                      | 54 (14.6)                    | 72 (19.5)                    | 0 (0.0)                      | 48 (13.0)                    |
| >=14                         | 96 (25.9)                    | 0 (0.0)                      | 50 (13.5)                    | 59 (15.9)                    | 0 (0.0)                      | 36 (9.7)                     |
| >=15                         | 88 (23.8)                    | 0 (0.0)                      | 43 (11.6)                    | 53 (14.3)                    | 0 (0.0)                      | 32 (8.6)                     |
| >=16                         | 82 (22.2)                    | 0 (0.0)                      | 39 (10.5)                    | 42 (11.4)                    | 0 (0.0)                      | 25 (6.8)                     |
| >=17                         | 80 (21.6)                    | 0 (0.0)                      | 38 (10.3)                    | 40 (10.8)                    | 0 (0.0)                      | 23 (6.2)                     |
| >=18                         | 76 (20.5)                    | 0 (0.0)                      | 38 (10.3)                    | 35 (9.5)                     | 0 (0.0)                      | 19 (5.1)                     |
| >=19                         | 70 (18.9)                    | 0 (0.0)                      | 36 (9.7)                     | 26 (7.0)                     | 0 (0.0)                      | 13 (3.5)                     |
| >=20                         | 66 (17.8)                    | 0 (0.0)                      | 33 (8.9)                     | 26 (7.0)                     | 0 (0.0)                      | 12 (3.2)                     |
| >=21                         | 57 (15.4)                    | 0 (0.0)                      | 28 (7.6)                     | 21 (5.7)                     | 0 (0.0)                      | 10 (2.7)                     |
| >=22                         | 52 (14.1)                    | 0 (0.0)                      | 25 (6.8)                     | 21 (5.7)                     | 0 (0.0)                      | 10 (2.7)                     |
| >=23                         | 50 (13.5)                    | 0 (0.0)                      | 24 (6.5)                     | 18 (4.9)                     | 0 (0.0)                      | 8 (2.2)                      |
| >=24                         | 48 (13.0)                    | 0 (0.0)                      | 23 (6.2)                     | 17 (4.6)                     | 0 (0.0)                      | 8 (2.2)                      |
| >=25                         | 45 (12.2)                    | 0 (0.0)                      | 21 (5.7)                     | 12 (3.2)                     | 0 (0.0)                      | 6 (1.6)                      |
| >=26                         | 45 (12.2)                    | 0 (0.0)                      | 19 (5.1)                     | 9 (2.4)                      | 0 (0.0)                      | 5 (1.4)                      |
| >=27                         | 41 (11.1)                    | 0 (0.0)                      | 17 (4.6)                     | 8 (2.2)                      | 0 (0.0)                      | 5 (1.4)                      |
| >=28                         | 38 (10.3)                    | 0 (0.0)                      | 16 (4.3)                     | 6 (1.6)                      | 0 (0.0)                      | 4 (1.1)                      |
| >=29                         | 34 (9.2)                     | 0 (0.0)                      | 16 (4.3)                     | 5 (1.4)                      | 0 (0.0)                      | 4 (1.1)                      |
| >=30                         | 30 (8.1)                     | 0 (0.0)                      | 13 (3.5)                     | 5 (1.4)                      | 0 (0.0)                      | 4 (1.1)                      |
| >=31                         | 28 (7.6)                     | 0 (0.0)                      | 13 (3.5)                     | 5 (1.4)                      | 0 (0.0)                      | 4 (1.1)                      |
| >=32                         | 22 (5.9)                     | 0 (0.0)                      | 9 (2.4)                      | 4 (1.1)                      | 0 (0.0)                      | 3 (0.8)                      |
| >=33                         | 18 (4.9)                     | 0 (0.0)                      | 9 (2.4)                      | 4 (1.1)                      | 0 (0.0)                      | 3 (0.8)                      |
| >=34                         | 15 (4.1)                     | 0 (0.0)                      | 8 (2.2)                      | 2 (0.5)                      | 0 (0.0)                      | 2 (0.5)                      |
| =35                          | 14 (3.8)                     | 0 (0.0)                      | 8 (2.2)                      | 2 (0.5)                      | 0 (0.0)                      | 2 (0.5)                      |
| Mean                         | 10.8                         | 4.7                          | 8.0                          | 8.4                          | 4.7                          | 7.1                          |
| SD                           | 9.3                          | 1.7                          | 7.2                          | 6.4                          | 1.8                          | 5.4                          |
| Median                       | 8.0                          | 6.0                          | 6.0                          | 7.0                          | 6.0                          | 6.0                          |
| Range                        | 1 to 35                      | 1 to 6                       | 1 to 35                      | 1 to 35                      | 1 to 6                       | 1 to 35                      |
| DatabaseCutoffDate:02JUL2020 | DatabaseCutoffDate:02JUL2020 | DatabaseCutoffDate:02JUL2020 | DatabaseCutoffDate:02JUL2020 | DatabaseCutoffDate:02JUL2020 | DatabaseCutoffDate:02JUL2020 | DatabaseCutoffDate:02JUL2020 |

Source:[P590V01MK3475:adam-adsl:adexsum]

Table 32: Summary of drug exposure by component (ASaT population)

|           | KN590 Data for Pembrolizumab + Chemotherapyit                              | KN590 Data for Pembrolizumab + Chemotherapyit   | KN590 Data for Placebo + Chemotherapyll   | Pooled Esophageal Safety Dataset forPembrolizumab Monotherapy* (N = 458) Pembrolizumab   | ReferenceSafetyDataset for PembrolizumabMonotherapys (N =5884)   |
|-----------|----------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------|
|           | (N=370)                                                                    | (N=370)                                         | (N=370)                                   |                                                                                          |                                                                  |
| Number of | Cisplatin                                                                  | Pembrolizumab                                   | Cisplatin                                 |                                                                                          | Pembrolizumab                                                    |
| Cycles    | n (%)                                                                      | n (%)                                           | n (%)                                     | n (%)                                                                                    | n (%)                                                            |
| >=1       | 369 (99.7)                                                                 | 370 (100.0)                                     | 370 (100.0)                               | 458 (100.0)                                                                              | 5884 (100.0)                                                     |
| >=2       | 335 (90.5)                                                                 | 339 (91.6)                                      | 331 (89.5)                                | 412 (90.0)                                                                               | 4977 (84.6)                                                      |
| >=3       | 314 (84.9)                                                                 | 321 (86.8)                                      | 312 (84.3)                                | 347 (75.8)                                                                               | 4534 (77.1)                                                      |
| >=4       | 282 (76.2)                                                                 | 292 (78.9)                                      | 274 (74.1)                                | 249 (54.4)                                                                               | 3960 (67.3)                                                      |
| >=5       | 245 (66.2)                                                                 | 267 (72.2)                                      | 241 (65.1)                                | 205 (44.8)                                                                               | 3558 (60.5)                                                      |
| >=6       | 206 (55.7)                                                                 | 240 (64.9)                                      | 205 (55.4)                                | 173 (37.8)                                                                               | 3178 (54.0)                                                      |
| >=7       | 0 (0.00)                                                                   | 213 (57.6)                                      | 0 (0.00)                                  | 135 (29.5)                                                                               | 2855 (48.5)                                                      |
| Mean      | 4.7                                                                        | 10.8                                            | 4.7                                       | 6.9                                                                                      | 10.5                                                             |
| SD        | 1.7                                                                        | 9.3                                             | 1.8                                       | 7.9                                                                                      | 10.4                                                             |
| Median    | 6.0                                                                        | 8.0                                             | 6.0                                       | 4.0                                                                                      | 6.0                                                              |
| Range     | 1 to 6 Each subject is counted once on each applicable cycle category row. | 1 to 35                                         | 1 to 6                                    | 1 to 51                                                                                  | 1 to 59                                                          |

Each subject is counted once on each applicable cycle category row.

Includes all subjects who received at least one dose of chemotherapy in KN590.

t Includes all subjects who received at least one dose of Pembrolizumab or chemothearpy inKN590.

# Includes all subjects who received at least one dose of Pembrolizumab in KN181, KN180 and KN028.

$ Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2,F3, KN002 (original phase), KN006, KN010, KN012-HNSCC, KN013-Cohort 3 (HodgkinLymphoma),KN024,KN040,KN042,KN045,KN048,KN052,KN054,KN055 andKN087

Databasecutoff date forMelanoma (KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054:02OCT2017)

Database cutoff date forLung (KN001-NSCLC:23JAN2015,KN010:30SEP2015,KN024:10JUL2017,KN042:04SEP2018)

Databasecutoff dateforHNSCC(KN012-HNSCC:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055:22APR2016)

Database cutoff date for cHL(KN013-Cohort3:28SEP2018,KN087:21MAR2019)

Database cutoff date forBladder (KN045: 26OCT2017,KN052:26SEP2018)

<div style=\"page-break-after: always\"></div>

## Adverse events

## Table 33: Adverse Event Summary (ASaT Population)

|                                                                    | KN590 Data for Pembrolizumab + Chemotherapy ††   | KN590 Data for Pembrolizumab + Chemotherapy ††   | KN590 Data for Placebo + Chemotherapy ¶¶   | KN590 Data for Placebo + Chemotherapy ¶¶   | Pooled Oesophageal Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Pooled Oesophageal Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|--------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                                                    | n                                                | (%)                                              | n                                          | (%)                                        | n                                                                    | (%)                                                                  | n                                                           | (%)                                                         |
| Subjects in population                                             | 370                                              |                                                  | 370                                        |                                            | 458                                                                  |                                                                      | 5,884                                                       |                                                             |
| with one or more adverse events                                    | 370                                              | (100.0)                                          | 368                                        | (99.5)                                     | 437                                                                  | (95.4)                                                               | 5,690                                                       | (96.7)                                                      |
| with no adverse event                                              | 0                                                | (0.0)                                            | 2                                          | (0.5)                                      | 21                                                                   | (4.6)                                                                | 194                                                         | (3.3)                                                       |
| with drug-related † adverse events                                 | 364                                              | (98.4)                                           | 360                                        | (97.3)                                     | 281                                                                  | (61.4)                                                               | 4,132                                                       | (70.2)                                                      |
| with toxicity grade 3-5 adverse events                             | 318                                              | (85.9)                                           | 308                                        | (83.2)                                     | 245                                                                  | (53.5)                                                               | 2,829                                                       | (48.1)                                                      |
| with toxicity grade 3-5 drug-related adverse events                | 266                                              | (71.9)                                           | 250                                        | (67.6)                                     | 80                                                                   | (17.5)                                                               | 913                                                         | (15.5)                                                      |
| with serious adverse events                                        | 205                                              | (55.4)                                           | 204                                        | (55.1)                                     | 180                                                                  | (39.3)                                                               | 2,266                                                       | (38.5)                                                      |
| with serious drug-related adverse events                           | 117                                              | (31.6)                                           | 97                                         | (26.2)                                     | 56                                                                   | (12.2)                                                               | 656                                                         | (11.1)                                                      |
| who died                                                           | 28                                               | (7.6)                                            | 38                                         | (10.3)                                     | 39                                                                   | (8.5)                                                                | 312                                                         | (5.3)                                                       |
| who died due to a drug-related adverse event                       | 9                                                | (2.4)                                            | 5                                          | (1.4)                                      | 6                                                                    | (1.3)                                                                | 39                                                          | (0.7)                                                       |
| discontinued any drug due to an adverse event                      | 90                                               | (24.3)                                           | 74                                         | (20.0)                                     | 55                                                                   | (12.0)                                                               | 790                                                         | (13.4)                                                      |
| discontinued Pembrolizumab or placebo                              | 54                                               | (14.6)                                           | 45                                         | (12.2)                                     | 55                                                                   | (12.0)                                                               | 790                                                         | (13.4)                                                      |
| discontinued any chemotherapy                                      | 75                                               | (20.3)                                           | 69                                         | (18.6)                                     | 55                                                                   | (12.0)                                                               | 790                                                         | (13.4)                                                      |
| discontinued all drugs                                             | 23                                               | (6.2)                                            | 28                                         | (7.6)                                      | 55                                                                   | (12.0)                                                               | 790                                                         | (13.4)                                                      |
| discontinued any drug due to a drug-related adverse event          | 72                                               | (19.5)                                           | 43                                         | (11.6)                                     | 27                                                                   | (5.9)                                                                | 410                                                         | (7.0)                                                       |
| discontinued Pembrolizumab or placebo                              | 35                                               | (9.5)                                            | 15                                         | (4.1)                                      | 27                                                                   | (5.9)                                                                | 410                                                         | (7.0)                                                       |
| discontinued any chemotherapy                                      | 58                                               | (15.7)                                           | 42                                         | (11.4)                                     | 27                                                                   | (5.9)                                                                | 410                                                         | (7.0)                                                       |
| discontinued all drugs                                             | 16                                               | (4.3)                                            | 10                                         | (2.7)                                      | 27                                                                   | (5.9)                                                                | 410                                                         | (7.0)                                                       |
| discontinued any drug due to a serious adverse event               | 58                                               | (15.7)                                           | 47                                         | (12.7)                                     | 44                                                                   | (9.6)                                                                | 572                                                         | (9.7)                                                       |
| discontinued Pembrolizumab or placebo                              | 47                                               | (12.7)                                           | 43                                         | (11.6)                                     | 44                                                                   | (9.6)                                                                | 572                                                         | (9.7)                                                       |
| discontinued any chemotherapy                                      | 43                                               | (11.6)                                           | 41                                         | (11.1)                                     | 44                                                                   | (9.6)                                                                | 572                                                         | (9.7)                                                       |
| discontinued all drugs                                             | 21                                               | (5.7)                                            | 27                                         | (7.3)                                      | 44                                                                   | (9.6)                                                                | 572                                                         | (9.7)                                                       |
| discontinued any drug due to a serious drug- related adverse event | 38                                               | (10.3)                                           | 17                                         | (4.6)                                      | 18                                                                   | (3.9)                                                                | 245                                                         | (4.2)                                                       |
| discontinued Pembrolizumab or placebo                              | 29                                               | (7.8)                                            | 14                                         | (3.8)                                      | 18                                                                   | (3.9)                                                                | 245                                                         | (4.2)                                                       |
| discontinued any chemotherapy                                      | 25                                               | (6.8)                                            | 16                                         | (4.3)                                      | 18                                                                   | (3.9)                                                                | 245                                                         | (4.2)                                                       |
| discontinued all drugs                                             | 14                                               | (3.8)                                            | 10                                         | (2.7)                                      | 18                                                                   | (3.9)                                                                | 245                                                         | (4.2)                                                       |

† Determined by the investigator to be related to the drug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

†† Includes all subjects who received at least one dose of Pembrolizumab or chemotherapy in KN590.

¶¶ Includes all subjects who received at least one dose of chemotherapy in KN590.

‡‡ Includes all subjects who received at least one dose of Pembrolizumab in KN181, KN180 and KN028.

§§ Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012-HNSCC, KN013-Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 21MAR2019)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052:26SEP2018)

Database Cutoff date for Oesophageal (KN028: 31JAN2018, KN180: 30JUL2018, KN181: 15OCT2018, KN590: 02JUL2020)

Table 34: Exposure-Adjusted Adverse Event Summary (Including Multiple Occurrences of Events) (ASaT Population)

(4.2)

<div style=\"page-break-after: always\"></div>

|                                                                       | Event Count and Rate (Events/100 person-months)t   | Event Count and Rate (Events/100 person-months)t   | Event Count and Rate (Events/100 person-months)t                 | Event Count and Rate (Events/100 person-months)t        |
|-----------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------------------|---------------------------------------------------------|
|                                                                       | KN590 Data for Pembrolizumab + Chemotherapyit      | KN590DataforPlacebo+ Chemotherapyl                 | Pooled Esophageal Safety Dataset for Pembrolizumab Monotherapyit | Reference Safety Dataset for Pembrolizumab Monotherapy? |
| Number of subjects exposed                                            | 370                                                | 370                                                | 458                                                              | 5884                                                    |
| Total exposure in person-months                                       | 3198.57                                            | 2516.83                                            | 2340.50                                                          | 47883.80                                                |
| Total events (rate)                                                   |                                                    |                                                    |                                                                  |                                                         |
| adverse events                                                        | 7383 (230.82)                                      | 6733 (267.52)                                      | 3421 (146.17)                                                    | 61600 (128.64)                                          |
| drug-related adverse events                                           | 4661 (145.72)                                      | 4167 (165.57)                                      | 795 (33.97)                                                      | 19283 (40.27)                                           |
| toxicity grade 3-5 adverse events                                     | 1141 (35.67)                                       | 1105 (43.90)                                       | 571 (24.40)                                                      | 6162 (12.87)                                            |
| toxicity grade 3-5 drug-related adverse events                        | 722 (22.57)                                        | 642 (25.51)                                        | 116 (4.96)                                                       | 1374 (2.87)                                             |
| serious adverse events                                                | 399 (12.47)                                        | 379 (15.06)                                        | 294 (12.56)                                                      | 4094 (8.55)                                             |
| serious drug-related adverse events                                   | 179 (5.60)                                         | 154 (6.12)                                         | 68 (2.91)                                                        | 916 (1.91)                                              |
| adverse events leading to death                                       | 31 (0.97)                                          | 38 (1.51)                                          | 39 (1.67)                                                        | 319 (0.67)                                              |
| drug-related adverse events leading to death                          | 9 (0.28)                                           | 5 (0.20)                                           | 6 (0.26)                                                         | 39 (0.08)                                               |
| adverse events resulting in drug discontinuation                      | 116 (3.63)                                         | 84 (3.34)                                          | 55 (2.35)                                                        | 863 (1.80)                                              |
| drug-related adverse events resulting in drug discontinuation         | 89 (2.78)                                          | 49 (1.95)                                          | 27 (1.15)                                                        | 448 (0.94)                                              |
| serious adverse eventsresulting in drugdiscontinuation                | 69 (2.16)                                          | 52 (2.07)                                          | 44 (1.88)                                                        | 609 (1.27)                                              |
| serious drug-related adverse events resulting in drug discontinuation | 44 (1.38)                                          | 19 (0.75)                                          | 18 (0.77)                                                        | 259 (0.54)                                              |

Event rate per 100 person-months of exposure=event count *100/person-months of exposure.

+ Drug exposure is defined as the between the first dose date + 1 day and the earlier of the last dose date + 30 or the database cutoff date.

$ Determined by the investigator to be related to the drug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms *Neoplasm progression\", \"Malignant neoplasm progression” and \"Disease progression” not related to the drug are excluded.

A pooled safety data from studies of pembrolizumab plus chemotherapy in approved indications (NSCLC: KEYNOTE-021, KEYNOTE-189, and KEYNOTE-407; HNSCC: KEYNOTE-048) is also provided below:

Table 35: Adverse event summary (subjects in ASaT population)

|                                                         | KN590DataforPembrolizumab+ Chemotherapytt   | KN590DataforPembrolizumab+ Chemotherapytt   | KN590DataforPlacebo+ Chemotherapyff   | KN590DataforPlacebo+ Chemotherapyff   | KN021 +KN048 + KN189 +KN407 Datas   | KN021 +KN048 + KN189 +KN407 Datas   |
|---------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------|---------------------------------------|-------------------------------------|-------------------------------------|
|                                                         | n                                           | (%)                                         | n                                     | (%)                                   | n                                   | (%)                                 |
| Subjects in population                                  | 370                                         |                                             | 370                                   |                                       | 1,067                               |                                     |
| with one or more adverse events                         | 370                                         | (100.0)                                     | 368                                   | (99.5)                                | 1,057                               | (99.1)                              |
| with no adverse event                                   | 0                                           | (0.0)                                       | 2                                     | (0.5)                                 | 10                                  | (0.9)                               |
| with drug-related adverse events                        | 364                                         | (98.4)                                      | 360                                   | (97.3)                                | 1,010                               | (94.7)                              |
| with toxicity grade3-5adverse events                    | 318                                         | (85.9)                                      | 308                                   | (83.2)                                | 800                                 | (75.0)                              |
| with toxicity grade 3-5 drug-related adverse events     | 266                                         | (71.9)                                      | 250                                   | (67.6)                                | 612                                 | (57.4)                              |
| with serious adverse events                             | 205                                         | (55.4)                                      | 204                                   | (55.1)                                | 576                                 | (54.0)                              |
| with serious drug-related adverse events                | 117                                         | (31.6)                                      | 97                                    | (26.2)                                | 328                                 | (30.7)                              |
| who died                                                | 28                                          | (7.6)                                       | 38                                    | (10.3)                                | 96                                  | (9.0)                               |
| whodied due to a drug-related adverse event             | 9                                           | (2.4)                                       | 5                                     | (1.4)                                 | 32                                  | (3.0)                               |
| discontinueddrug duetoanadverseevent                    | 90                                          | (24.3)                                      | 74                                    | (20.0)                                | 331                                 | (31.0)                              |
| discontinueddrugdue toadrug-related adverseevent        | 72                                          | (19.5)                                      | 43                                    | (11.6)                                | 249                                 | (23.3)                              |
| discontinued drug due toa serious adverse event         | 58                                          | (15.7)                                      | 47                                    | (12.7)                                | 217                                 | (20.3)                              |
| discontinueddrugduetoa seriousdrug-related adverseevent | 38                                          | (10.3)                                      | 17                                    | (4.6)                                 | 140                                 | (13.1)                              |

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

Determined by the investigator to be related to the drug.

MedDRA preferred terms\"Neoplasm Progression\",\"Malignant Neoplasm Progression\"and\"Disease Progression\"not related to the drug are excluded.

ft Includes all subjects who received at least one dose of Pembrolizumab or chemotherapy in KN590.

MIncludes all subjects who received at least one dose of chemotherapy inKN590.

S Includes all subjects who received at least one dose of Pembrolizumab combo therapy in KN021-A/C/G, KN048, KN189 and KN407.

Database cutoff date for Lung (KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)

Database cutoff date for HNSCC (KN048: 25FEB2019)

Database cutoff dateforEsophageal(KN590:02JUL2020)

## All adverse events

Table 36: Subjects with adverse events (i ncidence ≥ 10% in one or more treatment groups) by decreasing frequency of preferred term (ASaT population)

| KN590 Data for   | KN590 Data for   | Pooled   | Reference Safety   |
|------------------|------------------|----------|--------------------|

Source:[ISS:adam-adsl:adae]

<div style=\"page-break-after: always\"></div>

5,884

5,690

(96.7)

(3.3)

1,213

(20.6)

(14.2)

1,136

(19.3)

1,884

(32.0)

(16.9)

37

(0.6)

1,200

(20.4)

(12.4)

(2.4)

49

(0.8)

57

(1.0)

(9.5)

(4.4)

(5.9)

(4.6)

73

(1.2)

(11.3)

(3.0)

1,148

(19.5)

92

(1.6)

25

(0.4)

87

(1.5)

(12.7)

(7.4)

(7.3)

(2.0)

(15.4)

(11.1)

(1.9)

(2.0)

(16.8)

(3.2)

1,060

(18.0)

(12.1)

89

(1.5)

(8.2)

(11.3)

(14.5)

|                                  | Pembrolizumab + Chemotherapy ††   | Pembrolizumab + Chemotherapy ††   | Placebo + Chemotherapy ¶¶   | Placebo + Chemotherapy ¶¶   | Oesophageal Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Oesophageal Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Dataset for Pembrolizumab Monotherapy §§   | Dataset for Pembrolizumab Monotherapy §§   |
|----------------------------------|-----------------------------------|-----------------------------------|-----------------------------|-----------------------------|---------------------------------------------------------------|---------------------------------------------------------------|--------------------------------------------|--------------------------------------------|
|                                  | n                                 | (%)                               | n                           | (%)                         | n                                                             | (%)                                                           | n                                          | (%)                                        |
| Subjects in population           | 370                               |                                   | 370                         |                             | 458                                                           |                                                               | 5,884                                      |                                            |
| with one or more adverse events  | 370                               | (100.0)                           | 368                         | (99.5)                      | 437                                                           | (95.4)                                                        | 5,690                                      | (96.7)                                     |
| with no adverse events           | 0                                 | (0.0)                             | 2                           | (0.5)                       | 21                                                            | (4.6)                                                         | 194                                        | (3.3)                                      |
| Nausea                           | 249                               | (67.3)                            | 232                         | (62.7)                      | 87                                                            | (19.0)                                                        | 1,213                                      | (20.6)                                     |
| Anaemia                          | 187                               | (50.5)                            | 208                         | (56.2)                      | 77                                                            | (16.8)                                                        | 836                                        | (14.2)                                     |
| Decreased appetite               | 164                               | (44.3)                            | 141                         | (38.1)                      | 109                                                           | (23.8)                                                        | 1,136                                      | (19.3)                                     |
| Fatigue                          | 149                               | (40.3)                            | 126                         | (34.1)                      | 110                                                           | (24.0)                                                        | 1,884                                      | (32.0)                                     |
| Constipation                     | 148                               | (40.0)                            | 149                         | (40.3)                      | 85                                                            | (18.6)                                                        | 995                                        | (16.9)                                     |
| Neutrophil count decreased       | 139                               | (37.6)                            | 111                         | (30.0)                      | 4                                                             | (0.9)                                                         | 37                                         | (0.6)                                      |
| Diarrhoea                        | 135                               | (36.5)                            | 123                         | (33.2)                      | 61                                                            | (13.3)                                                        | 1,200                                      | (20.4)                                     |
| Vomiting                         | 126                               | (34.1)                            | 117                         | (31.6)                      | 61                                                            | (13.3)                                                        | 732                                        | (12.4)                                     |
| Stomatitis                       | 100                               | (27.0)                            | 95                          | (25.7)                      | 10                                                            | (2.2)                                                         | 144                                        | (2.4)                                      |
| Neutropenia                      | 97                                | (26.2)                            | 90                          | (24.3)                      | 0                                                             | (0.0)                                                         | 49                                         | (0.8)                                      |
| White blood cell count decreased | 97                                | (26.2)                            | 69                          | (18.6)                      | 4                                                             | (0.9)                                                         | 57                                         | (1.0)                                      |
| Weight decreased                 | 87                                | (23.5)                            | 90                          | (24.3)                      | 49                                                            | (10.7)                                                        | 561                                        | (9.5)                                      |
| Blood creatinine increased       | 79                                | (21.4)                            | 78                          | (21.1)                      | 15                                                            | (3.3)                                                         | 256                                        | (4.4)                                      |
| Hyponatraemia                    | 68                                | (18.4)                            | 77                          | (20.8)                      | 26                                                            | (5.7)                                                         | 345                                        | (5.9)                                      |
| Hypokalaemia                     | 67                                | (18.1)                            | 71                          | (19.2)                      | 25                                                            | (5.5)                                                         | 270                                        | (4.6)                                      |
| Platelet count decreased         | 62                                | (16.8)                            | 62                          | (16.8)                      | 9                                                             | (2.0)                                                         | 73                                         | (1.2)                                      |
| Asthenia                         | 60                                | (16.2)                            | 45                          | (12.2)                      | 55                                                            | (12.0)                                                        | 666                                        | (11.3)                                     |
| Dysphagia                        | 60                                | (16.2)                            | 63                          | (17.0)                      | 60                                                            | (13.1)                                                        | 174                                        | (3.0)                                      |
| Cough                            | 59                                | (15.9)                            | 56                          | (15.1)                      | 65                                                            | (14.2)                                                        | 1,148                                      | (19.5)                                     |
| Mucosal inflammation             | 59                                | (15.9)                            | 68                          | (18.4)                      | 7                                                             | (1.5)                                                         | 92                                         | (1.6)                                      |
| Hiccups                          | 56                                | (15.1)                            | 53                          | (14.3)                      | 5                                                             | (1.1)                                                         | 25                                         | (0.4)                                      |
| Alopecia                         | 55                                | (14.9)                            | 39                          | (10.5)                      | 4                                                             | (0.9)                                                         | 87                                         | (1.5)                                      |
| Pyrexia                          | 55                                | (14.9)                            | 44                          | (11.9)                      | 45                                                            | (9.8)                                                         | 746                                        | (12.7)                                     |
| Pneumonia                        | 54                                | (14.6)                            | 52                          | (14.1)                      | 49                                                            | (10.7)                                                        | 433                                        | (7.4)                                      |
| Insomnia                         | 49                                | (13.2)                            | 44                          | (11.9)                      | 36                                                            | (7.9)                                                         | 429                                        | (7.3)                                      |
| Malaise                          | 48                                | (13.0)                            | 43                          | (11.6)                      | 22                                                            | (4.8)                                                         | 115                                        | (2.0)                                      |
| Rash                             | 44                                | (11.9)                            | 26                          | (7.0)                       | 32                                                            | (7.0)                                                         | 904                                        | (15.4)                                     |
| Hypothyroidism                   | 40                                | (10.8)                            | 24                          | (6.5)                       | 49                                                            | (10.7)                                                        | 651                                        | (11.1)                                     |
| Dysgeusia                        | 38                                | (10.3)                            | 32                          | (8.6)                       | 10                                                            | (2.2)                                                         | 110                                        | (1.9)                                      |
| Neuropathy peripheral            | 37                                | (10.0)                            | 37                          | (10.0)                      | 13                                                            | (2.8)                                                         | 116                                        | (2.0)                                      |
| Dyspnoea                         | 36                                | (9.7)                             | 30                          | (8.1)                       | 48                                                            | (10.5)                                                        | 989                                        | (16.8)                                     |
| Hypoalbuminaemia                 | 35                                | (9.5)                             | 49                          | (13.2)                      | 20                                                            | (4.4)                                                         | 187                                        | (3.2)                                      |
| Pruritus                         | 31                                | (8.4)                             | 12                          | (3.2)                       | 38                                                            | (8.3)                                                         | 1,060                                      | (18.0)                                     |
| Headache                         | 30                                | (8.1)                             | 25                          | (6.8)                       | 23                                                            | (5.0)                                                         | 711                                        | (12.1)                                     |
| Thrombocytopenia                 | 28                                | (7.6)                             | 37                          | (10.0)                      | 5                                                             | (1.1)                                                         | 89                                         | (1.5)                                      |
| Abdominal pain                   | 27                                | (7.3)                             | 20                          |                             |                                                               |                                                               | 480                                        | (8.2)                                      |
| Back pain                        | 26                                | (7.0)                             | 31                          | (5.4)                       | 48 50                                                         | (10.5) (10.9)                                                 | 662                                        | (11.3)                                     |
| Arthralgia                       | 22                                | (5.9)                             | 10                          | (8.4) (2.7)                 | 24                                                            | (5.2)                                                         | 851                                        | (14.5)                                     |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Table  37:  Exposure-adjusted  adverse  events  by  observation  period  (including  multiple occurrences of events) (incidence ≥10% in one or more treatment groups) (ASaT population)

<div style=\"page-break-after: always\"></div>

|                                                    | Event Count and Rate (Events/100 person-months) t   | Event Count and Rate (Events/100 person-months) t   | Event Count and Rate (Events/100 person-months) t   | Event Count and Rate (Events/100 person-months) t   | Event Count and Rate (Events/100 person-months) t   | Event Count and Rate (Events/100 person-months) t   | Event Count and Rate (Events/100 person-months) t   | Event Count and Rate (Events/100 person-months) t   |
|----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                                    | Pembrolizumab+SOC                                   | Pembrolizumab+SOC                                   | Pembrolizumab+SOC                                   | Pembrolizumab+SOC                                   |                                                     |                                                     |                                                     |                                                     |
| Observation period of drug exposure                | 0-3 months                                          | 3-6 months                                          | 6-12 months                                         | Beyond 12 months                                    | 0-3 months                                          | 3-6 months                                          | 6-12 months                                         | Beyond 12 months                                    |
| Number of subjects exposedt                        | 370                                                 | 302                                                 | 210                                                 | 85                                                  | 370                                                 | 295                                                 | 190                                                 | 45                                                  |
| Total exposureperson-months                        | 1029.73                                             | 762.13                                              | 773.55                                              | 633.17                                              | 1022.83                                             | 715.99                                              | 569.80                                              | 208.21                                              |
| Total events (rate)                                | 2956(287.07)                                        | 1015(133.18)                                        | 373(48.22)                                          | 177(27.95)                                          | 2760(269.84)                                        | 951(132.82)                                         | 337(59.14)                                          | 80(38.42)                                           |
| AE Category                                        |                                                     |                                                     |                                                     |                                                     |                                                     |                                                     |                                                     |                                                     |
| Blood andlymphaticsystem                           | 339(31.1)                                           | 146(46.9)                                           | 37(21.2)                                            | 14(24.2)                                            | 354(33.1)                                           | 133(41.4)                                           | 40(20.3)                                            | 19(26.6)                                            |
| disorders Anaemia                                  | 180(31.8)                                           | 67(33.5)                                            | 30(21.9)                                            | 11(23.3)                                            | 200(33.3)                                           | 70(35.9)                                            | 26(19.4)                                            | 13(43.4)                                            |
| Neutropenia                                        | 130(32.6)                                           | 60(83.5)                                            | 3(45.0)                                             | 0(0)                                                | 124(35.3)                                           | 41(47.9)                                            | 11(26.5)                                            | 4(12.6)                                             |
| Thrombocytopenia                                   | 29(23.1)                                            | 19(48.7)                                            | 4(13.0)                                             | 3(28.6)                                             | 30(25.4)                                            | 22(53.5)                                            | 3(13.6)                                             | 2(20.3)                                             |
| Endocrine disorders                                | 13(10.6)                                            | 14(18.9)                                            | 16(30.7)                                            | 3(31.6)                                             | 15(23.8)                                            | 6(24.9)                                             | 6(45.6)                                             | 0(0)                                                |
| Hypothyroidism                                     | 13(10.6)                                            | 14(18.9)                                            | 16(30.7)                                            | 3(31.6)                                             | 15(23.8)                                            | 6(24.9)                                             | 6(45.6)                                             | 0(0)                                                |
| Gastrointestinaldisorders                          | 1015(43.3)                                          | 276(33.6)                                           | 115(18.2)                                           | 62(25.6)                                            | 958(45.4)                                           | 249(35.0)                                           | 110(27.4)                                           | 28(30.7)                                            |
| Constipation                                       | 156(41.0)                                           | 49(31.9)                                            | 23(19.8)                                            | 10(29.9)                                            | 157(52.3)                                           | 35(36.3)                                            | 13(23.5)                                            | 4(22.8)                                             |
| Diarrhoea                                          | 144(34.5)                                           | 42(21.3)                                            | 30(18.1)                                            | 17(23.0)                                            | 138(47.4)                                           | 31(29.6)                                            | 14(20.1)                                            | 8(27.0)                                             |
| Dysphagia                                          | 34(19.6)                                            | 13(11.9)                                            | 17(16.8)                                            | 12(28.2)                                            | 27(14.0)                                            | 24(20.0)                                            | 24(27.9)                                            | 4(39.5)                                             |
| Nausea                                             | 384(51.1)                                           | 94(43.2)                                            | 26(15.0)                                            | 18(28.3)                                            | 383(50.3)                                           | 94(47.5)                                            | 29(33.6)                                            | 4(29.3)                                             |
| Stomatitis                                         | 126(53.2)                                           | 31(59.5)                                            | 5(20.7)                                             | 2(16.2)                                             | 120(60.0)                                           | 10(13.2)                                            | 14(20.2)                                            | 6(30.8)                                             |
| Vomiting                                           | 171(44.4)                                           | 47(51.0)                                            | 14(27.4)                                            | 3(18.3)                                             | 133(36.4)                                           | 55(46.7)                                            | 16(46.2)                                            | 2(229.5)                                            |
| General disorders and administrationsiteconditions | 393(36.9)                                           | 123(29.6)                                           | 56(17.0)                                            | 32(25.7)                                            | 338(39.3)                                           | 108(36.3)                                           | 46(30.0)                                            | 11(33.6)                                            |
| Asthenia                                           | 55(25.3)                                            | 17(14.3)                                            | 17(11.7)                                            | 16(20.3)                                            | 45(33.8)                                            | 17(35.6)                                            | 7(30.0)                                             | 3(33.3)                                             |
| Fatigue                                            | 159(42.4)                                           | 48(39.6)                                            | 14(18.6)                                            | 8(36.9)                                             | 143(48.9)                                           | 29(38.0)                                            | 13(30.8)                                            | 2(26.0)                                             |
| Malaise                                            | 56(45.7)                                            | 18(56.7)                                            | 3(42.9)                                             | 1(35.9)                                             | 42(39.0)                                            | 19(60.6)                                            | 1(7.8)                                              | 2(77.5)                                             |
| Mucosalinflammation                                | 81(44.6)                                            | 21(32.3)                                            | 9(20.0)                                             | 3(20.7)                                             | 75(36.3)                                            | 23(25.3)                                            | 20(35.1)                                            | 2(21.1)                                             |
| Pyrexia                                            | 42(24.8)                                            | 19(24.2)                                            | 13(22.7)                                            | 4(58.8)                                             | 33(27.2)                                            | 20(39.3)                                            | 5(27.5)                                             | 2(50.9)                                             |
| Infections and infestations                        | 23(15.9)                                            | 22(32.9)                                            | 6(10.4)                                             | 8(22.5)                                             | 17(11.8)                                            | 26(33.2)                                            | 14(34.2)                                            | 2(24.2)                                             |
| Pneumonia                                          | 23(15.9)                                            | 22(32.9)                                            | 6(10.4)                                             | 8(22.5)                                             | 17(11.8)                                            | 26(33.2)                                            | 14(34.2)                                            | 2(24.2)                                             |
| Investigations                                     | 527(32.3)                                           | 224(49.0)                                           | 55(22.3)                                            | 23(29.0)                                            | 477(33.0)                                           | 214(55.1)                                           | 39(35.7)                                            | 6(44.3)                                             |
| Blood creatinine increased                         | 66(23.7)                                            | 38(29.9)                                            | 18(20.2)                                            | 9(22.6)                                             | 67(30.3)                                            | 36(41.4)                                            | 8(18.8)                                             | 5(42.7)                                             |
| Neutrophil count decreased                         | 187(34.4)                                           | 80(75.1)                                            | 10(24.1)                                            | 4(27.7)                                             | 163(34.6)                                           | 71(72.2)                                            | 8(49.5)                                             | (0)0                                                |
| Platelet count decreased                           | 60(27.4)                                            | 38(61.9)                                            | 5(25.9)                                             | 1(25.4)                                             | 76(34.4)                                            | 29(58.0)                                            | 4(40.9)                                             | 0(0)                                                |
| Weight decreased                                   | 71(44.1)                                            | 15(31.2)                                            | 6(15.9)                                             | 4(55.1)                                             | 61(27.2)                                            | 35(37.4)                                            | 14(41.6)                                            | 1(54.6)                                             |
| White blood cell count decreased                   | 143(33.4)                                           | 53(46.6)                                            | 16(27.5)                                            | 5(36.4)                                             | 110(36.0)                                           | 43(72.2)                                            | 5(71.2)                                             | 0(0)                                                |
| Metabolismandnutrition                             | 365(38.9)                                           | 123(41.1)                                           | 44(24.0)                                            | 13(18.9)                                            | 342(35.3)                                           | 138(40.0)                                           | 49(29.9)                                            | 10(28.2)                                            |
| disorders                                          |                                                     |                                                     |                                                     |                                                     |                                                     |                                                     |                                                     |                                                     |
| Decreased appetite                                 | 207(46.7)                                           | 52(39.7)                                            | 19(21.3)                                            | 7(34.5)                                             | 168(42.5)                                           | 48(33.4)                                            | 24(31.2)                                            | 5(34.8)                                             |
| Hypoalbuminaemia                                   | 22(23.6)                                            | 17(47.1)                                            | 4(35.4)                                             | 1(21.6)                                             | 36(26.1)                                            | 21(35.6)                                            | 8(25.7)                                             | 2(17.7)                                             |
| Hypokalaemia                                       | 72(34.2)                                            | 30(47.9)                                            | 9(29.0)                                             | 2(9.8)                                              | 71(32.1)                                            | 35(54.7)                                            | 5(15.9)                                             | 3(30.7)                                             |
| Hyponatraemia                                      | 64(33.4)                                            | 24(34.6)                                            | 12(23.0)                                            | 3(12.8)                                             | 67(31.4)                                            | 34(43.2)                                            | 12(49.1)                                            | 0(0)                                                |
| Nervoussystem disorders                            | 47(29.8)                                            | 26(34.9)                                            | 11(40.3)                                            | 2(69.6)                                             | 43(27.7)                                            | 24(35.6)                                            | 10(45.1)                                            | 1(15.1)                                             |
| Dysgeusia                                          | 35(54.0)                                            | 7(53.2)                                             | 1(6.8)                                              | 2(69.6)                                             | 32(72.6)                                            | 3(83.7)                                             | 0(0)                                                | (0)0                                                |
| Neuropathy peripheral                              | 12(12.9)                                            | 19(30.9)                                            | 10(80.1)                                            | 0(0)                                                | 11(9.9)                                             | 21(32.9)                                            | 10(45.1)                                            | 1(15.1)                                             |
| Psychiatricdisorders                               | 41(40.5)                                            | 6(12.9)                                             | 11(34.0)                                            | 1(13.5)                                             | 40(41.3)                                            | 11(38.9)                                            | 4(39.6)                                             | 1(27.7)                                             |
| Insomnia                                           | 41(40.5)                                            | 6(12.9)                                             | 11(34.0)                                            | 1(13.5)                                             | 40(41.3)                                            | 11(38.9)                                            | 4(39.6)                                             | 1(27.7)                                             |
| Respiratory, thoracic and                          | 117(38.5)                                           | 35(30.4)                                            | 13(11.6)                                            | 13(30.0)                                            | 118(45.1)                                           | 33(39.3)                                            | 13(32.8)                                            | 2(33.2)                                             |
| mediastinaldisorders Cough                         | 37(25.9)                                            | 17(24.7)                                            | 6(8.2)                                              | 9(30.7)                                             | 35(27.9)                                            | 17(30.8)                                            | 10(29.6)                                            | 2(33.2)                                             |
|                                                    | 80(49.7)                                            | 18(39.0)                                            | 7(18.0)                                             | 4(28.7)                                             | 83(60.9)                                            | 16(55.6)                                            | 3(51.3)                                             | (0)                                                 |
| Hiccups Skin andsubcutaneous tissue disorders      | 76(43.7)                                            | 20(26.7)                                            | 9(12.0)                                             | 6(25.7)                                             | 58(49.3)                                            | 9(31.0)                                             | 6(30.8)                                             | (0)0                                                |
| Alopecia                                           | 53(96.7)                                            | 2(230.8)                                            | 0(0)                                                | 0(0)                                                | 34(61.8)                                            | 6(105.5)                                            | 0(0)                                                | 0(0)                                                |

Rash

23(19.3)

18(24.3)

9(12.0)

Event rate per 100 person-month of exposure=event count *100/person-month of exposure.

Number of subjects exposed to drug at the start of indicated time interval.

$ Drug exposure is defined as the interval of min (last dose date + 30, Cutoff Date) - first dose date + 1.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

DatabaseCutoffDate:02JUL2020

## Drug-related adverse events

## Table 38: Subjects with drug-related adverse events (i ncidence ≥ 5% in one or more treatment groups) by decreasing frequency of preferred term (ASaT population)

| KN590 Data for Pembrolizumab + Chemotherapy ††   | KN590 Data for Placebo + Chemotherapy ¶¶   | Pooled Oesophageal Safety Dataset for Pembrolizumab   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|--------------------------------------------------|--------------------------------------------|-------------------------------------------------------|-------------------------------------------------------------|

6(25.7)

24(38.4)

3(12.8)

6(30.8)

0(0)

<div style=\"page-break-after: always\"></div>

5,884

4,132

(70.2)

1,752

(29.8)

(9.1)

(7.8)

(3.4)

1,170

(19.9)

26

(0.4)

(3.4)

(10.7)

30

(0.5)

71

(1.2)

28

(0.5)

68

(1.2)

32

(0.5)

48

(0.8)

46

(0.8)

(2.6)

(6.2)

45

(0.8)

(2.3)

(0.2)

(9.6)

60

(1.0)

36

(0.6)

29

(0.5)

(0.1)

59

(1.0)

41

(0.7)

(11.5)

41

(0.7)

29

(0.5)

(14.2)

32

(0.5)

47

(0.8)

33

(0.6)

(3.8)

(3.7)

(3.7)

(7.4)

|                                      |     |        |     |             | Monotherapy ‡‡   | Monotherapy ‡‡   |       |        |
|--------------------------------------|-----|--------|-----|-------------|------------------|------------------|-------|--------|
|                                      | n   | (%)    | n   | (%)         | n                | (%)              | n     | (%)    |
| Subjects in population               | 370 |        | 370 |             | 458              |                  | 5,884 |        |
| with one or more adverse events      | 364 | (98.4) | 360 | (97.3)      | 281              | (61.4)           | 4,132 | (70.2) |
| with no adverse events               | 6   | (1.6)  | 10  | (2.7)       | 177              | (38.6)           | 1,752 | (29.8) |
| Nausea                               | 233 | (63.0) | 220 | (59.5)      | 25               | (5.5)            | 535   | (9.1)  |
| Decreased appetite                   | 145 | (39.2) | 119 | (32.2)      | 32               | (7.0)            | 461   | (7.8)  |
| Anaemia                              | 143 | (38.6) | 162 | (43.8)      | 9                | (2.0)            | 202   | (3.4)  |
| Fatigue                              | 135 | (36.5) | 107 | (28.9)      | 50               | (10.9)           | 1,170 | (19.9) |
| Neutrophil count decreased           | 135 | (36.5) | 109 | (29.5)      | 3                | (0.7)            | 26    | (0.4)  |
| Vomiting                             | 110 | (29.7) | 99  | (26.8)      | 11               | (2.4)            | 198   | (3.4)  |
| Diarrhoea                            | 97  | (26.2) | 85  | (23.0)      | 24               | (5.2)            | 630   | (10.7) |
| Neutropenia                          | 96  | (25.9) | 88  | (23.8)      | 0                | (0.0)            | 30    | (0.5)  |
| Stomatitis                           | 96  | (25.9) | 93  | (25.1)      | 5                | (1.1)            | 71    | (1.2)  |
| White blood cell count decreased     | 89  | (24.1) | 69  | (18.6)      | 3                | (0.7)            | 28    | (0.5)  |
| Blood creatinine increased           | 67  | (18.1) | 70  | (18.9)      | 6                | (1.3)            | 68    | (1.2)  |
| Platelet count decreased             | 61  | (16.5) | 56  | (15.1)      | 3                | (0.7)            | 32    | (0.5)  |
| Mucosal inflammation                 | 59  | (15.9) | 65  | (17.6)      | 2                | (0.4)            | 48    | (0.8)  |
| Alopecia                             | 51  | (13.8) | 39  | (10.5)      | 2                | (0.4)            | 46    | (0.8)  |
| Constipation                         | 50  | (13.5) | 63  | (17.0)      | 6                | (1.3)            | 155   | (2.6)  |
| Asthenia                             | 45  | (12.2) | 35  | (9.5)       | 26               | (5.7)            | 363   | (6.2)  |
| Malaise                              | 43  | (11.6) | 39  | (10.5)      | 12               | (2.6)            | 45    | (0.8)  |
| Weight decreased                     | 43  | (11.6) | 47  | (12.7)      | 2                | (0.4)            | 137   | (2.3)  |
| Hiccups                              | 40  | (10.8) | 33  | (8.9)       | 0                | (0.0)            | 9     | (0.2)  |
| Hypothyroidism                       | 38  | (10.3) | 22  | (5.9)       | 42               | (9.2)            | 565   | (9.6)  |
| Dysgeusia                            | 34  | (9.2)  | 32  | (8.6)       | 3                | (0.7)            | 60    | (1.0)  |
| Hypokalaemia                         | 34  | (9.2)  | 41  | (11.1)      | 0                | (0.0)            | 36    | (0.6)  |
| Peripheral sensory neuropathy        | 34  | (9.2)  | 29  | (7.8)       | 1                | (0.2)            | 29    | (0.5)  |
| Tinnitus                             | 33  | (8.9)  | 25  | (6.8)       | 1                | (0.2)            | 5     | (0.1)  |
| Hyponatraemia                        | 32  | (8.6)  | 40  | (10.8)      | 6                | (1.3)            | 59    | (1.0)  |
| Neuropathy peripheral                | 32  | (8.6)  | 32  | (8.6)       | 4                | (0.9)            | 41    | (0.7)  |
| Rash                                 | 29  | (7.8)  | 18  | (4.9)       | 24               | (5.2)            | 676   | (11.5) |
| Thrombocytopenia                     | 25  | (6.8)  | 33  | (8.9)       | 1                | (0.2)            | 41    | (0.7)  |
| Leukopenia                           | 24  | (6.5)  | 28  | (7.6)       | 0                | (0.0)            | 29    | (0.5)  |
| Pruritus                             | 23  | (6.2)  | 8   | (2.2)       | 23               | (5.0)            | 836   | (14.2) |
| Hypomagnesaemia                      | 21  | (5.7)  | 14  | (3.8)       | 0                | (0.0)            | 32    | (0.5)  |
| Lymphocyte count decreased           | 21  | (5.7)  | 20  | (5.4)       | 7                | (1.5)            | 47    | (0.8)  |
| Dehydration                          | 20  | (5.4)  | 16  | (4.3)       | 3                | (0.7)            | 33    | (0.6)  |
| Pneumonitis                          | 20  | (5.4)  | 0   |             |                  | (4.6)            | 223   | (3.8)  |
| Hyperthyroidism                      | 19  | (5.1)  | 2   | (0.0) (0.5) | 21 15            | (3.3)            | 219   | (3.7)  |
| Aspartate aminotransferase increased | 18  | (4.9)  | 19  | (5.1)       | 18               | (3.9)            | 220   | (3.7)  |
|                                      | 11  | (3.0)  | 4   |             |                  |                  | 437   | (7.4)  |
| Arthralgia                           |     |        |     | (1.1)       | 10               | (2.2)            |       |        |

<div style=\"page-break-after: always\"></div>

Figure 21: Between-treatment Comparisons in Drug-related Adverse Events Selected Adverse Events (&gt;=5% Incidence) and Sorted by Risk Difference (ASaT Population)

<!-- image -->

## All Grade 3 to 5 Adverse Events

Table 39: Subjects With Adverse Events by Maximum Toxicity Grade (extract)

Table 40: Subjects With Grade 35 Adverse Events (Incidence ≥ 5% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (ASaT Population)

|                            | KN590Datafor Pembrolizumab+ Chemotherapyft   | KN590Datafor Pembrolizumab+ Chemotherapyft   | KN590Datafor Placebo+ Chemotherapyll   | KN590Datafor Placebo+ Chemotherapyll   | PooledEsophageal SafetyDatasetfor Pembrolizumab Monotherapytt   | PooledEsophageal SafetyDatasetfor Pembrolizumab Monotherapytt   | ReferenceSafety Datasetfor Pembrolizumab Monotherapys   | ReferenceSafety Datasetfor Pembrolizumab Monotherapys   |
|----------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------|----------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
|                            |                                              | (%)                                          |                                        | (%)                                    |                                                                 | (%)                                                             | n                                                       | (%)                                                     |
| Subjectsinpopulation       | 370                                          |                                              | 370                                    |                                        | 458                                                             |                                                                 | 5,884                                                   |                                                         |
| withoneormoreadverseevents | 370                                          | (100.0)                                      | 368                                    | (99.5)                                 | 437                                                             | (95.4)                                                          | 5,690                                                   | (96.7)                                                  |
| Grade 1                    | 7                                            | (1.9)                                        | 3                                      | (0.8)                                  | 58                                                              | (12.7)                                                          | 757                                                     | (12.9)                                                  |
| Grade 2                    | 45                                           | (12.2)                                       | 57                                     | (15.4)                                 | 134                                                             | (29.3)                                                          | 2,104                                                   | (35.8)                                                  |
| Grade 3                    | 219                                          | (59.2)                                       | 210                                    | (56.8)                                 | 174                                                             | (38.0)                                                          | 2,165                                                   | (36.8)                                                  |
| Grade 4                    | 71                                           | (19.2)                                       | 60                                     | (16.2)                                 | 32                                                              | (7.0)                                                           | 353                                                     | (6.0)                                                   |
| Grade 5                    | 28                                           | (7.6)                                        | 38                                     | (10.3)                                 | 39                                                              | (8.5)                                                           | 311                                                     | (5.3)                                                   |
| withnoadverseevents        | 0                                            | (0.0)                                        | 2                                      | (0.5)                                  | 21                                                              | (4.6)                                                           | 194                                                     | (3.3)                                                   |

5,884

2,829

(48.1)

|                                 | KN590 Data for Pembrolizumab + Chemotherapy ††   | KN590 Data for Pembrolizumab + Chemotherapy ††   | KN590 Data for Placebo + Chemotherapy ¶¶   | KN590 Data for Placebo + Chemotherapy ¶¶   | Pooled Oesophageal Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Pooled Oesophageal Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|---------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                 | n                                                | (%)                                              | n                                          | (%)                                        | n                                                                    | (%)                                                                  | n                                                           | (%)                                                         |
| Subjects in population          | 370                                              |                                                  | 370                                        |                                            | 458                                                                  |                                                                      | 5,884                                                       |                                                             |
| with one or more adverse events | 318                                              | (85.9)                                           | 308                                        | (83.2)                                     | 245                                                                  | (53.5)                                                               | 2,829                                                       | (48.1)                                                      |

<div style=\"page-break-after: always\"></div>

3,055

(51.9)

(0.1)

(4.0)

15

(0.3)

(2.6)

(4.1)

(0.1)

30

(0.5)

(2.4)

50

(0.8)

42

(0.7)

58

(1.0)

(0.2)

74

(1.3)

30

(0.5)

(0.1)

| with no adverse events           |   52 | (14.1)   |   62 | (16.8)   |   213 | (46.5)   |   3,055 | (51.9)   |
|----------------------------------|------|----------|------|----------|-------|----------|---------|----------|
| Neutrophil count decreased       |   89 | (24.1)   |   64 | (17.3)   |     2 | (0.4)    |       8 | (0.1)    |
| Anaemia                          |   63 | (17.0)   |   81 | (21.9)   |    31 | (6.8)    |     233 | (4.0)    |
| Neutropenia                      |   54 | (14.6)   |   61 | (16.5)   |     0 | (0.0)    |      15 | (0.3)    |
| Hyponatraemia                    |   45 | (12.2)   |   41 | (11.1)   |    11 | (2.4)    |     153 | (2.6)    |
| Pneumonia                        |   35 | (9.5)    |   35 | (9.5)    |    31 | (6.8)    |     242 | (4.1)    |
| White blood cell count decreased |   34 | (9.2)    |   18 | (4.9)    |     1 | (0.2)    |       4 | (0.1)    |
| Dysphagia                        |   29 | (7.8)    |   26 | (7.0)    |    20 | (4.4)    |      30 | (0.5)    |
| Fatigue                          |   29 | (7.8)    |   25 | (6.8)    |     9 | (2.0)    |     144 | (2.4)    |
| Nausea                           |   27 | (7.3)    |   26 | (7.0)    |     5 | (1.1)    |      50 | (0.8)    |
| Vomiting                         |   27 | (7.3)    |   20 | (5.4)    |     6 | (1.3)    |      42 | (0.7)    |
| Hypokalaemia                     |   24 | (6.5)    |   32 | (8.6)    |     4 | (0.9)    |      58 | (1.0)    |
| Stomatitis                       |   21 | (5.7)    |   14 | (3.8)    |     0 | (0.0)    |       9 | (0.2)    |
| Decreased appetite               |   15 | (4.1)    |   20 | (5.4)    |    15 | (3.3)    |      74 | (1.3)    |
| Weight decreased                 |   11 | (3.0)    |   19 | (5.1)    |     6 | (1.3)    |      30 | (0.5)    |
| Platelet count decreased         |    7 | (1.9)    |   20 | (5.4)    |     1 | (0.2)    |       8 | (0.1)    |

Table 41: Exposure-Adjusted Grade 3-5 Adverse Events (Including Multiple Occurrences of Events) (Incidence ≥5% i n One or More Treatment Groups) (ASaT Population)

|                                                  | Event Count and Rate (Events/100 person-year) t   | Event Count and Rate (Events/100 person-year) t   |
|--------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                                  | Pembrolizumab+SOC                                 | SOC                                               |
| Number of Subjects exposedt                      | 370                                               | 370                                               |
| Total exposures person-years                     | 266.55                                            | 209.74                                            |
| Total events (rate)                              | 653(244.98)                                       | 616(293.70)                                       |
| AE Category                                      |                                                   |                                                   |
| Bloodandlynphaticsystemdisorders                 | 153(57.4)                                         | 181(86.3)                                         |
| Anaemia                                          | 70(26.3)                                          | 96(45.8)                                          |
| Neutropenia                                      | 83(31.1)                                          | 85(40.5)                                          |
| Gastrointestinaldisorder's                       | 118(44.3)                                         | 92(43.9)                                          |
| Dysphagia                                        | 33(12.4)                                          | 28(13.4)                                          |
| Nausea                                           | 30(11.3)                                          | 27(12.9)                                          |
| Stomatitis                                       | 22(8.3)                                           | 16(7.6)                                           |
| Vomiting                                         | 33(12.4)                                          | 21(10.0)                                          |
| Generaldisordersand administrationsiteconditions | 33(12.4)                                          | 31(14.8)                                          |
| Fatigue                                          | 33(12.4)                                          | 31(14.8)                                          |
| Infections andinfestations                       | 37(13.9)                                          | 39(18.6)                                          |
| Pneumonia                                        | 37(13.9)                                          | 39(18.6)                                          |
| Investigations                                   | 211(79.2)                                         | 156(74.4)                                         |
| Neutrophil count decreased                       | 145(54.4)                                         | 93(44.3)                                          |
| Platelet count decreased                         | 7(2.6)                                            | 23(11.0)                                          |
| Weight decreased                                 | 11(4.1)                                           | 19(9.1)                                           |
| Whiteblood cell count decreased                  | 48(18.0)                                          | 21(10.0)                                          |
| Metabolismandnutritiondisorder's                 | 101(37.9)                                         | 117(55.8)                                         |
| Decreased appetite                               | 15(5.6)                                           | 25(11.9)                                          |
| Hypokalaemia                                     | 32(12.0)                                          | 41(19.6)                                          |
| Hyponatraemia                                    | 54(20.3)                                          | 51(24.3)                                          |

Event rate per 100 person-year of exposure=event count *100/person-year of exposure.

+ Number of subjects exposed to drug at the start of indicated time interval.

$ Drug exposure is defined as the interval of min (last dose date + 30, Cutof Date) - first dose date + 1. Grades arebasedonNCICTCAEversion 4.03.

Non-serious adverse events up to30days oflast dose andserious adverseevents up to90days oflast dose are included.

MedDRA preferred terms \"Neoplasm Progression\",\"Malignant Neoplasm Progression\"and\"Disease Progression\"not related to the drug are excluded.

DatabaseCutoffDate:02JUL2020

## Adverse Drug Reactions

The MAH has updated section 4.8 of the SmPC to include the population of Oesophageal Cancer patients receiving Keytruda in combination with chemotherapy (study KEYNOTE-590) into the current chemotherapy combination Reference Safety Dataset which includes all chemotherapy combination indications approved in the EU. Table below serves as support for the updates made to SmPC Section 4.8.

<div style=\"page-break-after: always\"></div>

## AdverseReactionsinPatientsTreated withPembrolizumabin Combinationwith Chemotherapy

|                                                  | Combination Therapy                          | Combination Therapy   |
|--------------------------------------------------|----------------------------------------------|-----------------------|
|                                                  | All AEs                                      | Gr 3-5 AEs            |
| Infectionsandinfestations                        | Infectionsandinfestations                    |                       |
| Verycommon Pneumonia                             | 13.4% (193)                                  | 124                   |
| Bloodandlymphaticsystemdisorders                 | Bloodandlymphaticsystemdisorders             |                       |
| Very common Anaemia                              | 51.1% (735)                                  | 267                   |
| Very common Neutropenia                          | 29.2% (420)                                  | 237                   |
| Very common Thrombocytopenia                     | 19.4% (279)                                  | 92                    |
| Common Febrile neutropenia                       | 5.8% (83)                                    | 82                    |
| Common Leukopenia                                | 7.9% (113)                                   | 39                    |
| Common Lymphopenia                               | 1.7% (25)                                    | 8                     |
| Uncommon Eosinophilia                            | 0.3% (4)                                     | 1                     |
| Immunesystemdisorders                            | Immunesystemdisorders                        |                       |
| Common Infusion Reactionsa                       | 2.9% (42)                                    | 10                    |
| Endocrinedisorders                               | Endocrinedisorders                           |                       |
| Very common hypothyroidism                       | 11.5% (165)                                  | 3                     |
| Common Hyperthyroidismb                          | 5.4% (78)                                    | 2                     |
| Uncommon Hypophysitise                           | 0.8% (11)                                    | 4                     |
| Uncommon Adrenal Insufficiencyd                  | 0.6% (9)                                     | 4                     |
| Uncommon Thyroiditise                            | 0.4% (6)                                     | 1                     |
| Metabolismandnutritiondisorders                  | Metabolismandnutritiondisorders              |                       |
| Very common Hyponatraemia                        | 10.5% (151)                                  | 89                    |
| Very common Hypokalaemia                         | 13.0% (187)                                  | 64                    |
| Very common Decreased appetite                   | 33.6% (483)                                  | 42                    |
| Common Hypocalcaemia                             | 5.5% (79)                                    | 15                    |
| Uncommon Type 1 Diabetes Mellitus                | 0.2% (3)                                     | 3                     |
| Psychiatric disorders                            | Psychiatric disorders                        |                       |
| Very common Insomnia                             | 11.0% (158)                                  | 0                     |
| Nervoussystemdisorders                           | Nervoussystemdisorders                       |                       |
| Very common Dizziness                            | 11.9% (171)                                  | 5                     |
| Very common Neuropathy peripheral                | 10.7% (154)                                  | 4                     |
| Very common Headache                             | 11.9% (171)                                  | 3                     |
| Common Dysgeusia                                 | 9.1% (131)                                   | 1                     |
| Common Lethargy                                  | 1.7% (25)                                    | 0                     |
| Uncommon Encephalitis                            | 0.1% (2)                                     | 2                     |
| Uncommon Epilepsy                                | 0.3% (5)                                     | 2                     |
| Rare Guillain-BarreSyndrome                      | 0.07% (1)                                    | 1                     |
| Eye disorders                                    | Eye disorders                                |                       |
| Common Dry eye                                   | 3.2% (46)                                    | 0                     |
| Cardiac disorders                                | Cardiac disorders                            |                       |
| Common cardiac arrhythmia (including atrial      | 4.0% (58)                                    | 18                    |
| fibrillation)f Uncommon Myocarditiss             | 0.1% (2)                                     | 2                     |
| Uncommon Pericardial effusion                    | 0.3% (4)                                     | 2                     |
| Rare Pericarditis                                | 0.07% (1)                                    | 1                     |
| Vascular disorders                               | Vascular disorders                           |                       |
| Common Hypertension                              | 6.6% (95)                                    | 41                    |
| Respiratory,thoracicandmediastinal disorders     | Respiratory,thoracicandmediastinal disorders |                       |
| Very common Dyspnoea                             | 16.5% (237)                                  | 36                    |
| Very common Cough                                | 20.9% (300)                                  | 4                     |
| Common Pneumonitish                              | 6.0% (86)                                    | 36                    |
| Gastrointestinaldisorders                        | Gastrointestinaldisorders                    |                       |
| Very common Nausea                               | 54.9% (789)                                  | 63                    |
| Very common Diarrhoea                            | 33.1% (476)                                  | 60                    |
| Very common Vomiting Very common abdominal paini | 28.2% (405) 13.6% (195)                      | 56 13                 |
| Very common Constipation Common Colitisi         | 36.7% (527) 3.1% (44)                        | 6 22                  |

<div style=\"page-break-after: always\"></div>

| Common                                             | Dry mouth                                          | 4.7% (68)                                          | 1                                                  |
|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Uncommon                                           | Pancreatitisk                                      | 0.4% (6)                                           | 3                                                  |
| Uncommon                                           | gastrointestinal ulceration'                       | 0.4% (6)                                           | 1                                                  |
| Hepatobiliary disorders                            | Hepatobiliary disorders                            | Hepatobiliary disorders                            | Hepatobiliary disorders                            |
| Common                                             | Hepatitism                                         | 1.3% (19)                                          | 18                                                 |
| Skin andsubcutaneous tissue disorders              | Skin andsubcutaneous tissue disorders              | Skin andsubcutaneous tissue disorders              | Skin andsubcutaneous tissue disorders              |
| Very common                                        | rashn                                              | 20.8% (299)                                        | 3                                                  |
| Very common                                        | Alopecia                                           | 17.3% (248)                                        | 1                                                  |
| Very common                                        | prurituso                                          | 13.9% (200)                                        | 1                                                  |
| Common                                             | Severe Skin Reactionsp                             | 1.7% (25)                                          | 23                                                 |
| Common                                             | Dry skin                                           | 5.6% (81)                                          | 0                                                  |
| Common                                             | Erythema                                           | 3.7% (53)                                          | 0                                                  |
| Common                                             | Dermatitis                                         | 1.0% (15)                                          | 0                                                  |
| Uncommon                                           | Psoriasis                                          | 0.8% (11)                                          | 3                                                  |
| Uncommon                                           | vitiligoq                                          | 0.8% (12)                                          | 0                                                  |
| Uncommon                                           | Eczema                                             | 0.7% (10)                                          | 0                                                  |
| Uncommon                                           | Dermatitis acneiform                               | 0.6% (9)                                           | 0                                                  |
| Uncommon                                           | Papule                                             | 0.1% (2)                                           | 0                                                  |
| Uncommon                                           | lichenoid keratosis                                | 0.1% (2)                                           | 0                                                  |
| Rare                                               | Hair colour changes                                | 0.07% (1)                                          | 0                                                  |
| Musculoskeletal and connective tissue disorders    | Musculoskeletal and connective tissue disorders    | Musculoskeletal and connective tissue disorders    | Musculoskeletal and connective tissue disorders    |
| Very common                                        | musculoskeletal pain'                              | 18.5% (266)                                        | 18                                                 |
| Very common                                        | Arthralgia                                         | 12.2% (176)                                        | 9                                                  |
| Common                                             | myositiss                                          | 6.4% (92)                                          | 6                                                  |
| Common                                             | Pain in extremity                                  | 7.1% (102)                                         | 1                                                  |
| Common                                             | arthritist                                         | 2.2% (31)                                          | 0                                                  |
| Uncommon                                           | tenosynovitisu                                     | 0.3% (5)                                           | 1                                                  |
| Renal andurinary disorders                         | Renal andurinary disorders                         | Renal andurinary disorders                         | Renal andurinary disorders                         |
| Common                                             | Acute kidney injury                                | 5.6% (81)                                          | 31                                                 |
| Uncommon                                           | Nephritisv                                         | 0.9% (13)                                          | 8                                                  |
| General disorders and administrationsiteconditions | General disorders and administrationsiteconditions | General disorders and administrationsiteconditions | General disorders and administrationsiteconditions |
| Very common                                        | Fatigue                                            | 39.1% (562)                                        | 99                                                 |
| Very common                                        | Asthenia                                           | 18.1% (260)                                        | 58                                                 |
| Very common                                        | Pyrexia                                            | 17.0% (245)                                        | 7                                                  |
| Very common                                        | oedemaw                                            | 17.0% (244)                                        | 6                                                  |
| Common                                             | Influenza like illness                             | 2.5% (36)                                          | 0                                                  |
| Common                                             | Chills                                             | 2.2% (31)                                          | 0                                                  |
| Investigations                                     | Investigations                                     | Investigations                                     | Investigations                                     |
| Very common                                        | Blood creatinine increased                         | 15.3% (220)                                        | 12                                                 |
| Common                                             | Aspartate aminotransferase increased               | 9.2% (132)                                         | 15                                                 |
| Common                                             | Hypercalcaemia                                     | 2.8% (40)                                          | 13                                                 |
| Common                                             | Alanine aminotransferaseincreased                  | 9.5% (137)                                         | 12                                                 |
| Common                                             | Blood alkaline phosphatase increased               | 3.8% (54)                                          | 3                                                  |
| Common                                             | Blood bilirubin increased                          | 1.3% (18)                                          | 1                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Serious adverse event/deaths/other significant events

## Serious adverse events

Table 42: Subjects with serious adverse events up to 90 days of last dose by decreasing incidence in KEYNOTE-590 (incidence ≥2% in one or more treatment groups) (ASaT population)

|                                         | Pembrolizumab+SOC   | Pembrolizumab+SOC   |   SOC | SOC    |
|-----------------------------------------|---------------------|---------------------|-------|--------|
|                                         | n                   | (%)                 |    11 | (%)    |
| Subjects in population                  | 370                 |                     |   370 |        |
| with one or more serious adverse events | 205                 | (55.4)              |   204 | (55.1) |
| withno serious adverse events           | 165                 | (44.6)              |   166 | (44.9) |
| Pneumonia                               | 38                  | (10.3)              |    32 | (8.6)  |
| Dysphagia                               | 17                  | (4.6)               |    13 | (3.5)  |
| Pneumonitis                             | 12                  | (3.2)               |     0 | (0.0)  |
| Acute kidney injury                     | 11                  | (3.0)               |     6 | (1.6)  |
| Pneumonia aspiration                    | 11                  | (3.0)               |     7 | (1.9)  |
| Febrile neutropenia                     | 9                   | (2.4)               |    13 | (3.5)  |
| Vomiting                                | 9                   | (2.4)               |     6 | (1.6)  |
| Dehydration                             | 6                   | (1.6)               |     8 | (2.2)  |
| Platelet count decreased                | 5                   | (1.4)               |    10 | (2.7)  |
| Anaemia                                 | 3                   | (0.8)               |    10 | (2.7)  |

Every subject is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" notrelated to the drug are excluded.

DatabaseCutoffDate:02JUL2020

<div style=\"page-break-after: always\"></div>

Table 43: Subjects with serious adverse events up to 90 days of last dose (i ncidence ≥ 5% in one or more treatment groups) by decreasing frequency of preferred term (ASaT population)

5,884

2,266

(38.5)

3,618

(61.5)

(4.2)

|                                 | KN590 Data for Pembrolizumab + Chemotherapy ††   | KN590 Data for Pembrolizumab + Chemotherapy ††   | KN590 Data for Placebo + Chemotherapy ¶¶   | KN590 Data for Placebo + Chemotherapy ¶¶   | Pooled Oesophageal Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Pooled Oesophageal Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|---------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                 | n                                                | (%)                                              | n                                          | (%)                                        | n                                                                    | (%)                                                                  | n                                                           | (%)                                                         |
| Subjects in population          | 370                                              |                                                  | 370                                        |                                            | 458                                                                  |                                                                      | 5,884                                                       |                                                             |
| with one or more adverse events | 205                                              | (55.4)                                           | 204                                        | (55.1)                                     | 180                                                                  | (39.3)                                                               | 2,266                                                       | (38.5)                                                      |
| with no adverse events          | 165                                              | (44.6)                                           | 166                                        | (44.9)                                     | 278                                                                  | (60.7)                                                               | 3,618                                                       | (61.5)                                                      |
| Pneumonia                       | 38                                               | (10.3)                                           | 32                                         | (8.6)                                      | 30                                                                   | (6.6)                                                                | 246                                                         | (4.2)                                                       |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Table 44: Subjects With Drug-related Serious Adverse Events Up to 90 Days of Last Dose (Incidence ≥ 5% i n One or More Treatment Groups) By Decreasing Frequency of Preferred Term (ASaT Population)

|                               | KN590Datafor Pembrolizumab+ Chemotherapylt   | KN590Datafor Pembrolizumab+ Chemotherapylt   | KN590Datafor Placebo+ Chemotherapy   | KN590Datafor Placebo+ Chemotherapy   | PooledEsophageal SafetyDatasetfor Pembrolizumab Monotherapytt   | PooledEsophageal SafetyDatasetfor Pembrolizumab Monotherapytt   | Reference Safety Datasetfor Pembrolizumab Monotherapy\"$   | Reference Safety Datasetfor Pembrolizumab Monotherapy\"$   |
|-------------------------------|----------------------------------------------|----------------------------------------------|--------------------------------------|--------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
|                               | n                                            | (%)                                          |                                      | (%)                                  | n1                                                              | (%)                                                             | n1                                                        | (%)                                                       |
| Subjectsinpopulation          | 370                                          |                                              | 370                                  |                                      | 458                                                             |                                                                 | 5,884                                                     |                                                           |
| with one ormore adverseevents | 117                                          | (31.6)                                       | 97                                   | (26.2)                               | 56                                                              | (12.2)                                                          | 656                                                       | (11.1)                                                    |
| withnoadverseevents           | 253                                          | (68.4)                                       | 273                                  | (73.8)                               | 402                                                             | (87.8)                                                          | 5,228                                                     | (88.9)                                                    |

The most frequently reported drugrelated SAEs (≥2%) in the pembrolizumab plus chemotherapy group and the chemotherapy group of KN590 study were: pneumonia (3.5% vs 0.8%), pneumonitis (3.2% vs 0.0%), febrile neutropenia (2.4% vs 3.2%), acute kidney injury (2.2% vs 1.4%), vomiting (2.2% vs 1.6%), and platelet count decreased (1.4% vs 2.2%).

## Deaths Due to Adverse Events

Table 45: Subjects With Adverse Events Resulting in Death Up to 90 Days of Last Dose (Incidence &gt; 0% in One or More Treatment Groups) By Dec reasing Frequency of Preferred Term (ASaT Population) (extract)

5,884

(5.3)

5,572

(94.7)

36

(0.6)

(0.1)

(0.0)

|                                 | KN590 Data for Pembrolizumab + Chemotherapy ††   | KN590 Data for Pembrolizumab + Chemotherapy ††   | KN590 Data for Placebo + Chemotherapy ¶¶   | KN590 Data for Placebo + Chemotherapy ¶¶   | Pooled Oesophageal Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Pooled Oesophageal Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|---------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                 | n                                                | (%)                                              | n                                          | (%)                                        | n                                                                    | (%)                                                                  | n                                                           | (%)                                                         |
| Subjects in population          | 370                                              |                                                  | 370                                        |                                            | 458                                                                  |                                                                      | 5,884                                                       |                                                             |
| with one or more adverse events | 28                                               | (7.6)                                            | 38                                         | (10.3)                                     | 39                                                                   | (8.5)                                                                | 312                                                         | (5.3)                                                       |
| with no adverse events          | 342                                              | (92.4)                                           | 332                                        | (89.7)                                     | 419                                                                  | (91.5)                                                               | 5,572                                                       | (94.7)                                                      |
| Pneumonia                       | 6                                                | (1.6)                                            | 10                                         | (2.7)                                      | 4                                                                    | (0.9)                                                                | 36                                                          | (0.6)                                                       |
| Pneumonia aspiration            | 3                                                | (0.8)                                            | 2                                          | (0.5)                                      | 6                                                                    | (1.3)                                                                | 8                                                           | (0.1)                                                       |
| Pulmonary sepsis                | 3                                                | (0.8)                                            | 0                                          | (0.0)                                      | 0                                                                    | (0.0)                                                                | 2                                                           | (0.0)                                                       |

<div style=\"page-break-after: always\"></div>

42

(0.7)

(0.1)

(0.0)

(0.1)

(0.0)

(0.1)

(0.0)

(0.0)

(0.0)

(0.1)

(0.0)

(0.1)

(0.0)

(0.0)

(0.1)

10

(0.2)

(0.0)

(0.0)

(0.1)

(0.2)

(0.0)

(0.1)

(0.0)

(0.0)

17

(0.3)

(0.2)

(0.0)

| Death                               | 2 (0.5)   |   7 | (1.9)   |   5 | (1.1)   |   42 | (0.7)   |
|-------------------------------------|-----------|-----|---------|-----|---------|------|---------|
| Acute kidney injury                 | 1 (0.3)   |   0 | (0.0)   |   0 | (0.0)   |    3 | (0.1)   |
| Acute myocardial infarction         | 1 (0.3)   |   0 | (0.0)   |   0 | (0.0)   |    1 | (0.0)   |
| Acute respiratory failure           | 1 (0.3)   |   1 | (0.3)   |   1 | (0.2)   |    5 | (0.1)   |
| COVID-19                            | 1 (0.3)   |   0 | (0.0)   |   0 | (0.0)   |    0 | (0.0)   |
| Cardio-respiratory arrest           | 1 (0.3)   |   0 | (0.0)   |   1 | (0.2)   |    4 | (0.1)   |
| Clostridium difficile colitis       | 1 (0.3)   |   0 | (0.0)   |   0 | (0.0)   |    0 | (0.0)   |
| Diarrhoea                           | 1 (0.3)   |   1 | (0.3)   |   0 | (0.0)   |    0 | (0.0)   |
| Febrile neutropenia                 | 1 (0.3)   |   1 | (0.3)   |   0 | (0.0)   |    1 | (0.0)   |
| Hepatic failure                     | 1 (0.3)   |   0 | (0.0)   |   0 | (0.0)   |    3 | (0.1)   |
| Interstitial lung disease           | 1 (0.3)   |   1 | (0.3)   |   0 | (0.0)   |    1 | (0.0)   |
| Multiple organ dysfunction syndrome | 1 (0.3)   |   1 | (0.3)   |   0 | (0.0)   |    5 | (0.1)   |
| Oesophageal fistula                 | 1 (0.3)   |   0 | (0.0)   |   0 | (0.0)   |    0 | (0.0)   |
| Oesophagobronchial fistula          | 1 (0.3)   |   0 | (0.0)   |   0 | (0.0)   |    0 | (0.0)   |
| Pneumonitis                         | 1 (0.3)   |   0 | (0.0)   |   3 | (0.7)   |    8 | (0.1)   |
| Pulmonary embolism                  | 1 (0.3)   |   0 | (0.0)   |   0 | (0.0)   |   10 | (0.2)   |
| Sudden cardiac death                | 1 (0.3)   |   0 | (0.0)   |   0 | (0.0)   |    0 | (0.0)   |
| Upper gastrointestinal haemorrhage  | 1 (0.3)   |   2 | (0.5)   |   0 | (0.0)   |    1 | (0.0)   |
| Aspiration                          | 0 (0.0)   |   1 | (0.3)   |   0 | (0.0)   |    3 | (0.1)   |
| Cardiac arrest                      | 0 (0.0)   |   2 | (0.5)   |   0 | (0.0)   |    9 | (0.2)   |
| Cerebral haemorrhage                | 0 (0.0)   |   1 | (0.3)   |   0 | (0.0)   |    1 | (0.0)   |
| Cerebrovascular accident            | 0 (0.0)   |   1 | (0.3)   |   2 | (0.4)   |    5 | (0.1)   |
| Gastrointestinal haemorrhage        | 0 (0.0)   |   1 | (0.3)   |   2 | (0.4)   |    0 | (0.0)   |
| Haematemesis                        | 0 (0.0)   |   1 | (0.3)   |   0 | (0.0)   |    0 | (0.0)   |
| Respiratory failure                 | 0 (0.0)   |   1 | (0.3)   |   0 | (0.0)   |   17 | (0.3)   |
| Sepsis                              | 0 (0.0)   |   3 | (0.8)   |   1 | (0.2)   |    9 | (0.2)   |
| Tracheal haemorrhage                | 0 (0.0)   |   1 | (0.3)   |   0 | (0.0)   |    0 | (0.0)   |

NOTE: The PT 'death' was reported in situations where limited information on the cause of death was available, or where the investigator could not assign a specific AE term in a participant with comorbidities and confounding factors that led to death.

## Adverse event of special interest (AEOSI)

AEOSI are immune-related events and IRRs associated with pembrolizumab (list of MK-3475 AEOSI Preferred Terms Version 18, 05-MAY-2020).

Table 46: Adverse Event Summary for AEOSI (ASaT Population)

|                                                           | KN590 Data for Pembrolizumab + Chemotherapy ††   | KN590 Data for Pembrolizumab + Chemotherapy ††   | KN590 Data for Placebo + Chemotherapy ¶¶   | KN590 Data for Placebo + Chemotherapy ¶¶   | Pooled Oesophageal Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Pooled Oesophageal Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|-----------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                                           | n                                                | (%)                                              | n                                          | (%)                                        | n                                                                    | (%)                                                                  | n                                                           | (%)                                                         |
| Subjects in population                                    | 370                                              |                                                  | 370                                        |                                            | 458                                                                  |                                                                      | 5,884                                                       |                                                             |
| with one or more adverse events                           | 95                                               | (25.7)                                           | 43                                         | (11.6)                                     | 106                                                                  | (23.1)                                                               | 1,474                                                       | (25.1)                                                      |
| with no adverse event                                     | 275                                              | (74.3)                                           | 327                                        | (88.4)                                     | 352                                                                  | (76.9)                                                               | 4,410                                                       | (74.9)                                                      |
| with drug-related † adverse events                        | 91                                               | (24.6)                                           | 35                                         | (9.5)                                      | 95                                                                   | (20.7)                                                               | 1,281                                                       | (21.8)                                                      |
| with toxicity grade 3-5 adverse events                    | 26                                               | (7.0)                                            | 8                                          | (2.2)                                      | 27                                                                   | (5.9)                                                                | 381                                                         | (6.5)                                                       |
| with toxicity grade 3-5 drug-related adverse events       | 25                                               | (6.8)                                            | 6                                          | (1.6)                                      | 26                                                                   | (5.7)                                                                | 331                                                         | (5.6)                                                       |
| with serious adverse events                               | 30                                               | (8.1)                                            | 7                                          | (1.9)                                      | 29                                                                   | (6.3)                                                                | 381                                                         | (6.5)                                                       |
| with serious drug-related adverse events                  | 28                                               | (7.6)                                            | 5                                          | (1.4)                                      | 27                                                                   | (5.9)                                                                | 337                                                         | (5.7)                                                       |
| who died                                                  | 2                                                | (0.5)                                            | 1                                          | (0.3)                                      | 4                                                                    | (0.9)                                                                | 11                                                          | (0.2)                                                       |
| who died due to a drug-related adverse event              | 2                                                | (0.5)                                            | 1                                          | (0.3)                                      | 4                                                                    | (0.9)                                                                | 11                                                          | (0.2)                                                       |
| discontinued any drug due to an adverse event             | 16                                               | (4.3)                                            | 2                                          | (0.5)                                      | 19                                                                   | (4.1)                                                                | 232                                                         | (3.9)                                                       |
| discontinued Pembrolizumab or placebo                     | 14                                               | (3.8)                                            | 2                                          | (0.5)                                      | 19                                                                   | (4.1)                                                                | 232                                                         | (3.9)                                                       |
| discontinued any chemotherapy                             | 6                                                | (1.6)                                            | 1                                          | (0.3)                                      | 19                                                                   | (4.1)                                                                | 232                                                         | (3.9)                                                       |
| discontinued all drugs                                    | 3                                                | (0.8)                                            | 0                                          | (0.0)                                      | 19                                                                   | (4.1)                                                                | 232                                                         | (3.9)                                                       |
| discontinued any drug due to a drug-related adverse event | 16                                               | (4.3)                                            | 2                                          | (0.5)                                      | 19                                                                   | (4.1)                                                                | 228                                                         | (3.9)                                                       |
| discontinued Pembrolizumab or placebo                     | 14                                               | (3.8)                                            | 2                                          | (0.5)                                      | 19                                                                   | (4.1)                                                                | 228                                                         | (3.9)                                                       |
| discontinued any chemotherapy                             | 6                                                | (1.6)                                            | 1                                          | (0.3)                                      | 19                                                                   | (4.1)                                                                | 228                                                         | (3.9)                                                       |
| discontinued all drugs                                    | 3                                                | (0.8)                                            | 0                                          | (0.0)                                      | 19                                                                   | (4.1)                                                                | 228                                                         | (3.9)                                                       |
| discontinued any drug due to a serious adverse event      | 12                                               | (3.2)                                            | 2                                          | (0.5)                                      | 12                                                                   | (2.6)                                                                | 156                                                         | (2.7)                                                       |
| discontinued Pembrolizumab or placebo                     | 11                                               | (3.0)                                            | 2                                          | (0.5)                                      | 12                                                                   | (2.6)                                                                | 156                                                         | (2.7)                                                       |

(25.1)

(74.9)

(21.8)

(0.2)

(0.2)

<div style=\"page-break-after: always\"></div>

| discontinued any chemotherapy                                     | 4 (1.1)   | 1 (0.3)   |   12 | (2.6)   |   156 | (2.7)   |
|-------------------------------------------------------------------|-----------|-----------|------|---------|-------|---------|
| discontinued all drugs                                            | 2 (0.5)   | 0 (0.0)   |   12 | (2.6)   |   156 | (2.7)   |
| discontinued any drug due to a serious drug-related adverse event | 12 (3.2)  | 2 (0.5)   |   12 | (2.6)   |   154 | (2.6)   |
| discontinued Pembrolizumab or placebo                             | 11 (3.0)  | 2 (0.5)   |   12 | (2.6)   |   154 | (2.6)   |
| discontinued any chemotherapy                                     | 4 (1.1)   | 1 (0.3)   |   12 | (2.6)   |   154 | (2.6)   |

## Table 47: Subjects With Adverse Events of Special Interest (AEOSI) By AEOSI Category and Preferred Term (ASaT Population) (extract, PT incidence &gt; 0% in the KN590 pembrolizumab + chemotherapy arm)

5,884

1,474

(25.1)

4,410

(74.9)

42

(0.7)

95

(1.6)

(0.1)

(0.1)

24

(0.4)

25

(0.4)

(4.2)

(0.0)

14

(0.2)

22

(0.4)

(11.1)

56

(1.0)

47

(0.8)

(0.1)

11

(0.2)

14

(0.2)

(4.1)

22

(0.4)

16

(0.3)

12

(0.2)

|                                       | KN590 Data for Pembrolizumab + Chemotherapy ††   | KN590 Data for Pembrolizumab + Chemotherapy ††   | KN590 Data for Placebo + Chemotherapy ¶¶   | KN590 Data for Placebo + Chemotherapy ¶¶   | Pooled Oesophageal Safety Dataset for Pembrolizumab ‡‡   | Pooled Oesophageal Safety Dataset for Pembrolizumab ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|---------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                       | n                                                | (%)                                              | n (%)                                      | n (%)                                      | n (%)                                                    | n (%)                                                    | n (%)                                                       | n (%)                                                       |
| Subjects in population                | 370                                              |                                                  | 370                                        |                                            | 458                                                      |                                                          | 5,884                                                       |                                                             |
| with one or more adverse events       | 95                                               | (25.7)                                           | 43                                         | (11.6)                                     | 106                                                      | (23.1)                                                   | 1,474                                                       | (25.1)                                                      |
| with no adverse events                | 275                                              | (74.3)                                           | 327                                        | (88.4)                                     | 352                                                      | (76.9)                                                   | 4,410                                                       | (74.9)                                                      |
| Adrenal Insufficiency                 | 4                                                | (1.1)                                            | 2                                          | (0.5)                                      | 1                                                        | (0.2)                                                    | 47                                                          | (0.8)                                                       |
| Adrenal insufficiency                 | 4                                                | (1.1)                                            | 2                                          | (0.5)                                      | 1                                                        | (0.2)                                                    | 42                                                          | (0.7)                                                       |
| Colitis                               | 8                                                | (2.2)                                            | 6                                          | (1.6)                                      | 7                                                        | (1.5)                                                    | 110                                                         | (1.9)                                                       |
| Colitis                               | 6                                                | (1.6)                                            | 4                                          | (1.1)                                      | 5                                                        | (1.1)                                                    | 95                                                          | (1.6)                                                       |
| Autoimmune colitis                    | 1                                                | (0.3)                                            | 0                                          | (0.0)                                      | 0                                                        | (0.0)                                                    | 3                                                           | (0.1)                                                       |
| Enterocolitis                         | 1                                                | (0.3)                                            | 2                                          | (0.5)                                      | 2                                                        | (0.4)                                                    | 8                                                           | (0.1)                                                       |
| Encephalitis                          | 0                                                | (0.0)                                            | 0                                          | (0.0)                                      | 0                                                        | (0.0)                                                    | 3                                                           | (0.1)                                                       |
| Guillain-Barre Syndrome               | 0                                                | (0.0)                                            | 0                                          | (0.0)                                      | 1                                                        | (0.2)                                                    | 4                                                           | (0.1)                                                       |
| Hepatitis                             | 5                                                | (1.4)                                            | 0                                          | (0.0)                                      | 7                                                        | (1.5)                                                    | 56                                                          | (1.0)                                                       |
| Hepatitis                             | 3                                                | (0.8)                                            | 0                                          | (0.0)                                      | 0                                                        | (0.0)                                                    | 24                                                          | (0.4)                                                       |
| Autoimmune hepatitis                  | 2                                                | (0.5)                                            | 0                                          | (0.0)                                      | 6                                                        | (1.3)                                                    | 25                                                          | (0.4)                                                       |
| Hyperthyroidism                       | 21                                               | (5.7)                                            | 3                                          | (0.8)                                      | 18                                                       | (3.9)                                                    | 247                                                         | (4.2)                                                       |
| Hyperthyroidism                       | 20                                               | (5.4)                                            | 3                                          | (0.8)                                      | 18                                                       | (3.9)                                                    | 247                                                         | (4.2)                                                       |
| Basedow's disease                     | 1                                                | (0.3)                                            | 0                                          | (0.0)                                      | 0                                                        | (0.0)                                                    | 0                                                           | (0.0)                                                       |
| Hypophysitis                          | 3                                                | (0.8)                                            | 0                                          | (0.0)                                      | 3                                                        | (0.7)                                                    | 36                                                          | (0.6)                                                       |
| Hypopituitarism                       | 2                                                | (0.5)                                            | 0                                          | (0.0)                                      | 2                                                        | (0.4)                                                    | 14                                                          | (0.2)                                                       |
| Hypophysitis                          | 1                                                | (0.3)                                            | 0                                          | (0.0)                                      | 1                                                        | (0.2)                                                    | 22                                                          | (0.4)                                                       |
| Hypothyroidism                        | 40                                               | (10.8)                                           | 24                                         | (6.5)                                      | 50                                                       | (10.9)                                                   | 652                                                         | (11.1)                                                      |
| Hypothyroidism                        | 40                                               | (10.8)                                           | 24                                         | (6.5)                                      | 49                                                       | (10.7)                                                   | 651                                                         | (11.1)                                                      |
| Infusion Reactions                    | 6                                                | (1.6)                                            | 4                                          | (1.1)                                      | 4                                                        | (0.9)                                                    | 138                                                         | (2.3)                                                       |
| Infusion related reaction             | 4                                                | (1.1)                                            | 0                                          | (0.0)                                      | 4                                                        | (0.9)                                                    | 56                                                          | (1.0)                                                       |
| Hypersensitivity                      | 2                                                | (0.5)                                            | 2                                          | (0.5)                                      | 0                                                        | (0.0)                                                    | 47                                                          | (0.8)                                                       |
| Myasthenic Syndrome                   | 0                                                | (0.0)                                            | 0                                          | (0.0)                                      | 0                                                        | (0.0)                                                    | 3                                                           | (0.1)                                                       |
| Myelitis                              | 0                                                | (0.0)                                            | 0                                          | (0.0)                                      | 0                                                        | (0.0)                                                    | 2                                                           | (0.0)                                                       |
| Myocarditis                           | 0                                                | (0.0)                                            | 0                                          | (0.0)                                      | 1                                                        | (0.2)                                                    | 5                                                           | (0.1)                                                       |
| Myositis                              | 1                                                | (0.3)                                            | 0                                          | (0.0)                                      | 2                                                        | (0.4)                                                    | 19                                                          | (0.3)                                                       |
| Myopathy                              | 1                                                | (0.3)                                            | 0                                          | (0.0)                                      | 0                                                        | (0.0)                                                    | 4                                                           | (0.1)                                                       |
| Nephritis                             | 1                                                | (0.3)                                            | 2                                          | (0.5)                                      | 3                                                        | (0.7)                                                    | 23                                                          | (0.4)                                                       |
| Tubulointerstitial nephritis          | 1                                                | (0.3)                                            | 1                                          | (0.3)                                      | 0                                                        | (0.0)                                                    | 11                                                          | (0.2)                                                       |
| Pancreatitis                          | 2                                                | (0.5)                                            | 1                                          | (0.3)                                      | 1                                                        | (0.2)                                                    | 18                                                          | (0.3)                                                       |
| Pancreatitis                          | 2                                                | (0.5)                                            | 1                                          | (0.3)                                      | 1                                                        | (0.2)                                                    | 14                                                          | (0.2)                                                       |
| Pneumonitis                           | 23                                               | (6.2)                                            | 2                                          | (0.5)                                      | 24                                                       | (5.2)                                                    | 264                                                         | (4.5)                                                       |
|                                       | 21                                               | (5.7)                                            | 0                                          | (0.0)                                      |                                                          |                                                          |                                                             | (0.4)                                                       |
| Pneumonitis                           |                                                  |                                                  |                                            |                                            | 21                                                       | (4.6)                                                    | 242                                                         | (4.1)                                                       |
| Interstitial lung disease Sarcoidosis | 2 0                                              | (0.5) (0.0)                                      | 2 0                                        | (0.5) (0.0)                                | 3 0                                                      | (0.7) (0.0)                                              | 22 10                                                       | (0.2)                                                       |
|                                       |                                                  | (1.1)                                            |                                            | (0.5)                                      |                                                          | (0.9)                                                    |                                                             |                                                             |
| Severe Skin Reactions                 | 4                                                |                                                  | 2                                          |                                            | 4                                                        |                                                          | 97                                                          | (1.6)                                                       |
| Rash maculo-papular Pruritus          | 4 1                                              | (1.1) (0.3)                                      | 1 0                                        | (0.3) (0.0)                                | 0 0                                                      | (0.0) (0.0)                                              | 16 12                                                       | (0.3) (0.2)                                                 |
|                                       |                                                  | (0.3)                                            | 0                                          |                                            | 2                                                        | (0.4)                                                    | 58                                                          | (1.0)                                                       |
| Thyroiditis                           | 1                                                |                                                  |                                            | (0.0)                                      |                                                          |                                                          |                                                             |                                                             |

<div style=\"page-break-after: always\"></div>

41

(0.7)

16

| Thyroiditis                                                                | 1 (0.3)                                                                    | 0 (0.0)                                                                    | 2 (0.4)                                                                    | 41 (0.7)                                                                   |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Type 1 Diabetes Mellitus                                                   | 1 (0.3)                                                                    | 0 (0.0)                                                                    | 3 (0.7)                                                                    | 20 (0.3)                                                                   |
| Type 1 diabetes mellitus                                                   | 1 (0.3)                                                                    | 0 (0.0)                                                                    | 2 (0.4)                                                                    | 16 (0.3)                                                                   |
| Uveitis                                                                    | 0 (0.0)                                                                    | 0 (0.0)                                                                    | 1 (0.2)                                                                    | 21 (0.4)                                                                   |
| Every subject is counted a single time for each applicable row and column. | Every subject is counted a single time for each applicable row and column. | Every subject is counted a single time for each applicable row and column. | Every subject is counted a single time for each applicable row and column. | Every subject is counted a single time for each applicable row and column. |

(0.3)

Table 48: Subjects With Adverse Events of Special Interest (AEOSI) by Maximum Toxicity Grade (ASaT Population) (extract)

|                            |   KN590Datafor Pembrolizumab+ Chemotherapyit | KN590Datafor Pembrolizumab+ Chemotherapyit   |   KN590Datafor Placebo+ Chemotherapyfl | KN590Datafor Placebo+ Chemotherapyfl   | PooledEsophageal SafetyDatasetfor Pembrolizumab Monotherapytt   | PooledEsophageal SafetyDatasetfor Pembrolizumab Monotherapytt   | Reference Safety Datasetfor Pembrolizumab Monotherapy\"   | Reference Safety Datasetfor Pembrolizumab Monotherapy\"   |
|----------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------|----------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                            |                                           11 | (%)                                          |                                     11 | (%)                                    | 1n1                                                             | (%)                                                             | 11                                                       | (%)                                                      |
| Subjectsinpopulation       |                                          370 |                                              |                                    370 |                                        | 458                                                             |                                                                 | 5,884                                                    |                                                          |
| withoneormoreadverseevents |                                           95 | (25.7)                                       |                                     43 | (11.6)                                 | 106                                                             | (23.1)                                                          | 1,474                                                    | (25.1)                                                   |
| Grade 1                    |                                           26 | (7.0)                                        |                                     16 | (4.3)                                  | 20                                                              | (4.4)                                                           | 367                                                      | (6.2)                                                    |
| Grade 2                    |                                           43 | (11.6)                                       |                                     19 | (5.1)                                  | 59                                                              | (12.9)                                                          | 726                                                      | (12.3)                                                   |
| Grade 3                    |                                           24 | (6.5)                                        |                                      7 | (1.9)                                  | 18                                                              | (3.9)                                                           | 325                                                      | (5.5)                                                    |
| Grade 4                    |                                            0 | (0.0)                                        |                                      0 | (0.0)                                  | 5                                                               | (1.1)                                                           | 45                                                       | (0.8)                                                    |
| Grade 5                    |                                            2 | (0.5)                                        |                                      1 | (0.3)                                  | 4                                                               | (0.9)                                                           | 11                                                       | (0.2)                                                    |
| withnoadverseevents        |                                          275 | (74.3)                                       |                                    327 | (88.4)                                 | 352                                                             | (76.9)                                                          | 4.410                                                    | (74.9)                                                   |

Table 49: Summary of Outcome for Subjects With AEOSI (ASaT Population) (extract)

|                       |             | KN590Datafor Pembrolizumab+ Chemotherapyit   | KN590Datafor Pembrolizumab+ Chemotherapyit   | KN590DataforPlacebo+ Chemotherapyl   | KN590DataforPlacebo+ Chemotherapyl   | PooledEsophagealSafety DatasetforPembrolizumab Monotherapytt   | PooledEsophagealSafety DatasetforPembrolizumab Monotherapytt   | ReferenceSafetyDatasetfor Pembrolizumab Monotherapy'   | ReferenceSafetyDatasetfor Pembrolizumab Monotherapy'   |
|-----------------------|-------------|----------------------------------------------|----------------------------------------------|--------------------------------------|--------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                       | Outcome     | n                                            | (%)                                          |                                      | (%)                                  | n                                                              | (%)                                                            |                                                        | (%)                                                    |
| Subjects inpopulation |             | 370                                          |                                              | 370                                  |                                      | 458                                                            |                                                                | 5884                                                   |                                                        |
| IWithoneormoreAEOSI   | Overall     | 95                                           | (25.7)                                       | 43                                   | (11.6)                               | 106                                                            | (23.1)                                                         | 1474                                                   | (25.1)                                                 |
|                       | Fatal       | 2                                            | (2.1)                                        | 1                                    | (2.3)                                | 4                                                              | (3.8)                                                          | 11                                                     | (0.7)                                                  |
|                       | NotResolved | 41                                           | (43.2)                                       | 15                                   | (34.9)                               | 57                                                             | (53.8)                                                         | 693                                                    | (47.0)                                                 |
|                       | Resolving   | 12                                           | (12.6)                                       | 7                                    | (16.3)                               | 10                                                             | (9.4)                                                          | 97                                                     | (6.6)                                                  |
|                       | Unknown     | 0                                            | (0.0)                                        | 0                                    | (0.0)                                | 0                                                              | (0.0)                                                          | 27                                                     | (1.8)                                                  |
|                       | Sequelae    | 2                                            | (2.1)                                        | 0                                    | (0.0)                                | 1                                                              | (0.9)                                                          | 33                                                     | (2.2)                                                  |
|                       | Resolved    | 38                                           | (40.0)                                       | 20                                   | (46.5)                               | 34                                                             | (32.1)                                                         | 613                                                    | (41.6)                                                 |

Hypothyroidism : most AEOSI events for hypothyroidism were considered drug related (10.3%), were all Grade 1 or 2; at the time of data cut-off, 57.5% were not resolved, 12.5% were considered resolving and 27.5% resolved. Only 1 out of 46 subjects with hypothyroidism received corticosteroids.

Pneumonitis : pneumonitis occurred in 23 participants in the pembrolizumab plus chemotherapy group (6.2%), and most of those events were considered drug related (5.9%). Almost half were grade 2 in severity (G1 0.8%, G2 3%, G3 1.9%, G4 0%, G5 0.5%). The median time to onset for the AEOSI pneumonitis in the pembrolizumab + chemotherapy group compared with pembrolizumab monotherapy RSD was longer (149 vs 106 days) and lasted longer (median episode duration 216 vs 58 days). Most of the patients experiencing were treated with corticosteroids (78.3%), starting usually at high (≥40 mg/day prednisone or equivalent) dose (68%). Events were mostly considered resolving (21.7%) or resolved (47.8%) at the time of data cut-off, while 21.7% were not resolved.

In the 23 patients with pneumonitis in the pembrolizumab plus chemotherapy group, 3 (all G2) had prior thoracic radiation. In the 2 participants in the chemotherapy group who had pneumonitis, 1 (G1) had prior thoracic radiation. The small number of participants with pneumonitis who had prior thoracic radiation precludes clinically meaningful conclusions about the role of prior radiation in the events.

<div style=\"page-break-after: always\"></div>

Hyperthyroidism : most AEOSI events for hyperthyroidism were considered drug related (5.4%), the majority were Grade 1 or 2 in severity, and at the time of data cut-off, the majority (66.7%) were considered resolved.

## Laboratory findings

In KEYNOTE-590 study, the most frequently reported ( ≥ 5%) laboratory abnormalities were similar in the pembrolizumab plus chemotherapy group and the chemotherapy group, and the majority were CTCAE Grade 1 to 2 toxicity. The largest between-treatment difference (&gt;5%) in laboratory abnormalities (all grades) between the pembrolizumab plus chemotherapy compared with the chemotherapy were: ALT increased (23.2% vs 17.7%), calcium decreased (43.8% vs 37.6%), calcium increased (7.5% vs 12.6%), and phosphate decreased (36.9% vs 30.5%). There was 1 participant in each treatment arm of KN590 who met the specified threshold of abnormal hepatic tests (i.e., AST or ALT ≥ 3x the upper limit of normal (ULN) and total bilirubin ≥ 2x ULN and alkaline phosphatase &lt;2× ULN).

The following Grade 3 to 4 laboratory abnormalities were reported with an incidence ≥ 5% and were higher ( ≥ 5% point difference) in the pembrolizumab plus chemotherapy group compared with the pembrolizumab monotherapy RSD: Haemoglobin decreased (20.9% vs 6.4%), leukocytes decreased (20.9% vs 0.8%), lymphocytes decreased (22.3% vs 11.0%), neutrophils decreased (43.3% vs 1.9%), potassium decreased (11.9% vs 2.3%), and sodium decreased (19.2% vs 8.3%). Those are consistent with the established safety profiles of the chemotherapies.

In the pool of patients treated with pembrolizumab in combination with chemotherapy, the proportion of patients who experienced a shift from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 33.0% for neutrophils decreased, 25.5% for lymphocytes decreased, 20.3% for haemoglobin decreased, 19.3% for leucocytes decreased, 13.9% for sodium decreased, 10.8% for platelets decreased, 9.7% for phosphate decreased, 8.4% for potassium decreased, 7.6% for glucose increased, 3.9% for AST increased, 3.8% for potassium increased, 3.7% for calcium decreased, 3.6% for ALT increased, 3.1% for creatinine increased, 3.0% for albumin decreased, 2.2% for calcium increased, 1.6% for alkaline phosphatase increased, 1.2% for bilirubin increased, 0.8% for glucose decreased,  and 0.4% for sodium increased (see section 4.8 of the SmPC).

## Safety in special populations

## Age

Table 50: Adverse Event Summary by Age Category (&lt;65, ≥ 65 Years) (ASaT Population)

<div style=\"page-break-after: always\"></div>

|                                                            |                           | KN590 Data forPembrolizumab+ Chemotherapyit   | KN590 Data forPembrolizumab+ Chemotherapyit   | KN590 Data forPembrolizumab+ Chemotherapyit   | KN590Data forPlacebo+ Chemotherapy!   | KN590Data forPlacebo+ Chemotherapy!   | KN590Data forPlacebo+ Chemotherapy!   | KN590Data forPlacebo+ Chemotherapy!   | Pooled EsophagealSafetyDataset forPembrolizumab Monotherapyit   | Pooled EsophagealSafetyDataset forPembrolizumab Monotherapyit   | Pooled EsophagealSafetyDataset forPembrolizumab Monotherapyit   | Pooled EsophagealSafetyDataset forPembrolizumab Monotherapyit   | ReferenceSafetyDatasetfor  Pembrolizumab Monotherapy?$   | ReferenceSafetyDatasetfor  Pembrolizumab Monotherapy?$   | ReferenceSafetyDatasetfor  Pembrolizumab Monotherapy?$   | ReferenceSafetyDatasetfor  Pembrolizumab Monotherapy?$   |
|------------------------------------------------------------|---------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                                            |                           |                                               | >=65                                          | >=65                                          | <65                                   | <65                                   | >=65                                  | >=65                                  | <65                                                             | <65                                                             | >=65                                                            | >=65                                                            | <65                                                      | <65                                                      | >=65                                                     | >=65                                                     |
|                                                            | n                         | (%)                                           | n (%)                                         | n (%)                                         | n (%)                                 | n (%)                                 | n (%)                                 | n (%)                                 | n (%)                                                           | n (%)                                                           | n (%)                                                           | n (%)                                                           | n (%)                                                    | n (%)                                                    | n (%)                                                    | n (%)                                                    |
| Subjects in population                                     | 201                       |                                               | 169                                           |                                               | 221                                   |                                       | 149                                   |                                       | 242                                                             |                                                                 | 216                                                             |                                                                 | 3,385                                                    |                                                          | 2,499                                                    |                                                          |
| with one or more adverse events                            | 201                       | (100.0)                                       | 169                                           | (100.0)                                       | 220                                   | (99.5)                                | 148                                   | (99.3)                                | 233                                                             | (96.3)                                                          | 204                                                             | (94.4)                                                          | 3,268                                                    | (96.5)                                                   | 2,422                                                    | (96.9)                                                   |
| with no adverse event                                      | 0                         | (0.0)                                         | 0                                             | (0.0)                                         | 1                                     | (0.5)                                 | 1                                     | (0.7)                                 | 9                                                               | (3.7)                                                           | 12                                                              | (5.6)                                                           | 117                                                      | (3.5)                                                    | 77                                                       | (3.1)                                                    |
| with drug-relatedadverse events                            | 200                       | (99.5)                                        | 164                                           | (97.0)                                        | 213                                   | (96.4)                                | 147                                   | (98.7)                                | 145                                                             | (59.9)                                                          | 136                                                             | (63.0)                                                          | 2,366                                                    | (69.9)                                                   | 1,766                                                    | (70.7)                                                   |
| with toxicity grade 3-5 adverse events                     | 171                       | (85.1)                                        | 147                                           | (87.0)                                        | 182                                   | (82.4)                                | 126                                   | (84.6)                                | 132                                                             | (54.5)                                                          | 113                                                             | (52.3)                                                          | 1,505                                                    | (44.5)                                                   | 1,324                                                    | (53.0)                                                   |
| with toxicity grade 3-5 drug-related adverse events        | 143                       | (71.1)                                        | 123                                           | (72.8)                                        | 143                                   | (64.7)                                | 107                                   | (71.8)                                | 37                                                              | (15.3)                                                          | 43                                                              | (6:61)                                                          | 456                                                      | (13.5)                                                   | 457                                                      | (18.3)                                                   |
| withserious adverse events                                 | 107                       | (53.2)                                        | 98                                            | (58.0)                                        | 121                                   | (54.8)                                | 83                                    | (55.7)                                | 94                                                              | (38.8)                                                          | 86                                                              | (39.8)                                                          | 1,182                                                    | (34.9)                                                   | 1,084                                                    | (43.4)                                                   |
| withseriousdrug-related adverseevents                      | 60                        | (29.9)                                        | 57                                            | (33.7)                                        | 51                                    | (23.1)                                | 46                                    | (30.9)                                | 27                                                              | (11.2)                                                          | 29                                                              | (13.4)                                                          | 346                                                      | (10.2)                                                   | 310                                                      | (12.4)                                                   |
| who died                                                   | 15                        | (7.5)                                         | 13                                            | (7.7)                                         | 21                                    | (9.5)                                 | 17                                    | (11.4)                                | 17                                                              | (7.0)                                                           | 22                                                              | (10.2)                                                          | 144                                                      | (4.3)                                                    | 168                                                      | (6.7)                                                    |
| who died due to a drug-related adverse event               | 4                         | (2.0)                                         | 5                                             | (3.0)                                         | 1                                     | (0.5)                                 | 4                                     | (2.7)                                 | 1                                                               | (0.4)                                                           | 5                                                               | (2.3)                                                           | 21                                                       | (0.6)                                                    | 18                                                       | (0.7)                                                    |
| discontinued any drug due to an adverse event              | 41                        | (20.4)                                        | 49                                            | (29.0)                                        | 34                                    | (15.4)                                | 40                                    | (26.8)                                | 29                                                              | (12.0)                                                          | 26                                                              | (12.0)                                                          | 399                                                      | (11.8)                                                   | 391                                                      | (15.6)                                                   |
| discontinuedPembrolizumaborplacebo                         | 24                        | (11.9)                                        | 30                                            | (17.8)                                        | 24                                    | (10.9)                                | 21                                    | (14.1)                                | 29                                                              | (12.0)                                                          | 26                                                              | (12.0)                                                          | 399                                                      | (11.8)                                                   | 391                                                      | (15.6)                                                   |
| discontinued any chemotherapy                              | 35                        | (17.4)                                        | 40                                            | (23.7)                                        | 31                                    | (14.0)                                | 38                                    | (25.5)                                | 29                                                              | (12.0)                                                          | 26                                                              | (12.0)                                                          | 399                                                      | (11.8)                                                   | 391                                                      | (15.6)                                                   |
| discontinued all drugs                                     | 10                        | (5.0)                                         | 13                                            | (7.7)                                         | 14                                    | (6.3)                                 | 14                                    | (9.4)                                 | 29                                                              | (12.0)                                                          | 26                                                              | (12.0)                                                          | 399                                                      | (11.8)                                                   | 391                                                      | (15.6)                                                   |
| discontinued any drug due to a drug- related adverse event | 34                        | (16.9)                                        | 38                                            | (22.5)                                        | 18                                    | (8.1)                                 | 25                                    | (16.8)                                | 12                                                              | (5.0)                                                           | 15                                                              | (6.9)                                                           | 207                                                      | (6.1)                                                    | 203                                                      | (8.1)                                                    |
| discontinuedPembrolizumaborplacebo                         | 14                        | (7.0)                                         | 21                                            | (12.4)                                        | 9                                     | (4.1)                                 | 6                                     | (4.0)                                 | 12                                                              | (5.0)                                                           | 15                                                              | (6.9)                                                           | 207                                                      | (6.1)                                                    | 203                                                      | (8.1)                                                    |
| discontinuedany chemotherapy                               | 29                        | (14.4)                                        | 29                                            | (17.2)                                        | 18                                    | (8.1)                                 | 24                                    | (16.1)                                | 12                                                              | (5.0)                                                           | 15                                                              | (6.9)                                                           | 207                                                      | (6.1)                                                    | 203                                                      | (8.1)                                                    |
| discontinued all drugs                                     | 7                         | (3.5)                                         | 9                                             | (5.3)                                         | 7                                     | (3.2)                                 | 3                                     | (2.0)                                 | 12                                                              | (5.0)                                                           | 15                                                              | (6.9)                                                           | 207                                                      | (6.1)                                                    | 203                                                      | (8.1)                                                    |
| discontinued any drug due to a serious adverse event       | 27                        | (13.4)                                        | 31                                            | (18.3)                                        | 24                                    | (10.9)                                | 23                                    | (15.4)                                | 25                                                              | (10.3)                                                          | 19                                                              | (8.8)                                                           | 287                                                      | (8.5)                                                    | 285                                                      | (11.4)                                                   |
| discontinuedPembrolizumaborplacebo                         | 19                        | (9.5)                                         | 28                                            | (16.6)                                        | 23                                    | (10.4)                                | 20                                    | (13.4)                                | 25                                                              | (10.3)                                                          | 19                                                              | (8.8)                                                           | 287                                                      | (8.5)                                                    | 285                                                      | (11.4)                                                   |
| discontinued any chemotherapy                              | 20                        | (10.0)                                        | 23                                            | (13.6)                                        | 20                                    | (9.0)                                 | 21                                    | (14.1)                                | 25                                                              | (10.3)                                                          | 19                                                              | (8.8)                                                           | 287                                                      | (8.5)                                                    | 285                                                      | (11.4)                                                   |
| discontinued all drugs                                     | 8                         | (4.0)                                         | 13                                            | (7.7)                                         | 14                                    | (6.3)                                 | 13                                    | (8.7)                                 | 25                                                              | (10.3)                                                          | 19                                                              | (8.8)                                                           | 287                                                      | (8.5)                                                    | 285                                                      | (11.4)                                                   |
| discontinued any drug due toa serious                      | 18                        | (9.0)                                         | 20                                            | (11.8)                                        | 8                                     | (3.6)                                 | 9                                     | (6.0)                                 | 9                                                               | (3.7)                                                           | 9                                                               | (4.2)                                                           | 123                                                      | (3.6)                                                    | 122                                                      | (4.9)                                                    |
| drug-relatedadverse event                                  | drug-relatedadverse event | drug-relatedadverse event                     | drug-relatedadverse event                     | drug-relatedadverse event                     | drug-relatedadverse event             | drug-relatedadverse event             | drug-relatedadverse event             | drug-relatedadverse event             | drug-relatedadverse event                                       | drug-relatedadverse event                                       | drug-relatedadverse event                                       | drug-relatedadverse event                                       | drug-relatedadverse event                                | drug-relatedadverse event                                | drug-relatedadverse event                                | drug-relatedadverse event                                |
| discontinued 10 Pembrolizumab or placebo                   | (5.0) 19                  | (11.2)                                        | 8                                             | (3.6)                                         | 6                                     | (4.0)                                 | 9                                     | (3.7)                                 | 9                                                               | (4.2)                                                           | (4.2)                                                           | 123                                                             | (3.6)                                                    | 122                                                      |                                                          | (4.9)                                                    |
| discontinued any 13 chemotherapy                           | (6.5) 12                  | (7.1)                                         | 8                                             | (3.6)                                         | 8                                     | (5.4)                                 | 9                                     | (3.7)                                 | 9                                                               | (4.2)                                                           | (4.2)                                                           | 123                                                             | (3.6)                                                    | 122                                                      |                                                          | (4.9)                                                    |
| discontinued all drugs 5                                   | (2.5) 9                   | (5.3)                                         | 7                                             | (3.2)                                         | 3                                     | (2.0)                                 | 9                                     | (3.7)                                 | 9                                                               | (4.2)                                                           | (4.2)                                                           | 123                                                             | (3.6)                                                    | 122                                                      |                                                          | (4.9)                                                    |

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

t Determined by the investigator to be related to the drug.

## Table 51: Adverse Event Summary by Age Category (&lt;65, 65-74, 75-84, ≥ 85 Years) (ASaT Population)

|                                                                    | <65   | <65           | 65-74   | 65-74         | 75-84   | 75-84         | >=85   | >=85          | <65   | <65          | 65-74   | 65-74           | 75-84         | >=85              |
|--------------------------------------------------------------------|-------|---------------|---------|---------------|---------|---------------|--------|---------------|-------|--------------|---------|-----------------|---------------|-------------------|
|                                                                    | n     | (%)           | n       | (%)           | n       | (%)           | n      | (%)           | n     | (%)          | n       | (%) n           | (%)           | n (%)             |
| Subjects in population                                             | 201   |               | 132     |               | 36      |               | 1      |               | 221   |              | 117     | 30              |               | 2                 |
| with one or more adverse events with no adverse event              | 201 0 | (100.0) (0.0) | 132 0   | (100.0) (0.0) | 36 0    | (100.0) (0.0) | 1 0    | (100.0) (0.0) | 220 1 | (99.5) (0.5) | 116 1   | (99.1) 30 0     | (100.0) (0.0) | 2 (100.0) 0 (0.0) |
| with drug-related adverse events                                   | 200   | (99.5)        | 128     | (97.0)        | 36      | (100.0)       | 0      | (0.0)         | 213   | (96.4)       | 115     | (0.9) (98.3)    | (100.0)       | 2 (100.0)         |
| with toxicity grade 3-5 adverse events                             | 171   | (85.1)        | 111     | (84.1)        | 35      | (97.2)        | 1      | (100.0)       | 182   | (82.4)       | 100     | 30 (85.5) 24    | (80.0)        | 2 (100.0)         |
| with toxicity grade 3-5 drug-related adverse events                | 143   | (71.1)        | 92      | (69.7)        | 31      | (86.1)        | 0      | (0.0)         | 143   | (64.7)       | 83      | (70.9) 22       | (73.3)        | 2 (100.0)         |
| with serious adverse events                                        | 107   | (53.2)        | 69      | (52.3)        | 28      | (77.8)        | 1      | (100.0)       | 121   | (54.8)       | 67      | (57.3) 15       | (50.0)        | 1 (50.0)          |
| with serious drug-related adverse events                           | 60    | (29.9)        | 36      | (27.3)        | 21      | (58.3)        | 0      | (0.0)         | 51    | (23.1)       | 35      | (29.9) 10       | (33.3)        | (50.0)            |
| who died                                                           | 15    | (7.5)         | 3       | (2.3)         | 9       | (25.0)        | 1      | (100.0)       | 21    | (9.5)        | 13      | (11.1) 3        | (10.0)        | 1 (50.0)          |
| who died due toa drug-related adverseevent                         | 4     | (2.0)         | 1       | (0.8)         | 4       | (11.1)        | 0      | (0.0)         | 1     | (0.5)        | 1       | 2               | (6.7)         | (50.0)            |
| discontinued any drug due to an adverse event                      | 41    | (20.4)        | 33      | (25.0)        | 15      | (41.7)        | 1      | (100.0)       | 34    | (15.4)       | 28      | (0.9) (23.9) 11 | (36.7)        | (50.0)            |
| discontinuedPembrolizumaborplacebo                                 | 24    | (11.9)        | 16      | (12.1)        | 13      | (36.1)        | 1      | (100.0)       | 24    | (10.9)       | 14      | (12.0) 6 (22.2) | (20.0)        | 1 (50.0)          |
| discontinued any chemotherapy                                      | 35    | (17.4)        | 25      | (18.9)        | 14      | (38.9)        | 1      | (100.0)       | 31    | (14.0)       | 26      | 11 5            | (36.7)        | 1 (50.0)          |
| discontinued all drugs                                             | 10    | (5.0)         | 4       | (3.0)         | 8       | (22.2)        | 1      | (100.0)       | 14    | (6.3)        | 9       | (7.7)           | (16.7)        | 0 (0.0)           |
| discontinued any drug due to a drug-related adverse event          | 34    | (16.9)        | 26      | (19.7)        | 12      | (33.3)        | 0      | (0.0)         | 18    | (8.1)        | 16      | (13.7) 8        | (26.7)        | 1 (50.0)          |
| discontinuedPembrolizumaborplacebo                                 | 14    | (7.0)         | 11      | (8.3)         | 10      | (27.8)        | 0      | (0.0)         | 9     | (4.1)        | 2       | (1.7) 3         | (10.0)        | 1 (50.0)          |
| discontinued any chemotherapy                                      | 29    | (14.4)        | 19      | (14.4)        | 10      | (27.8)        | 0      | (0.0)         | 18    | (8.1)        | 15      | (12.8) 8        | (26.7)        | 1 (50.0)          |
| discontinued all drugs                                             | 7     | (3.5)         | 2       | (1.5)         | 7       | (19.4)        | 0      | (0.0)         | 7     | (3.2)        | 1       | (0.9) 2         | (6.7)         | 0 (0.0)           |
| discontinued any drug due to a serious adverse event               | 27    | (13.4)        | 17      | (12.9)        | 13      | (36.1)        | 1      | (100.0)       | 24    | (10.9)       | 15      | (12.8) 7        | (23.3)        | 1 (50.0)          |
| discontinuedPembrolizumaborplacebo                                 | 19    | (9.5)         | 14      | (10.6)        | 13      | (36.1)        | 1      | (100.0)       | 23    | (10.4)       | 13      | (11.1) 6        | (20.0)        | 1 (50.0)          |
| discontinued any chemotherapy                                      | 20    | (10.0)        | 10      | (7.6)         | 12      | (33.3)        | 1      | (100.0)       | 20    | (9.0)        | 13      | (11.1) 7        | (23.3)        | 1 (50.0)          |
| discontinued all drugs                                             | 8     | (4.0)         | 4       | (3.0)         | 8       | (22.2)        | 1      | (100.0)       | 14    | (6.3)        | 8       | 5               | (16.7)        | 0 (0.0)           |
| discontinued any drug due to a serious drug- related adverse event | 18    | (9.0)         | 10      | (7.6)         | 10      | (27.8)        | 0      | (0.0)         | 8     | (3.6)        | 4       | (6.8) (3.4) 4   | (13.3)        | (50.0)            |
| discontinuedPembrolizumaborplacebo                                 | 10    | (5.0)         | 9       | (6.8)         | 10      | (27.8)        | 0      | (0.0)         | 8     | (3.6)        | 2       | (2.6) (1.7)     | 3 (10.0)      | 1 (50.0)          |
| discontinued any chemotherapy                                      | 13    | (6.5)         | 4       | (3.0)         | 8       | (22.2)        | 0      | (0.0)         | 8     | (3.6)        | 3       |                 | 4 (13.3)      | 1 (50.0)          |
| discontinued all drugs                                             | 5     | (2.5)         | 2       | (1.5)         | 7       | (19.4)        | 0      | (0.0)         | 7     | (3.2)        | 1       | (0.9) 2         | (6.7)         | 0 (0.0)           |

<div style=\"page-break-after: always\"></div>

|                                                                  | Pooled Esophageal Safety Dataset for Pembrolizumab Monotherapyit   | Pooled Esophageal Safety Dataset for Pembrolizumab Monotherapyit   | Pooled Esophageal Safety Dataset for Pembrolizumab Monotherapyit   | Pooled Esophageal Safety Dataset for Pembrolizumab Monotherapyit   | Pooled Esophageal Safety Dataset for Pembrolizumab Monotherapyit   | Pooled Esophageal Safety Dataset for Pembrolizumab Monotherapyit   | Pooled Esophageal Safety Dataset for Pembrolizumab Monotherapyit   | Reference Safety Dataset for Pembrolizumab Monotherapys   | Reference Safety Dataset for Pembrolizumab Monotherapys   | Reference Safety Dataset for Pembrolizumab Monotherapys   | Reference Safety Dataset for Pembrolizumab Monotherapys   | Reference Safety Dataset for Pembrolizumab Monotherapys   | Reference Safety Dataset for Pembrolizumab Monotherapys   | Reference Safety Dataset for Pembrolizumab Monotherapys   | Reference Safety Dataset for Pembrolizumab Monotherapys   |
|------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
|                                                                  | <65                                                                | <65                                                                | 65-74                                                              | 65-74                                                              | 75-84                                                              | 75-84                                                              | >=85                                                               | <65                                                       | <65                                                       | 65-74                                                     | 65-74                                                     | 75-84                                                     | 75-84                                                     | >=85                                                      | >=85                                                      |
|                                                                  | n (%)                                                              | n (%)                                                              | n (%)                                                              | n (%)                                                              | n (%)                                                              | n (%)                                                              | n (%)                                                              | n (%)                                                     | n (%)                                                     | n (%)                                                     | n (%)                                                     | n (%)                                                     | n (%)                                                     | n (%)                                                     | n (%)                                                     |
| Subjects in population                                           | 242                                                                |                                                                    | 166                                                                |                                                                    | 49                                                                 |                                                                    | 1                                                                  | 3,385                                                     |                                                           | 1,737                                                     |                                                           | 663 646                                                   |                                                           | 66                                                        |                                                           |
| with one or more adverse events                                  | 233                                                                | (96.3) (3.7)                                                       | 154                                                                | (92.8)                                                             | 49                                                                 | (100.0)                                                            | 1 (100.0)                                                          | 3,268                                                     | (96.5)                                                    | 1,678 59                                                  | (96.6) (3.4)                                              | 17                                                        | (97.4) (2.6)                                              | 98 1                                                      | (99.0) (1.0)                                              |
| with no adverse event with drug-related adverse events           | 9 145                                                              | (59.9)                                                             | 12 104                                                             | (7.2) (62.7)                                                       | 0 32                                                               | (0.0) (65.3)                                                       | 0 (0.0) 0 (0.0)                                                    | 117 2,366                                                 | (3.5) (69.9)                                              | 1,224                                                     | (70.5)                                                    | 467                                                       | (70.4)                                                    | 75                                                        | (75.8)                                                    |
| with toxicity grade 3-5 adverse events                           | 132                                                                | (54.5)                                                             | 80                                                                 | (48.2)                                                             | 32                                                                 | (65.3)                                                             | 1 (100.0)                                                          | 1,505                                                     | (44.5)                                                    | 891                                                       | (51.3)                                                    | 373                                                       | (56.3)                                                    | 60                                                        | (60.6)                                                    |
| with toxicity grade 3-5 drug-related adverse events              | 37                                                                 | (15.3)                                                             | 29                                                                 | (17.5)                                                             | 14                                                                 | (28.6)                                                             | 0 (0.0)                                                            | 456                                                       | (13.5)                                                    | 311                                                       | (17.9)                                                    | 128                                                       | (19.3)                                                    | 18                                                        | (18.2)                                                    |
| with serious adverse events                                      | 94                                                                 | (38.8)                                                             | 58                                                                 | (34.9)                                                             | 28                                                                 | (57.1)                                                             | 0 (0.0)                                                            | 1,182                                                     | (34.9)                                                    | 719                                                       | (41.4)                                                    | 315                                                       | (47.5)                                                    | 50                                                        | (50.5)                                                    |
| with serious drug-related adverse events                         | 27                                                                 | (11.2)                                                             | 20                                                                 | (12.0)                                                             | 9                                                                  | (18.4)                                                             | 0 (0.0)                                                            | 346                                                       | (10.2)                                                    | 213                                                       | (12.3)                                                    | 85                                                        | (12.8)                                                    | 12                                                        | (12.1)                                                    |
| who died                                                         | 17                                                                 | (7.0)                                                              | 13                                                                 | (7.8)                                                              | 9                                                                  | (18.4)                                                             | 0 (0.0)                                                            | 144                                                       | (4.3)                                                     | 103                                                       | (5.9)                                                     | 54                                                        | (8.1)                                                     | 11                                                        | (11.1)                                                    |
|                                                                  | 1                                                                  |                                                                    | 2                                                                  |                                                                    | 3                                                                  | (6.1)                                                              | 0 (0.0)                                                            | 21                                                        |                                                           |                                                           |                                                           |                                                           |                                                           | 1                                                         |                                                           |
| who died due to a drug-related adverse event                     |                                                                    | (0.4)                                                              |                                                                    | (1.2)                                                              |                                                                    | (20.4)                                                             |                                                                    |                                                           | (0.6)                                                     | 12                                                        | (0.7)                                                     | 5                                                         | (0.8)                                                     |                                                           | (1.0)                                                     |
| discontinued any drug due to an adverse event                    | 29                                                                 | (12.0)                                                             | 16                                                                 | (9.6)                                                              | 10                                                                 |                                                                    | 0 (0.0)                                                            | 399                                                       | (11.8)                                                    | 246                                                       | (14.2)                                                    | 131                                                       | (19.8) (19.8)                                             | 14                                                        | (14.1)                                                    |
| discontinuedPembrolizumab orplacebo                              | 29 29                                                              | (12.0) (12.0)                                                      | 16 16                                                              | (9.6)                                                              | 10 10                                                              | (20.4)                                                             | 0 (0.0) 0 (0.0)                                                    | 399 399                                                   | (11.8) (11.8)                                             | 246 246                                                   | (14.2) (14.2)                                             | 131 131                                                   | (19.8)                                                    | 14 14                                                     | (14.1) (14.1)                                             |
| discontinued any chemotherapy                                    | 29                                                                 |                                                                    | 16                                                                 | (9.6)                                                              | 10                                                                 | (20.4) (20.4)                                                      | 0 (0.0)                                                            | 399                                                       | (11.8)                                                    | 246                                                       | (14.2)                                                    | 131                                                       | (19.8)                                                    | 14                                                        | (14.1)                                                    |
| discontinued all drugs                                           |                                                                    | (12.0)                                                             |                                                                    | (9.6) (4.8)                                                        | 7                                                                  | (14.3)                                                             | 0 (0.0)                                                            | 207                                                       |                                                           | 135                                                       | (7.8)                                                     | 62                                                        | (9.4)                                                     | 6                                                         | (6.1)                                                     |
| discontinued any drug due to a drug-related adverse event        | 12                                                                 | (5.0)                                                              | 8                                                                  |                                                                    | 7                                                                  | (14.3)                                                             | 0 (0.0)                                                            | 207                                                       | (6.1)                                                     | 135                                                       | (7.8)                                                     | 62                                                        | (9.4)                                                     | 6                                                         | (6.1)                                                     |
| discontinuedPembrolizumaborplacebo discontinued any chemotherapy | 12 12                                                              | (5.0) (5.0)                                                        | 8 8                                                                | (4.8) (4.8)                                                        | 7                                                                  | (14.3)                                                             | 0 (0.0)                                                            | 207                                                       | (6.1) (6.1)                                               | 135                                                       | (8L)                                                      | 62                                                        | (9.4)                                                     | 6                                                         | (6.1)                                                     |
| discontinued all drugs                                           | 12                                                                 | (5.0)                                                              | 8                                                                  | (4.8)                                                              | 7                                                                  | (14.3)                                                             | 0 (0.0)                                                            | 207                                                       | (6.1)                                                     | 135                                                       | (7.8)                                                     | 62                                                        | (9.4)                                                     | 6                                                         | (6.1)                                                     |
| discontinued any drug due to a serious adverse                   | 25                                                                 | (10.3)                                                             | 11                                                                 | (6.6)                                                              | 8                                                                  | (16.3)                                                             | 0 (0.0)                                                            | 287                                                       | (8.5)                                                     | 174                                                       | (10.0)                                                    | 100                                                       | (15.1)                                                    | 11                                                        | (11.1)                                                    |
| event                                                            |                                                                    |                                                                    |                                                                    |                                                                    |                                                                    |                                                                    |                                                                    |                                                           |                                                           |                                                           | (10.0)                                                    | 100                                                       |                                                           | 11                                                        |                                                           |
| discontinuedPembrolizumabor placebo                              | 25                                                                 | (10.3)                                                             | 11                                                                 | (6.6)                                                              | 8                                                                  | (16.3)                                                             | 0 (0.0)                                                            | 287                                                       | (8.5)                                                     | 174 174                                                   | (10.0)                                                    |                                                           | (15.1)                                                    |                                                           | (11.1)                                                    |
| discontinued any chemotherapy discontinued all drugs             | 25 25                                                              | (10.3) (10.3)                                                      | 11 11                                                              | (6.6) (6.6)                                                        | 8 8                                                                | (16.3) (16.3)                                                      | 0 (0.0) 0 (0.0)                                                    | 287 287                                                   | (8.5) (8.5)                                               | 174                                                       | (10.0)                                                    | 100 100                                                   | (15.1) (15.1)                                             | 11 11                                                     | (11.1) (11.1)                                             |
| discontinued any drug due to a serious drug-                     | 9                                                                  |                                                                    | 4                                                                  |                                                                    |                                                                    | (10.2)                                                             |                                                                    | 123                                                       |                                                           |                                                           | (4.7)                                                     | 38                                                        |                                                           | 3                                                         |                                                           |
| related adverse event                                            |                                                                    | (3.7)                                                              |                                                                    | (2.4)                                                              | 5                                                                  |                                                                    | 0 (0.0)                                                            |                                                           | (3.6)                                                     | 81                                                        |                                                           |                                                           | (5.7)                                                     |                                                           | (3.0)                                                     |
| discontinued any chemotherapy                                    | 9 9                                                                | (3.7)                                                              | 4                                                                  | (2.4)                                                              | 5 5                                                                | (10.2)                                                             | 0 (0.0)                                                            | 123                                                       | (3.6)                                                     | 81                                                        | (4.7)                                                     | 38                                                        | (5.7)                                                     | 3                                                         | (3.0)                                                     |
| discontinuedPembrolizumaborplacebo                               |                                                                    | (3.7)                                                              | 4                                                                  | (2.4)                                                              |                                                                    | (10.2)                                                             | 0 (0.0)                                                            | 123                                                       | (3.6)                                                     | 81                                                        | (4.7)                                                     | 38                                                        | (5.7)                                                     | 3                                                         | (3.0)                                                     |
| discontinued all drugs                                           | 9                                                                  | (3.7)                                                              | 4                                                                  | (2.4)                                                              | 5                                                                  | (10.2)                                                             | 0 (0.0)                                                            | 123                                                       | (3.6)                                                     | 81                                                        | (4.7)                                                     | 38                                                        | (5.7)                                                     | 3                                                         | (3.0)                                                     |

Table 52: Adverse Event Summary for Elderly Subjects by Age in KN590 (ASaT Population)

|                                 | Age (Years) Pembrolizumab+SOC   | Age (Years) Pembrolizumab+SOC   | Age (Years) Pembrolizumab+SOC   | Age (Years) Pembrolizumab+SOC   | Age (Years) Pembrolizumab+SOC   | Age (Years) Pembrolizumab+SOC   | Age (Years) Pembrolizumab+SOC   |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                 | <65                             | <65                             | 65-74                           | 65-74                           | 75-84                           | 75-84                           | 85+                             |
|                                 | 1n                              | (%)                             | n                               | (%)                             | n                               | (%)                             | n (%)                           |
| Subjects in Population          | 201                             |                                 | 132                             |                                 | 36                              |                                 | 1                               |
| with one or more adverse events | 201                             | (100.0)                         | 132                             | (100.0)                         | 36                              | (100.0)                         | 1 (100.0)                       |
| who died                        | 15                              | (7.5)                           | 3                               | (2.3)                           | 9                               | (25.0)                          | 1 (100.0)                       |
| with serious adverse events     | 107                             | (53.2)                          | 69                              | (52.3)                          | 28                              | (77.8)                          | 1 (100.0)                       |
| discontinuedduetoanadverseevent | 41                              | (20.4)                          | 33                              | (25.0)                          | 15                              | (41.7)                          | 1 (100.0)                       |
| CNS (confusion/extrapyramidal)  | 14                              | (7.0)                           | 9                               | (6.8)                           | 2                               | (5.6)                           | 0 (0.0)                         |
| AE related to falling           | 6                               | (3.0)                           | 9                               | (6.8)                           | 6                               | (16.7)                          | 0 (0.0)                         |
| CV events                       | 50                              | (24.9)                          | 46                              | (34.8)                          | 12                              | (33.3)                          | 0 (0.0)                         |
| Cerebrovascular events          | 3                               | (1.5)                           | 3                               | (2.3)                           | 1                               | (2.8)                           | 0 (0.0)                         |
| Infections                      | 81                              | (40.3)                          | 57                              | (43.2)                          | 14                              | (38.9)                          | 0 (0.0)                         |

|                                 | Age (Years) SOC   | Age (Years) SOC   | Age (Years) SOC   | Age (Years) SOC   | Age (Years) SOC   | Age (Years) SOC   | Age (Years) SOC   | Age (Years) SOC   |
|---------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
|                                 | <65               | <65               | 65 -74            | 65 -74            | 75 -84            | 75 -84            | 85+               | 85+               |
|                                 | n                 | (%)               | n                 | (%)               | n                 | (%)               | n                 | (%)               |
| Subjects in Population          | 221               |                   | 117               |                   | 30                |                   | 2                 |                   |
| with one or more adverse events | 220               | (99.5)            | 116               | (99.1)            | 30                | (100.0)           | 2                 | (100.0)           |
| who died                        | 21                | (9.5)             | 13                | (11.1)            | 3                 | (10.0)            | 1                 | (50.0)            |
| with serious adverse events     | 121               | (54.8)            | 67                | (57.3)            | 15                | (50.0)            | 1                 | (50.0)            |
| discontinuedduetoanadverseevent | 34                | (15.4)            | 28                | (23.9)            | 11                | (36.7)            | 1                 | (50.0)            |
| CNS (confusion/extrapyramidal)  | 12                | (5.4)             | 14                | (12.0)            | 0                 | (0.0)             | 0                 | (0.0)             |
| AE related to falling           | 13                | (5.9)             | 11                | (9.4)             | 3                 | (10.0)            | 0                 | (0.0)             |
| CV events                       | 55                | (24.9)            | 40                | (34.2)            | 5                 | (16.7)            | 1                 | (50.0)            |
| Cerebrovascular events          | 8                 | (3.6)             | 5                 | (4.3)             | 3                 | (10.0)            | 0                 | (0.0)             |
| Infections                      | 80                | (36.2)            | 53                | (45.3)            | 14                | (46.7)            | 2                 | (100.0)           |

AEswerefollowed 30days afterlast dose of studytreatment;SAEswerefollowed 90days afterlast doseof studytreatment.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded. DatabaseCutoffDate:02JUL2020.

Table 53: Adverse Event Summary (ASaT Population, Age ≥75 )

|                                 | Pembrolizumab + SOC   | Pembrolizumab + SOC   | SOC   | SOC     |
|---------------------------------|-----------------------|-----------------------|-------|---------|
|                                 | n                     | (%)                   | n     | (%)     |
| Subjects in population          | 37                    |                       | 32    |         |
| with one or more adverse events | 37                    | (100.0)               | 32    | (100.0) |
| with no adverse event           | 0                     | (0.0)                 | 0     | (0.0)   |

(100.0)

<div style=\"page-break-after: always\"></div>

(100.0)

(81.3)

(75.0)

(100.0)

(50.0)

(34.4)

(12.5)

(37.5)

(28.1)

(25.0)

(15.6)

| with drug-related † adverse events                            |   36 | (97.3)   |   32 | (100.0)   |
|---------------------------------------------------------------|------|----------|------|-----------|
| with toxicity grade 3-5 adverse events                        |   36 | (97.3)   |   26 | (81.3)    |
| with toxicity grade 3-5 drug-related adverse events           |   31 | (83.8)   |   24 | (75.0)    |
| with non-serious adverse events                               |   36 | (97.3)   |   32 | (100.0)   |
| with serious adverse events                                   |   29 | (78.4)   |   16 | (50.0)    |
| with serious drug-related adverse events                      |   21 | (56.8)   |   11 | (34.4)    |
| who died                                                      |   10 | (27.0)   |    4 | (12.5)    |
| who died due to a drug-related adverse event                  |    4 | (10.8)   |    3 | (9.4)     |
| discontinued drug due to an adverse event                     |   16 | (43.2)   |   12 | (37.5)    |
| discontinued drug due to a drug-related adverse event         |   12 | (32.4)   |    9 | (28.1)    |
| discontinued drug due to a serious adverse event              |   14 | (37.8)   |    8 | (25.0)    |
| discontinued drug due to a serious drug-related adverse event |   10 | (27.0)   |    5 | (15.6)    |

† Determined by the investigator to be related to the drug.

Grades are based on NCI CTCAE version 4.03.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Database Cutoff Date: 02JUL2020

Table 54: Exposure-Adjusted Adverse Event Summary (Including Multiple Occurrences of Events) (ASaT Population, Age ≥ 75 )

(2798.88)

(1869.77)

(571.32)

(352.02)

(230.84)

(109.65)

(536.69)

(23.08)

(17.31)

(80.79)

(63.48)

(51.94)

(34.63)

|                                                                       | Event Count and Rate (Events/100 person-years) †   | Event Count and Rate (Events/100 person-years) †   | Event Count and Rate (Events/100 person-years) †   | Event Count and Rate (Events/100 person-years) †   |
|-----------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
|                                                                       | Pembrolizumab + SOC                                | Pembrolizumab + SOC                                | SOC                                                | SOC                                                |
| Number of Subjects exposed                                            | 37                                                 |                                                    | 32                                                 |                                                    |
| Total exposure ‡ in person-years                                      | 17.65                                              |                                                    | 17.33                                              |                                                    |
| Total events (rate)                                                   |                                                    |                                                    |                                                    |                                                    |
| adverse events                                                        | 688                                                | (3898.92)                                          | 485                                                | (2798.88)                                          |
| drug-related § adverse events                                         | 402                                                | (2278.15)                                          | 324                                                | (1869.77)                                          |
| toxicity grade 3-5 adverse events                                     | 146                                                | (827.39)                                           | 99                                                 | (571.32)                                           |
| toxicity grade 3-5 drug-related adverse events                        | 93                                                 | (527.03)                                           | 61                                                 | (352.02)                                           |
| serious adverse events                                                | 64                                                 | (362.69)                                           | 40                                                 | (230.84)                                           |
| serious drug-related adverse events                                   | 37                                                 | (209.68)                                           | 19                                                 | (109.65)                                           |
| adverse events resulting in dose modification ║                       | 124                                                | (702.71)                                           | 93                                                 | (536.69)                                           |
| adverse events leading to death                                       | 11                                                 | (62.34)                                            | 4                                                  | (23.08)                                            |
| drug-related adverse events leading to death                          | 4                                                  | (22.67)                                            | 3                                                  | (17.31)                                            |
| adverse events resulting in drug discontinuation                      | 18                                                 | (102.01)                                           | 14                                                 | (80.79)                                            |
| drug-related adverse events resulting in drug discontinuation         | 12                                                 | (68.00)                                            | 11                                                 | (63.48)                                            |
| serious adverse events resulting in drug discontinuation              | 16                                                 | (90.67)                                            | 9                                                  | (51.94)                                            |
| serious drug-related adverse events resulting in drug discontinuation | 10                                                 | (56.67)                                            | 6                                                  | (34.63)                                            |

† Event rate per 100 person-years of exposure = event count *100/person-years of exposure.

‡ Drug exposure is defined as the between the first dose date + 1 day and the earlier of the last dose date + 30 or the database cutoff date.

§ Determined by the investigator to be related to the drug.

║  Defined as an action taken of dose reduced, drug interrupted or drug withdrawn.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded.

Database Cutoff Date: 02JUL2020

Pooled safety data of pembrolizumab plus chemotherapy from KEYNOTE-590 and studies of other approved indications in combination with chemotherapy (NSCLC: KEYNOTE-021, KEYNOTE-189, and

<div style=\"page-break-after: always\"></div>

KEYNOTE-407; HNSCC: KEYNOTE-048) versus chemotherapy alone is provided by age groups in the tables below:

Table 55: Adverse Event Summary by Age for Elderly Subjects (ASaT Population)

|                                  | KN021+KN048+KN189+KN407+KN590DataforPembrolizumab+ Chemotherapyft   | KN021+KN048+KN189+KN407+KN590DataforPembrolizumab+ Chemotherapyft   | KN021+KN048+KN189+KN407+KN590DataforPembrolizumab+ Chemotherapyft   | KN021+KN048+KN189+KN407+KN590DataforPembrolizumab+ Chemotherapyft   | KN021+KN048+KN189+KN407+KN590DataforPembrolizumab+ Chemotherapyft   | KN021+KN048+KN189+KN407+KN590DataforPembrolizumab+ Chemotherapyft   | KN021+KN048+KN189+KN407+KN590DataforPembrolizumab+ Chemotherapyft   | KN021+KN048+KN189+KN407+KN590DataforPembrolizumab+ Chemotherapyft   | KN021 + KN048 + KN189 + KN407 + KN590 Data for Chemotherapys§   | KN021 + KN048 + KN189 + KN407 + KN590 Data for Chemotherapys§   | KN021 + KN048 + KN189 + KN407 + KN590 Data for Chemotherapys§   | KN021 + KN048 + KN189 + KN407 + KN590 Data for Chemotherapys§   | KN021 + KN048 + KN189 + KN407 + KN590 Data for Chemotherapys§   | KN021 + KN048 + KN189 + KN407 + KN590 Data for Chemotherapys§   | KN021 + KN048 + KN189 + KN407 + KN590 Data for Chemotherapys§   | KN021 + KN048 + KN189 + KN407 + KN590 Data for Chemotherapys§   |
|----------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
|                                  | <65                                                                 | <65                                                                 | 65-74                                                               | 65-74                                                               | 75-84                                                               | 75-84                                                               | >= 85                                                               | >= 85                                                               | <65                                                             | <65                                                             | 65-74                                                           | 65-74                                                           | 75-84                                                           | 75-84                                                           |                                                                 |                                                                 |
|                                  | n                                                                   | (%)                                                                 | n                                                                   | (%)                                                                 | n                                                                   | (%)                                                                 | n                                                                   | (%)                                                                 | n                                                               | (%)                                                             | n                                                               | (%)                                                             | n                                                               | (%)                                                             | n (%)                                                           |                                                                 |
| Subjectsin population            | 759                                                                 | (100.0)                                                             | 550                                                                 | (100.0)                                                             | 124                                                                 | (100.0)                                                             | 4                                                                   | (100.0)                                                             | 671                                                             | (100.0)                                                         | 416                                                             | (100.0)                                                         | 111                                                             | (100.0)                                                         | 3 (100.0)                                                       |                                                                 |
| withone ormore adverseevents     | 754                                                                 | (99.3)                                                              | 546                                                                 | (99.3)                                                              | 123                                                                 | (99.2)                                                              | 4                                                                   | (100.0)                                                             | 668                                                             | (99.6)                                                          | 410                                                             | (98.6)                                                          | 109                                                             | (98.2)                                                          | 3 (100.0)                                                       |                                                                 |
| who died                         | 48                                                                  | (6.3)                                                               | 46                                                                  | (8.4)                                                               | 26                                                                  | (21.0)                                                              | 4                                                                   | (100.0)                                                             | 48                                                              | (7.2)                                                           | 39                                                              | (9.4)                                                           | 13                                                              | (11.7)                                                          | 1 (33.3)                                                        |                                                                 |
| with serious adverse events      | 380                                                                 | (50.1)                                                              | 317                                                                 | (57.6)                                                              | 80                                                                  | (64.5)                                                              | 4                                                                   | (100.0)                                                             | 311                                                             | (46.3)                                                          | 210                                                             | (50.5)                                                          | 60                                                              | (54.1)                                                          | 1 (33.3)                                                        |                                                                 |
| discontinuedduetoan adverseevent | 186                                                                 | (24.5)                                                              | 179                                                                 | (32.5)                                                              | 52                                                                  | (41.9)                                                              | 4                                                                   | (100.0)                                                             | 115                                                             | (17.1)                                                          | 92                                                              | (22.1)                                                          | 27                                                              | (24.3)                                                          | 1 (33.3)                                                        |                                                                 |
| CNS(confusion/extrapyramidal)    | 63                                                                  | (8.3)                                                               | 61                                                                  | (11.1)                                                              | 15                                                                  | (12.1)                                                              | 0                                                                   | (0.0)                                                               | 49                                                              | (7.3)                                                           | 38                                                              | (9.1)                                                           | 10                                                              | (9.0)                                                           | 0 (0.0)                                                         |                                                                 |
| AErelated tofalling              | 54                                                                  | (7.1)                                                               | 62                                                                  | (11.3)                                                              | 18                                                                  | (14.5)                                                              | 0                                                                   | (0.0)                                                               | 39                                                              | (5.8)                                                           | 49                                                              | (11.8)                                                          | II                                                              | (9.9)                                                           | 0 (0.0)                                                         |                                                                 |
| CVevents                         | 193                                                                 | (25.4)                                                              | 176                                                                 | (32.0)                                                              | 39                                                                  | (31.5)                                                              | 2                                                                   | (50.0)                                                              | 154                                                             | (23.0)                                                          | 118                                                             | (28.4)                                                          | 26                                                              | (23.4)                                                          | 1 (33.3)                                                        |                                                                 |
| Cerebrovascularevents            | 20                                                                  | (2.6)                                                               | 19                                                                  | (3.5)                                                               | 9                                                                   | (7.3)                                                               | 0                                                                   | (0.0)                                                               | 23                                                              | (3.4)                                                           | 15                                                              | (3.6)                                                           | 5                                                               | (4.5)                                                           | 0 (0.0)                                                         |                                                                 |
| Infections                       | 392                                                                 | (51.6)                                                              | 324                                                                 | (58.9)                                                              | 61                                                                  | (49.2)                                                              | 1                                                                   | (25.0)                                                              | 308                                                             | (45.9)                                                          | 212                                                             | (51.0)                                                          | 62                                                              | (55.9)                                                          | 3 (100.0)                                                       |                                                                 |

AEs were followed 30 days after last dose of study treatment; SAEs were followed 90 days after last dose of study treatment.

Includes all subjects who received at least one dose of Pembrolizumab combo therapy in KN021-A/C/G, KN048, KN189, KN407 and KN590.

Includes all subjects who received at least one dose of chemotherapy in KN021-A/C/G, KN048, KN189, KN407 and KN590.

Database cutoff dateforLung (KN021:19AUG2019,KN189:20MAY2019,KN407:09MAY2019)

Database cutoff dateforHNSCC(KN048:25FEB2019)

Database cutoff date forEsophageal (KN590:02JUL2020)

Table 2 : Adverse Event Summary by Age Category (&lt;65, 65-74, 75+ Years) (Subjects in ASaT Population)

|                                                              | KN021+KN048+KN189+KN407+KN590Data forPembrolizumab + Chemotherapytt   | KN021+KN048+KN189+KN407+KN590Data forPembrolizumab + Chemotherapytt   | KN021+KN048+KN189+KN407+KN590Data forPembrolizumab + Chemotherapytt   | KN021+KN048+KN189+KN407+KN590Data forPembrolizumab + Chemotherapytt   | KN021+KN048+KN189+KN407+KN590Data forPembrolizumab + Chemotherapytt   | KN021+KN048+KN189+KN407+KN590Data forPembrolizumab + Chemotherapytt   | KN021+KN048+KN189+KN407+KN590Data for Chemotherapy§5   | KN021+KN048+KN189+KN407+KN590Data for Chemotherapy§5   | KN021+KN048+KN189+KN407+KN590Data for Chemotherapy§5   | KN021+KN048+KN189+KN407+KN590Data for Chemotherapy§5   | KN021+KN048+KN189+KN407+KN590Data for Chemotherapy§5   | KN021+KN048+KN189+KN407+KN590Data for Chemotherapy§5   |
|--------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                              | <65                                                                   | <65                                                                   | 65-74                                                                 | 65-74                                                                 | 75+                                                                   | 75+                                                                   | <65                                                    | <65                                                    | 65-74                                                  | 65-74                                                  | 75+                                                    | 75+                                                    |
|                                                              | n                                                                     | (%)                                                                   | n (%)                                                                 | n (%)                                                                 | n                                                                     | (%)                                                                   | n                                                      | (%)                                                    | n                                                      | (%)                                                    | n                                                      | (%)                                                    |
| Subjects in population                                       | 759                                                                   |                                                                       | 550                                                                   |                                                                       | 128                                                                   |                                                                       | 671                                                    |                                                        | 416                                                    |                                                        | 114                                                    |                                                        |
| with one ormore adverse events                               | 754                                                                   | (99.3)                                                                | 546                                                                   | (99.3)                                                                | 127                                                                   | (99.2)                                                                | 668                                                    | (99.6)                                                 | 410                                                    | (98.6)                                                 | 112                                                    | (98.2)                                                 |
| with no adverse event                                        | 5                                                                     | (0.7)                                                                 | 4                                                                     | (0.7)                                                                 | 1                                                                     | (0.8)                                                                 | 3                                                      | (0.4)                                                  | 6                                                      | (1.4)                                                  | 2                                                      | (1.8)                                                  |
| with drug-related adverse events                             | 724                                                                   | (95.4)                                                                | 529                                                                   | (96.2)                                                                | 121                                                                   | (94.5)                                                                | 630                                                    | (93.9)                                                 | 393                                                    | (94.5)                                                 | 108                                                    | (94.7)                                                 |
| with toxicity grade 3-5adverse events                        | 584                                                                   | (76.9)                                                                | 425                                                                   | (77.3)                                                                | 109                                                                   | (85.2)                                                                | 502                                                    | (74.8)                                                 | 316                                                    | (76.0)                                                 | 93                                                     | (81.6)                                                 |
| with toxicity grade 3-5 drug-related adverse events          | 448                                                                   | (59.0)                                                                | 349                                                                   | (63.5)                                                                | 81                                                                    | (63.3)                                                                | 383                                                    | (57.1)                                                 | 251                                                    | (60.3)                                                 | 74                                                     | (64.9)                                                 |
| with serious adverse events                                  | 380                                                                   | (50.1)                                                                | 317                                                                   | (57.6)                                                                | 84                                                                    | (65.6)                                                                | 311                                                    | (46.3)                                                 | 210                                                    | (50.5)                                                 | 61                                                     | (53.5)                                                 |
| with serious drug-related adverse events                     | 208                                                                   | (27.4)                                                                | 188                                                                   | (34.2)                                                                | 49                                                                    | (38.3)                                                                | 140                                                    | (20.9)                                                 | 107                                                    | (25.7)                                                 | 25                                                     | (21.9)                                                 |
| who died                                                     | 48                                                                    | (6.3)                                                                 | 46                                                                    | (8.4)                                                                 | 30                                                                    | (23.4)                                                                | 48                                                     | (7.2)                                                  | 39                                                     | (9.4)                                                  | 14                                                     | (12.3)                                                 |
| who died due to a drug-related adverse event                 | 15                                                                    | (2.0)                                                                 | 15                                                                    | (2.7)                                                                 | II                                                                    | (8.6)                                                                 | 8                                                      | (1.2)                                                  | 9                                                      | (2.2)                                                  | 5                                                      | (4.4)                                                  |
| discontinued drug due to an adverse event                    | 186                                                                   | (24.5)                                                                | 179                                                                   | (32.5)                                                                | 56                                                                    | (43.8)                                                                | 115                                                    | (17.1)                                                 | 92                                                     | (22.1)                                                 | 28                                                     | (24.6)                                                 |
| discontinued drug due toa drug-related adverse event         | 150                                                                   | (19.8)                                                                | 134                                                                   | (24.4)                                                                | 37                                                                    | (28.9)                                                                | 72                                                     | (10.7)                                                 | 59                                                     | (14.2)                                                 | 20                                                     | (17.5)                                                 |
| discontinued drugdue toa serious adverse event               | 118                                                                   | (15.5)                                                                | 111                                                                   | (20.2)                                                                | 46                                                                    | (35.9)                                                                | 72                                                     | (10.7)                                                 | 54                                                     | (13.0)                                                 | 20                                                     | (17.5)                                                 |
| discontinued drug due toa serious drug-related adverse event | 82                                                                    | (10.8)                                                                | 69                                                                    | (12.5)                                                                | 27                                                                    | (21.1)                                                                | 33                                                     | (4.9)                                                  | 23                                                     | (5.5)                                                  | I                                                      | (9.6)                                                  |

Determined by theinvestigator tobe related to the drug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms “Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Includes all subjects who received at least one dose of Pembrolizumab combo therapy in KN021-A/C/G, KN048, KN189, KN407 and KN590.

Includes all subjects who received at least one dose of chemotherapy in KN021-A/C/G, KN048, KN189, KN407 and KN590.

Database cutoff date for Lung (KN021: 19AUG2019,KN189: 20MAY2019, KN407: 09MAY2019)

Database cutoff date for HNSCC (KN048:25FEB2019)

Database cutoff date for Esophageal (KN590: 02JUL2020)

## Gender

Table 57: Adverse Event Summary by Gender (Male, Female) (ASaT Population)

<div style=\"page-break-after: always\"></div>

|                                                                    | KN590Data forPembrolizumab+ Chemotherapylt   | KN590Data forPembrolizumab+ Chemotherapylt   | KN590Data forPembrolizumab+ Chemotherapylt   | KN590Data forPembrolizumab+ Chemotherapylt   | KN590 Data forPlacebo+ Chemotherapyl   | KN590 Data forPlacebo+ Chemotherapyl   | KN590 Data forPlacebo+ Chemotherapyl   | KN590 Data forPlacebo+ Chemotherapyl   | Pooled EsophagealSafetyDataset for PembrolizumabMonotherapy*   | Pooled EsophagealSafetyDataset for PembrolizumabMonotherapy*   | Pooled EsophagealSafetyDataset for PembrolizumabMonotherapy*   | Pooled EsophagealSafetyDataset for PembrolizumabMonotherapy*   | ReferenceSafetyDatasetfor Pembrolizumab Monotherapys   | ReferenceSafetyDatasetfor Pembrolizumab Monotherapys   | ReferenceSafetyDatasetfor Pembrolizumab Monotherapys   | ReferenceSafetyDatasetfor Pembrolizumab Monotherapys   |
|--------------------------------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                                    | M                                            | M                                            | F                                            | F                                            | M                                      | M                                      | F                                      | F                                      | M                                                              | M                                                              | F                                                              | F                                                              | M                                                      | M                                                      | F                                                      | F                                                      |
|                                                                    | n (%)                                        | n (%)                                        | n (%)                                        | n (%)                                        | n (%)                                  | n (%)                                  | n (%)                                  | n (%)                                  | n (%)                                                          | n (%)                                                          | n (%)                                                          | n (%)                                                          | n (%)                                                  | n (%)                                                  | n (%)                                                  | n (%)                                                  |
| Subjects in population                                             | 305                                          |                                              | 65                                           |                                              | 314                                    |                                        | 56                                     |                                        | 392                                                            |                                                                | 66                                                             |                                                                | 3,887                                                  |                                                        | 1,997                                                  |                                                        |
| with one or more adverse events                                    | 305                                          | (100.0)                                      | 65                                           | (100.0)                                      | 312                                    | (99.4)                                 | 56                                     | (100.0)                                | 372                                                            | (94.9)                                                         | 65                                                             | (98.5)                                                         | 3,756                                                  | (96.6)                                                 | 1,934                                                  | (96.8)                                                 |
| with no adverse event                                              | 0                                            | (0.0)                                        | 0                                            | (0.0)                                        | 2                                      | (0.6)                                  | 0                                      | (0.0)                                  | 20                                                             | (5.1)                                                          | 1                                                              | (1.5)                                                          | 131                                                    | (3.4)                                                  | 63                                                     | (3.2)                                                  |
| with drug-related adverse events                                   | 300                                          | (98.4)                                       | 64                                           | (98.5)                                       | 306                                    | (97.5)                                 | 54                                     | (96.4)                                 | 236                                                            | (60.2)                                                         | 45                                                             | (68.2)                                                         | 2,710                                                  | (69.7)                                                 | 1,422                                                  | (71.2)                                                 |
| with toxicity grade 3-5 adverse events                             | 259                                          | (84.9)                                       | 59                                           | (90.8)                                       | 256                                    | (81.5)                                 | 52                                     | (92.9)                                 | 211                                                            | (53.8)                                                         | 34                                                             | (51.5)                                                         | 1,894                                                  | (48.7)                                                 | 935                                                    | (46.8)                                                 |
| with toxicity grade 3-5 drug-related adverse events                | 217                                          | (71.1)                                       | 49                                           | (75.4)                                       | 207                                    | (65.9)                                 | 43                                     | (76.8)                                 | 68                                                             | (17.3)                                                         | 12                                                             | (18.2)                                                         | 630                                                    | (16.2)                                                 | 283                                                    | (14.2)                                                 |
| with serious adverse events                                        | 168                                          | (55.1)                                       | 37                                           | (56.9)                                       | 169                                    | (53.8)                                 | 35                                     | (62.5)                                 | 157                                                            | (40.1)                                                         | 23                                                             | (34.8)                                                         | 1,534                                                  | (39.5)                                                 | 732                                                    | (36.7)                                                 |
| with serious drug-related adverse events                           | 93                                           | (30.5)                                       | 24                                           | (36.9)                                       | 80                                     | (25.5)                                 | 17                                     | (30.4)                                 | 47                                                             | (12.0)                                                         | 9                                                              | (13.6)                                                         | 448                                                    | (11.5)                                                 | 208                                                    | (10.4)                                                 |
| who died                                                           | 23                                           | (7.5)                                        | 5                                            | (7.7)                                        | 31                                     | (9.9)                                  | 7                                      | (12.5)                                 | 35                                                             | (8.9)                                                          | 4                                                              | (6.1)                                                          | 221                                                    | (5.7)                                                  | 91                                                     | (4.6)                                                  |
| who died due to a drug-related adverse event                       | 8                                            | (2.6)                                        | 1                                            | (1.5)                                        | 3                                      | (1.0)                                  | 2                                      | (3.6)                                  | 5                                                              | (1.3)                                                          | 1                                                              | (1.5)                                                          | 25                                                     | (0.6)                                                  | 14                                                     | (0.7)                                                  |
| discontinued any drug due to an adverse event                      | 75                                           | (24.6)                                       | 15                                           | (23.1)                                       | 62                                     | (19.7)                                 | 12                                     | (21.4)                                 | 46                                                             | (11.7)                                                         | 9                                                              | (13.6)                                                         | 529                                                    | (13.6)                                                 | 261                                                    | (13.1)                                                 |
| discontinuedPembrolizumaborplacebo                                 | 44                                           | (14.4)                                       | 10                                           | (15.4)                                       | 38                                     | (12.1)                                 | 7                                      | (12.5)                                 | 46                                                             | (11.7)                                                         | 9                                                              | (13.6)                                                         | 529                                                    | (13.6)                                                 | 261                                                    | (13.1)                                                 |
| discontinued any chemotherapy                                      | 64                                           | (21.0)                                       | 11                                           | (16.9)                                       | 57                                     | (18.2)                                 | 12                                     | (21.4)                                 | 46                                                             | (11.7)                                                         | 9                                                              | (13.6)                                                         | 529                                                    | (13.6)                                                 | 261                                                    | (13.1)                                                 |
| discontinued all drugs                                             | 20                                           | (6.6)                                        | 3                                            | (4.6)                                        | 21                                     | (6.7)                                  | 7                                      | (12.5)                                 | 46                                                             | (11.7)                                                         | 9                                                              | (13.6)                                                         | 529                                                    | (13.6)                                                 | 261                                                    | (13.1)                                                 |
| discontinued any drug due to a drug-related adverse event          | 60                                           | (19.7)                                       | 12                                           | (18.5)                                       | 35                                     | (11.1)                                 | 8                                      | (14.3)                                 | 21                                                             | (5.4)                                                          | 6                                                              | (9.1)                                                          | 278                                                    | (7.2)                                                  | 132                                                    | (6.6)                                                  |
| discontinuedPembrolizumab orplacebo                                | 29                                           | (9.5)                                        | 6                                            | (9.2)                                        | 11                                     | (3.5)                                  | 4                                      | (7.1)                                  | 21                                                             | (5.4)                                                          | 6                                                              | (9.1)                                                          | 278                                                    | (7.2)                                                  | 132                                                    | (6.6)                                                  |
| discontinued any chemotherapy                                      | 50                                           | (16.4)                                       | 8                                            | (12.3)                                       | 34                                     | (10.8)                                 | 8                                      | (14.3)                                 | 21                                                             | (5.4)                                                          | 6                                                              | (9.1)                                                          | 278                                                    | (7.2)                                                  | 132                                                    | (6.6)                                                  |
| discontinued all drugs                                             | 15                                           | (4.9)                                        | 1                                            | (1.5)                                        | 6                                      | (61)                                   | 4                                      | (7.1)                                  | 21                                                             | (5.4)                                                          | 6                                                              | (9.1)                                                          | 278                                                    | (7.2)                                                  | 132                                                    | (6.6)                                                  |
| discontinued any drug due to a serious adverse event               | 48                                           | (15.7)                                       | 10                                           | (15.4)                                       | 39                                     | (12.4)                                 | 8                                      | (14.3)                                 | 37                                                             | (9.4)                                                          | 7                                                              | (10.6)                                                         | 386                                                    | (9.9)                                                  | 186                                                    | (9.3)                                                  |
| discontinuedPembrolizumaborplacebo                                 | 37                                           | (12.1)                                       | 10                                           | (15.4)                                       | 36                                     | (11.5)                                 | 7                                      | (12.5)                                 | 37                                                             | (9.4)                                                          | 7                                                              | (10.6)                                                         | 386                                                    | (9.9)                                                  | 186                                                    | (9.3)                                                  |
| discontinued any chemotherapy                                      | 39                                           | (12.8)                                       | 4                                            | (6.2)                                        | 33                                     | (10.5)                                 | 8                                      | (14.3)                                 | 37                                                             | (9.4)                                                          | 7                                                              | (10.6)                                                         | 386                                                    | (9.9)                                                  | 186                                                    | (9.3)                                                  |
| discontinued all drugs                                             | 18                                           | (5.9)                                        | 3                                            | (4.6)                                        | 20                                     | (6.4)                                  | 7                                      | (12.5)                                 | 37                                                             | (9.4)                                                          | 7                                                              | (10.6)                                                         | 386                                                    | (9.9)                                                  | 186                                                    | (9.3)                                                  |
| discontinued any drug due to a serious drug- related adverse event | 32                                           | (10.5)                                       | 6                                            | (9.2)                                        | 13                                     | (4.1)                                  | 4                                      | (7.1)                                  | 14                                                             | (3.6)                                                          | 4                                                              | (6.1)                                                          | 167                                                    | (4.3)                                                  | 78                                                     | (3.9)                                                  |
|                                                                    | 23                                           | (7.5)                                        |                                              |                                              | 10                                     | (3.2)                                  | 4                                      | (7.1)                                  | 14                                                             | (3.6)                                                          | 4                                                              | (6.1)                                                          | 167                                                    | (4.3)                                                  | 78                                                     | (3.9)                                                  |
| discontinuedPembrolizumaborplacebo                                 | 24                                           | (6L)                                         | 6                                            | (9.2)                                        | 12                                     |                                        | 4                                      | (7.1)                                  | 14                                                             | (3.6)                                                          | 4                                                              | (6.1)                                                          | 167                                                    | (4.3)                                                  | 78                                                     | (3.9)                                                  |
| discontinued any chemotherapy discontinued all drugs               |                                              |                                              | 1 1                                          | (1.5)                                        |                                        | (3.8)                                  |                                        |                                        |                                                                |                                                                |                                                                |                                                                |                                                        |                                                        |                                                        |                                                        |
|                                                                    | 13                                           | (4.3)                                        |                                              | (1.5)                                        | 6                                      | (61)                                   | 4                                      | (7.1)                                  | 14                                                             | (3.6)                                                          | 4                                                              | (6.1)                                                          | 167                                                    | (4.3)                                                  | 78                                                     | (3.9)                                                  |

## ECOG

## Table 58: Adverse Event Summary by ECOG Status Category (0, 1) (ASaT Population)

|                                                                    | KN590DataforPembrolizumab+ Chemotherapyit   | KN590DataforPembrolizumab+ Chemotherapyit   | KN590DataforPembrolizumab+ Chemotherapyit   | KN590DataforPembrolizumab+ Chemotherapyit   | KN590DataforPlacebo+ Chemotherapyf   | KN590DataforPlacebo+ Chemotherapyf   | KN590DataforPlacebo+ Chemotherapyf   | Pooled EsophagealSafetyDataset for Pembrolizumab Monotherapyit   | Pooled EsophagealSafetyDataset for Pembrolizumab Monotherapyit   | Pooled EsophagealSafetyDataset for Pembrolizumab Monotherapyit   | Pooled EsophagealSafetyDataset for Pembrolizumab Monotherapyit   | Reference SafetyDataset for Pembrolizumab Monotherapy'5   | Reference SafetyDataset for Pembrolizumab Monotherapy'5   | Reference SafetyDataset for Pembrolizumab Monotherapy'5   | Reference SafetyDataset for Pembrolizumab Monotherapy'5   |
|--------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
|                                                                    | [0] Normal Activity                         | [0] Normal Activity                         | [1] Symptoms, but ambulatory                | [1] Symptoms, but ambulatory                | [0]Normal Activity                   | [0]Normal Activity                   | [1] Symptoms, but ambulatory         | [1] Symptoms, but ambulatory                                     | [0] Normal Activity                                              | [0] Normal Activity                                              | [1] Symptoms, but ambulatory                                     | [1] Symptoms, but ambulatory                              | [0] Normal [1] Symptoms, but Activity ambulatory          | [0] Normal [1] Symptoms, but Activity ambulatory          | [0] Normal [1] Symptoms, but Activity ambulatory          |
|                                                                    | n (%)                                       | n (%)                                       | n (%)                                       | n (%)                                       | n (%)                                | n (%)                                | n (%)                                | n (%)                                                            | n (%)                                                            | n (%)                                                            | n (%)                                                            | n (%)                                                     | n (%) n                                                   | n (%) n                                                   | (%)                                                       |
| Subjects in population                                             | 148                                         |                                             | 221                                         |                                             | 146                                  | 146                                  | 223                                  | 223                                                              | 178                                                              | 178                                                              | 279 2,761                                                        | 279 2,761                                                 | 2,931                                                     | 2,931                                                     |                                                           |
| with one or more adverse events                                    | 148                                         | (100.0)                                     | 221                                         | (100.0)                                     | 146                                  | (100.0)                              | 221                                  | (99.1)                                                           | 169                                                              | (94.9) 267                                                       | (95.7)                                                           | 2,671                                                     | (96.7)                                                    | 2,835                                                     | (96.7)                                                    |
| with no adverse event                                              | 0                                           | (0.0)                                       | 0                                           | (0.0)                                       | 0                                    | (0.0)                                | 2                                    | (0.9)                                                            | 9                                                                | (5.1) 12                                                         | (4.3)                                                            | 90                                                        | (3.3)                                                     | 96                                                        | (3.3)                                                     |
| with drug-related adverse events                                   | 146                                         | (98.6)                                      | 217                                         | (98.2)                                      | 145                                  | (99.3)                               | 214                                  | (96.0)                                                           | 124                                                              | (69.7) 156                                                       | (55.9)                                                           | 2,085                                                     | (75.5)                                                    | 1,940                                                     | (66.2)                                                    |
| with toxicity grade 3-5 adverse events                             | 120                                         | (81.1)                                      | 197                                         | (89.1)                                      | 114                                  | (78.1)                               | 193                                  | (86.5)                                                           | 77                                                               | (43.3) 167                                                       | (59.9)                                                           | 1,112                                                     | (40.3)                                                    | 1,605                                                     | (54.8)                                                    |
| with toxicity grade 3-5 drug-related adverse events                | 100                                         | (67.6)                                      | 165                                         | (74.7)                                      | 93                                   | (63.7)                               | 156                                  | (70.0)                                                           | 27                                                               | (15.2) 53                                                        | (19.0)                                                           | 410                                                       | (14.8)                                                    | 471                                                       | (16.1)                                                    |
| with serious adverse events                                        | 70                                          | (47.3)                                      | 134                                         | (60.6)                                      | 72                                   | (49.3)                               | 131                                  | (58.7)                                                           | 58                                                               | (32.6)                                                           | 121 (43.4) 31                                                    | 872                                                       | (31.6)                                                    | 1,294                                                     | (44.1)                                                    |
| with serious drug-related adverse events                           | 33                                          | (22.3)                                      | 84                                          | (38.0)                                      | 33                                   | (22.6)                               | 63                                   | (28.3)                                                           | 25                                                               | (14.0)                                                           | (11.1)                                                           | 311                                                       | (11.3)                                                    | 325                                                       | (11.1)                                                    |
| who died                                                           | 5                                           | (3.4)                                       | 23                                          | (10.4)                                      | 10                                   | (6.8)                                | 28                                   | (12.6)                                                           | 8                                                                | (4.5) 31                                                         | (11.1)                                                           | 79                                                        | (2.9)                                                     | 217                                                       | (7.4)                                                     |
| who died due to a drug-related adverse event                       | 3                                           | (2.0)                                       | 6                                           | (2.7)                                       | 1                                    | (0.7)                                | 4                                    | (1.8)                                                            | 2                                                                | (1.1)                                                            | 4 (1.4)                                                          | 14                                                        | (0.5)                                                     | 25                                                        | (0.9)                                                     |
| discontinued any drug due to an adverse event                      | 31                                          | (20.9)                                      | 59                                          | (26.7)                                      | 32                                   | (21.9)                               | 42                                   | (18.8)                                                           | 16                                                               | (9.0) 39                                                         | (14.0)                                                           | 304                                                       | (11.0)                                                    | 452                                                       | (15.4)                                                    |
| discontinuedPembrolizumaborplacebo                                 | 15                                          | (10.1)                                      | 39                                          | (17.6)                                      | 15                                   | (10.3)                               | 30                                   | (13.5)                                                           | 16                                                               | (9.0) 39                                                         | (14.0)                                                           | 304                                                       | (11.0)                                                    | 452                                                       | (15.4)                                                    |
| discontinued any chemotherapy                                      | 26                                          | (17.6)                                      | 49                                          | (22.2)                                      | 31                                   | (21.2)                               | 38                                   | (17.0)                                                           | 16                                                               | (9.0) 39                                                         | (14.0)                                                           | 304                                                       | (11.0)                                                    | 452                                                       | (15.4)                                                    |
| discontinued all drugs                                             | 4                                           | (2.7)                                       | 19                                          | (8.6)                                       | 8                                    | (5.5)                                | 20                                   | (9.0)                                                            | 16                                                               | (9.0) 39                                                         | (14.0)                                                           | 304                                                       | (11.0)                                                    | 452                                                       | (15.4)                                                    |
| discontinued any drug due to a drug-related                        | 28                                          | (18.9)                                      | 44                                          | (19.9)                                      | 22                                   | (15.1)                               | 21                                   | (9.4)                                                            | 13                                                               | (7.3) 14                                                         | (5.0)                                                            | 193                                                       | (0:L)                                                     | 200                                                       | (6.8)                                                     |
| adverse event discontinuedPembrolizumab orplacebo                  | 10                                          | (6.8)                                       | 25                                          | (11.3)                                      | 5                                    | (3.4)                                | 10                                   | (4.5)                                                            | 13                                                               | (7.3)                                                            | (5.0)                                                            | 193                                                       | (0'L)                                                     | 200                                                       | (6.8)                                                     |
| discontinuedany chemotherapy                                       | 23                                          | (15.5)                                      | 35                                          | (15.8)                                      | 21                                   | (14.4)                               | 21                                   | (9.4)                                                            | 13                                                               | 14 (7.3) 14                                                      | (5.0)                                                            | 193                                                       | (0:L)                                                     | 200                                                       | (6.8)                                                     |
| discontinued all drugs                                             | 4                                           | (2.7)                                       | 12                                          | (5.4)                                       | 3                                    | (2.1)                                | 7                                    | (3.1)                                                            | 13                                                               | (7.3) 14                                                         | (5.0)                                                            | 193                                                       | (7.0)                                                     | 200                                                       | (6.8)                                                     |
| discontinued any drug due toa serious adverse event                | 17                                          | (11.5)                                      | 41                                          | (18.6)                                      | 14                                   | (9.6)                                | 33                                   | (14.8)                                                           | 10                                                               | (5.6) 34                                                         | (12.2)                                                           | 198                                                       | (7.2)                                                     | 350                                                       | (11.9)                                                    |
| discontinuedPembrolizumaborplacebo                                 | 14                                          | (9.5)                                       | 33                                          | (14.9)                                      | 13                                   | (8.9)                                | 30                                   | (13.5)                                                           | 10                                                               | (5.6) 34                                                         | (12.2)                                                           | 198                                                       | (7.2)                                                     | 350                                                       | (11.9)                                                    |
| discontinued any chemotherapy                                      | 11                                          | (7.4)                                       | 32                                          | (14.5)                                      | 12                                   | (8.2)                                | 29                                   | (13.0)                                                           | 10                                                               | (5.6) 34                                                         | (12.2)                                                           | 198                                                       | (7.2)                                                     | 350                                                       | (11.9)                                                    |
| discontinued all drugs                                             | 3                                           | (2.0)                                       | 18                                          | (8.1)                                       | 7                                    | (4.8)                                | 20                                   | (9.0)                                                            | 10                                                               | (5.6) 34                                                         | (12.2)                                                           | 198                                                       | (7.2)                                                     | 350                                                       | (11.9)                                                    |
| discontinued any drug due to a serious drug- related adverse event | 12                                          | (8.1)                                       | 26                                          | (11.8)                                      | 5                                    | (3.4)                                | 12                                   | (5.4)                                                            | 8                                                                | (4.5) 10                                                         | (3.6)                                                            | 106                                                       | (3.8)                                                     | 130                                                       | (4.4)                                                     |
| discontinuedPembrolizumaborplacebo                                 | 9                                           | (6.1)                                       | 20                                          | (9.0)                                       | 4                                    | (2.7)                                | 10                                   | (4.5)                                                            | 8 (4.5)                                                          | 10                                                               | (3.6)                                                            | 106                                                       | (3.8)                                                     | 130                                                       | (4.4)                                                     |
| discontinued any chemotherapy                                      | 7                                           | (4.7)                                       | 18                                          | (8.1)                                       | 4                                    | (2.7)                                | 12                                   | (5.4)                                                            | 8 (4.5)                                                          | 10                                                               | (3.6)                                                            | 106                                                       | (3.8)                                                     | 130                                                       | (4.4)                                                     |
| discontinued all drugs                                             | 3                                           |                                             | 11                                          | (5.0)                                       | 3                                    |                                      | 7                                    | (3.1)                                                            | 8                                                                |                                                                  | (3.6)                                                            |                                                           |                                                           | 130                                                       |                                                           |
|                                                                    |                                             | (2.0)                                       |                                             |                                             |                                      | (2.1)                                |                                      |                                                                  | (4.5)                                                            | 10                                                               |                                                                  | 106                                                       | (3.8)                                                     |                                                           | (4.4)                                                     |

## Region

Table 59: Adverse Event Summary by Region (EU, Ex-EU) (ASaT Population)

<div style=\"page-break-after: always\"></div>

|                                                                    | KN590DataforPembrolizumab+ Chemotherapyit   | KN590DataforPembrolizumab+ Chemotherapyit   | KN590DataforPembrolizumab+ Chemotherapyit   | KN590DataforPembrolizumab+ Chemotherapyit   | KN590 Data forPlacebo+ Chemotherapy   | KN590 Data forPlacebo+ Chemotherapy   | KN590 Data forPlacebo+ Chemotherapy   | KN590 Data forPlacebo+ Chemotherapy   | Pooled Esophageal SafetyDataset for Pembrolizumab Monotherapyit   | Pooled Esophageal SafetyDataset for Pembrolizumab Monotherapyit   | Pooled Esophageal SafetyDataset for Pembrolizumab Monotherapyit   | Pooled Esophageal SafetyDataset for Pembrolizumab Monotherapyit   | ReferenceSafety Dataset for Pembrolizumab Monotherapys   | ReferenceSafety Dataset for Pembrolizumab Monotherapys   | ReferenceSafety Dataset for Pembrolizumab Monotherapys   | ReferenceSafety Dataset for Pembrolizumab Monotherapys   |
|--------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                                                    | EU                                          | EU                                          | Ex-EU                                       | Ex-EU                                       | EU                                    | EU                                    | Ex-EU                                 | Ex-EU                                 | EU                                                                | EU                                                                |                                                                   |                                                                   | EU                                                       | EU                                                       | Ex-EU                                                    | Ex-EU                                                    |
|                                                                    | n                                           | (%)                                         | n                                           | (%)                                         | n                                     | (%)                                   | n                                     | (%)                                   | n                                                                 | (%)                                                               | n                                                                 | Ex-EU (%)                                                         | n                                                        | (%)                                                      | n                                                        | (%)                                                      |
| Subjects in population                                             | 60                                          |                                             | 310                                         |                                             | 50                                    |                                       | 320                                   |                                       | 144                                                               |                                                                   | 314                                                               |                                                                   | 2,092                                                    |                                                          | 3,792                                                    |                                                          |
| with one or more adverse events                                    | 60                                          | (100.0)                                     | 310                                         | (100.0)                                     | 49                                    | (98.0)                                | 319                                   | (99.7)                                | 140                                                               | (97.2)                                                            | 297                                                               | (94.6)                                                            | 2,014                                                    | (96.3)                                                   | 3,676                                                    | (96.9)                                                   |
| with no adverse event                                              | 0                                           | (0.0)                                       | 0                                           | (0.0)                                       | 1                                     | (2.0)                                 | 1                                     | (0.3)                                 | 4                                                                 | (2.8)                                                             | 17                                                                | (5.4)                                                             | 78                                                       | (3.7)                                                    | 116                                                      | (3.1)                                                    |
| with drug-related adverse events                                   | 59                                          | (98.3)                                      | 305                                         | (98.4)                                      | 49                                    | (98.0)                                | 311                                   | (97.2)                                | 77                                                                | (53.5)                                                            | 204                                                               | (65.0)                                                            | 1,430                                                    | (68.4)                                                   | 2,702                                                    | (71.3)                                                   |
| with toxicity grade 3-5 adverse events                             | 54                                          | (90.0)                                      | 264                                         | (85.2)                                      | 41                                    | (82.0)                                | 267                                   | (83.4)                                | 75                                                                | (52.1)                                                            | 170                                                               | (54.1)                                                            | 960                                                      | (45.9)                                                   | 1,869                                                    | (49.3)                                                   |
| with toxicity grade 3-5drug-related adverse events                 | 38                                          | (63.3)                                      | 228                                         | (73.5)                                      | 28                                    | (56.0)                                | 222                                   | (69.4)                                | 21                                                                | (14.6)                                                            | 59                                                                | (18.8)                                                            | 317                                                      | (15.2)                                                   | 596                                                      | (15.7)                                                   |
| with serious adverse events                                        | 42                                          | (70.0)                                      | 163                                         | (52.6)                                      | 28                                    | (56.0)                                | 176                                   | (55.0)                                | 61                                                                | (42.4)                                                            | 119                                                               | (37.9)                                                            | 796                                                      | (38.0)                                                   | 1,470                                                    | (38.8)                                                   |
| with serious drug-related adverse events                           | 16                                          | (26.7)                                      | 101                                         | (32.6)                                      | 10                                    | (20.0)                                | 87                                    | (27.2)                                | 11                                                                | (7.6)                                                             | 45                                                                | (14.3)                                                            | 241                                                      | (11.5)                                                   | 415                                                      | (10.9)                                                   |
| who died                                                           | 3                                           | (5.0)                                       | 25                                          | (8.1)                                       | 3                                     | (6.0)                                 | 35                                    | (10.9)                                | 14                                                                | (9.7)                                                             | 25                                                                | (8.0)                                                             | 109                                                      | (5.2)                                                    | 203                                                      | (5.4)                                                    |
| who died due to a drug-related adverse event                       | 1                                           | (1.7)                                       | 8                                           | (2.6)                                       | 0                                     | (0.0)                                 | 5                                     | (1.6)                                 | 2                                                                 | (1.4)                                                             | 4                                                                 | (1.3)                                                             | 12                                                       | (0.6)                                                    | 27                                                       | (0.7)                                                    |
| discontinued any drug due to an adverse event                      | 19                                          | (31.7)                                      | 71                                          | (22.9)                                      | 13                                    | (26.0)                                | 61                                    | (19.1)                                | 17                                                                | (11.8)                                                            | 38                                                                | (12.1)                                                            | 267                                                      | (12.8)                                                   | 523                                                      | (13.8)                                                   |
| discontinuedPembrolizumab orplacebo                                | 11                                          | (18.3)                                      | 43                                          | (13.9)                                      | 4                                     | (8.0)                                 | 41                                    | (12.8)                                | 17                                                                | (11.8)                                                            | 38                                                                | (12.1)                                                            | 267                                                      | (12.8)                                                   | 523                                                      | (13.8)                                                   |
| discontinued any chemotherapy                                      | 16                                          | (26.7)                                      | 59                                          | (19.0)                                      | 13                                    | (26.0)                                | 56                                    | (17.5)                                | 17                                                                | (11.8)                                                            | 38                                                                | (12.1)                                                            | 267                                                      | (12.8)                                                   | 523                                                      | (13.8)                                                   |
| discontinued all drugs                                             | 3                                           | (5.0)                                       | 20                                          | (6.5)                                       | 3                                     | (6.0)                                 | 25                                    | (7.8)                                 | 17                                                                | (11.8)                                                            | 38                                                                | (12.1)                                                            | 267                                                      | (12.8)                                                   | 523                                                      | (13.8)                                                   |
| discontinued any drug due to a drug-related adverse event          | 16                                          | (26.7)                                      | 56                                          | (18.1)                                      | 10                                    | (20.0)                                | 33                                    | (10.3)                                | 5                                                                 | (3.5)                                                             | 22                                                                | (0'L)                                                             | 151                                                      | (7.2)                                                    | 259                                                      | (6.8)                                                    |
| discontinuedPembrolizumab orplacebo                                | 6                                           | (10.0)                                      | 29                                          | (9.4)                                       | 2                                     | (4.0)                                 | 13                                    | (4.1)                                 | 5                                                                 | (3.5)                                                             | 22                                                                | (0'L)                                                             | 151                                                      | (7.2)                                                    | 259                                                      | (6.8)                                                    |
| discontinued any chemotherapy                                      | 14                                          | (23.3)                                      | 44                                          | (14.2)                                      | 10                                    | (20.0)                                | 32                                    | (10.0)                                | 5                                                                 | (3.5)                                                             | 22                                                                | (7.0)                                                             | 151                                                      | (7.2)                                                    | 259                                                      | (6.8)                                                    |
| discontinued all drugs                                             | 3                                           | (5.0)                                       | 13                                          | (4.2)                                       | 2                                     | (4.0)                                 | 8                                     | (2.5)                                 | 5                                                                 | (3.5)                                                             | 22                                                                | (0:L)                                                             | 151                                                      | (7.2)                                                    | 259                                                      | (6.8)                                                    |
| discontinued any drug due to a serious adverse event               | 11                                          | (18.3)                                      | 47                                          | (15.2)                                      | 5                                     | (10.0)                                | 42                                    | (13.1)                                | 15                                                                | (10.4)                                                            | 29                                                                | (9.2)                                                             | 193                                                      | (9.2)                                                    | 379                                                      | (10.0)                                                   |
| discontinuedPembrolizumab orplacebo                                | 9                                           | (15.0)                                      | 38                                          | (12.3)                                      | 4                                     | (8.0)                                 | 39                                    | (12.2)                                | 15                                                                | (10.4)                                                            | 29                                                                | (9.2)                                                             | 193                                                      | (9.2)                                                    | 379                                                      | (10.0)                                                   |
| discontinued any chemotherapy                                      | 8                                           | (13.3)                                      | 35                                          | (11.3)                                      | 4                                     | (8.0)                                 | 37                                    | (11.6)                                | 15                                                                | (10.4)                                                            | 29                                                                | (9.2)                                                             | 193                                                      | (9.2)                                                    | 379                                                      | (10.0)                                                   |
| discontinued all drugs                                             | 3                                           | (5.0)                                       | 18                                          | (5.8)                                       | 3                                     | (6.0)                                 | 24                                    | (7.5)                                 | 15                                                                | (10.4)                                                            | 29                                                                | (9.2)                                                             | 193                                                      | (9.2)                                                    | 379                                                      | (10.0)                                                   |
| discontinued any drug due to a serious drug- related adverse event | 7                                           | (11.7)                                      | 31                                          | (10.0)                                      | 2                                     | (4.0)                                 | 15                                    | (4.7)                                 | 3                                                                 | (2.1)                                                             | 15                                                                | (4.8)                                                             | 89                                                       | (4.3)                                                    | 156                                                      | (4.1)                                                    |
|                                                                    | 5                                           | (8.3)                                       | 24                                          | (7.7)                                       | 2                                     | (4.0)                                 | 12                                    | (3.8)                                 | 3                                                                 | (2.1)                                                             | 15                                                                | (4.8)                                                             | 89                                                       | (4.3)                                                    | 156                                                      | (4.1)                                                    |
| discontinuedPembrolizumaborplacebo                                 |                                             | (8.3)                                       | 20                                          |                                             |                                       |                                       | 14                                    |                                       |                                                                   |                                                                   |                                                                   |                                                                   | 89                                                       | (4.3)                                                    |                                                          | (4.1)                                                    |
| discontinued any chemotherapy discontinued all drugs               | 5 3                                         | (5.0)                                       | 11                                          | (6.5) (3.5)                                 | 2 2                                   | (4.0) (4.0)                           | 8                                     | (4.4) (2.5)                           | 3 3                                                               | (2.1) (2.1)                                                       | 15 15                                                             | (4.8) (4.8)                                                       | 89                                                       | (4.3)                                                    | 156 156                                                  | (4.1)                                                    |

## Safety related to drug-drug interactions and other interactions

No new drug-drug interaction data are available.

## Immunogenicity

No new immunogenicity data are available.

## Discontinuation due to adverse events

## Adverse Events Leading to Treatment Discontinuation

## Table 60: adverse event summary-treatment discontinuation

|                                                                    | KN590 Data for Pembrolizumab + Chemotherapy ††   | KN590 Data for Pembrolizumab + Chemotherapy ††   | KN590 Data for Placebo + Chemotherapy ¶¶   | KN590 Data for Placebo + Chemotherapy ¶¶   | Pooled Oesophageal Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Pooled Oesophageal Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|--------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                                                    | n                                                | (%)                                              | n                                          | (%)                                        | n                                                                    | (%)                                                                  | n                                                           | (%)                                                         |
| Subjects in population                                             | 370                                              |                                                  | 370                                        |                                            | 458                                                                  |                                                                      | 5,884                                                       |                                                             |
| discontinued any drug due to an adverse event                      | 90                                               | (24.3)                                           | 74                                         | (20.0)                                     | 55                                                                   | (12.0)                                                               | 790                                                         | (13.4)                                                      |
| discontinued Pembrolizumab or placebo                              | 54                                               | (14.6)                                           | 45                                         | (12.2)                                     | 55                                                                   | (12.0)                                                               | 790                                                         | (13.4)                                                      |
| discontinued any chemotherapy                                      | 75                                               | (20.3)                                           | 69                                         | (18.6)                                     | 55                                                                   | (12.0)                                                               | 790                                                         | (13.4)                                                      |
| discontinued all drugs                                             | 23                                               | (6.2)                                            | 28                                         | (7.6)                                      | 55                                                                   | (12.0)                                                               | 790                                                         | (13.4)                                                      |
| discontinued any drug due to a drug-related adverse event          | 72                                               | (19.5)                                           | 43                                         | (11.6)                                     | 27                                                                   | (5.9)                                                                | 410                                                         | (7.0)                                                       |
| discontinued Pembrolizumab or placebo                              | 35                                               | (9.5)                                            | 15                                         | (4.1)                                      | 27                                                                   | (5.9)                                                                | 410                                                         | (7.0)                                                       |
| discontinued any chemotherapy                                      | 58                                               | (15.7)                                           | 42                                         | (11.4)                                     | 27                                                                   | (5.9)                                                                | 410                                                         | (7.0)                                                       |
| discontinued all drugs                                             | 16                                               | (4.3)                                            | 10                                         | (2.7)                                      | 27                                                                   | (5.9)                                                                | 410                                                         | (7.0)                                                       |
| discontinued any drug due to a serious adverse event               | 58                                               | (15.7)                                           | 47                                         | (12.7)                                     | 44                                                                   | (9.6)                                                                | 572                                                         | (9.7)                                                       |
| discontinued Pembrolizumab or placebo                              | 47                                               | (12.7)                                           | 43                                         | (11.6)                                     | 44                                                                   | (9.6)                                                                | 572                                                         | (9.7)                                                       |
| discontinued any chemotherapy                                      | 43                                               | (11.6)                                           | 41                                         | (11.1)                                     | 44                                                                   | (9.6)                                                                | 572                                                         | (9.7)                                                       |
| discontinued all drugs                                             | 21                                               | (5.7)                                            | 27                                         | (7.3)                                      | 44                                                                   | (9.6)                                                                | 572                                                         | (9.7)                                                       |
| discontinued any drug due to a serious drug- related adverse event | 38                                               | (10.3)                                           | 17                                         | (4.6)                                      | 18                                                                   | (3.9)                                                                | 245                                                         | (4.2)                                                       |
| discontinued Pembrolizumab or placebo                              | 29                                               | (7.8)                                            | 14                                         | (3.8)                                      | 18                                                                   | (3.9)                                                                | 245                                                         | (4.2)                                                       |
| discontinued any chemotherapy                                      | 25                                               | (6.8)                                            | 16                                         | (4.3)                                      | 18                                                                   | (3.9)                                                                | 245                                                         | (4.2)                                                       |
| discontinued all drugs                                             | 14                                               | (3.8)                                            | 10                                         | (2.7)                                      | 18                                                                   | (3.9)                                                                | 245                                                         | (4.2)                                                       |

(4.2)

<div style=\"page-break-after: always\"></div>

Table 61: Subjects With Adverse Events Resulting in Any Treatment Discontinuation (ASaT Population) (extract)

|                                                   | KN590 Data for Pembrolizumab + Chemotherapylt   | KN590 Data for Pembrolizumab + Chemotherapylt   | KN590 Data for Placebo + Chemotherapy   | KN590 Data for Placebo + Chemotherapy   | Pooled Esophageal SafetyDatasetfor Pembrolizumab Monotherapytt   | Pooled Esophageal SafetyDatasetfor Pembrolizumab Monotherapytt   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   |
|---------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-----------------------------------------|-----------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                                   | n1                                              | (%)                                             | n                                       | (%)                                     | 1n1                                                              | (%)                                                              | 1n                                                       | (%)                                                      |
| Subjects in population withoneormoreadverseevents | 370                                             |                                                 | 370                                     |                                         | 458                                                              |                                                                  | 5,884                                                    |                                                          |
|                                                   | 90                                              | (24.3)                                          | 74                                      | (20.0)                                  | 55                                                               | (12.0)                                                           | 790                                                      | (13.4)                                                   |
| withnoadverseevents                               | 280                                             | (75.7)                                          | 296                                     | (80.0)                                  | 403                                                              | (88.0)                                                           | 5,094                                                    | (86.6)                                                   |
| Pneumonia                                         | 10                                              | (2.7)                                           | 9                                       | (2.4)                                   | 4                                                                | (0.9)                                                            | 31                                                       | (0.5)                                                    |
| Bloodcreatinineincreased                          | 8                                               | (2.2)                                           | 11                                      | (3.0)                                   | 0                                                                | (0.0)                                                            | 1                                                        | (0.0)                                                    |
| Acute kidney injury                               | 4                                               | (1.1)                                           | 2                                       | (0.5)                                   | 1                                                                | (0.2)                                                            | 6                                                        | (0.1)                                                    |
| Pneumonitis                                       | 6                                               | (1.6)                                           | 0                                       | (0.0)                                   | 7                                                                | (1.5)                                                            | 96                                                       | (1.6)                                                    |

Table 62: Subjects With Adverse Events Resulting in Treatment Interruption (ASaT Population) (extract)

| Treatment interruption of ANY drugs:             | Treatment interruption of ANY drugs:             | Treatment interruption of ANY drugs:             | Treatment interruption of ANY drugs:             | Treatment interruption of ANY drugs:             | Treatment interruption of ANY drugs:             | Treatment interruption of ANY drugs:             | Treatment interruption of ANY drugs:             | Treatment interruption of ANY drugs:             |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Treatment interruption of ALL drugs:             | Treatment interruption of ALL drugs:             | Treatment interruption of ALL drugs:             | Treatment interruption of ALL drugs:             | Treatment interruption of ALL drugs:             | Treatment interruption of ALL drugs:             | Treatment interruption of ALL drugs:             | Treatment interruption of ALL drugs:             | Treatment interruption of ALL drugs:             |
| Treatment interruption of pembrolizumab/placebo: | Treatment interruption of pembrolizumab/placebo: | Treatment interruption of pembrolizumab/placebo: | Treatment interruption of pembrolizumab/placebo: | Treatment interruption of pembrolizumab/placebo: | Treatment interruption of pembrolizumab/placebo: | Treatment interruption of pembrolizumab/placebo: | Treatment interruption of pembrolizumab/placebo: | Treatment interruption of pembrolizumab/placebo: |

The most common AE leading to treatment interruption was neutropenia.

## Post marketing experience

The safety profile of pembrolizumab was summarized in the Periodic Safety Update Report covering the period 04-SEP-2018 through 03-SEP-2019. No revocation or withdrawal of pembrolizumab registration for safety reasons has occurred in any country. Within the period reviewed, 3,776,415 dosage units were sold in  post-authorisation setting (cumulatively 7,684,671). The cumulative post-marketing exposure of the previous PSUR was approximately 99,173 patient-years of treatment with pembrolizumab.

From  clinical  trials,  a  total  of  32,845  serious  adverse  events  were  reported  cumulatively.  From  postauthorisation sources, a total of 53,255  adverse  reactions were  reported cumulatively  (36,092 spontaneous;  17,163    solicited).  Of  these,  15,653  reactions  were  considered  non-serious  and  37,602 reactions  were  classified  as  serious  (20,439  spontaneous;  17,163  solicited).  During  the  period  under

<div style=\"page-break-after: always\"></div>

review, there were 8,569 serious spontaneous; 5,703 non-serious spontaneous and 6,139 serious solicited. The most frequently  reported  serious  adverse  reactions  during  the  period  under  review  are  malignant neoplasm  progression,  death  and  known  immune-related  adverse  reactions  such  as  colitis,  hepatitis, pneumonitis/interstitial lung disease, thyroid disorders and adrenal insufficiency.

## 3.5.1. Discussion on clinical safety

Data from the primary analysis of the pivotal study KEYNOTE-590 (KN590) with data cut-off of 02-JUL2020 were submitted.

The median duration of exposure to therapy was similar between the two arms of KN590 study (5.7 vs 5.1 months). The median number of cycles of pembrolizumab in the experimental arm of KN590 were doubled compared to the oesophageal monotherapy dataset (8 vs 4), which can be explained by the more advanced setting of the studies included in the pooled dataset. Treatment with 5-FU may have continued beyond 6 cycles per local standard up to 35 cycles: median number of 5-FU cycles were 6 in both arms of KN590, as this was balanced no impact on efficacy or safety results are expected.

Regarding  the summary  of  adverse  events ,  no  major  relevant  differences  are  observed  between pembrolizumab + platinum/5-FU vs placebo + platinum-5-FU, also after adjusting for exposure. The noted exception is that more patients discontinued any drug due to drug-related AEs (19.5% vs 11.6%) and drugrelated  SAEs  (10.3%  vs  4.6%)  in  the  pembrolizumab  combination  arm,  and  a  small  difference  of  the discontinuation rate is maintained after exposure adjustment. In addition, the observed incidence of related SAEs  (31.6%  vs  26.2%)  and  drug-related  Grade  3-5  AEs  (71.9%  vs  67.6%)  was  higher  for  the pembrolizumab chemo combo, as well as few more deaths due to drug-related AEs were observed (9 vs 5 deaths, i.e. 2.4% vs 1.4%).

As expected, the toxicity in the pembrolizumab + chemotherapy arm of KN590 study was worse compared to pembrolizumab monotherapy in the oesophageal dataset and in the RSD.

To better contextualize KN590 safety data with respect to the overall toxicity of pembrolizumab given with chemotherapy, a pooled safety dataset representing the established safety profile for pembrolizumab plus platinum-based chemotherapy in currently EU approved indications was provided (KN-021, KN-189, KN407 and KN-048 studies). KN-590 appears to have a quite similar summary of adverse events, with the exception of a higher incidence of Grade 3-5 (85-9% vs 75%) and drug-related grade 3-5 AEs (71.9% vs 57.4%). However, since a higher incidence is also noted in the placebo+chemotherapy arm of KN-590, this could be related to backbone chemotherapy and baseline disease.

In KN590 a comparison of the frequencies of the most common AEs by  treatment group showed high incidences of nausea, anaemia, decreased appetite and constipation in both arms (&gt;40%). Higher rates of fatigue,  WBC  count  decreased,  neutrophil  count  decreased,  rash,  hypothyroidism  and  pruritus  were observed in the pembrolizumab + chemotherapy group than in the chemotherapy group, and remained higher even after adjustment for exposure, with the exception of fatigue and neutrophil count decreased. Severe skin reactions and hypothyroidism are known AEOSI for pembrolizumab. The differences in safety profile observed between the pembrolizumab + chemotherapy arm of KN590 and the monotherapy datasets are consistent with the established safety profiles of the chemotherapies administered.

Regarding drug-related AEs pembrolizumab + chemotherapy could be regarded as comparable to placebo+chemotherapy; differences (&gt;3%) were detected for neutrophil count decreased and white blood cell count decreased toxicities with higher incidences in the pembrolizumab+chemotherapy arm; anaemia was reported with higher rates in the placebo+chemotherapy arm. When comparing the pembrolizumab + chemotherapy KN590 Dataset with the monotherapy RSD, the rates for drug-related AEs were overall significantly higher, as expected.

<div style=\"page-break-after: always\"></div>

In both arms, most of the AEs were Grade 3-5 , with similar rate in both arms (85.9% vs 86.2%). Neutrophil count decreased, anemia, neutropenia and hyponatremia were the most common G3-5 AEs in both arms (≥10%). Despite the higher incidence of WBC and neutrophil count decrease in the pembroliz umab + chemotherapy  arm,  observed  also  after  adjustment  for  exposure,  rates  of  febrile  neutropenia  were comparable between the 2 groups (3.2% vs 4.1%). As expected, G3-5 AEs occurred more frequently when pembrolizumab was administered with chemotherapy than as a single agent (85.9% vs 48.1% in the RSD), and reflected the known safety profile of the cytotoxic agents and the underlying oesophageal disease.

Drug-related Grade 3 to 5 AEs occurred also at similar rate in the two treatment arms (71.9% vs 67.6%). The  most  frequently  reported  drug-related  Grade  3  to  5  AEs  in  both  treatment  arms  were  decreased neutrophil count, neutropenia and anaemia. The rate of drug-related grade 3-5 febrile neutropenia was similar between arms (3% vs 3.8%), with one death due to febrile neutropenia in each arm. A total of 7 cases (1.9%) of grade 3-5 drug-related pneumonitis occurred in the pembrolizumab combination arm, vs none in the control. This incidence is however similar to the pembrolizumab monotherapy safety datasets (1.3%) and therefore can be considered consistent with the known pembrolizumab safety profile. Compared to the monotherapy safety datasets, the overall incidence of drug-related Grade 3 to 5 AEs was substantially higher in the pembrolizumab plus chemotherapy group (71.9% vs 15.5% in the RSD).

The overall incidence of SAEs was approximately 55% in both treatment groups of KN590 study, pneumonia being  the  most  common  SAE  in  both  arms  (10.3%  vs  8.6%);  although  at  higher  incidence  in  the pembrolizumab + chemotherapy group, reassuringly no difference is observed when pneumonia is adjusted for exposure (15 vs 17.2 Events/100 person-year). Drug-related SAE by investigator also occurred at a similar incidence in the two arms (31.6% vs 26.2%), but were numerically higher compared to the RSD, which seems to generally reflect the course of the chemotherapy (cisplatin and 5-fluorouracil) and the underlying disease.

It  is  noted  that  incidence  of acute  kidney  injury SAE  was  almost  doubled  in  the  pembrolizumab  + chemotherapy group compared to the chemotherapy group of KN590 study (3% vs 1.6%), as well as Grade 3-5 events (2.7% vs 1.9%), including one fatal grade 5 event (vs none in the SOC). Acute kidney injury lead also more frequently to treatment discontinuation in the experimental arm (1.1% vs 0.5%). Acute kidney injury is reported as a common ADR in section 4.8 of the SmPC, which is considered sufficient at this stage based on the data provided. Narratives for the 13 cases (8 in the pembro combo and 5 in the control  arm  of  KN590)  of  acute  kidney  injury  were  reviewed,  all  (except  of  1  fatal  event  in  the pembrolizumab and chemotherapy arm) were Grade 2-3 and often resolved or resolving. All events were considered related to cisplatin. Incidences are too small and the difference in incidences between the control and the pembrolizumab + chemotherapy arm is not clear enough to allow any conclusions about potential additive effects of pembrolizumab on the known renal toxicities of cisplatin.

The overall incidence of AEs resulting in death was not worse with the combination pembrolizumab + chemotherapy compared to chemotherapy alone (28 vs 38 patients, 7.6% vs 10.3%). The most frequently reported AEs leading to death in the pembrolizumab combination arm were related to respiratory infections (pneumonia, pneumonia aspiration, and pulmonary sepsis). Pneumonia was the most common cause of death in the chemotherapy arm as well. The overall incidence of AEs resulting in death in the pembrolizumab + chemotherapy group (7.6%) was higher than that of the pembrolizumab monotherapy RSD (5.3%), but similar to the oesophageal monotherapy dataset (8.5%); in this latter dataset, again respiratory infections (pneumonia aspiration and pneumonia) were the most frequent cause of death, which appeared to be related to the underlying oesophageal disease.

Deaths considered drug-related by the investigator were 9 vs 5 (2.4% vs 1.4%) in the pembrolizumab + chemotherapy vs chemotherapy arm of KN590 study. Although drug-related death has been observed at higher incidence in the experimental arm, such difference appears negligible after adjustment for exposure

<div style=\"page-break-after: always\"></div>

(0.28 vs 0.20 event/100 person-month), which is reassuring. In most of the cases, it is difficult to clearly attribute the events to one or the other drug of the combination.

The  most  common  AEOSI  categories  ( ≥ 5%)  in  the  pembrolizumab  plus  chemotherapy  group  were hypothyroidism,  pneumonitis,  and  hyperthyroidism,  having  similar  incidences  to  the  pembrolizumab monotherapy RSD. The majority of AEOSI reported in the pembrolizumab + chemotherapy group were mild to moderate (Grade 1 or 2). There were two cases of fatal AEOSI (pneumonitis and interstitial lung disease, vs 1 patient in the control arm who died due for pneumonitis).

The rate of pneumonitis was 6.2% for the combination (vs 0.5% in the chemotherapy arm), higher than what was reported with pembrolizumab alone (5.2% in the oesophageal dataset and 4.5% in the RSD), which were also more severe. The exposure-adjusted rate of pneumonitis showed a similar event rate compared  to  pembrolizumab  monotherapy  oesophageal  dataset,  the  latter  slightly  higher  than  the monotherapy RSD, possibly related to the oesophageal localization of the disease than of the combination in itself. Due to the small number of patients with pneumonitis who had prior thoracic RT, it is not possible to draw meaningful conclusion about the role of prior thoracic RT in the risk of pneumonitis.

No new safety concerns based on laboratory abnormalities were reported in the pembrolizumab plus chemotherapy group, and differences observed between pembrolizumab combination and pembrolizumab monotherapy are consistent with the established safety profile of the chemotherapy drugs administered.

While  the  incidence  of  AEs  (24.3%  vs  20%)  and  SAEs  (15.7%  vs  12.7%)  leading  to treatment discontinuation was higher in the pembrolizumab + chemotherapy arm vs chemotherapy, the difference between arms is reduced when adjusted for exposure. Pneumonia, blood creatinine increase, pneumonitis and  acute  kidney  injury  were  the  most  common  AEs  leading  to  treatment  discontinuation  in  the pembrolizumab + chemotherapy group.

Most of the patients in the pembrolizumab + chemotherapy group had treatment interruption of any treatment due to AEs (70.8% vs 65.4%), and almost half of the subjects in both arms interrupted all treatment drugs.

Safety profile by subgroups : The AE profile according to age in the pembrolizumab plus chemotherapy group was generally similar between participants w ho were &lt;65 years and ≥65 years, with the exception of discontinuation due to AE/SAE which occurred more frequently in the older age group, although the same trend is observed also in the chemotherapy arm.

When safety is analysed by age groups (&lt;65, 65-74, 75-84, 85+), in the pembrolizumab + chemotherapy arm an increased percentage of patients who experienced Grade 3-5 AEs, SAE, death due to AEs and discontinuation in the 75-84 age group is observed compared to younger patients. The same trend is seen in the chemotherapy arm only for death due to drug-related AEs and treatment discontinuation. The toxicity of the pembrolizumab combination in patients aged 75-84 appears to be overall higher compared to the same age group of the chemotherapy arms (G3-5 AEs and drug-related AEs, SAE and drug-related SAE, death due to AE, discontinuation due to SAE and drug-related SAE, as well as slight increase in CNS and AE related to falling, CV and cerebrovascular events, infections).

In KEYNOTE 590, patients aged ≥75 years reported higher incidences (&gt;10% difference) of Grade 3 to 5 AEs (84% vs. 75%), SAEs (78% vs. 50%), drug-related SAE (57% vs. 34%), deaths (27% vs. 13%), discontinuations due to SAEs (38% vs. 25%) and discontinuations due to drug-related SAEs (27% vs. 16%) in the pembrolizumab plus chemotherapy group compared to the chemotherapy group. Even in exposure adjusted analyses higher event rates were reported for pneumonitis (23 vs. 0 events/100 person year), pneumonia (45 vs. 12 events), neutrophil count decreased (96 vs. 35 events), diarrhea (40 vs. 6 events), vomiting (18 vs. 6 events), hyponatremia (74 vs. 35 events) and hypophosphatemia (23 vs. 0 events). Higher events for exposure-adjusted SAEs in the combination arm were reported for example for the SOCs gastrointestinal  disorders  (57  vs.  17  events/100  person  year),  infections  and  infestations  (74  vs.  56

<div style=\"page-break-after: always\"></div>

events), metabolism and nutrition disorders (51 vs. 12 events), and respiratory, thoracic and mediastinal disorders (62 vs. 17 events). In conclusion, data from KN-590 study showed a clear trend towards an increased toxicity for patients aged ≥75 years thus raising concern over the tolerability of pembrolizumab + chemotherapy combination in the elderly.

This increased risk of AEs in the elderly should be considered in the context of an expected lower benefit with higher age (see clinical efficacy). The limited sample size is acknowledged, however as the median age  of  patients  with  oesophageal  cancer  is  approximately  68  years,  the  B/R  in  elderly  is  of  special importance. As a result, it is considered clinically relevant to inform physicians in the SmPC (leaving room to treat especially fit patients despite the nominal age).

The tolerability o f pembrolizumab combined with chemotherapy in patients aged ≥ 75 was questioned also in the assessment  of previously approved combinations of pembrolizumab  plus platinum-based chemotherapy in HNSCC and NSCLC (see EPAR var II/60 and II/65). However, the limited number of subjects in this age category in KN590 as well as in previous clinical trials hampered definitive conclusion. A pooled safety analysis of KN590 with pivotal studies for the EU approved combo indications (KN021, KN189,  KN407  and  KN048)  included  128  vs  114  patients  75  years  and  older  in  the  pembrolizumab combination vs chemotherapy, respectively, representing approximately 9% of the overall population. A trend  toward  higher  incidence  of  overall  toxicity  by  class  of  age  is  observed  in  the  pembrolizumab combination  pooled  arm,  although  the  same  trend  is  present  also  in  the  chemotherapy  group.  When comparing each class of age (&lt;65, 65-74, &gt;=75) in both arms, overall a higher toxicity is evident with the addition of Keytruda to the combination.

Acknowledging the limited number, no meaningful differences in the overall AE profile between male and female participants are observed.

The  AE  profile  based  on region (EU  vs  Ex-EU)  did  not  show  relevant  differences,  although  with  the limitations of interpretability of the small sample size in the EU.

## 3.5.2. Conclusions on clinical safety

The  combination  of  pembrolizumab  +  chemotherapy  did  not  widely  worsen  the  overall  toxicity  of chemotherapy alone. The safety profile of the combination reflected the established safety profiles of the chemotherapy administered (cisplatin and 5-Fluoruracil) and of pembrolizumab monotherapy. Toxicities could be mainly attributed to the chemotherapy regimen and the underlying disease. AEOSI were similar to the established  safety profile for pembrolizumab monotherapy. Data from KEYNOTE-590 study showed a trend towards an increased toxicity for patients aged ≥ 75 years, thus raising concern over the tolerability of pembrolizumab + chemotherapy combination in the elderly. No new safety concerns were identified.

## 3.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 3.6. Risk management plan

The MAH submitted an updated RMP version 30.0 with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 30.0 is acceptable.

The CHMP endorsed the Risk Management Plan version 30.0 with the following content:

<div style=\"page-break-after: always\"></div>

## Safety concerns

Table 63: List of safety concerns

| List of safety concerns    | List of safety concerns                                                                                                                                                                                                                                                                                           |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks | Immune-related adverse reactions (including immune-related pneumonitis, colitis, hepatitis, nephritis, and endocrinopathies)                                                                                                                                                                                      |
| Important potential risks  | For hematologic malignancies: increased risk of severe complications of allogeneic stem cell transplantation (SCT) in patients who have previously received pembrolizumab Graft versus host disease (GVHD) after pembrolizumab administration in patients with a history of allogeneic stem cell transplant (SCT) |
| Missing information        | None                                                                                                                                                                                                                                                                                                              |

The list of the safety specifications remains unchanged. No new safety concerns have been identified from the submitted data supporting the new indication.

## Pharmacovigilance plan

There are no ongoing or planned additional pharmacovigilance studies that are required for pembrolizumab. Routine pharmacovigilance activities are sufficient to address the risk of Keytruda in all approved indications.

## Risk minimisation measures

Table 64: Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                                              | Risk minimisation Measures                                                                                                                                                                                                                                                                                                                             | Pharmacovigilance Activities                                                                                                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks: Immune-Related Adverse Reactions                                                                | Important Identified Risks: Immune-Related Adverse Reactions                                                                                                                                                                                                                                                                                           | Important Identified Risks: Immune-Related Adverse Reactions                                                                                                                                                           |
| Immune-related adverse reactions (including immune-related pneumonitis, colitis, hepatitis, nephritis and endocrinopathies) | Routine risk minimisation measures: • The risk of the immune-related adverse reactions (including immune- related pneumonitis colitis, hepatitis, nephritis, and endocrinopathies) associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. | Routine pharmacovigilance activities Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : Targeted questionnaire for spontaneous postmarketing reports of all adverse events |
|                                                                                                                             | Additional risk minimisation measures: Patient educational materials                                                                                                                                                                                                                                                                                   | Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumor types                                                                      |

<div style=\"page-break-after: always\"></div>

## Summary Table of Pharmacovigilance Activities and Risk Minimisation

Table 64: Activities by Safety Concern

| Safety Concern                                                                                                                                | Risk minimisation Measures                                                                                                                                                                                                                                                                                                                                       | Pharmacovigilance Activities                                                                                                                                                            |
|-----------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks                                                                                                                     | Important Potential Risks                                                                                                                                                                                                                                                                                                                                        | Important Potential Risks                                                                                                                                                               |
| For hematologic malignancies: increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab | Routine risk minimisation measures: • For Hematologic malignancies: the increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab is described in the SmPC, Section 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted | Routine pharmacovigilance activities Additional pharmacovigilance including: • Safety monitoring in the ongoing                                                                         |
| GVHD after pembrolizumab administration in patients with a history of allogeneic SCT                                                          | Routine risk minimisation measures: • GVHD after pembrolizumab administration in patients with a history of allogeneic SCT is described in the SmPC, Section 4.4 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted                                                                   | Routine pharmacovigilance activities Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH- sponsored clinical trials for pembrolizumab in various tumor types |

The risk minimisation measures remain unchanged and sufficient to mitigate the risks in all approved indications.

## 3.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.8, and 5.1, 5.2 and 5.3 of the SmPC are being updated. The Package Leaflet (PL) is updated accordingly. Minor updates are also included in Annex II of the Product Information.

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

## 3.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

- no significant changes are made to the package leaflet; in particular, the key messages for the safe use of the medicinal product are not impacted.
- the design, layout and format of the package leaflet will not be affected.

<div style=\"page-break-after: always\"></div>

## 4. Benefit-Risk Balance

## 4.1.1. Disease or condition

Unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults.

The  CHMP  adopted  an  extension  of  indication  for  KEYTRUDA,  in  combination  with  platinum  and fluoropyrimidine  based  chemotherapy,  in  the  first-line  treatment  of  patients  with  locally  advanced unresectable or  metastatic  carcinoma  of  the  oesophagus  or  HER-2  negative  gastroesophageal  junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 10.

## 4.1.2. Available therapies and unmet medical need

Currently, the management of inoperable locally advanced and/or metastatic (stage IV) disease is palliative in intent, with different chemotherapy-based options being indicated as first-line option in fit patients. For HER-2 negative adenocarcinoma (AC) tumours, doublet combinations of platinum (cisplatin, oxaliplatin, or carboplatin) and fluoropyrimidines (5-FU or capecitabine) are generally used; triplet regimens with the addition of anthracycline or taxanes can also be considered, although controversy remains as regards their clinical advantage. In HER-2 positive AC tumours, trastuzumab in addition to cisplatin and 5-fluorouracil or cisplatin and capecitabine is indicated. In SCC, cisplatin-based combinations showed increased response rate but no survival gain compared with monotherapy; overall, results with palliative chemotherapy are worse than AC tumours (for references see section 3.1.1. )

## 4.1.3. Main clinical studies

KEYNOTE-590 is an ongoing, Phase 3, randomized, double-blind, placebo-controlled, multisite study to evaluate the efficacy and safety of pembrolizumab in combination with chemotherapy (cisplatin and 5-FU) versus  chemotherapy  (cisplatin  with  5-FU)  as  1L  treatment  in  participants  with  locally  advanced unresectable metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction

## 4.2. Favourable effects

In  participants  with  ESCC  and  PD-L1  CPS ≥ 10,  pembrolizumab as add-on to chemotherapy provided a statistically significant improvement in OS compared with chemotherapy alone (HR:0.57; 95% CI: 0.43, 0.75; p&lt;0.0001)

Within the entire ESCC group regardless of PD-L1 score, the positive effect of pembrolizumab on OS was attenuated in magnitude but remains statistically significant compared to control (HR:0.72; 95% CI: 0.60, 0.88; p&lt;0.0006).

OS analysis  in  the  adenocarcinoma  subtype  showed  superiority  of  pembrolizumab  +  chemotherapy  vs control (HR:0.74; 95% CI: 0.54, 1.02; p&lt;0.0006).

Within the totality of PD-L1 positive tumours pembrolizumab plus chemotherapy was more advantageous than control in terms of OS (HR:0.62; 95% CI: 0.49, 0.78; p&lt;0.0001).

Within the ITT population encompassing all histologies and PD-L1 status, pembrolizumab demonstrated superiority on OS relative to control (HR:0.73; 95% CI: 0.62, 0.86; p&lt;0.0001) with a 3 month gain in median OS (12.4 vs 9.8 months in control).

<div style=\"page-break-after: always\"></div>

Investigator-Based Analysis showed superiority of pembrolizumab plus chemotherapy versus chemotherapy alone  within  the  ESCC  population  (HR:0.65;  95%  CI:0.54,  0.78;  p&lt;0.0001),  PD-L1  positive  group (HR:0.51; 95% CI:0.41, 0.65; p&lt;0.0001) and ITT population (HR:0.65; 95% CI:0.55, 0.76; p&lt;0.0001).

Within  the  ITT  population,  ORR  (CR+PR)  was  judged  similarly  by  Investigators  (45%  vs  29.3%  in pembrolizumab and control arm, respectively) and centralised analysis (43.4% vs 29% in pembrolizumab and control arm, respectively).

## 4.3. Uncertainties and limitations about favourable effects

- The benefit in the overall study population was driven by the biomarker positive subgroup. No clinically  meaningful benefit was observed for subjects whose tumours express PD-L1 CPS &lt;10 (n=347).
- Elderly patients ≥ 75 years do not derive an obvious benefit (n=69; OS HR 0.98, PFS HR 0.93) in the  overall  study  population. Data  are  limited  in  patients  ≥ 75 years  for  pembrolizumab  in chemotherapy combination in patients with oesophageal carcinoma as reflected in section 4.2 of the SmPC.

CPS &lt;10:

OS HR 0.86 (95% CI 0.68, 1.10)

median OS 10.5 vs. 10.6 months

PFS HR 0.8 (95% CI 0.64, 1.01)

median PFS 6.2 vs. 6.0 months

ORR difference 6.8%

38.9% vs. 32.0%

## 4.4. Unfavourable effects

The most co mmon AEs (incidence ≥ 40%) in both arms were nausea, anemia, decreased appetite, fatigue and  constipation.  Higher  rates  of  fatigue,  WBC  count  decreased,  neutrophil  count  decreased,  rash, hypothyroidism  and  pruritus  were  observed  in  the  pembrolizumab  +  chemotherapy  group  than  in  the chemotherapy group, and remained higher even after adjustment for exposure, with the exception of fatigue and neutrophil count decreased.

The rate of Grade 3 to 5 AEs in KEYNOTE-590 was similar in both arms (85.9% vs 86.2%). Neutrophil count decreased, anemia, neutropenia and hyponatremia were the most common G3-5 AEs (incidence ≥10%). Reassuringly, rates of febrile neutropenia were comparable between the 2 groups (3.2% vs 4.1%).

The overall incidence of SAEs was approximately 55% in both treatment groups of KN590 study, being pneumonia the most common SAE in both arms (10.3% vs 8.6%). The largest difference between treatment arms was noted for the SAE pneumonitis (3.2% vs 0%).

The overall incidence of AEs resulting in death was 7.6% vs 10.3%. The most frequently reported AEs leading to death were related to respiratory infections in both arms of KN590 as well as in the oesophageal pembrolizumab monotherapy dataset, which is possibly related to the oesophageal site of the tumour.

Drug-related deaths according to the investigator were 9 vs 5 (2.4% vs 1.4%), although such difference appears negligible after adjustment for exposure (0.28 vs 0.20 event/100 person-month)

The incidence of AEOSI in the pembrolizumab plus chemotherapy group was 25.7%. The most common AEOSI  categories  ( ≥ 5%)  in  the  pembrolizumab  plus  chemotherapy  group  were  hypothyroidism, pneumonitis, and hyperthyroidism. Grade 3 to 5 AEOSI occurred in 7% of participants, including 2 fatal cases (pneumonitis and interstitial lung disease).

Treatment discontinuation occurred in 24.3% vs 20% due to AEs and in 15.7% vs 12.7% due to SAEs in the pembrolizumab + chemotherapy arm vs chemotherapy, respectively. The difference between arms

<div style=\"page-break-after: always\"></div>

is  reduced  when  adjusted  for  exposure.  Pneumonia,  blood  creatinine  increase,  pneumonitis  and  acute kidney injury were the most common AEs leading to treatment discontinuation.

Data from KN-590 study showed a clear trend towards an increased toxicity for patients aged ≥ 75 years, thus raising concern over the tolerability of pembrolizumab + chemotherapy combination in the elderly. This is also relevant in the context of an expected lower benefit with higher age (see clinical efficacy). The limited sample size is acknowledged, however as the median age of patients with oesophageal cancer is considered to be 68 years, the B/R in elderly is of special importance (see sections 4.4 and 5.1 of the SmPC).

## 4.5. Uncertainties and limitations about unfavourable effects

None

## 4.6. Effects Table

Table 65: Effects Table for KEYTRUDA in combination with platinum and fluoropyrimidine based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma with PDL1 status CPS≥10 in adults (KEYNOTE-590 study, data cutoff: 02-JUL-2020)

| Effect                      | Short description                                                                                   | Unit                        | Treatment Control                    | Treatment Control                    | Uncertainties / Strength of evidence                                                                                                                                                                                      | References                  |
|-----------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------|--------------------------------------|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| Favourable Effects (CPS≥10) | Favourable Effects (CPS≥10)                                                                         | Favourable Effects (CPS≥10) | Favourable Effects (CPS≥10)          | Favourable Effects (CPS≥10)          | Favourable Effects (CPS≥10)                                                                                                                                                                                               | Favourable Effects (CPS≥10) |
| OS                          | duration of survival from randomization to death regardless of cause                                | months (95% CI)             | 13.5 (11.1,15.6)                     | 9.4 (8.0,10.7)                       | Study double-blind, consistent results between INV and independent assessment of PFS Response was PD-L1 dependent. Trend for lower treatment effect for ex- Asian population, elderly ≥75 years and female subpopulation. | CSR KN-590                  |
| OS                          | duration of survival from randomization to death regardless of cause                                | months (95% CI)             | HR 0.62 (95% CI 0.49, 0.78) P<0.0001 | HR 0.62 (95% CI 0.49, 0.78) P<0.0001 | Study double-blind, consistent results between INV and independent assessment of PFS Response was PD-L1 dependent. Trend for lower treatment effect for ex- Asian population, elderly ≥75 years and female subpopulation. | CSR KN-590                  |
| PFS                         | duration of survival without progression from randomization to PD or death whichever occurred first | months (95% CI)             | 7.5 (6.2, 8.2)                       | 5.5 (4.3, 6.0)                       |                                                                                                                                                                                                                           |                             |
| PFS                         | duration of survival without progression from randomization to PD or death whichever occurred first | months (95% CI)             | HR 0.51 (95% CI 0.41, 0.65) P<0.0001 | HR 0.51 (95% CI 0.41, 0.65) P<0.0001 |                                                                                                                                                                                                                           |                             |
| ORR                         | Confirmed CR + PR                                                                                   | % (95% CI)                  | 51.1 (43.7, 58.5)                    | 26.9 (20.8, 33.7)                    |                                                                                                                                                                                                                           |                             |
| DoR                         | Duration of CR/PR until documented PD                                                               | months (range)              | 10.4 (1.9, 28.9+)                    | 5.6 (1.5+, 25+)                      |                                                                                                                                                                                                                           |                             |
| Unfavourable Effects        | Unfavourable Effects                                                                                | Unfavourable Effects        | Unfavourable Effects                 | Unfavourable Effects                 | Unfavourable Effects                                                                                                                                                                                                      | Unfavourable Effects        |
| AE summary                  | AE drug related AE G3-5 AE drug related G3-5 AE                                                     | %                           | 100 98.4 85.9 71.9                   | 99.5 97.3 83.2 67.6                  | No major relevant worsening of the toxicity compared to chemotherapy alone.                                                                                                                                               | CSR KN-590                  |

<div style=\"page-break-after: always\"></div>

| Effect   | Short description                                   | Unit   |   Treatment Control |   Treatment Control | Uncertainties / Strength of evidence                                                                                                                                                                                                                                        | References   |
|----------|-----------------------------------------------------|--------|---------------------|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
|          | SAE                                                 |        |                55.4 |                55.1 | Safety of the combination consistent with the established safety profile of the chemotherapy (cisplatin+5 FU) and pembrolizumab. No new safety concern identified. Worse toxicity in elderly, ( ≥ 75 years) compared to chemotherapy and to the combination in younger age. |              |
|          | drug related SAE                                    |        |                31.6 |                26.2 | Safety of the combination consistent with the established safety profile of the chemotherapy (cisplatin+5 FU) and pembrolizumab. No new safety concern identified. Worse toxicity in elderly, ( ≥ 75 years) compared to chemotherapy and to the combination in younger age. |              |
|          | death due to AE                                     |        |                 7.6 |                10.3 | Safety of the combination consistent with the established safety profile of the chemotherapy (cisplatin+5 FU) and pembrolizumab. No new safety concern identified. Worse toxicity in elderly, ( ≥ 75 years) compared to chemotherapy and to the combination in younger age. |              |
|          | death due to drug related AE                        |        |                 2.4 |                 1.4 | Safety of the combination consistent with the established safety profile of the chemotherapy (cisplatin+5 FU) and pembrolizumab. No new safety concern identified. Worse toxicity in elderly, ( ≥ 75 years) compared to chemotherapy and to the combination in younger age. |              |
|          | discontinuation of any drug due to AE               |        |                24.3 |                20   | Safety of the combination consistent with the established safety profile of the chemotherapy (cisplatin+5 FU) and pembrolizumab. No new safety concern identified. Worse toxicity in elderly, ( ≥ 75 years) compared to chemotherapy and to the combination in younger age. |              |
|          | discontinuation of any drug due to drug related AE  |        |                19.5 |                11.6 | Safety of the combination consistent with the established safety profile of the chemotherapy (cisplatin+5 FU) and pembrolizumab. No new safety concern identified. Worse toxicity in elderly, ( ≥ 75 years) compared to chemotherapy and to the combination in younger age. |              |
|          | discontinuation of any drug due to SAE              |        |                15.7 |                12.7 | Safety of the combination consistent with the established safety profile of the chemotherapy (cisplatin+5 FU) and pembrolizumab. No new safety concern identified. Worse toxicity in elderly, ( ≥ 75 years) compared to chemotherapy and to the combination in younger age. |              |
|          | discontinuation of any drug due to drug related SAE |        |                10.3 |                 4.6 | Safety of the combination consistent with the established safety profile of the chemotherapy (cisplatin+5 FU) and pembrolizumab. No new safety concern identified. Worse toxicity in elderly, ( ≥ 75 years) compared to chemotherapy and to the combination in younger age. |              |
| AEOSI    | hypothyroidism                                      |        |                10.8 |                 6.5 | Safety of the combination consistent with the established safety profile of the chemotherapy (cisplatin+5 FU) and pembrolizumab. No new safety concern identified. Worse toxicity in elderly, ( ≥ 75 years) compared to chemotherapy and to the combination in younger age. |              |
|          | pneumonitis                                         |        |                 6.2 |                 0.5 | Safety of the combination consistent with the established safety profile of the chemotherapy (cisplatin+5 FU) and pembrolizumab. No new safety concern identified. Worse toxicity in elderly, ( ≥ 75 years) compared to chemotherapy and to the combination in younger age. |              |
|          | hyperthyroidism                                     |        |                 5.7 |                 0.8 | Safety of the combination consistent with the established safety profile of the chemotherapy (cisplatin+5 FU) and pembrolizumab. No new safety concern identified. Worse toxicity in elderly, ( ≥ 75 years) compared to chemotherapy and to the combination in younger age. |              |

Abbreviations: AE: adverse event; SAE: serious adverse event; AEOSI: adverse event of special interest.

## 4.7. Benefit-risk assessment and discussion

## 4.7.1. Importance of favourable and unfavourable effects

The combination of pembrolizumab + cisplatin/5-fluorouracil provided a clinically and statistically significant advantage on primary and secondary outcomes over chemotherapy alone in the ITT population. However, these results were driven by the treatment effect of pembrolizumab in the biomarker positive subgroup and the observed benefit for subjects whose tumours express PD-L1 CPS &lt;10, representing approximately half of the study population, cannot be regarded as clinically meaningful.

The combination pembrolizumab + cisplatin/5-fluoruracil causes an increase in toxicity as the typical AE of checkpoint inhibition do not overlap with the toxicity of chemotherapy. As chemotherapy in itself is already rather toxic the increase toxicity by the combination is not reflected in simple metrics such as patients with SAE or higher grade AE. Nonetheless, higher toxicity rates were reported for nearly all categories in the pembrolizumab/chemo combination compared to the chemotherapy control or the pembrolizumab monotherapy reference data; however, no new safety concerns were identified. For elderly patients ( ≥ 75 years) increased toxicity is noted compared to chemotherapy alone.

## 4.7.2. Balance of benefits and risks

Study KEYNOTE-590 demonstrated a clinically relevant advantage in OS, PFS and ORR of pembrolizumab in combination with cisplatin/5-fluoruracil compared to chemotherapy alone in the first line treatment of advanced/metastatic oesophageal cancer patients. However, the observed benefit in the large CPS&lt;10 subgroup is not considered to outweigh the increased toxicity that is associated with the add-on therapy.

## 4.7.3. Additional considerations on the benefit-risk balance

Considerations regarding the benefit in the PD-L1 CPS&lt;10 subgroup:

The treatment benefit of pembrolizumab in the overall study population is driven by the subgroup of patients with high PD-L1 expression status. For participants whose tumours express PD-L1 CPS &lt;10, the OS HR was 0.86 (95% CI: 0.68, 1.10). Median OS (10.5 vs 10.6 months) as well as OS rates at 12 and 18 months

<div style=\"page-break-after: always\"></div>

(differences 4.8% and 3.9%) were similar between the two treatment groups. OS KM curves illustrate that the OS curve of the combination therapy lies only marginally above the chemotherapy arm and a small separation  is  shown  only  from  months  11  onwards.  Taken  together,  the  OS  curves  indicate  that  only uncertain or little survival advantage by the addition of pembrolizumab to the combination therapy. This is also reflected by the OS events: n=132 (75.4%) in the pembrolizumab + chemotherapy arm compared to n=139 (80.8%) in the placebo + chemotherapy arm. The difference in ORR rate was 6.8% in the PD-L1 &lt;10 subgroup (difference in patient numbers with response n=13 for the 175 patients in the PD-L1 &lt;10 population). A clinically meaningful benefit could neither be shown regarding PFS (HR 0.8; 95% CI 0.64, 1.01) in the PD-L1 &lt;10 subgroup; Median PFS is 6.2 vs 6.0 months, the difference in the PFS rate is 4% at 12 and 18 months. For comparison, in subjects with PD-L1 CPS ≥ 10, the OS HR was 0.62, the PFS HR was 0.51 and the difference in ORR was 24%.

It is acknowledged that efficacy analyses in the PD-L1 CPS &lt;10 population were not prespecified and PDL1 expression was not included as stratification factor. Nonetheless, biomarker negative patients represent nearly  half  of  the  study  population,  the  distribution  of  PD-L1  expression  status  was  balanced  between treatment arms and the difference in treatment effect in both biomarker subgroups is biologically plausible in view of the MoA and consistent considering the known predictive value based on previous study results in gastroesophageal cancer. The CHMP had highlighted the necessity to account for biomarker status when planning  stratification  and  analyses  strategy  and  emphasised  that  'at  the  time  of  assessment,  the magnitude of the effect in the overall population and in both biomarker positive and negative subgroups will be taken into account' (procedure EMEA/H/SA/2437/19/2017/II).

The overall evidence appears to suggest that indeed only very few patients would benefit from the addition of pembrolizumab to the already toxic chemotherapy combination. In this context, the rather vulnerable and in clinical practise mostly elderly patient population and the palliative treatment setting should be considered. Exposing all patients to the additional toxicity of pembrolizumab when only half of the patient population would be expected to benefit with a reasonable probability is not considered justified. The B/R would be judged differently in a situation, where the experimental therapy could be applied as an alternative treatment and with a possibly different safety profile providing further treatment options for individual treatment decisions.

To conclude, the add-on nature of the proposed treatment inevitably carries increased toxicity to patients, which are even more compelling in elderly people. Within the setting of a combined therapy, the uncertainties around the add-on efficacy is a critical aspect to conclude on a favourable B/R ratio. In this case, the uncertainties in efficacy relatively to increased toxicity, render the benefit/risk balance unfavourable in the CPS&lt;10 group.

## 4.8. Conclusions

The overall B/R of Keytruda in combination with platinum-and fluoropyrimidine-based chemotherapy for the 1L treatment of patients with advanced oesophageal or EGJ carcinoma is positive for the biomarker positive subgroup PDL1 CPS≥10 .

## 5. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends, by a majority of 28 out of 31 votes, the variation to the terms of the Marketing Authorisation, concerning the following change:

<div style=\"page-break-after: always\"></div>

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include in combination with platinum and fluoropyrimidine based chemotherapy, first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 10, based on the results from the pivotal KEYNOTE-590 (KN590) trial. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Minor updates are also included in Annex II of the Product Information. Version of the RMP (Version 31.0) has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I, II and IIIB and to the Risk Management Plan are recommended.

Divergent position to the majority recommendation is appended to this report.

## 6. APPENDIX

1. APPENDIX Divergent position dated 20 May 2021.

<div style=\"page-break-after: always\"></div>

## APPENDIX

DIVERGENT POSITION DATED 20 May 2021

<div style=\"page-break-after: always\"></div>

## DIVERGENT POSITION DATED 20 May 2021 Keytruda EMEA/H/C/003820/II/0097

The undersigned members of the CHMP did not agree with the CHMP's positive opinion recommending the granting of the following restricted new indication for Keytruda: in combination with platinum and fluoropyrimidine based chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 10.

The reason for divergent opinion was the following:

Within the ITT population, encompassing patients irrespective of PD-L1 expression, the add on of pembrolizumab to chemotherapy demonstrated superiority on OS relative to chemotherapy alone (HR:0.73; 95% CI: 0.62, 0.86; p&lt;0.0001). Therefore, the pivotal trial for this application was positive on the primary endpoint in the all-comer population.

In the subgroup of patients with CPS&lt;10, the OS HR was 0.86 (95%CI 0.68-1.10). The size of this subgroup does not allow for an independent establishment of efficacy with statistical certainty. However, the reality of an effect is supported by a PFS HR of 0.8 (95%CI 0.64-1.01) and a modest increase in objective response rate. While the addition of Keytruda to chemotherapy does increase toxicity, this is considered moderate and manageable.

Thus, a positive B/R has been demonstrated in the full study population.

Given these circumstances, we do not support the decision to limit the indication to patients with a CPS score ≥ 10.

Hillege Johann Lodewijk Dunder Kristina Concha Prieto Yerro